<SEC-DOCUMENT>0001178879-21-000006.txt : 20210510
<SEC-HEADER>0001178879-21-000006.hdr.sgml : 20210510
<ACCEPTANCE-DATETIME>20210510160607
ACCESSION NUMBER:		0001178879-21-000006
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210510
DATE AS OF CHANGE:		20210510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		21907153

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(215) 921-7600

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>fold-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:f3229f4b-7f57-4682-b4ab-77fd47b9060c,g:39b7c24e-a424-4896-93b0-dad319cae6ae,d:1bc67c508bb54073af2079a7d36bd749--><html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:fold="http://www.amicustherapeutics.com/20210331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>fold-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80L2ZyYWc6NGY1ODJjM2E1YWYyNDdiM2E4OWQ2MjgzZWJkMjNjODEvdGFibGU6NjU1NWNmNTUzMWI3NDQzZDgwN2Y5MzI1YmQzY2RmNTcvdGFibGVyYW5nZTo2NTU1Y2Y1NTMxYjc0NDNkODA3ZjkzMjViZDNjZGY1N18zLTEtMS0xLTA_f25afaad-0abb-4918-8853-e11b51db57e0">0001178879</ix:nonNumeric><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80L2ZyYWc6NGY1ODJjM2E1YWYyNDdiM2E4OWQ2MjgzZWJkMjNjODEvdGFibGU6NjU1NWNmNTUzMWI3NDQzZDgwN2Y5MzI1YmQzY2RmNTcvdGFibGVyYW5nZTo2NTU1Y2Y1NTMxYjc0NDNkODA3ZjkzMjViZDNjZGY1N180LTEtMS0xLTA_b3d7c21d-e675-423d-8b14-e408fcb74a0d">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80L2ZyYWc6NGY1ODJjM2E1YWYyNDdiM2E4OWQ2MjgzZWJkMjNjODEvdGFibGU6NjU1NWNmNTUzMWI3NDQzZDgwN2Y5MzI1YmQzY2RmNTcvdGFibGVyYW5nZTo2NTU1Y2Y1NTMxYjc0NDNkODA3ZjkzMjViZDNjZGY1N181LTEtMS0xLTA_ceff687a-4c7e-41bf-86f4-80e9eb72f43a">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80L2ZyYWc6NGY1ODJjM2E1YWYyNDdiM2E4OWQ2MjgzZWJkMjNjODEvdGFibGU6NjU1NWNmNTUzMWI3NDQzZDgwN2Y5MzI1YmQzY2RmNTcvdGFibGVyYW5nZTo2NTU1Y2Y1NTMxYjc0NDNkODA3ZjkzMjViZDNjZGY1N182LTEtMS0xLTA_ee96168e-c21b-477c-bca4-01a276c85041">2021</ix:nonNumeric><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80L2ZyYWc6NGY1ODJjM2E1YWYyNDdiM2E4OWQ2MjgzZWJkMjNjODEvdGFibGU6NjU1NWNmNTUzMWI3NDQzZDgwN2Y5MzI1YmQzY2RmNTcvdGFibGVyYW5nZTo2NTU1Y2Y1NTMxYjc0NDNkODA3ZjkzMjViZDNjZGY1N183LTEtMS0xLTA_ceaf6b50-b3b1-4b1b-adcd-1dc7ae412653">Q1</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="fold-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if28eb188bd19434e8fa22bdbc05ce6ed_I20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i085324ad68f040cab6d186478f2dac9f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4106d82d54f040ab8a176e31e97e485d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id288f022ad3e4df48660873a6e9fea15_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46ce59af193c4c868c341c26afa4148b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fa2ef2f3d8442d9b9a0ada40c1530dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8fc939cca8b43d0920b98c1049e39f3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03da422e5e5b41988fb9336c36774604_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ad9c5f70914438a056f21590c29a77_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58b1a856d6014eafa34817652747a42b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a64d12323e541d285585950b069b321_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec56b4d95a9040f691ae98d1932ff45b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97fd1af684a34d1a9cebb50ef794c543_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e9a645c33e64a77841416360656deb9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b4a5c424f2945d7bd2f559c6b986d5b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd1b47a0c9e8402fbff7bffee12db9fd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i517fd281a28749d78656d0a3c7970477_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c7e2aad59ba4f578e5e314f37acb879_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if21cdcddb1bf4bc0beb5bdf9f9bc15d0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18c0cf87387948d38739af8f77a6b421_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e38b37ec5484f9da915405503e03bd6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia75e14a1366d45c3b7e75e7e9a700855_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91e38d29dead4f2785069422f620c2d0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43f99be30a2947fca4d5d0dc3b99d26b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i020ee144910d46a2aec0495b12e94578_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i843e6fbfc6d34a439da0268c8c325cf1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d77582b16b44d15a065c048a584eeb0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc16447402d44046a7451c1acd97ace7_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd32f0ef41fb4c0eb71b5ff4f53781b9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91abb571e5b04f10ab1bb7976314f183_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0db45e1d6c1c4528adbb181b99592123_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice1b8156e8124fb381e0a08494f81a37_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie422fb8df9cc41a8898b1ecdbc54b0ba_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4f9bae82114ff29db94ce7ce943250_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef534e19d7042548a667fe11fe7f8df_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d172b37766a4bff90df25277ccbedb9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i806c5d2d5f15482c81c841bd96d6e68a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia838f9184beb47c297d0a9b6544f7d24_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62fb03830de7497887830162220ec3d7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86075c190d2342278bca860d772e4fc9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69afd1d0068b46408516b4e05dbea56d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52a446687d324ec99e46667ddf742275_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e96be861b404667ab8e185f54dce138_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90263ef14b3e490f92f545e8f1abec6d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7a9bf8271f74640842b35661ede6ee6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i471af39f23494beca4b65d011f8a7d44_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide7d1fdcbabf448182fada4f80efd849_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96b2d9a6834748be93f41e359fed6f91_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1859eeb446e743c997733b443de3f5c8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64bce1e96a6b41f88ce6934c6afe246c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec32650d30684749839221747f88aa14_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec6a6de4b2d49b0a233b7ac18dc5fc0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i99f52dc175e143b393b832e43be95df1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>fold:day</xbrli:measure></xbrli:unit><xbrli:context id="iac3a273d2c644f5780e23dc81b7297ff_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e22a2bd23524e7ab906f08199397062_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc272117737541f1b41cbaf126872267_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f487fde288f4011b4b648177324c5df_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a5a6bdf179e45b4aa77d6a3a56433ed_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70e0a9292cfa42c8845f33beb7296ef3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i383d26a8b8bd42e3ac89f235894e1cbf_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if040fef71ada406393452b0b39e0a2e1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27a30ae4c9ce4d2e910e5d6a3b595381_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18b0bfea8fa64c228509348665fc54c8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafc0c4bbc6714c919e4c4906d4cbc02d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0abd1fb5725a4bedad2d8202c502b854_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cdf6bb18bf446948b40dfbf1cb8cf1e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i290692dfef66483bbda493456b3bc22a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0570ee1bbea436e8e48eef0fd3bd67c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic314dbac744e4ddea724b9e8a9812eef_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6eb20145e2874e789ae1c2623304be15_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e6bf707c01a42f88c4ac502aa81d78f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dca0209b8ee4d85a4cfb8abbdde80a1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9312ad97e83344808a753c2777b9f467_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6936379467174bf0b8d397139372390d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d80b53cc024638bae2f43fb6d44a08_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3072184bd964b5c80a501c985ee8879_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0595419a51734a4191e082d87b615eb2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4936c29e819c4df1803afec2e7346d1f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bf8b70d9e4c47a798d27a71f86e9dc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93bf63ec6fe74e25acfb12d7d93c414a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6283b4e42587498eb64b1d806d8e10e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ebe9d99985f4e54a4e7b34d261a0b63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4887cc5b8ad47438f6ddb6830f15cc0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525ca3a76a74424385c3cfcd34a9894d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia39206c7064840cc993f0d99c3d83ac6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925eb208debe4acf8dbeded140f69103_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i037b121761ef436aabc14ae0bdc430a2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba028b38e31b4ee9b5ccfc7c44f23b30_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i505945357e0a4dc4b3ca2122d1d0441f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic95386b7dca242ae8b4eb32c56d32799_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0863e5d54c41c88117aaf4a26aba0d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i534dddc6b1d74accbbb4df2865f0432a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0adf3d441ca04bac95b5ee95c7459225_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbfc7637aea4b6b9a703e4bdfd9e9c6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4d9cbe713d437ba0d38b04a1e4b8db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d2ae022e9674e9889a69b4ecabc8ec5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1bc67c508bb54073af2079a7d36bd749_1"></div><div style="min-height:40.5pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMDk1_7f7e9c36-f438-4c7a-a9a1-a9681961a346">10-Q</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMDk2_d5726fa8-f3eb-4808-a050-b605c7bb0ccb">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMzI_7910f314-23ff-4c60-a887-e94a8999fc56">March 31, 2021</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMDk3_b12b7ddf-5daf-49b6-9aab-115e3c8248e5">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMDk5_01e07766-89e5-4382-964c-994171a4d3af">001-33497</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMTAw_49290a89-aeed-4b29-810a-edd3ce3004be">Amicus Therapeutics,&#160;Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.001%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF8wLTAtMS0xLTA_aea655d0-3911-4787-9d2a-5ceed876af46">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF8wLTQtMS0xLTA_69e13589-3537-4758-ae72-08bc13af399c">71-0869350</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identification Number)</span></td></tr><tr style="height:3pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF80LTAtMS0xLTA_e31144a3-dfe5-43c7-903a-cadf20309790">3675 Market Street,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF80LTEtMS0xLTA_6dd7f8bf-4497-45f5-b307-6a1b4be693f3">Philadelphia,</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF80LTItMS0xLTA_8a1d9bc0-1f5e-4456-ae89-30adc79c6b23">PA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF80LTQtMS0xLTA_1bb2f9fe-e15d-4ed8-8885-3735d6972cff">19104</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr style="height:5pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF83LTAtMS0xLTA_34fd571a-56f7-4c45-8d91-4fa80fe14204">(215)</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF83LTMtMS0xLTA_4512853a-107d-477d-8da4-2a7855dcb8d6">921-7600</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant's Telephone Number,&#160;Including Area Code)</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6NTJmZjdiZjk4ODMyNDI5OTgyYmU3ZjQ4OTVkMGZkNzcvdGFibGVyYW5nZTo1MmZmN2JmOTg4MzI0Mjk5ODJiZTdmNDg5NWQwZmQ3N18xLTAtMS0xLTA_28a98f89-fb28-4b7f-9a55-40442cae4bbe">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6NTJmZjdiZjk4ODMyNDI5OTgyYmU3ZjQ4OTVkMGZkNzcvdGFibGVyYW5nZTo1MmZmN2JmOTg4MzI0Mjk5ODJiZTdmNDg5NWQwZmQ3N18xLTEtMS0xLTA_0dee00ff-42a6-45d1-b2e3-accd5feb012d">FOLD</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6NTJmZjdiZjk4ODMyNDI5OTgyYmU3ZjQ4OTVkMGZkNzcvdGFibGVyYW5nZTo1MmZmN2JmOTg4MzI0Mjk5ODJiZTdmNDg5NWQwZmQ3N18xLTItMS0xLTA_eedcebdd-dcfd-4b31-b4c6-04f7b9db98da">NASDAQ Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160; <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMTAx_96be524d-1905-477e-b904-8b48385122ce">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMDk4_a7d3b581-5407-49e8-9db2-f713efec94f7">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:28.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6ZGUwMWQ0YmRiNDgxNDJkNTk0MDU0YWM2MjJmNzJlZjQvdGFibGVyYW5nZTpkZTAxZDRiZGI0ODE0MmQ1OTQwNTRhYzYyMmY3MmVmNF8wLTAtMS0xLTA_681a1dda-f082-4fd7-912e-0555592692a2">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6ZGUwMWQ0YmRiNDgxNDJkNTk0MDU0YWM2MjJmNzJlZjQvdGFibGVyYW5nZTpkZTAxZDRiZGI0ODE0MmQ1OTQwNTRhYzYyMmY3MmVmNF8xLTQtMS0xLTA_5684f6b9-b417-4979-948c-04a73bfe752d">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6ZGUwMWQ0YmRiNDgxNDJkNTk0MDU0YWM2MjJmNzJlZjQvdGFibGVyYW5nZTpkZTAxZDRiZGI0ODE0MmQ1OTQwNTRhYzYyMmY3MmVmNF8yLTQtMS0xLTA_6ad109d3-beb8-412a-abb1-ae3548e8acbc">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMTAy_26a4b2c5-610b-4ed4-9b59-99babc27ffcd">&#9744;</ix:nonNumeric> No &#9746;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant's common stock, $0.01 par value per share, as of April&#160;26, 2021 was <ix:nonFraction unitRef="shares" contextRef="if28eb188bd19434e8fa22bdbc05ce6ed_I20210426" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF84MjQ2MzM3MjEwNDY2_085d893b-97ed-4371-92ab-4983eac1f022">266,060,455</ix:nonFraction> shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMICUS THERAPEUTICS,&#160;INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form&#160;10-Q for the Quarterly Period Ended March 31, 2021 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.712%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_13">PART&#160;I.&#160;&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_13">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_16">Consolidated Financial Statements and Notes (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_19">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_19">March </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_19">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_19">1, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_19"> and December 31, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_19">20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_19">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_19">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_22">Consolidated Statements of Operations for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_22"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_22">March 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_22"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_22">and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_22">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_25">Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_25">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_1099">Consolidated Statements of Changes in Stockholders' Equity for the Three Months Ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_1099">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_31">&#160;Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_31">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_34">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_34">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_67">19</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_79">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_79">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_82">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_82">28</a></span></div></td></tr><tr style="height:3pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_85">PART&#160;II.&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_85">28</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_88">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_88">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_91">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_91">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_94">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_94">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_97">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_97">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_100">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_100">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_103">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_103">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_106">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_106">30</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_109">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1bc67c508bb54073af2079a7d36bd749_109">31</a></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have filed applications to register certain trademarks in the United States and abroad, including AMICUS THERAPEUTICS and design, AMICUS ASSIST and design, CHART and design, AT THE FOREFRONT OF THERAPIES FOR RARE AND ORPHAN DISEASES, HEALING BEYOND DISEASE, OUR GOOD STUFF, and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and design. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form&#160;10-Q contains forward-looking statements that involve risks, uncertainties, and assumptions.&#160;Forward-looking statements are all statements, other than statements of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management. These statements may be preceded by, followed by, or include the words "aim," "anticipate," "believe," "can," "could," "estimate," "expect," "forecast," "intend," "likely," "may," "outlook," "plan," "potential," "predict," "project," "seek," "should," "will," "would," the negatives or plurals thereof, and other words and terms of similar meaning, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our clinical trials of our drug candidates and gene therapy candidates, including but not limited to AT-GAA, CLN6 and CLN3;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing drug supply for our clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200" or "cipaglucosidase alfa") and gene therapies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future results of on-going preclinical research and subsequent clinical trials for cyclin-dependent kinase-like 5 ("CDKL5") deficiency disorder, Pompe gene therapy, Fabry gene therapy, Mucopolysaccharidosis Type IIIB ("MPS IIIB"), next generation Mucopolysaccharidosis Type IIIA ("MPS IIIA") and other pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize these therapies and obtain market acceptance for such therapies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes in regulatory standards relating to the review of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other product candidates that we pursue;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies and other adverse market developments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat HCl") and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AT-GAA and our gene therapy candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain reimbursement for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to adjust to changes in the European and United Kingdom markets in the wake of the United Kingdom leaving the European Union; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our business could be adversely impacted by the effects of the novel coronavirus ("COVID-19") outbreak, including due to actions by us, governments, our customers or suppliers or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates; and</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of these risks and uncertainties, we may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in Part&#160;I Item 1A &#8212; Risk Factors of the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make.&#160;Those factors and the other risk factors described therein are not necessarily all of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations, or investments we may make. Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report on Form&#160;10-Q in conjunction with our Annual Report on Form 10-K  for the fiscal year ended December 31, 2020 (including the documents incorporated by reference therein) completely and with the understanding that our actual future results may be materially different from what we expect. These forward-looking statements speak only as of the date of this report. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law.&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_16"></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;CONSOLIDATED FINANCIAL STATEMENTS AND NOTES (UNAUDITED)</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_19"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMy0xLTEtMS0w_9ae2b5e8-6846-4a67-801e-e1fa20a56b2e">184,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMy0zLTEtMS0w_3da8df3c-288d-43c3-a1fc-71d01f5da96f">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNC0xLTEtMS0w_2fb6982e-0d3e-44f3-90b5-d0a636645695">232,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNC0zLTEtMS0w_f6365976-d568-4ad5-8319-56245acbb13b">320,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNS0xLTEtMS0w_32adc6b9-cf63-407e-87da-d2328bdf6b7d">44,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNS0zLTEtMS0w_c38b02ca-25bc-42fb-9bbb-40dfa481c97a">46,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNi0xLTEtMS0w_98ac7570-fda6-479f-8101-ecd4c536cbdc">18,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNi0zLTEtMS0w_67c0b3c9-56b3-4d16-aab8-6d8728154f62">19,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNy0xLTEtMS0w_9d6a6b9c-4aea-493e-ab88-693bb41a4052">21,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNy0zLTEtMS0w_e1ccb7d5-4282-41c7-bd04-815fcee50cdf">29,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOC0xLTEtMS0w_be27f0cc-2718-40bd-96dc-9c445fef8800">502,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOC0zLTEtMS0w_18691d04-f890-4130-9321-a4710a34ed16">579,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, less accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOS0wLTEtMS0wL3RleHRyZWdpb246MGRiMThlY2RiOWIxNDhiZWFhYTQ3MDQ3YzNkNmRhN2JfNzQ_e7fa2f76-14f7-485e-8154-e9884008d61a">7,499</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOS0wLTEtMS0wL3RleHRyZWdpb246MGRiMThlY2RiOWIxNDhiZWFhYTQ3MDQ3YzNkNmRhN2JfODE_57693e23-c5b9-4825-949b-8617fb08fd2e">7,574</ix:nonFraction> at March 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOS0xLTEtMS0w_cfb7eb44-e66e-4cab-8219-a72eeb7d8d91">22,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOS0zLTEtMS0w_08402797-4f58-4afc-91f4-e7d50c3751ed">23,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, less accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjNiMzRhOTdmMWQyNTRkNTg4ZmE3NTU5MGQyZDRlM2ZkXzYx_6b58a70b-04ca-40c5-95cf-a54cb2257ad0">15,961</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjNiMzRhOTdmMWQyNTRkNTg4ZmE3NTU5MGQyZDRlM2ZkXzY4_f3a3633d-dd47-49dc-9a82-31e3cf428298">14,487</ix:nonFraction> at March 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTAtMS0xLTEtMA_33891be6-4709-421b-9498-5fc7c59796c6">43,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTAtMy0xLTEtMA_34d70851-0882-42b2-8094-e037852d7f19">43,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research&#160;&amp; development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTEtMS0xLTEtMA_04c70b50-535e-4af1-ad22-d94a4b49a77c">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTEtMy0xLTEtMA_2f60e2f9-b89a-4f03-b45e-5138a28eee55">23,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTItMS0xLTEtMA_16843b8e-6a01-4391-9ef7-b927108bbb15">197,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTItMy0xLTEtMA_453c55e0-d326-45a7-9854-591b740470f7">197,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTMtMS0xLTEtMA_66911bc9-3f43-4a77-940e-a646fd25feb3">20,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTMtMy0xLTEtMA_001c6bab-f0a4-4db3-8197-838ee2c1a413">19,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTQtMS0xLTEtMA_f545df7e-3bf4-4174-ab0b-f955a54339fd">810,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTQtMy0xLTEtMA_07169d3e-0dd7-4b33-a5f1-4985d69cb934">886,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTctMS0xLTEtMA_a8d5cf14-cd93-45d1-9461-4448dacf8a88">16,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTctMy0xLTEtMA_e0a1535b-ad82-493b-b704-1c451cbce3a1">17,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTgtMS0xLTEtMA_40b25a3c-5aff-49e3-9776-4d1dbdf92869">57,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTgtMy0xLTEtMA_19f550e5-c417-4763-8444-71229cd8b5f5">96,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTktMS0xLTEtMjA_39241c57-5e11-419f-adeb-4da339da3fe3">19,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTktMy0xLTEtMjA_cac1911f-ff5f-427c-8884-6c26f415a5e8">8,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTktMS0xLTEtMA_87042762-e302-4de7-b92d-ef716a63bd73">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTktMy0xLTEtMA_e0832aa1-c9e6-4a8d-85b1-284999066f5c">6,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjAtMS0xLTEtMA_24390a86-e6a0-42ca-9f5a-cb56620aa84c">99,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjAtMy0xLTEtMA_3e09d0c7-d09c-4fa4-b0d5-9cbdec09dc36">129,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjEtMS0xLTEtMA_848f3c5a-de83-4689-b6f8-aa3d1d93bcd9">7,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjEtMy0xLTEtMA_c51484bd-79a9-4d3e-9708-06b5a1c33c86">7,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjItMS0xLTEtMA_f4409d2f-89d2-4c6b-aab5-37cb32c40d6f">389,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjItMy0xLTEtMA_29035a85-7520-4970-8629-b5664cd63add">389,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjMtMS0xLTEtMA_0288da33-a236-4aeb-8e8e-76cb287263b4">6,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjMtMy0xLTEtMA_8abc1578-b078-4268-8e72-87a413056c8e">16,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjQtMS0xLTEtMA_45f1826c-979c-4eae-89a1-acc5b83f5702">4,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjQtMy0xLTEtMA_f6b54e96-faca-47ce-ad8c-1105bf8886a0">4,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjUtMS0xLTEtMA_f54283f0-8c94-441d-8fc1-2b4dd5c2f45d">44,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjUtMy0xLTEtMA_7019aff6-90bd-49a3-a0ae-43d03d28a12b">45,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjYtMS0xLTEtMA_1da41f8c-ffb4-48c7-bd38-e1e0028b7d1b">6,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjYtMy0xLTEtMA_ac8a0fbe-3124-4eba-bc68-2c97023a67d0">6,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjctMS0xLTEtMA_7a404ae6-2e0c-43ea-b987-de4f735e9ad3">559,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjctMy0xLTEtMA_006a9fbc-76db-4cb4-a69e-71bdfbb11aa5">600,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjgtMS0xLTEtMA_6d4512c6-bc06-4f51-aee6-cc0154256bb2"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjgtMy0xLTEtMA_b5f28fd4-45c8-4c68-9cf9-4e742da4818e"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzE4_0fdea5d7-3b08-49a1-9a6e-1953ce95b4a5"><ix:nonFraction unitRef="usdPerShare" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzE4_3a1a6499-fa00-44bb-ae6e-7baff1e9b82f">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzMy_4a328cc2-d467-4c19-9607-f6a5e0ce5259"><ix:nonFraction unitRef="shares" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzMy_84dc2e9a-e8ef-49fd-aed2-81e823329461">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzU0_22616a65-034d-49b4-b1bc-c0da86d5b504"><ix:nonFraction unitRef="shares" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzU0_7409f339-1d58-4bb4-a676-2d97fbc0e0ce">266,007,718</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzYx_c519862e-1000-419e-b9c6-e5712aee09a9"><ix:nonFraction unitRef="shares" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzYx_f0dae3d1-1d43-4e2d-8887-588ae0e736b6">262,063,461</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMS0xLTEtMA_5b4d1d17-0d39-43fc-bece-6332506dd697">2,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMy0xLTEtMA_07a7e486-69c8-431c-b6eb-105f0a46617a">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzEtMS0xLTEtMA_90c5e636-3ad0-42e9-9e26-38f166d8b97b">2,350,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzEtMy0xLTEtMA_42f0ba87-5e9d-4593-8ddb-33a6cb0b4ece">2,308,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzMtMS0xLTEtMA_d897edd4-ab73-4890-98fe-f303bd889331">9,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzMtMy0xLTEtMA_b9360e3e-7801-40b4-8d5e-864ba56d2d77">8,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzQtMS0xLTEtMA_2bc7608c-9f33-407a-ace9-72482383a7ed">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzQtMy0xLTEtMA_af50069c-8b0d-481d-ad96-1dc7f601ed40">185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzUtMS0xLTEtMA_b6e53e7c-2414-4618-9fb4-26201b68146b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzUtMy0xLTEtMA_8e51a7e5-52bd-4113-8b4f-f66217a83bd0">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzYtMS0xLTEtMA_0940f0dc-bf0b-4874-821c-492e2f1d486b">2,111,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzYtMy0xLTEtMA_57c55a75-63ef-426f-9e44-28f20da1c89f">2,045,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzctMS0xLTEtMA_c7d5ddd1-bde0-406c-acb9-004faf2ae5ca">250,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzctMy0xLTEtMA_2fdbe114-24db-48c9-a284-a67495bf8af5">286,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzgtMS0xLTEtMA_e1993128-76c4-4c88-b63b-7d3066ec05b8">810,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzgtMy0xLTEtMA_112d67ad-2cb1-41b2-83e3-e013fa6399fb">886,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMi0xLTEtMS0w_3276787a-fd3c-44e1-92d0-a795c58c086e">66,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMi0zLTEtMS0w_f2813100-ba71-4052-8db7-71d6e5ce55a4">60,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMy0xLTEtMS0w_949b4fe6-3690-4d13-8f9d-f78ed965e742">6,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMy0zLTEtMS0w_6ab137d5-642e-41d1-91f8-9ab9dff17a8f">6,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNC0xLTEtMS0w_d00bdede-0e6f-4772-b957-1eb1d642fe57">59,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNC0zLTEtMS0w_d6825172-07b7-4ae0-a1ed-6a635f3b05d8">53,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNi0xLTEtMS0w_04bcad7d-0275-4da6-a384-7f1830a7c15c">64,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNi0zLTEtMS0w_3c321447-a74e-4714-8697-68b660e2bbf9">89,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNy0xLTEtMS0w_10939f4c-5be1-4ec5-919b-a5b9253fa7c6">46,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNy0zLTEtMS0w_b7059dc4-0464-479e-ae0a-c78f0fc431b7">40,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfOC0xLTEtMS0w_eeab55d7-c431-4029-baf8-8f7fe8c069a3">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfOC0zLTEtMS0w_00064d62-66c3-4cde-b6b6-ce7be4f95969">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfOS0xLTEtMS0w_522b0989-f6b9-4ed5-8673-9653c8ad67fc">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfOS0zLTEtMS0w_a3008857-a45b-43fb-98cb-26be8fad84ab">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTAtMS0xLTEtMA_5fc5c718-df00-48a2-bb9e-832ccfd6ccc5">112,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTAtMy0xLTEtMA_ef1d52a3-3685-43b4-92fb-9b7f8bb51d4e">132,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTEtMS0xLTEtMA_5861042d-d5de-4566-b77b-bcc2b2286a72">53,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTEtMy0xLTEtMA_5c5963f1-a420-4cae-8502-4945023bb095">78,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTMtMS0xLTEtMA_29576be5-0d99-4c68-a51d-3b2ddc87931c">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTMtMy0xLTEtMA_45ba6187-89e8-4dc6-b65e-83ad187706af">1,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTQtMS0xLTEtMA_aa49743d-d448-4eb3-b75b-f38f7f33d25d">7,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTQtMy0xLTEtMA_328c52f3-83c0-41b6-b28c-e29eb20c9f49">3,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTctMS0xLTEtMA_4a8c3ab7-9ebf-4b44-bd59-feaea6c201c8">3,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTctMy0xLTEtMA_a8155ff7-6960-44aa-a77a-d4cd9a198a32">8,316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTgtMS0xLTEtMA_dce3594c-3d01-4b7b-bb4f-000b790a9fdc">64,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTgtMy0xLTEtMA_2f746a37-2ab3-4ffc-8daa-1ca52580009d">88,587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTktMS0xLTEtMA_6b18883f-d21e-490e-bcb3-d59fc364b805">1,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTktMy0xLTEtMA_2194eaec-247d-432f-b08e-291a01bf28f6">361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjAtMS0xLTEtMA_9ee2bff2-eac4-483f-99ad-6bc9c723bb13">65,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjAtMy0xLTEtMA_dbba8de3-573e-4684-8ea7-0a5893545276">88,948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders per common share&#160;&#8212; basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjEtMS0xLTEtMA_6c310874-5e21-4859-85ba-29126ce2f110">0.25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjEtMy0xLTEtMA_9bf3d4b4-87e2-4950-a004-436228d82080">0.35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjItMS0xLTEtMA_5e793483-030a-4816-98d9-b79d4733e5c2">264,369,317</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjItMy0xLTEtMA_f44dda7f-2ec4-45ed-a58e-5e1d35d73afb">256,968,248</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfMi0xLTEtMS0w_049656ea-f0bf-43a6-959a-772e48a06b3a">65,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfMi0zLTEtMS0w_446d0d1c-a22e-44d0-975b-339a412b44f6">88,948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive gain (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment gain, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNC0wLTEtMS0wL3RleHRyZWdpb246ZTc5MjdiN2VjNDNmNDY3N2FkMWUxMzhmNGNhZmUyNjBfNzg_43521081-dd62-4faf-aa2a-f534c8561171">132</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNC0wLTEtMS0wL3RleHRyZWdpb246ZTc5MjdiN2VjNDNmNDY3N2FkMWUxMzhmNGNhZmUyNjBfODI_1c551c12-f7d6-432d-88d0-17f06f7e2b08">1,536</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNC0xLTEtMS0w_e7d13c89-357d-4fdc-b2ac-1ff159fa5ed1">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNC0zLTEtMS0w_2930ed06-4b77-4ff1-8962-a998dd10447d">4,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities, net of tax impact of $<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNS0wLTEtMS0wL3RleHRyZWdpb246ZjVkOWEyZDlhYzMyNGI5NDgyMGVlYmI5NjRiYWM2YmRfMTY0OTI2NzQ0MTgxOQ_6dc841ad-3e2c-42ed-968f-0dca2db8c2ab">0</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNS0wLTEtMS0wL3RleHRyZWdpb246ZjVkOWEyZDlhYzMyNGI5NDgyMGVlYmI5NjRiYWM2YmRfODY_60da962e-967c-4320-9ab6-d8ca5734b727">56</ix:nonFraction>), respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNS0xLTEtMS0w_b1452619-11a1-4453-ba8d-d330cd1f5b9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNS0zLTEtMS0w_25feab05-4503-411f-b320-4eac3bdbe10a">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNi0xLTEtMS0w_65dd3e42-d323-46df-aaf3-27e0cd1f34d5">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNi0zLTEtMS0w_f72fd76c-4d1a-45c3-a579-ca79559b496f">3,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNy0xLTEtMS0w_768435dc-c7ac-4337-976d-81d19a159197">65,056</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNy0zLTEtMS0w_91ce5da0-6fae-4b10-ba7c-f6db61cc19d0">84,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_1099"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="margin-bottom:15pt;margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4106d82d54f040ab8a176e31e97e485d_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTEtMS0xLTc2NA_14dabdb8-c129-4fa9-b3d0-b42a8de0ebde">262,063,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4106d82d54f040ab8a176e31e97e485d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTMtMS0xLTc2NA_dab49069-f49f-46e0-a218-77ca7ae85b69">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id288f022ad3e4df48660873a6e9fea15_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTUtMS0xLTc2NA_9eff1b16-55d9-478d-8186-161a31e52d4d">2,308,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ce59af193c4c868c341c26afa4148b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTctMS0xLTc2NA_fc008ead-08fe-422f-a4c6-1923c5114f15">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fa2ef2f3d8442d9b9a0ada40c1530dd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTktMS0xLTc2NA_d0724703-7fde-4b89-a655-5797a7f46e2e">8,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8fc939cca8b43d0920b98c1049e39f3_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTExLTEtMS03NjQ_9af77ef2-ca70-4926-90e0-d691d246d32b">2,045,462</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTEzLTEtMS0xNjYy_c7da0822-b722-4c2a-aa6d-dd0685ec07b0">286,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock issued from exercise of stock options, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF81LTEtMS0xLTc2NA_036d842e-4b7e-4630-8b29-884df8ecdc00">488,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF81LTMtMS0xLTc2NA_1713c8b5-0ff8-4d0d-98b8-4dc777e37b5e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03da422e5e5b41988fb9336c36774604_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF81LTUtMS0xLTc2NA_512ee23d-169a-4795-a820-00abeb319521">4,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF81LTEzLTEtMS0xNjYy_4bbfbfe6-b938-4dd9-961c-695e68180a96">4,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock tax vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF82LTEtMS0xLTc2NA_bc1acd10-0576-442c-925a-1f7059fd177e">897,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03da422e5e5b41988fb9336c36774604_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF82LTUtMS0xLTc2NA_631cf983-3f57-4cd7-9211-d23bd608a17b">14,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF82LTEzLTEtMS0xNjYy_e3bfdce0-950c-4a01-a6f7-4d37aa600d7f">14,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03da422e5e5b41988fb9336c36774604_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF83LTUtMS0xLTc2NA_e56dca7b-7d7d-41c4-84bf-effdefd98185">20,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF83LTEzLTEtMS0xNjYy_0175557f-93d0-440e-a06c-507f2c78c0c7">20,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="fold:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF84LTEtMS0xLTc2NA_cf5ad971-bc02-4af5-8935-1a1c18b9a5a9">2,554,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF84LTMtMS0xLTc2NA_0c96211d-679b-4ffe-9343-5b8cbf0e31e6">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03da422e5e5b41988fb9336c36774604_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF84LTUtMS0xLTc2NA_cf2bdc01-2d13-47f5-a609-937efac08743">31,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i32ad9c5f70914438a056f21590c29a77_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF84LTctMS0xLTc2NA_88c4a6d4-e4e1-4960-9647-2b32527568a7">12,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF84LTEzLTEtMS0xNjY0_0a9700d9-e482-4a03-918f-5dbebbaedef8">19,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity component of the convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF85LTEtMS0xLTc2NA_08a5790b-a41c-4a9e-ba90-e5215a04c7cd">4,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF85LTMtMS0xLTc2NA_17f02eb6-f28b-4f20-adf6-1f33946d2a54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03da422e5e5b41988fb9336c36774604_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF85LTUtMS0xLTc2NA_789bb3fd-83ce-409d-a1e9-b7494358ae78">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF85LTEzLTEtMS0xNjY0_27228108-bd50-4d31-8a7e-ff31ec376822">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b1a856d6014eafa34817652747a42b_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMS05LTEtMS03NjQ_15672dc7-5949-45ca-b5cb-00763adb3e80">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMC0xMy0xLTEtMTY1OQ_7f4adf40-75f1-4922-ab04-4bf1cc3b3e36">608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a64d12323e541d285585950b069b321_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMi0xMS0xLTEtNzY0_415b2feb-37c9-4200-ba64-7baf4920d5f8">65,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMS0xMy0xLTEtMTY1OQ_12e21369-0e48-46ea-9fbc-1782f979eadf">65,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec56b4d95a9040f691ae98d1932ff45b_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy0xLTEtMS03NjQ_4fae13ca-fe41-4163-928c-fb0fb5a0e949">266,007,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec56b4d95a9040f691ae98d1932ff45b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy0zLTEtMS03NjQ_bac5f123-5645-49b5-9abd-cda497162777">2,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97fd1af684a34d1a9cebb50ef794c543_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy01LTEtMS03NjQ_0cce762f-bff4-485b-a759-bd53431c1732">2,350,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e9a645c33e64a77841416360656deb9_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy03LTEtMS03NjQ_04413473-ac32-4430-9052-ef102301b350">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b4a5c424f2945d7bd2f559c6b986d5b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy05LTEtMS03NjQ_2243c152-9157-4144-ad9e-97058c35bd45">8,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd1b47a0c9e8402fbff7bffee12db9fd_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy0xMS0xLTEtNzY0_b890edf3-cc4d-4a00-9efb-5b865bb809b9">2,111,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMi0xMy0xLTEtMTY1OQ_291ad9de-4037-4e11-8716-c974a8548d6d">250,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:15pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.857%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.919%"></td><td style="width:0.1%"></td></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i517fd281a28749d78656d0a3c7970477_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTEtMS0xLTc2NA_8a9f0f47-41b3-4ff6-8f2b-572dd604e022">255,417,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517fd281a28749d78656d0a3c7970477_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTMtMS0xLTc2NA_4750ee0b-38ee-4b3f-ae0e-6e1b75cb72c1">2,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7e2aad59ba4f578e5e314f37acb879_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTUtMS0xLTc2NA_e9c7f5b3-8797-43ae-b90c-1f1e7fcf27f9">2,227,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if21cdcddb1bf4bc0beb5bdf9f9bc15d0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTctMS0xLTc2NA_da9b789a-e09a-4ba5-b143-f566d0558ec7">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c0cf87387948d38739af8f77a6b421_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTktMS0xLTc2NA_3573d85d-bd40-46f2-b4ca-c8939e880fa0">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e38b37ec5484f9da915405503e03bd6_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTExLTEtMS03NjQ_1a7767bd-4550-45ce-a1af-a76b71915ffa">1,768,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75e14a1366d45c3b7e75e7e9a700855_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTEzLTEtMS0xNjU2_b21f31f1-28fd-42c2-a303-96e417641bb9">476,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock issued from exercise of stock options, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91e38d29dead4f2785069422f620c2d0_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF81LTEtMS0xLTc2NA_0367373f-9e96-4f30-a188-03385241dd6f">958,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91e38d29dead4f2785069422f620c2d0_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF81LTMtMS0xLTc2NA_04c61c19-39ae-425c-bf99-d09839d8bba8">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f99be30a2947fca4d5d0dc3b99d26b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF81LTUtMS0xLTc2NA_719704d2-934b-485f-bce6-e02f459c0f50">6,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF81LTEzLTEtMS0xNjUw_186704c2-6d0b-4308-8028-86950be1f8aa">6,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock tax vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91e38d29dead4f2785069422f620c2d0_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF82LTEtMS0xLTc2NA_238f5ae6-1f3d-44cc-a305-c5748c891a6a">1,073,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43f99be30a2947fca4d5d0dc3b99d26b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF82LTUtMS0xLTc2NA_cb64785d-cd75-403b-afa9-f922eccbb1fd">7,543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF82LTEzLTEtMS0xNjUw_2ae57707-8a94-448e-b286-68252f575f66">7,543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f99be30a2947fca4d5d0dc3b99d26b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF83LTUtMS0xLTc2NA_db20be3e-f75f-4f01-8fb3-a98bf673be9d">12,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF83LTEzLTEtMS0xNjUw_66648505-9faa-442b-a2af-b00e80d01c7a">12,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i020ee144910d46a2aec0495b12e94578_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF84LTktMS0xLTc2NA_ac6f8763-17b3-48d4-9ba6-fe0d08c291d4">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF84LTEzLTEtMS0xNjUw_7cf6cbc6-5bd9-411c-9db3-ed968b5eca7d">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020ee144910d46a2aec0495b12e94578_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF85LTktMS0xLTc2NA_4e26b44b-af0a-4ace-9ea0-fe8cb486143f">4,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF85LTEzLTEtMS0xNjUw_2b17c4d5-a61e-476d-83ae-e91de4052a4c">4,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i843e6fbfc6d34a439da0268c8c325cf1_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMC0xMS0xLTEtNzY0_605fcfe7-ee07-453d-bf13-4b16272b45ec">88,948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMC0xMy0xLTEtMTY1MA_4bb379b0-71d2-48f6-a7f0-710a081a55b0">88,948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d77582b16b44d15a065c048a584eeb0_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS0xLTEtMS0xNjUw_4d80674d-544c-4013-b3e9-ef6f0fff0aab">257,449,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d77582b16b44d15a065c048a584eeb0_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS0zLTEtMS0xNjUw_18c11f4a-1d2d-437a-a6d1-f206250d83f2">2,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc16447402d44046a7451c1acd97ace7_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS01LTEtMS0xNjUw_47682436-28e9-426d-b24d-c311fb2dcb51">2,238,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd32f0ef41fb4c0eb71b5ff4f53781b9_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS03LTEtMS0xNjUw_13646c40-645f-411b-a98d-8149adb96516">12,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91abb571e5b04f10ab1bb7976314f183_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS05LTEtMS0xNjUw_15fd4a39-d0dc-4bce-b8e4-962ceef8261b">6,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db45e1d6c1c4528adbb181b99592123_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS0xMS0xLTEtMTY1MA_cf66f606-f59e-4dbe-93c6-ac42b59e26a3">1,857,558</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS0xMy0xLTEtMTY1MA_08090089-ad7b-4ad0-9c06-e27b6e3e0646">402,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMy0xLTEtMS0w_0db932b6-9b80-4fc7-8103-90bbf1a7f536">65,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMy0zLTEtMS0w_289c5a46-b361-4e0b-a974-6cde48d761de">88,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and deferred financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNS0xLTEtMS0w_d17ba9ca-fc87-4523-b903-7fda7a063d07">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNS0zLTEtMS0w_13ed75eb-802f-4f20-bd9c-5be172caaacf">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNi0xLTEtMS0w_83b81a87-38eb-4f90-8534-e6e8f39bc2a0">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNi0zLTEtMS0w_88647100-4e90-4db4-bb09-5dec9ade1a99">1,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNy0xLTEtMS0w_da7a80fd-94b8-4568-a38c-0ba4b2766d9b">20,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNy0zLTEtMS0w_dca5fbce-a453-40dc-977a-7199ef0bae6b">12,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash changes in the fair value of contingent consideration payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTAtMS0xLTEtMA_b2efb9b1-0e84-4234-aae7-15a5f7a71a87">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTAtMy0xLTEtMA_2416dbc6-49bc-4196-bc1c-ea92f4bc5f6b">931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency remeasurement loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTEtMS0xLTEtMA_3403772e-b106-4cc4-badc-08bba760461d">2,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTEtMy0xLTEtMA_90210497-3e99-476d-80a3-787c23b20be3">10,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTQtMS0xLTEtMA_d1c305ed-0ad0-41f3-9585-97a57aafcf5d">839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTQtMy0xLTEtMA_1e85133e-66d7-4eff-aaa9-5993302f8362">8,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTUtMS0xLTEtMA_f423ce9e-6507-49dd-8bce-9f6bee088817">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTUtMy0xLTEtMA_c5fe1a60-0e8f-496f-bb77-33d8a7f00b3d">251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTYtMS0xLTEtMA_f2384cc6-df2e-4c9d-b934-c2142272db50">7,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTYtMy0xLTEtMA_c37a010e-a1b7-4dc2-b50f-341d9a73d228">4,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTctMS0xLTEtMA_d0b35a84-41ff-45c4-b200-1b97b7b77633">40,191</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTctMy0xLTEtMA_ca6154b4-4f18-4052-bc53-b6399ac28e4d">35,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTgtMS0xLTEtMA_78fdb4f4-6c79-43ef-9154-2e3fc300d80e">1,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTgtMy0xLTEtMA_d56b6f02-a5c1-4a36-9df5-0b93f32f8e7e">5,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjAtMS0xLTEtMA_8a452f99-76ff-4a0f-ab2a-60bd7d6accc5">72,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjAtMy0xLTEtMA_1501855e-6914-4391-8e62-5423d39df6b7">107,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale and redemption of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjItMS0xLTEtMA_006133aa-1def-4870-a93e-0252cf528167">163,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjItMy0xLTEtMA_69a12296-39d9-42cf-a8f5-5109ad23785d">106,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjMtMS0xLTEtMA_b0281a00-ce39-4ffa-beb7-533bc48e130f">76,247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjMtMy0xLTEtMA_0078c9d0-5079-444f-8709-bdec1dd0b114">12,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjQtMS0xLTEtMA_b9421d1a-5104-4bd9-a6d8-1ee618e09f43">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjQtMy0xLTEtMA_47692ac9-1c32-4ba1-b654-f58aff6ac100">806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjUtMS0xLTEtMA_8cf814d9-7069-475e-8614-779cb08610be">86,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjUtMy0xLTEtMA_8c873ab6-f91c-4f1a-8b65-090f9ec31c37">93,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzAtMS0xLTEtMA_8756eb6f-c02f-49d5-a7e0-6a4afc23536b">368</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzAtMy0xLTEtMA_90469e3d-30c2-4166-bcf8-4c404fc504b6">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of vested restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="fold:PaymentsForRepurchaseOfRestrictedStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzEtMS0xLTEtMA_b52a2c14-9fd5-4ef6-98b4-ff0883d4848e">14,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="fold:PaymentsForRepurchaseOfRestrictedStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzEtMy0xLTEtMA_70466892-588f-4e28-88c6-0d7748ee2383">7,543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzMtMS0xLTEtMA_b16344b4-68b5-44b8-b173-65b22704e349">4,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzMtMy0xLTEtMA_7b94d8e7-ae40-45d7-bb95-65145cc3935e">6,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzQtMS0xLTEtMA_dca9b241-328b-4c94-a12f-a0f3ea8e439d">19,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzQtMy0xLTEtMA_a1b82dca-49a3-4d48-b7ce-cbbec4fe62d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzUtMS0xLTEtMA_786a4dc9-964a-4b77-bbea-7be541a68202">8,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzUtMy0xLTEtMA_7e1e87a1-e1f0-4811-9b58-8f3aeda0a725">1,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzYtMS0xLTEtMA_de907722-add9-461e-a266-34eb7e31af0c">1,153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzYtMy0xLTEtMA_9a104765-4d87-4b99-a50c-a4aae1e34084">4,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net increase(decrease) in cash, cash equivalents, and restricted cash at the end of the period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzctMS0xLTEtMA_7b8feea3-daf5-48ea-85c7-546f736a0c91">21,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzctMy0xLTEtMA_3d30ad3b-c233-4d4f-99e4-d1adff0c89dd">20,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzgtMS0xLTEtMA_483cfaaa-7bc3-4f55-842c-b2695f7a2a41">166,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75e14a1366d45c3b7e75e7e9a700855_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzgtMy0xLTEtMA_6e9fdf11-159d-4e16-8db8-7f489b44af92">146,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at the end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzktMS0xLTEtMA_e36f89ad-c262-4590-988f-7a82de687d22">188,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzktMy0xLTEtMA_1851b618-11d0-478b-9f56-d2e3f226e694">125,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tenant improvements paid through lease incentives</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDEtMS0xLTEtMA_cd16219d-1e65-46d6-8fa1-c0560113a0e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDEtMy0xLTEtMA_ee91dc8c-ee69-4f71-a4bd-b844736988d6">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the period for interest </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDItMS0xLTEtMA_3edbe02f-d25c-44ef-9a8a-a7b20c442e28">7,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDItMy0xLTEtMA_23048ca6-8bf8-4639-ad5e-fe86c77563f6">3,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures unpaid at the end of period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDQtMS0xLTEtMA_725b71e5-8941-450f-b401-1010c51d9adc">188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDQtMy0xLTEtMA_867ffa2f-6c58-4ebc-b360-fd42d4d03d59">589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzctMS0xLTEtODQ3_033fa676-6214-4d79-8953-9ba68f54d977">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzctMy0xLTEtODQ3_8a2c2f8f-95e6-4b1a-a0a3-258748008fe1">1,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_37"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zNy9mcmFnOjhlNjYyNDA3ODljODQ3NTViMjgzNzZmMTFhNWRlZGQ0L3RleHRyZWdpb246OGU2NjI0MDc4OWM4NDc1NWIyODM3NmYxMWE1ZGVkZDRfNTY1Nw_00f7b62b-3fb2-4fb7-bebb-c9b987daed1d" continuedAt="id3e33cdccd8d413ba5372d158ecd36d1" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="id3e33cdccd8d413ba5372d158ecd36d1"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities led by the first, oral monotherapy for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease, and an industry leading rare disease gene therapy portfolio. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of the Company's portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several other geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late-onset Pompe disease. The Company initiated the rolling Biologic License Application ("BLA") submission to the FDA in the fourth quarter of 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("Nationwide Children's") and a research collaboration with the University of Pennsylvania ("Penn"). The Company's pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Mucopolysaccharidosis Type IIIB ("MPS IIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPS IIIA"). This research collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. In the first quarter of 2020, the FDA granted Fast Track designation to the CLN3 Batten disease gene therapy, AT-GTX-502, for the treatment of pediatric patients less than 18 years of age. In September 2020 and February 2021, the European Medicines Agency granted Priority Medicines designation and the FDA granted Fast Track Designation, respectively, to the CLN6 Batten disease gene therapy, AT-GTX-501, for the treatment of patients with variant late infantile neuronal ceroid lipofuscinosis 6 ("vLINCL6").</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations have not been significantly impacted from the novel coronavirus (&#8220;COVID-19&#8221;) pandemic thus far. However, the Company continued to observe increased lag times between patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation due to the resurgence of COVID-19 into 2021. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, and maintained the operational integrity of its clinical trials, with minimal disruption. The Company believes its ability to continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-8" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zNy9mcmFnOjhlNjYyNDA3ODljODQ3NTViMjgzNzZmMTFhNWRlZGQ0L3RleHRyZWdpb246OGU2NjI0MDc4OWM4NDc1NWIyODM3NmYxMWE1ZGVkZDRfNDg5NQ_eb0c590b-8649-43c5-9e33-adfb248749ce">2.1</ix:nonFraction> billion as of March 31, 2021 and anticipates incurring losses through the fiscal year ending December 31, 2021 and beyond. The Company has historically funded its operations through stock offerings, debt issuances, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, collaborations, and other financing arrangements. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on current operating models, the Company believes that the current cash position, which includes expected revenues, is sufficient to fund the Company's operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMjc_55aac8cc-28dc-4f3c-8676-f6645fa0ea1b" continuedAt="i0451341ec2f04ccca8d4aa618974d04c" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i0451341ec2f04ccca8d4aa618974d04c" continuedAt="i42b920419c1748e5b342bb62921d3040"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNjE_874f6b8f-4e07-4b94-8d62-fcafae181291" continuedAt="iaf15f858dde94063be219130e5c33f57" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaf15f858dde94063be219130e5c33f57">The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020.</ix:continuation> </span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMTM_be808e65-95d8-4638-9676-6e471adf786c" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMjg_5786c6c7-fcac-4180-9f74-6d4e749ffb9b" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMzg_3c1c1034-4db6-4806-acd6-318e8905c889" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2021 and through the issuance of this report. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNDI_bfb0feef-430e-4d76-ad5b-931ca62ec9a1" continuedAt="i57dfbe1f9727466b8cf587c36091ad9f" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i57dfbe1f9727466b8cf587c36091ad9f">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i42b920419c1748e5b342bb62921d3040" continuedAt="i91e2c3f93bdb4cfa8081c02d433dbf8c"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNTY_c9416b91-2095-4fe8-be47-a7ebf16a20c0" continuedAt="i33347d8407c5462ab33ade5c9e02ade4" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="i33347d8407c5462ab33ade5c9e02ade4" continuedAt="i420c2abda6e34fe9a0c1b771dda723bb"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i420c2abda6e34fe9a0c1b771dda723bb">. The Company's accounts receivable at March 31, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.</ix:continuation> As of March 31, 2021, the Company recorded an allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfNTE4MA_b666fb50-ae85-4e83-aa38-fa679f9e8bc2">0.1</ix:nonFraction> million.&#160;&#160;&#160;&#160;</span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNzE_8cd427d0-6bc3-44b7-9867-86ca241a2c67" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net product sales consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies with the ultimate payor often a government authority. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMzk_61cb9813-4d31-4bc3-950f-5afea9d194b6" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's net product sales from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by geographic area:</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.619%"><tr><td style="width:1.0%"></td><td style="width:69.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.615%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.605%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice1b8156e8124fb381e0a08494f81a37_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfMi0yLTEtMS0w_a87a5fea-f1ae-4af8-8ffc-4509c65226ec">20,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie422fb8df9cc41a8898b1ecdbc54b0ba_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfMi00LTEtMS0w_12e99f31-2d77-4a8d-9bd6-2c1407f056a4">17,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d4f9bae82114ff29db94ce7ce943250_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfMy0yLTEtMS0w_7a32669c-8ac4-4a97-a60a-b650e814a13a">45,549</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef534e19d7042548a667fe11fe7f8df_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfMy00LTEtMS0w_efa6129c-e34c-404a-a261-81462580bc8a">42,753</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfNC0yLTEtMS0w_20ebc0c5-5751-4533-93a5-3c6980c5e6f0">66,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfNC00LTEtMS0w_5e5f1341-96e4-4fb8-b7b5-311ed2750a62">60,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:InventoryCostsForContractsOrProgramsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNjc_7ba83e0c-6803-4a3a-9bd7-5535c1df63bd" continuedAt="i582543220d034fbda353642869960ca9" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i582543220d034fbda353642869960ca9">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</ix:continuation> </span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMzM_6fb7d642-5e51-4fc4-9d51-16484ab70434" continuedAt="i75f7a26f837c49e6abfe932a8ac6636e" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i91e2c3f93bdb4cfa8081c02d433dbf8c"><ix:continuation id="i75f7a26f837c49e6abfe932a8ac6636e" continuedAt="iab4313418d424994ac3b16d417db91e7"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iab4313418d424994ac3b16d417db91e7">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</ix:continuation> </span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNTg_d60672f2-39d3-4841-b155-88642216264a" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments - Guidance Adopted in 2021</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2019-12 - In December 2019, the Financial Accounting Standard Board issued Accounting Standard Update ("ASU")  2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following applies in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance prospectively on January 1, 2021. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments - Guidance Not Yet Adopted</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="i1bc67c508bb54073af2079a7d36bd749_43"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3.&#160;<ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjk4Nw_9fcf2440-a61d-4c06-9343-ee8b5ab8a61e" continuedAt="id971e0c713504c9d823550e7cb9e2027" escape="true">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="id971e0c713504c9d823550e7cb9e2027" continuedAt="i7b36a433e13d45989fed94e2c434195f"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company held $<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMTA3_1d9b6c3e-1f9b-43b6-b331-9b8f303fbe21">184.8</ix:nonFraction> million in cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMTQz_88c9639e-dc9d-4da0-93b7-e3eabf28935b">232.6</ix:nonFraction> million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#8217;s fair value is determined to less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i7b36a433e13d45989fed94e2c434195f" continuedAt="ia81e1794b07440db8712672457eb81ad"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjk4MQ_ce87a4f6-3623-4f46-a622-2181d985807f" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMi0yLTEtMS0w_0c2fffa4-da7e-4a35-a31d-e43b4233ab73">184,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMi04LTEtMS0w_f832b650-874e-4768-9fe5-7fbfd12ddbf0">184,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d172b37766a4bff90df25277ccbedb9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMy0yLTEtMS0w_95290d4e-e78d-4d0c-b460-f7bf204b4452">20,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d172b37766a4bff90df25277ccbedb9_I20210331" decimals="-3" format="ixt:zerodash" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMy00LTEtMS0w_25deb000-184c-48af-87de-4c16f70a344a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d172b37766a4bff90df25277ccbedb9_I20210331" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMy02LTEtMS0w_ab98bbbd-f410-45a8-8b80-11d87bc3a0c5">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d172b37766a4bff90df25277ccbedb9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMy04LTEtMS0w_82f9a076-9ebe-42d7-964c-0e36aed17ce0">20,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806c5d2d5f15482c81c841bd96d6e68a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNC0yLTEtMS0w_d2c2b76a-d38f-49b9-83e6-bdadebd51315">151,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806c5d2d5f15482c81c841bd96d6e68a_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNC00LTEtMS0w_6d079d3f-3ccd-48e9-9a88-17084912e2aa">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i806c5d2d5f15482c81c841bd96d6e68a_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNC02LTEtMS0w_1564a365-79f4-4168-b342-10c0933d9e94">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806c5d2d5f15482c81c841bd96d6e68a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNC04LTEtMS0w_72f2aa7a-b3eb-4770-be02-7717df1c344d">151,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia838f9184beb47c297d0a9b6544f7d24_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNS0yLTEtMS0w_1c35ab79-1915-46d6-a05e-9cd017819b7a">13,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia838f9184beb47c297d0a9b6544f7d24_I20210331" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNS00LTEtMS0w_98624b99-b887-4a8a-9bab-c3062378704b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia838f9184beb47c297d0a9b6544f7d24_I20210331" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNS02LTEtMS0w_f7e988f2-e322-43a8-84a7-3d42c21e5555">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia838f9184beb47c297d0a9b6544f7d24_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNS04LTEtMS0w_59cede09-cb09-4cc8-a2ca-545b7a232117">13,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62fb03830de7497887830162220ec3d7_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNi0yLTEtMS0w_ff40464e-46b0-475c-8031-1f9e5a4e4f57">46,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62fb03830de7497887830162220ec3d7_I20210331" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNi00LTEtMS0w_1f7b756c-bad6-4320-95d4-eaaa3a656f34">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62fb03830de7497887830162220ec3d7_I20210331" decimals="-3" format="ixt:zerodash" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNi02LTEtMS0w_6e68f46e-3390-4828-a44b-baad75cd0f08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62fb03830de7497887830162220ec3d7_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNi04LTEtMS0w_d99cd6b8-1164-4cdd-a2f2-36ca9cf2a7e1">46,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86075c190d2342278bca860d772e4fc9_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNy0yLTEtMS0w_ac3ed16f-4fe4-48fe-ab41-e5faa32eb9f3">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86075c190d2342278bca860d772e4fc9_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNy00LTEtMS0w_309490fc-52be-4abe-be1c-53d9d055dcfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86075c190d2342278bca860d772e4fc9_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNy02LTEtMS0w_406662bc-c64a-47fe-96e4-b158d2684a8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86075c190d2342278bca860d772e4fc9_I20210331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNy04LTEtMS0w_d0333769-64db-4a4b-bb9f-ceffe9ef9cd3">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69afd1d0068b46408516b4e05dbea56d_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOC0yLTEtMS0w_e2226788-00e6-45ed-b668-69d3cce1b430">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69afd1d0068b46408516b4e05dbea56d_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOC00LTEtMS0w_9f808826-d80d-4597-8658-43f152df5e9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69afd1d0068b46408516b4e05dbea56d_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOC02LTEtMS0w_2afe5248-1066-4cce-aa05-0f2f5e80ab62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69afd1d0068b46408516b4e05dbea56d_I20210331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOC04LTEtMS0w_4c81ce48-c00b-442c-8992-7e67d3a5830e">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOS0yLTEtMS0w_641ca937-5d29-4f98-ab9d-70020ee19eca">417,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOS00LTEtMS0w_aa3d07ff-ec14-4c2c-96bb-411ef91df266">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOS02LTEtMS0w_2d6f3ab3-1bce-47c5-b51f-4fef0b4b9bdc">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOS04LTEtMS0w_9a266152-648b-4685-a3a5-e93231156061">417,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTAtMi0xLTEtMA_c6b8a59b-9cb2-40f9-b70e-72e45aa02350">184,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTAtOC0xLTEtMA_64a9e202-72d5-46d0-b0c2-bb0870486dfc">184,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTEtMi0xLTEtMA_4e80f047-1128-4ffb-a673-6237f3c1101a">232,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTEtNC0xLTEtMA_56de3b7d-97b3-4873-9edd-70347a8296e4">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTEtNi0xLTEtMA_236fee50-8189-4019-bed8-037119d02472">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTEtOC0xLTEtMA_72b362ca-6c2a-468a-b20c-3bc0d50020d2">232,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTItMi0xLTEtMA_e035d252-eed8-4674-9a0e-90a33b1a084f">417,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTItNC0xLTEtMA_713d5167-4b40-4161-8c66-49df1bcb49c5">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTItNi0xLTEtMA_5b663968-80a8-47bc-91a8-9f00258fa380">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTItOC0xLTEtMA_6249551f-5e4b-4697-892b-badfb70591f7">417,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMi0yLTEtMS0w_95849177-2b8a-48b9-94c5-c7999c1ed45d">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMi04LTEtMS0w_14430206-ae35-450c-b188-08cf8bf0facc">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a446687d324ec99e46667ddf742275_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMy0yLTEtMS0w_cedd7323-e22b-4c4d-8a68-20dcc64c4390">39,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a446687d324ec99e46667ddf742275_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMy00LTEtMS0w_0a4340c5-7573-442c-b2d8-7c89333f72f8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52a446687d324ec99e46667ddf742275_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMy02LTEtMS0w_6810f838-5953-4fa1-adec-07e3ef92bb38">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52a446687d324ec99e46667ddf742275_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMy04LTEtMS0w_c1b96c13-64e0-44c4-8e2f-25f08bb05a0e">39,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e96be861b404667ab8e185f54dce138_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNC0yLTEtMS0w_278fa737-8122-4b5c-9ee7-188022e8cb44">217,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e96be861b404667ab8e185f54dce138_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNC00LTEtMS0w_f8c4917f-c6a1-49cd-824a-5b44a06327e2">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e96be861b404667ab8e185f54dce138_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNC02LTEtMS0w_c4c47054-8ede-47c3-9184-473d02bc0fce">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e96be861b404667ab8e185f54dce138_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNC04LTEtMS0w_246b51e7-a83f-4487-967b-661341f24882">217,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90263ef14b3e490f92f545e8f1abec6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNS0yLTEtMS0w_ca269bd2-bdd6-41ee-880f-7ce9aa755b0c">9,420</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90263ef14b3e490f92f545e8f1abec6d_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNS00LTEtMS0w_8bf99e52-f054-4c9d-abd0-0e98367c49c3">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90263ef14b3e490f92f545e8f1abec6d_I20201231" decimals="-3" format="ixt:zerodash" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNS02LTEtMS0w_3659dfd7-22a5-4e50-9eba-ef34fa0e3eac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90263ef14b3e490f92f545e8f1abec6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNS04LTEtMS0w_b1e9f601-b7fe-4002-963b-7805b45056dc">9,438</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a9bf8271f74640842b35661ede6ee6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNi0yLTEtMS0w_e1880b2b-c5c8-43a5-b9bc-4bc1210d2999">53,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a9bf8271f74640842b35661ede6ee6_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNi00LTEtMS0w_a1b40156-061e-4932-8c7b-433d45e876a8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7a9bf8271f74640842b35661ede6ee6_I20201231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNi02LTEtMS0w_92ca6bcd-f45f-4547-8636-2e2de292822a">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a9bf8271f74640842b35661ede6ee6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNi04LTEtMS0w_08187738-bf61-4cdc-b915-5a5ec6239268">53,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471af39f23494beca4b65d011f8a7d44_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNy0yLTEtMS0w_a7fe0bb0-a6ff-416a-9847-7709de6f2da6">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471af39f23494beca4b65d011f8a7d44_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNy00LTEtMS0w_f6378ae4-cd6e-47fd-aebb-f1dcefb9d3ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471af39f23494beca4b65d011f8a7d44_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNy02LTEtMS0w_a7aaf8fa-6855-402b-8f7b-67f483d2c7d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471af39f23494beca4b65d011f8a7d44_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNy04LTEtMS0w_0f08a099-d1c3-4823-8fd6-4a1b6a35ba88">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7d1fdcbabf448182fada4f80efd849_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOC0yLTEtMS0w_88e74c53-a5cd-4a6f-a06b-89807b706f83">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7d1fdcbabf448182fada4f80efd849_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOC00LTEtMS0w_cca6aa95-c61c-4782-99d0-0328530bf5e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7d1fdcbabf448182fada4f80efd849_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOC02LTEtMS0w_1004ff36-356b-4f17-a6cc-465edbacaffb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide7d1fdcbabf448182fada4f80efd849_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOC04LTEtMS0w_0a4d4862-1a6b-4ad1-9ccc-115e553b3bbb">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOS0yLTEtMS0w_db063da9-2257-4895-8126-7d9ecb55c3a7">483,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOS00LTEtMS0w_9615a10e-93bc-4183-9475-c1c2c207585f">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOS02LTEtMS0w_8ea67ad3-e0de-4423-9032-8bcfc0654586">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOS04LTEtMS0w_c5cf462e-42e2-433d-a006-3b3b190a7643">483,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTAtMi0xLTEtMA_03395f72-08ad-414d-9b36-4e406fe3cb07">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTAtOC0xLTEtMA_fd761b2a-b74e-4724-b44c-af0f8c364568">163,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTEtMi0xLTEtMA_109cd009-7c1f-4f3b-bce3-3367fb09ad4f">320,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTEtNC0xLTEtMA_78109cd6-3480-4591-938d-8335ec46f01f">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTEtNi0xLTEtMA_fbc28328-90e1-4ab8-826a-00a2ab82d429">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTEtOC0xLTEtMA_2f35da32-f953-428c-9ea2-847af7a94802">320,029</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTItMi0xLTEtMA_a080b98d-896d-4c95-9fde-5a847b8e3806">483,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTItNC0xLTEtMA_93cdcf4d-73c8-4aa5-ac35-5ce72460e431">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTItNi0xLTEtMA_df009d89-f6bc-4c47-a9af-5e45304f4e71">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTItOC0xLTEtMA_4226f493-9337-4948-aff6-55aeb54b1c3f">483,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 there were <ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjA4MA_dd142e08-9276-4d7b-9921-ce64da98472c">no</ix:nonFraction> realized gains or losses. For the fiscal year ended December 31, 2020, there were <ix:nonFraction unitRef="usd" contextRef="i96b2d9a6834748be93f41e359fed6f91_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjE0NQ_da61772f-4507-45f3-b1bf-99f8ee13a557">no</ix:nonFraction>minal realized gains. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss positions in the marketable securities as of March 31, 2021 and December 31, 2020 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive gain (loss). The fair value of these marketable securities in unrealized loss positions was $<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjY5Mw_1ffc2a88-d2bc-458b-819f-91677536f65a">114.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjcwMA_8512064b-1f63-406a-a088-5e2139b9d213">124.9</ix:nonFraction> million as of March 31, 2021 and December 31, 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="ia81e1794b07440db8712672457eb81ad"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjk5Mw_72f76721-c43d-4a7d-ad98-6a388b1ef61a" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMS0yLTEtMS0w_1becf21d-bc7a-4ebf-9d68-6a0179a687a0">184,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMS00LTEtMS0w_bdec9cbb-bc6c-43fd-9035-6b54801490d2">123,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMi0yLTEtMS0w_5f64b4bf-0858-431f-9ade-1c3caa2b1fda">3,216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMi00LTEtMS0w_36790ad5-ee7e-4d21-8478-48c9397c4406">2,662</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMy0yLTEtMS0w_af8e926b-f8cf-4323-89df-c9a7ef264443">188,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMy00LTEtMS0w_129dfae6-eb45-404f-a18a-5913fc8366b2">125,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div id="i1bc67c508bb54073af2079a7d36bd749_46"></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4.&#160;<ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RleHRyZWdpb246YjRlODBmMGY0MThkNGQ3NjhkZDVmZjVmNjg5NTE0ZTJfMzAx_4de71de3-91d1-476e-849e-2aec49f3e85b" continuedAt="i4e5444a9e6cf46b39b563c21fb1a2874" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i4e5444a9e6cf46b39b563c21fb1a2874"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of raw materials, work-in-process, and finished goods related to the manufacture of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RleHRyZWdpb246YjRlODBmMGY0MThkNGQ3NjhkZDVmZjVmNjg5NTE0ZTJfMzAw_e027d567-989d-451f-9c4b-76cca6c6d52e" continuedAt="idf318c0e1ae549958a72c753079a2f4c" escape="true">The following table summarizes the components of inventories: </ix:nonNumeric></span></div><div style="margin-bottom:15pt;text-align:center"><ix:continuation id="idf318c0e1ae549958a72c753079a2f4c"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMS0yLTEtMS0w_dc5acca2-4eb5-405a-92f9-2220e12bb2b6">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMS00LTEtMS0w_297682c1-5ae9-4745-9f4e-c3f31bd8d354">5,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMi0yLTEtMS0w_5467cf72-2544-4da6-b1df-5fa8c3701323">10,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMi00LTEtMS0w_21f0e2b4-91d7-441c-8924-282cc52b950a">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMy0yLTEtMS0w_bf69e2b5-50d2-48cd-a89c-d0923bcc7aba">5,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMy00LTEtMS0w_8334af8c-d2b3-4ef9-8dd5-eb716b40e303">6,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfNC0yLTEtMS0w_79780e74-72f1-489f-8bb9-99a6fe8220a5">18,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfNC00LTEtMS0w_95c3b662-8903-4f97-a161-79ed4864c11d">19,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a reserve for inventory of $<ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RleHRyZWdpb246YjRlODBmMGY0MThkNGQ3NjhkZDVmZjVmNjg5NTE0ZTJfMjUz_597e5af2-add9-49d1-a413-27c7cef89249">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RleHRyZWdpb246YjRlODBmMGY0MThkNGQ3NjhkZDVmZjVmNjg5NTE0ZTJfMjYw_922d8386-5f18-4c19-81ff-5d00f16a5a0f">0.1</ix:nonFraction> million as of March 31, 2021 and December 31, 2020, respectively.</span></div></ix:continuation><div id="i1bc67c508bb54073af2079a7d36bd749_49"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5.&#160;<ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNTA2NQ_9f239d4b-422b-443b-b9c8-ea62dfbec96b" continuedAt="i0d1094f826f542e29c6295a8f1bac589" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="i0d1094f826f542e29c6295a8f1bac589" continuedAt="idaa0455b85b7484e9e626ad22fd13a4f"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNTA1Mw_1edfc126-b82f-46f4-b3fb-da5ed54f8909" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1859eeb446e743c997733b443de3f5c8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMi0yLTEtMS0w_46c39037-5ee0-406e-bd69-2d6fe1b37591">400,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64bce1e96a6b41f88ce6934c6afe246c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMi00LTEtMS0w_feaa65fb-93e6-4e51-ad5e-8158864703d5">400,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1859eeb446e743c997733b443de3f5c8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMy0yLTEtMS0w_1061be5c-28f2-4d62-8fe2-2889c1d0d675">7,139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64bce1e96a6b41f88ce6934c6afe246c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMy00LTEtMS0w_87e101d0-1890-4ac9-b86f-7d06c7300c34">7,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1859eeb446e743c997733b443de3f5c8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfNC0yLTEtMS0w_adc9950a-a4d4-40bf-927d-ae1cf0ca5760">5,371</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64bce1e96a6b41f88ce6934c6afe246c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfNC00LTEtMS0w_2607716d-cf82-4780-8c5e-ea78e1a88172">5,592</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Senior Secured Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1859eeb446e743c997733b443de3f5c8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfNS0yLTEtMS0w_075fb91f-22c5-4b17-8cce-5ec6f24058c6">387,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64bce1e96a6b41f88ce6934c6afe246c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfNS00LTEtMS0w_6f655714-1ba2-41cc-8acf-8882a07234ca">386,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec32650d30684749839221747f88aa14_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTQtMi0xLTEtMA_4878928b-22d9-4440-ac25-76c6b398c62a">2,800</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec6a6de4b2d49b0a233b7ac18dc5fc0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTQtNC0xLTEtMA_c025e15d-524e-4747-a7a4-6569b9d37cde">2,825</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec32650d30684749839221747f88aa14_I20210331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTUtMi0xLTEtMA_9c7bf4f8-04ea-4cc0-a87b-6374fc0e7589">476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ec6a6de4b2d49b0a233b7ac18dc5fc0_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTUtNC0xLTEtMA_4c786a18-63e5-4703-adab-9338c7e025be">518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec32650d30684749839221747f88aa14_I20210331" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTYtMi0xLTEtMA_a118f0c9-cc21-4a0e-b861-df3689db6dfb">25</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ec6a6de4b2d49b0a233b7ac18dc5fc0_I20201231" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTYtNC0xLTEtMA_6ed4790f-5ade-4267-9cbd-31de7326af1a">27</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec32650d30684749839221747f88aa14_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTctMi0xLTEtMA_9bd9b38b-5ffb-4dad-a2b1-968a3aeaeb7b">2,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ec6a6de4b2d49b0a233b7ac18dc5fc0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTctNC0xLTEtMA_36fd1a99-a10f-40f8-8f62-3b179107896e">2,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTktMi0xLTEtMA_ba0a50e7-91ac-41e6-b5b8-443cf6215234">389,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTktNC0xLTEtMA_c63065b9-52a1-4caf-ac74-774d2184a4c6">389,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Convertible Notes are currently convertible as the last reported sale price of the Company's common stock was equal to or more than <ix:nonFraction unitRef="number" contextRef="i99f52dc175e143b393b832e43be95df1_D20210101-20210331" decimals="2" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNjI5_a47b8687-7769-440c-9421-3b31dcb72b59">130</ix:nonFraction>% of the conversion price for at least <ix:nonNumeric contextRef="i99f52dc175e143b393b832e43be95df1_D20210101-20210331" format="ixt-sec:durday" name="fold:DebtInstrumentsConvertibleThresholdTradingDays" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNjY5_379c2c2e-e6c3-4735-979a-b64b7e49cfa3">20</ix:nonNumeric> trading days of the <ix:nonFraction unitRef="day" contextRef="i99f52dc175e143b393b832e43be95df1_D20210101-20210331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNjky_2326d832-d5db-4ee5-bf80-33800437c7b7">30</ix:nonFraction> consecutive trading days ending on the last day of the quarter. </span></div><div style="margin-bottom:15pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In the first quarter of 2021, the Company exchanged an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i99f52dc175e143b393b832e43be95df1_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfODI0NjMzNzIzMzQyOQ_be12b70b-c17a-4d68-8c30-432e0a3a0213">25.0</ix:nonFraction>&#160;thousand of Convertible Notes in exchange for an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfODI0NjMzNzIzMzQ0NQ_06a1c167-1cb4-42c1-bfef-9311c551ac08">4.1</ix:nonFraction>&#160;thousand shares of Company common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfODI0NjMzNzIzMzQ2NQ_f9528a39-9fb6-47f7-b7f8-8eec2997cc6c">0.01</ix:nonFraction> per share.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="idaa0455b85b7484e9e626ad22fd13a4f"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNTA2Mw_9c6fcef3-9e86-4b3b-b47a-e3ee9a90a9ce" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the three months ended March 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfMi0yLTEtMS0w_dd586890-1340-42e6-8e95-2102696bbeb3">7,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfMi00LTEtMS0w_51d5f6ea-177f-4b7c-bf72-74359d723f3d">3,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfMy0yLTEtMS0w_8977ba96-848b-424a-8e14-b2d0ccc9e86d">332</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfMy00LTEtMS0w_d42d7dfb-85f0-402e-877e-3a1a09fb0ac8">206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfNC0yLTEtMS0w_5ecf2152-9ec3-4ad6-bde2-dbee5c23b56a">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfNC00LTEtMS0w_3a53349d-9351-4bca-aa21-bdd69a870295">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:3pt"><span><br/></span></div><div id="i1bc67c508bb54073af2079a7d36bd749_1057"></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjk1_e2ff3400-1927-463a-99a9-87dc2344f171" continuedAt="i42c2592b466349f9bd8a711d5b8817fe" escape="true">Stockholders' Equity </ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i42c2592b466349f9bd8a711d5b8817fe">In February 2021, <ix:nonFraction unitRef="shares" contextRef="iac3a273d2c644f5780e23dc81b7297ff_D20210201-20210228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjE1_c9ae4ae3-a2ca-4048-b959-dfc6d954a2d9">1,050,000</ix:nonFraction> warrants were exercised at $<ix:nonFraction unitRef="usdPerShare" contextRef="i3e22a2bd23524e7ab906f08199397062_I20210228" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjI2_4a058717-262d-4c63-ba4c-1a42806e67d3">7.06</ix:nonFraction> per share of common stock resulting in gross cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="iac3a273d2c644f5780e23dc81b7297ff_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjMz_45692f1c-a6cd-4394-97c1-c6df793dd017">7.4</ix:nonFraction>&#160;million. Additionally, in March 2021, <ix:nonFraction unitRef="shares" contextRef="idc272117737541f1b41cbaf126872267_D20210301-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjYy_48b62f80-125b-4f57-aca9-3f7b381f5f9a">1,294,999</ix:nonFraction> warrants were exercised at $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f487fde288f4011b4b648177324c5df_I20210331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjcz_d34fb602-f312-46d2-8b43-1a8fffc8fa7d">7.98</ix:nonFraction> per share of common stock and <ix:nonFraction unitRef="shares" contextRef="i7a5a6bdf179e45b4aa77d6a3a56433ed_D20210301-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjg3_d7443df3-608f-42c5-8183-363fb991e6cd">210,000</ix:nonFraction> warrants were exercised at $<ix:nonFraction unitRef="usdPerShare" contextRef="i70e0a9292cfa42c8845f33beb7296ef3_I20210331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjgw_821b38cf-d51b-47a5-a9a6-d3cd3bf57061">7.06</ix:nonFraction> per share of common stock resulting in gross cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i383d26a8b8bd42e3ac89f235894e1cbf_D20210301-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjQ3_811aac7f-2519-4ac4-b2b4-13a93d8c30f9">11.8</ix:nonFraction>&#160;million.</ix:continuation> </span></div><div id="i1bc67c508bb54073af2079a7d36bd749_55"></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjQ2Mw_2c20428f-8fb3-4dda-89be-476675468437" continuedAt="ia54c315beb6d4173bead8ec70da776f8" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ia54c315beb6d4173bead8ec70da776f8" continuedAt="i12b8bca7fbcc42eea4ab7bd1d5a8967f"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Grants</span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjQ2NA_d12e6cd9-bab6-4b1c-af98-85e55b2222a5" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfMi0xLTEtMS0w_70cdd1ad-3aa9-45db-ad9e-467770ef4b23">66.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if040fef71ada406393452b0b39e0a2e1_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfMi0zLTEtMS0w_82c6863d-4aed-4a30-ba72-c4242e2a931c">75.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfMy0xLTEtMS0w_bebde379-303c-416a-bf6e-808bec8e2efe">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if040fef71ada406393452b0b39e0a2e1_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfMy0zLTEtMS0w_59bcb3b4-6478-4bcc-ac95-060c52959333">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfNC0xLTEtMS0w_11f1dc1f-e358-4653-b107-5f7201112a84">5.40</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if040fef71ada406393452b0b39e0a2e1_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfNC0zLTEtMS0w_49ecd5d7-83cf-4503-bf9d-b2da8352c5ae">5.67</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" decimals="INF" format="ixt:zerodash" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfNS0xLTEtMS0w_199c0090-d1af-4c0c-a86a-4e1fd6bc42fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if040fef71ada406393452b0b39e0a2e1_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfNS0zLTEtMS0w_0efda38b-f834-4c63-8343-e6315b46a211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjQ2Nw_9e9503d0-db8b-46ee-8d02-20804d728e1f" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock options for the three months ended March 31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise&#160;<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining <br/>Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27a30ae4c9ce4d2e910e5d6a3b595381_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfMi0xLTEtMS0w_7defbfe4-3c71-40cf-871d-a952a3f36837">14,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27a30ae4c9ce4d2e910e5d6a3b595381_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfMi0zLTEtMS0w_907e2f1e-8d19-40de-b8da-f10ae187eac6">9.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfMy0xLTEtMS0w_6557659e-79be-4cd1-b5a4-b10c32c70811">1,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfMy0zLTEtMS0w_7ffd7c30-4558-44e1-bc3e-9955ea71cdee">21.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNC0xLTEtMS0w_1e2d0bb3-075b-4c98-b0b8-39a99ecfba97">493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNC0zLTEtMS0w_4712d9a8-ee18-4ada-835c-2e42031ea30f">8.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNS0xLTEtMS0w_ff0e93f4-9077-4991-8955-30cab2a83f66">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNS0zLTEtMS0w_b9c91acc-b75a-4cd2-9b4b-a724b0e1e829">12.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNy0xLTEtMS0w_b01273dc-f493-4c6b-b56a-8404ddac6aca">15,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNy0zLTEtMS0w_eec70055-5548-40eb-b691-2f58b99d0f82">10.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNy01LTEtMS0w_7c2befe4-df74-43d1-916f-983c8eaedd7b">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNy03LTEtMS0w_23df34c8-8a4b-4f81-b71a-96a4898cb624">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOC0xLTEtMS0w_7d6eeebb-a4fd-41d6-bf5b-ae208d2d0c67">13,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOC0zLTEtMS0w_0ed9a991-fc2d-4477-ab6c-371c122c6c79">10.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOC01LTEtMS0w_ef5146dc-8519-4504-b754-521c5aa0f37f">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOC03LTEtMS0w_9cbc6563-ceba-41b6-a089-bd7fc3e2f379">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOS0xLTEtMS0w_43210368-98e9-49f1-bfa4-a7ce11e74818">8,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOS0zLTEtMS0w_a08a7ca6-6d5c-471b-8278-758875145b58">9.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOS01LTEtMS0w_0db83895-07ef-40ed-b5e6-9838d44bd87e">5.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOS03LTEtMS0w_15750c6e-48ab-48bb-a191-5fb23b3d9c5c">17.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, nominal stock options expired at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfODI0NjMzNzIxMTQwMw_ef350ac2-5b0e-4cf9-907c-ad40a64eeb5e">15.36</ix:nonFraction>. As of March 31, 2021, the total unrecognized compensation cost related to non-vested stock options granted was $<ix:nonFraction unitRef="usd" contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMTI0NA_59ea03ad-4b46-499a-8218-34c4e3ec9c15">38.7</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMTMxNA_408093b3-9689-43e8-b43b-30e0943480ba">three years</ix:nonNumeric>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i12b8bca7fbcc42eea4ab7bd1d5a8967f"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. <ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjQ3Mg_d783d193-632c-435f-be14-80c8df07b811" continuedAt="ie33bc5746b644788b7a7ded2fadac1f9" escape="true">A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2021 is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:15pt;text-align:center"><ix:continuation id="ie33bc5746b644788b7a7ded2fadac1f9"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:38.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant  <br/>Date Fair <br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;<br/>Average<br/>Remaining&#160;<br/>Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafc0c4bbc6714c919e4c4906d4cbc02d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfMi0xLTEtMS0w_53ab8794-c451-4e2b-9829-adddd523b0ec">7,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iafc0c4bbc6714c919e4c4906d4cbc02d_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfMi0zLTEtMS0w_a163bf95-9552-4eb0-92e9-ae701a3be51d">11.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfMy0xLTEtMS0w_c9cc7cda-6559-4d9b-a335-f708be72b017">2,131</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfMy0zLTEtMS0w_3cd50e89-92a4-40a2-aa19-b362b55b0756">20.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNC0xLTEtMS0w_d72fdf10-47db-48c4-b5c8-948f239e6cf2">1,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNC0zLTEtMS0w_ad661ae9-788e-4d89-a409-c5dcf9ecae87">17.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNS0xLTEtMS0w_928f51a9-1dff-42df-8991-94ad51d1e562">310</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNS0zLTEtMS0w_8930a1a4-55fb-4082-8f55-07bf9206e6a7">13.36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0abd1fb5725a4bedad2d8202c502b854_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNi0xLTEtMS0w_404e6c81-92f9-4ecb-8fd3-ad3199f8249f">7,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0abd1fb5725a4bedad2d8202c502b854_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNi0zLTEtMS0w_dcafd2ca-f2de-4028-aa7a-336dcc7eee5f">14.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNi01LTEtMS0w_70e9dad6-dafe-46b1-b28e-3402ef8e758f">2.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0abd1fb5725a4bedad2d8202c502b854_I20210331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNi03LTEtMS0w_74957fd6-af9e-42f6-bd2e-e8fd245361cb">73.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All non-vested units are expected to vest over their normal term. As of March 31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i0abd1fb5725a4bedad2d8202c502b854_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjA1Nw_1aba0c23-918c-4854-abbc-93662400bace">64.5</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjI0MA_ba34db2f-f17a-480e-80d6-07f68af0cd62">three years</ix:nonNumeric>.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense Related to Equity Awards</span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjQ2OA_5c395d79-6d40-4b86-8dbd-d027662acc50" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation expense recognized in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cdf6bb18bf446948b40dfbf1cb8cf1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfMy0yLTEtMS0w_ff0722b3-9b86-4d6e-8624-e7c012860058">6,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290692dfef66483bbda493456b3bc22a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfMy00LTEtMS0w_27309864-fb10-43e6-9b26-7cffd139c9aa">5,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0570ee1bbea436e8e48eef0fd3bd67c_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfNC0yLTEtMS0w_2cb41a5d-1813-46a9-8311-997bce015573">14,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic314dbac744e4ddea724b9e8a9812eef_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfNC00LTEtMS0w_e38c818a-0d20-4b0e-95a2-ccd51b72522b">7,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfNS0yLTEtMS0w_15902fac-e93c-426d-b61e-345536ce9a34">20,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfNS00LTEtMS0w_bb81fb9c-3ebb-44c7-90ff-1f3acee3589e">12,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div id="i1bc67c508bb54073af2079a7d36bd749_58"></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8.&#160;<ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RleHRyZWdpb246YjI3ZWQzNDdmODNhNDYzNmFmMDI1YzQ4MTQzMzUzMzVfNDI1MQ_55abd219-671f-4a15-88fb-5befdb6691c0" continuedAt="i1bccca86bc274d539317f1585dabbcab" escape="true">Assets and Liabilities Measured at Fair Value</ix:nonNumeric></span></div><ix:continuation id="i1bccca86bc274d539317f1585dabbcab" continuedAt="i9b14e070a0ec4f8f9e1c62b9387d85d8"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs that are unobservable for the asset or liability.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i9b14e070a0ec4f8f9e1c62b9387d85d8" continuedAt="i6da2bc41b98447318fe64231a61cb207"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RleHRyZWdpb246YjI3ZWQzNDdmODNhNDYzNmFmMDI1YzQ4MTQzMzUzMzVfNDI1Mg_9fa87310-02c2-46cd-8ec7-387218782acb" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of March 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb20145e2874e789ae1c2623304be15_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfMi0yLTEtMS0w_751c6195-e4bc-43d7-90a0-8df59c1d4bac">151,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806c5d2d5f15482c81c841bd96d6e68a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfMi00LTEtMS0w_9c144585-317c-4dfa-875f-9424efb4f878">151,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e6bf707c01a42f88c4ac502aa81d78f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfMy0yLTEtMS0w_3748778f-4782-4f25-97f7-89d3061a1049">13,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia838f9184beb47c297d0a9b6544f7d24_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfMy00LTEtMS0w_325e6e7b-73b0-4af6-94c6-e4c6a2a643ef">13,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dca0209b8ee4d85a4cfb8abbdde80a1_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNC0yLTEtMS0w_b6822c24-5e83-45e1-9cf3-af31b0ced5df">20,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9312ad97e83344808a753c2777b9f467_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNC00LTEtMS0w_71a580e5-af6b-4181-8352-a116c54557d4">20,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6936379467174bf0b8d397139372390d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNS0yLTEtMS0w_41ed8e2b-01ba-4952-9492-cdc490eda808">46,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62fb03830de7497887830162220ec3d7_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNS00LTEtMS0w_26fc9a02-2b24-41e8-a878-99cc9a02333c">46,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d80b53cc024638bae2f43fb6d44a08_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNi0yLTEtMS0w_eea8ed1b-aa58-4c6c-94cc-9be96f153c74">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86075c190d2342278bca860d772e4fc9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNi00LTEtMS0w_bd4004ee-c761-47c1-9049-61d0de4730b7">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNy0yLTEtMS0w_7632ae1f-8d48-4bcb-a9b8-324a8738c5d6">236,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNy00LTEtMS0w_36445904-9ef8-4ba2-bab1-f064251b5ed4">236,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:58.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.384%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMi0yLTEtMS0w_531094e3-390a-438b-a4dc-633b69f6ec53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3072184bd964b5c80a501c985ee8879_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMi00LTEtMS0w_e842fdcf-39bb-40b8-9485-2d0425430048">26,296</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMi02LTEtMS0w_87b35a1c-01b8-4db8-81b9-796ab9add651">26,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMy0yLTEtMS0w_f7ed8f61-3fa5-4817-a742-cef93fff9054">3,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3072184bd964b5c80a501c985ee8879_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMy00LTEtMS0w_c19469f3-8349-4f37-b60c-af5429456834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMy02LTEtMS0w_4d1fa104-3bea-4c99-975e-2ab8db5a1c47">3,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfNC0yLTEtMS0w_2c8620db-8904-47a2-9d73-0aac36a29b32">3,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3072184bd964b5c80a501c985ee8879_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfNC00LTEtMS0w_201a5804-11e4-4e08-8fb6-0669d5ed7be8">26,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfNC02LTEtMS0w_c0a62a95-b9fb-40bd-b4eb-132fa323e74f">30,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2020 are identified in the following tables:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0595419a51734a4191e082d87b615eb2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfMi0yLTEtMS0w_cc22e45c-80e7-48e6-ab0e-2763ab503735">217,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e96be861b404667ab8e185f54dce138_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfMi00LTEtMS0w_807de469-b199-49b1-9c72-40e68e85eaa8">217,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4936c29e819c4df1803afec2e7346d1f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfMy0yLTEtMS0w_5a758398-96ec-4660-bac3-132f110cd807">9,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90263ef14b3e490f92f545e8f1abec6d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfMy00LTEtMS0w_3e76ae44-3ebd-4398-a026-0794bb3b62de">9,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bf8b70d9e4c47a798d27a71f86e9dc9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNC0yLTEtMS0w_c2382887-79b8-400b-ab41-12dcdd24f655">39,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93bf63ec6fe74e25acfb12d7d93c414a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNC00LTEtMS0w_0391f12e-062c-4552-b5fc-ba27cfa209b2">39,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6283b4e42587498eb64b1d806d8e10e6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNS0yLTEtMS0w_88aef05e-8019-4e68-933d-b464cc2d9e30">53,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7a9bf8271f74640842b35661ede6ee6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNS00LTEtMS0w_d4b54680-0a30-471a-8c86-ecbd6b045ad2">53,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ebe9d99985f4e54a4e7b34d261a0b63_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNi0yLTEtMS0w_44b515fe-41d2-41ec-a6e4-2515ee675e1e">4,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471af39f23494beca4b65d011f8a7d44_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNi00LTEtMS0w_ef75f02a-a04d-4912-9373-6b1a8593dd24">4,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4887cc5b8ad47438f6ddb6830f15cc0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNy0yLTEtMS0w_ed9802ec-e4e1-4d1e-b16e-45e11b7a356f">324,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNy00LTEtMS0w_4bd70d1c-c340-4ee1-8714-77c2588c7912">324,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:62.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4887cc5b8ad47438f6ddb6830f15cc0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMi0yLTEtMS0w_bc0d1b23-fb87-4cbd-b774-5c998891e2c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525ca3a76a74424385c3cfcd34a9894d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMi00LTEtMS0w_98a25fd5-38e3-46ba-9e9d-04906c457395">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMi02LTEtMS0w_77fad046-771d-4b0b-9e93-a10d328f570e">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4887cc5b8ad47438f6ddb6830f15cc0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMy0yLTEtMS0w_79642156-1243-430d-9826-7e528ec09baf">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525ca3a76a74424385c3cfcd34a9894d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMy00LTEtMS0w_1b4f9bc9-9378-48d3-b544-fb8278ce844a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMy02LTEtMS0w_6aa9a253-c9d7-4373-98b4-0ca91be7ac04">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4887cc5b8ad47438f6ddb6830f15cc0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfNC0yLTEtMS0w_11ab2a5a-41e5-49f0-bab0-2f6a8ce93067">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525ca3a76a74424385c3cfcd34a9894d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfNC00LTEtMS0w_2c4da609-abad-49c0-90ca-1ce28c480cfc">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfNC02LTEtMS0w_c67f906f-f9d4-4512-9b75-c68c93ee7ed7">29,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Convertible Notes fall into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the Convertible Notes at March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RleHRyZWdpb246YjI3ZWQzNDdmODNhNDYzNmFmMDI1YzQ4MTQzMzUzMzVfMTI0NA_f317bc8b-fb96-4dda-9726-c1553a2820df">4.5</ix:nonFraction> million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 approximates the fair value.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets as of March 31, 2021 or December 31, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><ix:continuation id="i6da2bc41b98447318fe64231a61cb207"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Money Market Funds, and Marketable Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market.&#160;If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. </span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RleHRyZWdpb246YjI3ZWQzNDdmODNhNDYzNmFmMDI1YzQ4MTQzMzUzMzVfNDI0Mw_7cdeb0b6-4ad4-4298-9b43-20f6c8bee303" escape="true"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: </span></div><div style="margin-bottom:20pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent&#160;Consideration</span></div><div style="margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation&#160;Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable&#160;Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia39206c7064840cc993f0d99c3d83ac6_I20210331" decimals="3" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNzFiMTdmZmQ0MzRhMDhhNzc4MzFiYzI2YmY4NTJhL3RhYmxlcmFuZ2U6MDI3MWIxN2ZmZDQzNGEwOGE3NzgzMWJjMjZiZjg1MmFfMy04LTEtMS0w_f943dcb1-81d7-460c-a53a-6dfc7fc77716">7.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925eb208debe4acf8dbeded140f69103_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNzFiMTdmZmQ0MzRhMDhhNzc4MzFiYzI2YmY4NTJhL3RhYmxlcmFuZ2U6MDI3MWIxN2ZmZDQzNGEwOGE3NzgzMWJjMjZiZjg1MmFfNS0yLTEtMS0w_c860671f-7b59-454f-a5ed-435aeed48318">25,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i037b121761ef436aabc14ae0bdc430a2_I20210331" decimals="2" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNzFiMTdmZmQ0MzRhMDhhNzc4MzFiYzI2YmY4NTJhL3RhYmxlcmFuZ2U6MDI3MWIxN2ZmZDQzNGEwOGE3NzgzMWJjMjZiZjg1MmFfNS04LTEtMS0wL3RleHRyZWdpb246ZjBhMzk0MjUwNTM5NGQ5YWEzNzRkNGNlZjc1YzYyYmJfMTY0OTI2NzQ0MTY4MA_9124de8d-624a-424f-a421-175531caa86f">75</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iba028b38e31b4ee9b5ccfc7c44f23b30_I20210331" decimals="2" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNzFiMTdmZmQ0MzRhMDhhNzc4MzFiYzI2YmY4NTJhL3RhYmxlcmFuZ2U6MDI3MWIxN2ZmZDQzNGEwOGE3NzgzMWJjMjZiZjg1MmFfNS04LTEtMS0wL3RleHRyZWdpb246ZjBhMzk0MjUwNTM5NGQ5YWEzNzRkNGNlZjc1YzYyYmJfMTY0OTI2NzQ0MTY5MA_41e12a54-a8b9-4941-b954-ecc5690fdd4a">78</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 - 2022</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RleHRyZWdpb246YjI3ZWQzNDdmODNhNDYzNmFmMDI1YzQ4MTQzMzUzMzVfNDI0OQ_6fc8019d-e45b-4e42-8861-76853313cb78" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the three months ended March 31, 2021 and March 31, 2020, respectively:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfMi0yLTEtMS0w_6267013e-facf-4bf5-8527-0956ced3796f">25,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75e14a1366d45c3b7e75e7e9a700855_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfMi00LTEtMS0w_be39ea91-e1ba-42c7-bd2e-eaa21e66af10">22,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfMy0yLTEtMS0w_b7806453-cbd3-4217-bf2d-964c61c9d8a0">471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfMy00LTEtMS0w_69b7aa93-1ce9-4e7e-af20-e87d95b12877">931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, end of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfNS0yLTEtMS0w_aa9d9a70-8e2b-43b1-a4a9-abd2a70a55b0">26,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfNS00LTEtMS0w_6cc0da4f-4018-4fdc-a6d0-1ff50a53ed6c">23,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Note 9.&#160;<ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RleHRyZWdpb246ZTBjZTM0YWZhYTNmNGMyZmJmMDU2MTI3YmE3MTBhMGZfNzM2_84479c92-6205-4cc1-bff4-a856aebacf24" continuedAt="ib004b7c3b03348179477128ded1dc240" escape="true">Basic and Diluted Net Loss per Common Share</ix:nonNumeric></span></div><ix:continuation id="ib004b7c3b03348179477128ded1dc240"><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RleHRyZWdpb246ZTBjZTM0YWZhYTNmNGMyZmJmMDU2MTI3YmE3MTBhMGZfNzI3_3058042d-8f4b-4ea3-824b-f1c1949f66e3" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.330%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOjA1OGZhNmIzODc3ODRlZTE5N2FmMzVmOGJiMDY3MmY1L3RhYmxlcmFuZ2U6MDU4ZmE2YjM4Nzc4NGVlMTk3YWYzNWY4YmIwNjcyZjVfMy0yLTEtMS0w_84401a78-5f38-4ea7-a719-eb43bfe692c5">65,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOjA1OGZhNmIzODc3ODRlZTE5N2FmMzVmOGJiMDY3MmY1L3RhYmxlcmFuZ2U6MDU4ZmE2YjM4Nzc4NGVlMTk3YWYzNWY4YmIwNjcyZjVfMy00LTEtMS0w_587773fb-c33a-4de9-91ff-434b03483c4c">88,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOjA1OGZhNmIzODc3ODRlZTE5N2FmMzVmOGJiMDY3MmY1L3RhYmxlcmFuZ2U6MDU4ZmE2YjM4Nzc4NGVlMTk3YWYzNWY4YmIwNjcyZjVfNS0yLTEtMS0w_dcfb938b-19df-4857-b815-ed6afc260ff4">264,369,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOjA1OGZhNmIzODc3ODRlZTE5N2FmMzVmOGJiMDY3MmY1L3RhYmxlcmFuZ2U6MDU4ZmE2YjM4Nzc4NGVlMTk3YWYzNWY4YmIwNjcyZjVfNS00LTEtMS0w_915fa291-7932-4991-b87c-67c832213f83">256,968,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs, and warrants for common stock equivalents.&#160;Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect.</span></div><ix:nonNumeric contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RleHRyZWdpb246ZTBjZTM0YWZhYTNmNGMyZmJmMDU2MTI3YmE3MTBhMGZfNzMw_29e2e186-1a6a-401b-8610-aba0ef2d79d6" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i505945357e0a4dc4b3ca2122d1d0441f_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfMi0yLTEtMS0w_dd722aa0-18f4-4d09-8bc1-277ed8746592">15,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic95386b7dca242ae8b4eb32c56d32799_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfMi00LTEtMS0w_a4f1de1c-daa0-435b-9d0f-2481e2f3047f">19,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f0863e5d54c41c88117aaf4a26aba0d_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfMy0yLTEtMS0w_616b58ec-f4e9-4c3a-9d96-5448c649f0c2">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i534dddc6b1d74accbbb4df2865f0432a_D20200101-20200331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfMy00LTEtMS0w_cce48800-47c5-4d93-a2bf-bac1e885d27e">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0adf3d441ca04bac95b5ee95c7459225_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNC0yLTEtMS0w_0cd00392-25ac-48fd-aa8e-a4e2f11b5336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iafbfc7637aea4b6b9a703e4bdfd9e9c6_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNC00LTEtMS0w_9ba05257-002c-4ade-bde6-6d4f88095467">2,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d4d9cbe713d437ba0d38b04a1e4b8db_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNS0yLTEtMS0w_dc0cd6eb-4bc3-4dc3-93b9-7b561aec8a92">7,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d2ae022e9674e9889a69b4ecabc8ec5_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNS00LTEtMS0w_f4a44db0-c800-4a87-a02b-03b050046a19">7,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNi0yLTEtMS0w_7e54c26c-d1fb-44a3-b654-35f3975a6c7f">23,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNi00LTEtMS0w_83fcb081-e00a-4e96-bd29-4ca9e1686e9a">29,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We have a portfolio of product opportunities led by the first, oral monotherapy for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease, and an industry leading rare disease gene therapy portfolio.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of our portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of our pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late-onset Pompe disease. We initiated the rolling Biologic License Application ("BLA") submission to the FDA in the fourth quarter of 2020. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("Nationwide Children&#8217;s") and a research collaboration with the University of Pennsylvania ("Penn"). Our pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Mucopolysaccharidosis Type IIIB ("MPS IIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPS IIIA"). Our research collaboration with Penn also provides us with exclusive disease-specific access and the option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. In the first quarter of 2020, the FDA granted Fast Track designation to the CLN3 Batten disease gene therapy, AT-GTX-502, for the treatment of pediatric patients less than 18 years of age. In September 2020 and February 2021, the European Medicines Agency ("EMA") granted Priority Medicines ("PRIME") designation and the FDA granted Fast Track designation, respectively, to the CLN6 Batten disease gene therapy, AT-GTX-501, for the treatment of patients with variant late infantile neuronal ceroid lipofuscinosis 6 ("vLINCL6").</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to create, manufacture, test, and deliver the highest quality medicines for people living with rare metabolic diseases through internally developed, acquired, or in-licensed products and product candidates that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. In addition to our programs in Fabry and Pompe diseases, we are leveraging our global capabilities to develop and expand our robust pipeline in genomic medicine. We have made significant progress toward fulfilling our vision of building a leading global biotechnology company focused on rare metabolic diseases. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have not been significantly impacted from the novel coronavirus (&#8220;COVID-19&#8221;) pandemic thus far. However, we continued to observe increased lag times between patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiation due to the resurgence of COVID-19 into 2021. We have maintained operations in all geographies, secured our global supply chain for our commercial and clinical products, as well as maintained the operational integrity of our clinical trials, with minimum disruptions. Our ability to continue to operate without any significant disruptions will depend on the continued health of our employees, the ongoing demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the continued operation of our global supply chain. We have continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of our global workforce. However, our results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights of our progress include:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commercial and regulatory success in Fabry disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For the three months ended March 31, 2021, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue totaled $66.4 million, an increase of $5.9 million compared to the same period in the prior year. We continue to see strong commercial momentum and expansion into additional geographies. In countries where we have been operating the longest, we see an increasing proportion of previously untreated patients come onto Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the U.S., we continue to see a significant increase in patients from a growing and very wide prescriber base. Across all markets, we see a high rate of compliance and adherence to this oral treatment option.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pompe clinical program milestones.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2020, we completed last patient, last visit in our global Phase 3 pivotal study of AT-GAA (ATB200-03, also known as "PROPEL") with 123 patients at 62 sites in 24 countries and initiated the rolling BLA submission to the FDA for AT-GAA. In February 2021, we subsequently reported topline results for the PROPEL study. Additionally, in 2020, orphan drug designation was received in Japan and the British Medicines and Healthcare Products Regulatory Agency issued a Promising Innovative Medicine ("PIM") designation for AT-GAA for the treatment of late-onset Pompe disease. Previously, the U.S. FDA granted BTD for AT-GAA for the treatment of late-onset Pompe disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Pipeline advancement and growth.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established an industry leading gene therapy portfolio of medicines for people living with rare metabolic diseases through a license with Nationwide Children&#8217;s and a research collaboration with Penn. Some recent advances include, in February 2021, we presented initial clinical data a from the Phase 1/2 CLN3 gene therapy study that suggests early signs of disease stabilization and the potential to slow the neurological disease progression in children living with CLN3 Batten disease. Additionally, in February 2021, we presented preclinical data from our Fabry disease gene therapy clinical candidate, AT-GTX-701, with an engineered GLA transgene improved for stability demonstrated greater substrate reduction than wild type constructs across all tissues and doses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued to manufacture our Pompe biologic at commercial scale (1,000L) for our clinical studies and early commercial inventory. Our supply agreement with WuXi Biologics and current capacity are expected to produce sufficient quantities to support commercial needs after receipt of applicable regulatory approvals if obtained. For gene therapy, we are working with our strategic partners to support our clinical manufacturing capabilities. Thus far, our global supply chains have not been interrupted and we have maintained our ability to manufacture Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as our clinical supply during the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Financial strength</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Total cash, cash equivalents, and marketable securities as of March 31, 2021 was $417.4 million. Based on current operating models, we believe that the current cash position, which includes expected revenues, is sufficient to fund our operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Product and Product Candidates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Migalastat HCl) for Fabry Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our oral precision medicine Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was granted accelerated approval by the FDA in August 2018 under the brand name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ("GLA") variant based on in vitro assay data. The FDA approved Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for 348 amenable GLA variants. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was approved in the E.U. and U.K. in May 2016 as a first-line therapy for long-term treatment of adults and adolescents, aged 16 years and older, with a confirmed diagnosis of Fabry disease and who have an amenable mutation (variant). The approved E.U. and U.K. labels include 1,384 mutations amenable to Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> treatment, which represent up to half of all patients with Fabry disease. In countries where mutations are provided only on the amenability website, these 1,384 amenable mutations are now available. Marketing authorization approvals have been granted in over 40 countries around the world, including the U.S., E.U., U.K., Japan, and others. We plan to continue to launch Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in additional countries during 2021. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an orally administered monotherapy, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to bind to and stabilize an endogenous alpha-galactosidase A ("alpha-Gal A") enzyme in those patients with genetic variants identified as amenable in a GLP cell-based amenability assay. Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an oral precision medicine intended to treat Fabry disease in patients who have amenable genetic variants, and at this time, it is not intended for concomitant use with ERT.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gene Therapy for Fabry Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to continued innovation for all people living with Fabry disease. For people living with Fabry disease who have non-amenable variants, which are not suitable for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy, our strategy is to develop a Fabry gene therapy. In October 2018, we expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies, including Fabry disease, and other indications. In October 2019, we disclosed preliminary data from a Fabry adeno-associate viral ("AAV") gene therapy using an Amicus-engineered transgene that demonstrated high levels of GLA activity and robust GL-3 reduction in a mouse model of Fabry disease. In February 2021, we presented initial preclinical data from our investigational AAV gene therapy program. This initial preclinical study assessed a range of single doses of AAV in Gla knockout mice with either wild-type hGLA (&#8220;unmodified hGLA&#8221;) or an Amicus/Penn engineered hGLA transgenes (&#8220;engineered hGLA&#8221; or &#8220;AT-GTX- 701&#8221;). The engineered hGLA AAV gene therapy demonstrated stable homodimer formation, enhanced temperature, plasma and neutral ph stability compared to the unmodified hGLA AAV gene therapy. In the lowest tested dose of AT-GTX-701, Gla knockout mice showed partial substrate reduction, while highest tested dose resulted in near complete substrate reduction. Additionally, AT-GTX-701 demonstrated significantly greater lyso-Gb3/GL-3 substrate reduction across all Fabry disease relevant tissues including the dorsal root ganglia (&#8220;DRG&#8221;), kidney, and heart, with reductions at low dose being equal to or greater than the reductions observed at higher doses with wildtype transgene and provided the first evidence for DRG storage reduction in a Fabry mouse model treated with an AAV gene therapy.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel ERT for Pompe Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our biologics capabilities to develop AT-GAA, a novel treatment paradigm for Pompe disease. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221, or miglustat, that functions as an enzyme stabilizer. The small molecule enzyme stabilizer, miglustat or AT2221, binds to and stabilizes ATB200, or cipaglucosidase alfa, preventing inactiviation of rhGAA in circulation to improve the uptake of active enzyme in key disease-relevant tissues, resulting in increased clearance of accumulated substrate, glycogen. Miglustat is not an active ingredient that contributes directly to substrate reduction ("glycogen").</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated ATB200-03 (or "PROPEL"), a global Phase 3 clinical study of AT-GAA in adult patients with late-onset Pompe disease in December 2018 and completed last patient, last visit in December 2020. In February 2021, we reported topline results from the Phase 3 PROPEL study. Patients in PROPEL were randomized 2:1 so that for every two patients randomized to be treated with AT-GAA, one was randomized to be treated with alglucosidase alfa. Of the Pompe patients enrolled, 77% were being treated with alglucosidase alfa (n=95) immediately prior to enrollment (&#8220;Switch&#8221;) and 23% had never been treated with any ERT (n=28) (&#8220;Na&#239;ve&#8221;). 117 patients completed the PROPEL study and all 117 voluntarily enrolled in the long-term extension study. The primary endpoint of the study was the mean change in 6-minute walk distance as compared with baseline measurements at 52 weeks across the combined ERT Switch and ERT Na&#239;ve patient populations. In this combined population patients taking AT-GAA (n=85) walked on average 21 meters farther at 52 weeks compared to 7 meters with those treated with alglucosidase alfa (n=37). This primary endpoint in the combined population was assessed for superiority and while numerically greater, statistical significance for superiority on this combined population was not achieved for the AT-GAA arm as compared to the alglucosidase alfa arm (p=0.072).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per the hierarchy of the statistical analysis plan, the first key secondary endpoint of the study was the mean change in percent-predicted Forced Vital Capacity (&#8220;FVC&#8221;) at 52 weeks across the combined population. In this combined population patients taking AT-GAA demonstrated a nominally statistically significant and clinically meaningful difference for superiority over those treated with alglucosidase alfa. AT-GAA significantly slowed the rate of respiratory decline in patients after 52 weeks. Patients treated with AT-GAA showed a 0.9% absolute decline in percent-predicted FVC, compared to a 4.0% absolute decline in the alglucosidase alfa arm (p=0.023). Patients within the combined study population demonstrated statistically significant improvements on the GSGC (&#8220;Gait, Stairs, Gower&#8217;s Chair&#8221;) key secondary endpoint, which captures strength, coordination and mobility, compared to a worsening for alglucosidase alfa treated patients in the overall population (p&lt;0.05). Additionally, lower MMT (Manual Muscle Testing), Patient-Reported Outcomes Measurement Information System (&#8220;PROMIS&#8221;) physical function and PROMIS fatigue secondary endpoints favored AT-GAA treated patients over alglucosidase alfa treated patients. Results also showed improvements in the two important biomarker endpoints of Pompe disease (Hex-4 and CK), which significantly favored AT-GAA compared to alglucosidase alfa (p&lt;0.001). AT-GAA demonstrated a similar safety profile to alglucosidase alfa. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PROPEL Switch patients entered the study having been treated with alglucosidase alfa for a minimum of two years. More than two thirds (67%+) of those patients had been on ERT treatment for more than five years prior to entering the PROPEL study (mean of 7.4 years). A pre-specified analysis of the patients switching from alglucosidase alfa on 6-minute walk </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distance showed that after 52 weeks from switching, AT-GAA treated patients (n=65) walked 16.9 meters farther than their baseline, compared to 0.0 meters for those patients who were randomized to remain on alglucosidase alfa (n=30) (p=0.046). A pre-specified analysis of the patients switching from alglucosidase alfa on percent-predicted FVC showed that AT-GAA treated patients stabilized and slightly improved their respiratory function on this important measure while those patients remaining on alglucosidase alfa continued to significantly decline in respiratory muscle function. AT-GAA patients showed a 0.1% absolute increase in percent-predicted FVC while the alglucosidase alfa patients showed a 4.0% absolute decline over the course of the year (p=0.006). </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PROPEL Na&#239;ve patients treated with AT-GAA for 52 weeks (n=20) walked 33 meters farther than their baseline, on the 6-minute walk distance endpoint. The Na&#239;ve patients treated with alglucosidase alfa (n=7) walked 38 meters further than their baseline. The difference between the two groups was not statistically significant (p=0.60). Additionally, patients never previously treated with any ERT showed similar declines in percent-predicted FVC at 52 weeks of &#8211;4.1% for AT-GAA treated patients and &#8211;3.6% for alglucosidase alpha treated patients. The difference between the two groups was not statistically significant (p=0.57).</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gene Therapy for Pompe Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our long-term commitment to provide multiple solutions to address the significant unmet needs of the Pompe community, we are also advancing a next-generation gene therapy treatment for Pompe disease. In October 2018, we expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for Pompe disease and other indications. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we presented initial preclinical data from our investigational AAV gene therapy program for Pompe disease. This initial preclinical study in Pompe knockout mice administered a single high dose of AAV gene therapy with either unmodified wild-type hGAA ("unmodified hGAA") or an Amicus/Penn engineered hGAA transgene with a Lysosomal-Targeting Cell receptor binding motif ("engineered hGAA"). The engineered hGAA AAV gene therapy demonstrated more robust and consistent glycogen reduction compared to unmodified hGAA AAV gene therapy, in all key tissues assessed in a Pompe mouse model. In the central nervous system, the engineered hGAA AAV gene therapy also showed robust glycogen reduction in neuronal cells, suggesting this may be an effective way to address neuronal aspects of Pompe disease. Unmodified hGAA AAV gene therapy showed minimal glycogen reduction in neuronal cells. This preclinical study provided initial validation for combining Amicus-engineered transgenes with Penn's AAV gene therapy technologies.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we presented preclinical data with the engineered hGAA AAV in single and combined central nervous system ("CNS") and systemic directed gene therapy in a mouse model of Pompe disease with advanced disease at treatment. The engineered hGAA AAV showed better targeting and clearance of glycogen storage at low doses in Pompe mice compared to unmodified hGAA AAV. High dose IV therapy showed strength rescue and the addition of high dose intracerabroventricular ("ICV") therapy to high dose IV provided incremental benefit.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gene Therapy for Various Types of Batten Disease</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our license with Nationwide Children&#8217;s and research collaboration with Penn, we are researching potential first-in-class gene therapies for multiple forms of Batten disease. Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system, also known as neuronal ceroid lipofuscinoses ("NCLs"). In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell's ability to recycle certain molecules. Each gene is called ceroid lipofuscinosis, neuronal ("CLN") and given a different number designation as its subtype. There are 13 known forms of Batten disease often referred to as CLN1-8; 10-14. The various types of Batten disease have similar features and symptoms but vary in severity and age of onset.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two clinical programs in CLN6 and CLN3 Batten disease, and several preclinical programs including CLN1 and other types of Batten disease. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Phase 1/2 study in CLN6 Batten disease enrolled thirteen patients who received a single one-time intrathecal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">administration of AAV-CLN6 gene therapy. In October 2020, we reported additional positive interim results from our CLN6 Batten disease AAV-CLN6 gene therapy program, AT-GTX-501. Interim safety data are available for 13 patients with CLN6 Batten disease. Interim safety data demonstrated the treatment with AT-GTX-501 was generally well tolerated. The majority of adverse events ("AEs") were mild and unrelated to treatment. No pattern of adverse events related to AAV or CLN6 immunogenicity was observed. Interim efficacy data are available within the Hamburg Motor and Language scores and showed a meaningful effect in slowing disease progression for twelve patients reaching the 12-month timepoint and for eight patients up to 24 months, post-administration of the AAV-CLN6 gene therapy. Additionally, in October 2019, we reported interim clinical data that suggested stabilization of various components of Hamburg Seizure and Vision scores in most patients from baseline to month 12 or 24, in particular those patients treated at a younger age, compared to the progression expected in matched untreated patients. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fourth quarter of 2018, we announced the initiation of a Phase 1/2 study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3 Batten disease. In the Phase 1/2 study, a total of three patients were dosed in the low-dose group, and based on the safety profile to date, the data safety monitoring board cleared us to begin enrollment in the high-dose cohort. One patient is currently dosed in the high-dose cohort. In February 2021, we announced initial safety for the first four patients up to 15 months post-administration of AT-GTX-502 and preliminary efficacy data for the first three patients in the low-dose cohort for up 15 months post-administration of AT-GTX-502, as well as one patient in the high-dose cohort for up to 3 months post-administration of AT-GTX-502. Initial results of the study suggest that AT-GTX-502 was well tolerated and demonstrated potential early signs of disease stabilization compared to a natural history dataset. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CDKL5 Deficiency Disorder</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are researching a potential first-in-class genetic medicine for CDD consisting of a CDKL5 protein engineered for cross correction, delivered as either a protein replacement or as a gene therapy through our collaboration with Penn. CDKL5 is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development. Genetic mutations in the CDKL5 gene result in CDKL5 protein deficiency and CDD. This disorder manifests clinically as persistent seizures starting in infancy, followed by severe impairment in neurological development. Most children affected by CDD cannot walk or care for themselves and may also suffer from scoliosis, visual impairment, sensory issues, and gastrointestinal complications.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Preclinical Gene Therapies</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a number of additional gene therapies in active preclinical development, including gene therapies for MPS IIIB as well as a next generation program in MPS IIIA. Our strategy is to develop first or best in class AAV gene therapies for these rare devastating pediatric neurological lysosomal storage diseases.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic Alliances and Arrangements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to evaluate business development opportunities as appropriate to build stockholder value and provide us with access to the financial, technical, clinical, and commercial resources necessary to develop and market technologies or products with a focus on rare and orphan diseases. We are exploring potential collaborations, alliances, and other business development opportunities on a regular basis. These opportunities may include business combinations, partnerships, the strategic out-licensing of certain assets, or the acquisitions of preclinical-stage, clinical-stage, or marketed products or platform technologies consistent with our strategic plan to develop and provide therapies to patients living with rare and orphan diseases.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Results of Operations</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March 31, 2021 compared to March 31, 2020 </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected financial information for the Company:</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold as a percentage of net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,992)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,316)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,221)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,664)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88,948)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,284&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Product Sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net product sales increased $5.9 million during the three months ended March 31, 2021 compared to the same period in the prior year. The increase was primarily due to continued growth in the U.S., Europe and Japan markets.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Research and Development Expense.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our principal product development programs for each product candidate in development and the out-of-pocket, third party expenses incurred with respect to each product candidate:</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:68.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Projects</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Third party direct project expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (Fabry Disease)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AT-GAA (Pompe Disease)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gene therapy programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-clinical and other programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total third-party direct project expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,225&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other project costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other project costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,892&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,252&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,117&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $25.0 million decrease in research and development costs was primarily due to the timing of clinical research and manufacturing costs associated with the advancement of clinical studies in the Pompe program, a decrease in the gene therapy programs driven by the timing of spend of the pipeline initiatives and a decrease in personnel costs primarily due to realignment with strategic priorities.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General, and Administrative Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Selling, general, and administrative expense increased $6.5 million, mainly driven by increased personnel costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Interest expense increased $4.3 million during the three months ended March 31, 2021 compared to the same period in the prior year. The increase was driven by the $400 million Senior Secured Loan due 2026 entered in July 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Expense.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $5.1 million variance was primarily driven by foreign exchange gains in the remeasurement of our intercompany transactions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The income tax expense for the three months ended March 31, 2021 was $1.6 million. We are subject to income taxes in various jurisdictions. Our tax liabilities are largely dependent on the distribution of pre-tax earnings among the many jurisdictions in which we operate.</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_73"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our significant research and development expenditures, as well as expenditures to build a commercial organization to support the launch of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we have not been profitable and have generated operating losses since we were incorporated in 2002. We have historically funded our operations through stock offerings, debt issuances, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, collaborations, and other financing arrangements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Discussion</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had cash, cash equivalents, and marketable securities of $417.4 million. We invest cash in excess of our immediate requirements in regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such cash balances. For more details on the cash, cash equivalents, and marketable securities, refer to "&#8212;Note 3.&#160;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash," in our Notes to Consolidated Financial Statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations for the three months ended March 31, 2021 was $72.4 million. The components of net cash used in operations included the net loss for the three months ended March 31, 2021 of $65.7 million and an overall decrease in cash from changes from operating assets and liabilities of $32.5 million, mainly related to the timing of contract manufacturing and research costs. This was partially offset by $20.4 million of stock compensation and $5.5 million of other non-cash adjustments. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operations for the three months ended March 31, 2020 was $107.9 million. The components of net cash used in operations included the net loss for the three months ended March 31, 2020 of $88.9 million and the net change in operating assets and liabilities of $45.2 million. The change in operating assets was primarily due to an increase in accounts receivable by $8.4 million due to increased commercial sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and a decrease in prepaid and other current assets of $4.0 million to support commercial activities for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net cash used in operations was also impacted by a decrease in accounts payable and accrued expenses of $35.3 million, mainly related to the payment of contract manufacturing and research costs, program expenses and personnel costs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Investing Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March 31, 2021 was $86.6 million. Our investing activities have consisted primarily of purchases and sales and maturities of investments and capital expenditures. Net cash provided by investing activities reflects $163.7 million for the sale and redemption of marketable securities, partially offset by $76.2 million for the purchase of marketable securities and $0.9 million for capital expenditures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March 31, 2020 was $93.2 million. Our investing activities have consisted primarily of purchases and sales and maturities of investments and capital expenditures. Net cash provided by investing activities reflects $106.1 million for the sale and redemption of marketable securities, partially offset by $12.1 million for the purchase of marketable securities and $0.8 million for capital expenditures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by (Used in) Financing Activities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March 31, 2021 was $8.8 million. Net cash provided by financing activities primarily reflects $19.2 million from the exercise of the remaining outstanding warrants and $4.2 million from the exercise of stock options, partially offset by $14.2 million from the purchase of vested restricted stock units.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the three months ended March 31, 2020 was $1.5 million. Net cash used in financing activities primarily reflects $7.5 million from the purchase of vested restricted stock units, partially offset by $6.1 million from the exercise of stock options.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur losses from operations for the foreseeable future primarily due to research and development expenses, including expenses related to conducting clinical trials.&#160;Our future capital requirements will depend on a number of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of our clinical trials of our drug candidates and gene therapy candidates, including but not limited to AT-GAA, CLN6 and CLN3;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing drug supply for our clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200" or "cipaglucosidase alfa") and gene therapies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future results of on-going preclinical research and subsequent clinical trials for CDD, Pompe gene therapy, Fabry gene therapy, MPS IIIB, next generation MPS IIIA, and other pipeline candidates we may identify from time to time, including our ability to obtain regulatory approvals and commercialize these therapies and obtain market acceptance for such therapies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing, and outcome of regulatory review of our product candidates, including AT-GAA;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes in regulatory standards relating to the review of our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of other product candidates that we pursue;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies and other adverse market developments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("migalastat HCl") and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AT-GAA and our gene therapy candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain reimbursement for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain market acceptance of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and, if our regulatory filings are accepted and approved, AT-GAA;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to adjust to changes in the European and U.K. markets in the wake of the U.K. leaving the E.U.;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our business could be adversely impacted by the effects of COVID-19 outbreak, including due to actions by us, governments, our customers or suppliers or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates; and </span></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to generate revenue from product sales, in the absence of additional funding, we expect our continuing operating losses to result in increases in our cash used in operations over the next several quarters and years.&#160;We may seek additional funding through public or private financings of debt or equity. Based on current operating models, we believe that the current cash position, which includes expected revenues, is sufficient to fund our operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Uncertainties Related to Potential Future Payments</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestone Payments / Royaltie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">s</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Celenex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In connection with our acquisition of Celenex in 2018, we agreed to pay up to an additional $10 million in connection with the achievement of certain development milestones, $220 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nationwide Children&#8217;s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Celenex has an exclusive license agreement with Nationwide Children&#8217;s. Under this license agreement, Nationwide Children&#8217;s is eligible to receive development and sales-based milestones of up to $7.8 million from us for each product.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Penn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Under our research collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $88.0 million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis. We will provide $10.0 million each year during the five-year agreement to fund the discovery research program.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In July 2012, as amended in November 2013, we entered into an agreement with GlaxoSmithKline ("GSK"), pursuant to which Amicus obtained global rights to develop and commercialize Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a monotherapy and in combination with ERT for Fabry disease (&#8220;Collaboration Agreement&#8221;). Under the terms of the Collaboration Agreement, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S.</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_76"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with U.S.&#160;GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no significant changes during the three months ended March 31, 2021 to the items that we disclosed as our significant accounting policies and estimates described in "&#8212;Note 2. Summary of Significant Accounting Policies" to the Company's financial statements as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to "&#8212;Note 2. Summary of Significant Accounting Policies" in our Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risk is the risk of change in fair value of a financial instrument due to changes in interest rates, equity prices, creditworthiness, financing, exchange rates, or other factors. Our primary market risk exposure relates to changes in interest rates in our cash, cash equivalents, and marketable securities. We place our investments in high-quality financial instruments, primarily money market funds, corporate debt securities, asset backed securities, and U.S. government agency notes with maturities of less than one year, which we believe are subject to limited interest rate and credit risk. The securities in our investment portfolio are not leveraged, are classified as available-for-sale and, due to the short-term nature, are subject to minimal interest rate risk. We believe that a 1% (100 basis points) change in average interest rates would either increase or decrease the market value of our investment portfolio by $0.8 million as of March 31, 2021. We currently do not hedge interest rate exposure and consistent with our investment policy, we do not use derivative financial instruments in our investment portfolio. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to interest rate risk with respect to variable rate debt. At March 31, 2021, we had a $400 million Senior Secured Term Loan due 2026 that bears interest at a rate equal to the 3-month LIBOR, subject to a 1% floor, plus 6.5% per year. We do not currently hedge our variable interest rate debt. The annual average variable interest rate for our variable rate debt as of March 31, 2021 was 7.5%. A hypothetical 100 basis point increase or decrease in the average interest rate on our variable rate debt would result in a $1.0 million change in the interest expense as of March 31, 2021.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Financial Conduct Authority has announced the intent to phase out the use of LIBOR by the end of 2021. If LIBOR is discontinued, we may need to renegotiate the terms of the Senior Secured Term Loan due 2026 in order to replace LIBOR with an alternative standard. As a result, we may incur incremental costs in transitioning to a new standard, and interest rates on our current or future indebtedness may be adversely affected by the new standard. The potential effect of any such event on our cost of capital cannot yet be determined, but we do not expect it to have a material impact on our consolidated financial condition, results of operations, or cash flows.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars. We are not currently engaged in any foreign currency hedging activities. The current exposures arise primarily from cash, accounts receivable, intercompany receivables and payables, and net product sales denominated in foreign currencies. Both positive and negative impacts to our international product sales from movements in foreign currency exchange rates may be partially mitigated by the natural, opposite impact that foreign currency exchange rates have on our international operating expenses. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our Consolidated Financial Statements.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;For information regarding our exposure to certain market risks, see Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. There have been no material changes in our financial instrument portfolio or market risk exposures since our fiscal year ended December 31, 2020.</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_82"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Quarterly Report on Form&#160;10-Q, an evaluation of the effectiveness of our disclosure controls and procedures (pursuant to Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the "Exchange Act") was carried out under the supervision of our Principal Executive Officer and Principal Financial Officer, with the participation of our management.&#160;Based on that evaluation, the Principal Executive Officer and the Principal Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal quarter covered by this report, there has been no change in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_85"></div><div style="margin-bottom:12pt;margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II. OTHER INFORMATION</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_88"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings.</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;RISK FACTORS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_94"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides certain information with respect to purchase of our common stock during the three months ended March 31, 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of Shares Purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2021 through January 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1, 2021 through February 28, 2021 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2021 through March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.60&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-bottom:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock awards</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_97"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_100"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1bc67c508bb54073af2079a7d36bd749_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fold-03312021xex311.htm">Certification of Principal Executive Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fold-03312021xex312.htm">Certification of Principal Financial Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="fold-03312021xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i1bc67c508bb54073af2079a7d36bd749_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMICUS THERAPEUTICS,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John F. Crowley</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John F. Crowley</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daphne Quimi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daphne Quimi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>fold-03312021xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i3d3ee517b32744c7bbfa4d29e4bb04d6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John F. Crowley, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Amicus Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John F. Crowley</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John F. Crowley</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>fold-03312021xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4417630833d54acd9ff2562a6fa4eefd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daphne Quimi, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">I have reviewed this quarterly report on Form&#160;10-Q of Amicus Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>fold-03312021xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic063fb2afecd43eca31b6eb85f57bf64_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Amicus Therapeutics,&#160;Inc. (the &#8220;Company&#8221;), that, to his knowledge, the Quarterly Report of the Company on Form&#160;10-Q for the period ended March 31, 2021, fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company. This written statement is being furnished to the Securities and Exchange Commission as an exhibit to such Form&#160;10-Q. A signed original of this statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:81.725%"><tr><td style="width:1.0%"></td><td style="width:46.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John F. Crowley</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John F. Crowley</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chairman and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>fold-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f3229f4b-7f57-4682-b4ab-77fd47b9060c,g:39b7c24e-a424-4896-93b0-dad319cae6ae-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:fold="http://www.amicustherapeutics.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amicustherapeutics.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.amicustherapeutics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsUnaudited" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical">
        <link:definition>1005006 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited">
        <link:definition>1006007 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1007008 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCash" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash">
        <link:definition>2107103 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables">
        <link:definition>2308302 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails">
        <link:definition>2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails">
        <link:definition>2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1">
        <link:definition>2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2">
        <link:definition>2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2411405 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.amicustherapeutics.com/role/Inventories">
        <link:definition>2112104 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.amicustherapeutics.com/role/InventoriesTables">
        <link:definition>2313303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails">
        <link:definition>2414406 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.amicustherapeutics.com/role/Debt">
        <link:definition>2115105 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.amicustherapeutics.com/role/DebtTables">
        <link:definition>2316304 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofLongTermDebtDetails" roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails">
        <link:definition>2417407 - Disclosure - Debt - Summary of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails">
        <link:definition>2418408 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity">
        <link:definition>2119106 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockandWarrantsDetails" roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails">
        <link:definition>2420409 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation">
        <link:definition>2121107 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>2322305 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedaverageAssumptionsDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails">
        <link:definition>2423410 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails">
        <link:definition>2424411 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2425412 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRSUsandPBRSUsSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails">
        <link:definition>2426413 - Disclosure - Share-Based Compensation - RSUs and PBRSUs Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationExpenseSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails">
        <link:definition>2427414 - Disclosure - Share-Based Compensation - Expense Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValue" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue">
        <link:definition>2128108 - Disclosure - Assets and Liabilities Measured at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueTables" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables">
        <link:definition>2329306 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails">
        <link:definition>2430415 - Disclosure - Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails">
        <link:definition>2431416 - Disclosure - Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails">
        <link:definition>2432417 - Disclosure - Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShare" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare">
        <link:definition>2133109 - Disclosure - Basic and Diluted Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShareTables" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables">
        <link:definition>2334307 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShareDetails" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails">
        <link:definition>2435418 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="fold_DebtInstrumentsConvertibleThresholdTradingDays" abstract="false" name="DebtInstrumentsConvertibleThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" abstract="false" name="AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInNoncurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" abstract="true" name="ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ShortTermCorporateDebtSecuritiesMember" abstract="true" name="ShortTermCorporateDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_ConvertibleSeniorNotes2016Due2023Member" abstract="true" name="ConvertibleSeniorNotes2016Due2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ForeignCurrencyRemeasurementGainLossBeforeTax" abstract="false" name="ForeignCurrencyRemeasurementGainLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ContingentConsiderationMeasurementInput" abstract="false" name="ContingentConsiderationMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" abstract="true" name="StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="fold_StockExercisesAt798Member" abstract="true" name="StockExercisesAt798Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_EmployeeAndDirectorsStockOptionsMember" abstract="true" name="EmployeeAndDirectorsStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_AmortizationDeferredFinancingCosts" abstract="false" name="AmortizationDeferredFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_PaymentsForRepurchaseOfRestrictedStockUnits" abstract="false" name="PaymentsForRepurchaseOfRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_StockExercisesAt706Member" abstract="true" name="StockExercisesAt706Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_ProbabilityWeightedDiscountedCashFlowMember" abstract="true" name="ProbabilityWeightedDiscountedCashFlowMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_SeniorSecuredTermLoanDue2026Member" abstract="true" name="SeniorSecuredTermLoanDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_MeasurementInputProbabilityOfMilestoneAchievementMember" abstract="true" name="MeasurementInputProbabilityOfMilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_CallidusBiopharmaIncMember" abstract="true" name="CallidusBiopharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_ATB200PompeProgramMember" abstract="true" name="ATB200PompeProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>fold-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f3229f4b-7f57-4682-b4ab-77fd47b9060c,g:39b7c24e-a424-4896-93b0-dad319cae6ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="fold-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_22bc3e43-c588-4e39-91ee-22b85f81f953" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eb0cdda2-265d-4907-a211-35e3943d14c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22bc3e43-c588-4e39-91ee-22b85f81f953" xlink:to="loc_us-gaap_AccountsPayableCurrent_eb0cdda2-265d-4907-a211-35e3943d14c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4e6ae98e-e76d-4eaa-97fc-234e9792aaff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22bc3e43-c588-4e39-91ee-22b85f81f953" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_4e6ae98e-e76d-4eaa-97fc-234e9792aaff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_729ee926-85ff-46e2-baaa-93776c4e29d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22bc3e43-c588-4e39-91ee-22b85f81f953" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_729ee926-85ff-46e2-baaa-93776c4e29d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15939d78-13bc-46b2-acb2-d415e2827673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_22bc3e43-c588-4e39-91ee-22b85f81f953" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15939d78-13bc-46b2-acb2-d415e2827673" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3119ec49-fe37-4b65-b265-a8fc0f809acb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8767ba3-9477-4da3-9c69-d1b79f9171b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3119ec49-fe37-4b65-b265-a8fc0f809acb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8767ba3-9477-4da3-9c69-d1b79f9171b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_990752e5-281c-40cd-8706-ee44f5f303cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3119ec49-fe37-4b65-b265-a8fc0f809acb" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_990752e5-281c-40cd-8706-ee44f5f303cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c231c422-a3d7-40d9-9e22-4aad473ef1c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3119ec49-fe37-4b65-b265-a8fc0f809acb" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c231c422-a3d7-40d9-9e22-4aad473ef1c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9b1bc9ce-f904-4107-884b-7326c341aa20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3119ec49-fe37-4b65-b265-a8fc0f809acb" xlink:to="loc_us-gaap_InventoryNet_9b1bc9ce-f904-4107-884b-7326c341aa20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_51dc3c1c-26d2-42c6-9181-d0ac1949194b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3119ec49-fe37-4b65-b265-a8fc0f809acb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_51dc3c1c-26d2-42c6-9181-d0ac1949194b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_542e0ab7-d029-47f7-9597-bc17b4541821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7b0f186b-1ed6-4897-9b31-78a0b47aa025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_542e0ab7-d029-47f7-9597-bc17b4541821" xlink:to="loc_us-gaap_AssetsCurrent_7b0f186b-1ed6-4897-9b31-78a0b47aa025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d453c344-9efc-4c03-83e7-ff21f2935a5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_542e0ab7-d029-47f7-9597-bc17b4541821" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d453c344-9efc-4c03-83e7-ff21f2935a5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0d888f1-545e-43cf-8d97-b561e9c0771c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_542e0ab7-d029-47f7-9597-bc17b4541821" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0d888f1-545e-43cf-8d97-b561e9c0771c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b1397fd5-71ea-49bf-af3f-3d11c06651c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_542e0ab7-d029-47f7-9597-bc17b4541821" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b1397fd5-71ea-49bf-af3f-3d11c06651c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_870d2a43-5666-4b06-8b35-f10f2fa79156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_542e0ab7-d029-47f7-9597-bc17b4541821" xlink:to="loc_us-gaap_Goodwill_870d2a43-5666-4b06-8b35-f10f2fa79156" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c7a32312-9bd6-4cf1-aa36-ce44814c9ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_542e0ab7-d029-47f7-9597-bc17b4541821" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c7a32312-9bd6-4cf1-aa36-ce44814c9ba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0b404f63-a4cd-41d8-a0c5-7100376c7671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7f3b1f46-4ce7-41a4-a3a9-c96205c903b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0b404f63-a4cd-41d8-a0c5-7100376c7671" xlink:to="loc_us-gaap_CommonStockValue_7f3b1f46-4ce7-41a4-a3a9-c96205c903b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cd0b1f3c-6954-440e-bb81-a2df03360f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0b404f63-a4cd-41d8-a0c5-7100376c7671" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_cd0b1f3c-6954-440e-bb81-a2df03360f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_be9cb61d-3529-4cab-8973-6b0bb1d62500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0b404f63-a4cd-41d8-a0c5-7100376c7671" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_be9cb61d-3529-4cab-8973-6b0bb1d62500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4dea42c4-dfa1-411d-b4dc-c99cb03dc9cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0b404f63-a4cd-41d8-a0c5-7100376c7671" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4dea42c4-dfa1-411d-b4dc-c99cb03dc9cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_33a3a8c6-4279-4fef-aba9-f08abd78922c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0b404f63-a4cd-41d8-a0c5-7100376c7671" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_33a3a8c6-4279-4fef-aba9-f08abd78922c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6ded8169-f2db-4169-a780-6aebf0708b7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0b404f63-a4cd-41d8-a0c5-7100376c7671" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6ded8169-f2db-4169-a780-6aebf0708b7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_009f52bd-b791-477d-a88d-7dccf301ee2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5e1a8a9b-5845-4c65-961a-b2d310f3935f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009f52bd-b791-477d-a88d-7dccf301ee2e" xlink:to="loc_us-gaap_LiabilitiesCurrent_5e1a8a9b-5845-4c65-961a-b2d310f3935f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_44c5c8cb-01f2-46c5-85b0-15c9a7b26bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009f52bd-b791-477d-a88d-7dccf301ee2e" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_44c5c8cb-01f2-46c5-85b0-15c9a7b26bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_498e8818-eb3e-4c84-9dcf-8d23dbb70535" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009f52bd-b791-477d-a88d-7dccf301ee2e" xlink:to="loc_us-gaap_LongTermDebt_498e8818-eb3e-4c84-9dcf-8d23dbb70535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ad56b989-6cec-4042-9410-f0b2ace4654d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009f52bd-b791-477d-a88d-7dccf301ee2e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ad56b989-6cec-4042-9410-f0b2ace4654d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8c90e819-cae5-48c8-bdb8-7789910e9680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009f52bd-b791-477d-a88d-7dccf301ee2e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8c90e819-cae5-48c8-bdb8-7789910e9680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_660b7665-d583-4deb-918a-736e293e88c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009f52bd-b791-477d-a88d-7dccf301ee2e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_660b7665-d583-4deb-918a-736e293e88c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c4093eb8-f7e6-4e6d-9dfd-86c070be13d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009f52bd-b791-477d-a88d-7dccf301ee2e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c4093eb8-f7e6-4e6d-9dfd-86c070be13d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d3edee6b-04a4-430a-a7dd-d422c519a19f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_55f986dd-bc06-4427-b45a-2873f0368586" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d3edee6b-04a4-430a-a7dd-d422c519a19f" xlink:to="loc_us-gaap_Liabilities_55f986dd-bc06-4427-b45a-2873f0368586" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ea745580-a25e-432a-a20d-e66a6d217e63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d3edee6b-04a4-430a-a7dd-d422c519a19f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ea745580-a25e-432a-a20d-e66a6d217e63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6fb53add-73f5-4709-9a3d-7c9f3868f591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d3edee6b-04a4-430a-a7dd-d422c519a19f" xlink:to="loc_us-gaap_StockholdersEquity_6fb53add-73f5-4709-9a3d-7c9f3868f591" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7c6f490e-bf60-45b6-bec0-aeb930fb4e97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6506eb4c-7316-43e4-88fd-870f7689a56c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7c6f490e-bf60-45b6-bec0-aeb930fb4e97" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6506eb4c-7316-43e4-88fd-870f7689a56c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a90ca506-78e1-40ad-9aab-a88c48fdf11c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7c6f490e-bf60-45b6-bec0-aeb930fb4e97" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_a90ca506-78e1-40ad-9aab-a88c48fdf11c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d2071f7a-f901-4810-ac14-53948e657596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7c6f490e-bf60-45b6-bec0-aeb930fb4e97" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d2071f7a-f901-4810-ac14-53948e657596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_a8903abb-028f-4bcd-ae02-a0184f3a0e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7c6f490e-bf60-45b6-bec0-aeb930fb4e97" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_a8903abb-028f-4bcd-ae02-a0184f3a0e24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_797787f4-8f1e-4028-a291-532d3d339d35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3015bea3-42bf-4b25-bd96-2e345bce31d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_797787f4-8f1e-4028-a291-532d3d339d35" xlink:to="loc_us-gaap_OperatingIncomeLoss_3015bea3-42bf-4b25-bd96-2e345bce31d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f3a718c7-4e8c-4ba3-b68d-205688ae6b53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_797787f4-8f1e-4028-a291-532d3d339d35" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f3a718c7-4e8c-4ba3-b68d-205688ae6b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b6999f8c-1735-4e1b-b78a-63a92222d41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_797787f4-8f1e-4028-a291-532d3d339d35" xlink:to="loc_us-gaap_InterestExpense_b6999f8c-1735-4e1b-b78a-63a92222d41d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6d24e0ca-ca4b-4197-bc14-3f7da7548706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_797787f4-8f1e-4028-a291-532d3d339d35" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6d24e0ca-ca4b-4197-bc14-3f7da7548706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20187990-1b5d-4680-a739-43854148f7f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e842dd1-aaf4-4568-a4f3-528e2e68313e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_20187990-1b5d-4680-a739-43854148f7f7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3e842dd1-aaf4-4568-a4f3-528e2e68313e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3bef73fc-b607-4216-98d9-8f2a3fee39ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_20187990-1b5d-4680-a739-43854148f7f7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3bef73fc-b607-4216-98d9-8f2a3fee39ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_cf0ad196-de0c-47a6-a8bc-3e6290d4d2ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4e123605-7e3c-4ac4-a368-f354df4fc0e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_cf0ad196-de0c-47a6-a8bc-3e6290d4d2ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_4e123605-7e3c-4ac4-a368-f354df4fc0e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a86562ff-2228-4896-b121-2651625cc007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_cf0ad196-de0c-47a6-a8bc-3e6290d4d2ed" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a86562ff-2228-4896-b121-2651625cc007" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3c4a2cb0-6fd1-472c-bce9-54693c1a5f7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5b2f3d1d-e363-4419-9f70-4f13bdda0852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3c4a2cb0-6fd1-472c-bce9-54693c1a5f7b" xlink:to="loc_us-gaap_GrossProfit_5b2f3d1d-e363-4419-9f70-4f13bdda0852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bbfdfefc-aea9-4d84-92d2-a117b559af5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3c4a2cb0-6fd1-472c-bce9-54693c1a5f7b" xlink:to="loc_us-gaap_OperatingExpenses_bbfdfefc-aea9-4d84-92d2-a117b559af5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_51a4dd0c-d849-48b8-b06c-1ccc35bd40c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d45ac14-11c0-494c-96ed-9b38a5b337f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_51a4dd0c-d849-48b8-b06c-1ccc35bd40c1" xlink:to="loc_us-gaap_NetIncomeLoss_8d45ac14-11c0-494c-96ed-9b38a5b337f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b34bb7c7-d622-4117-80d4-0d8e7e076319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_51a4dd0c-d849-48b8-b06c-1ccc35bd40c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b34bb7c7-d622-4117-80d4-0d8e7e076319" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4543f131-cd63-4de4-9cf8-4f3139ef1435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_96b0be25-65fb-4542-9b8c-16b8c93aa0f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4543f131-cd63-4de4-9cf8-4f3139ef1435" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_96b0be25-65fb-4542-9b8c-16b8c93aa0f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1f0b783a-e980-49cf-bc4d-5c3d1062feb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4543f131-cd63-4de4-9cf8-4f3139ef1435" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1f0b783a-e980-49cf-bc4d-5c3d1062feb8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_853a4268-6785-40d9-9b14-4e3247f62620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_us-gaap_ProfitLoss_853a4268-6785-40d9-9b14-4e3247f62620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5712a709-71a8-4a15-b68e-219521b4034c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5712a709-71a8-4a15-b68e-219521b4034c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e3298fed-075f-4a91-8363-4c7587b41387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e3298fed-075f-4a91-8363-4c7587b41387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9a378502-3d55-4a2a-9540-7a20b17e46a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_us-gaap_ShareBasedCompensation_9a378502-3d55-4a2a-9540-7a20b17e46a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_82fce0cc-edbc-44eb-9c85-23dc95d03ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_82fce0cc-edbc-44eb-9c85-23dc95d03ea1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_320ecfcb-5712-4bd2-8b57-6419fd39674a" xlink:href="fold-20210331.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_320ecfcb-5712-4bd2-8b57-6419fd39674a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2bb5f75c-5794-4c99-8e0d-6475ccd3e78d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2bb5f75c-5794-4c99-8e0d-6475ccd3e78d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_049d97d7-84ef-4e7e-baf5-49b326992fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_049d97d7-84ef-4e7e-baf5-49b326992fa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b9438a3c-37bc-4d14-8f10-74e9c933866f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b9438a3c-37bc-4d14-8f10-74e9c933866f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ce69f7c1-9210-4f66-9f10-ad176447405f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ce69f7c1-9210-4f66-9f10-ad176447405f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_854fea83-8b18-4b2a-890f-d1c914e4e739" xlink:href="fold-20210331.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c1ea55c-0c6e-4ac6-9015-df95875711db" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_854fea83-8b18-4b2a-890f-d1c914e4e739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4bc35285-7887-42aa-beeb-fd6c9bc84d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_de9fd653-853d-4af1-940a-02569474ded5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4bc35285-7887-42aa-beeb-fd6c9bc84d2d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_de9fd653-853d-4af1-940a-02569474ded5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_69fcc029-5458-4582-802d-52e4aab44ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4bc35285-7887-42aa-beeb-fd6c9bc84d2d" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_69fcc029-5458-4582-802d-52e4aab44ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91fafe3c-0376-4787-bfcf-199ee1729886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4bc35285-7887-42aa-beeb-fd6c9bc84d2d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_91fafe3c-0376-4787-bfcf-199ee1729886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da7b35fd-8781-4ce0-9562-ce1bb3468854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6ae6ae5-ab24-4798-852e-ec581b4617d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da7b35fd-8781-4ce0-9562-ce1bb3468854" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6ae6ae5-ab24-4798-852e-ec581b4617d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_453fe73c-3fa0-46e5-afcf-92d804e8a793" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da7b35fd-8781-4ce0-9562-ce1bb3468854" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_453fe73c-3fa0-46e5-afcf-92d804e8a793" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bf588ec-ba8e-4cfe-8c74-d8881fcf734d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da7b35fd-8781-4ce0-9562-ce1bb3468854" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7bf588ec-ba8e-4cfe-8c74-d8881fcf734d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01442369-2779-4e68-ac06-447aedaecf11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_da7b35fd-8781-4ce0-9562-ce1bb3468854" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01442369-2779-4e68-ac06-447aedaecf11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2024a724-e670-4081-aba6-179d0982df3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_cc6e034c-2be6-40d6-8a61-2aba373e38c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2024a724-e670-4081-aba6-179d0982df3f" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_cc6e034c-2be6-40d6-8a61-2aba373e38c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_2756693c-483e-4098-9148-7afb4e941b70" xlink:href="fold-20210331.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2024a724-e670-4081-aba6-179d0982df3f" xlink:to="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_2756693c-483e-4098-9148-7afb4e941b70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c9dc24be-8f61-47e6-b914-268d25d81bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2024a724-e670-4081-aba6-179d0982df3f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c9dc24be-8f61-47e6-b914-268d25d81bb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_d551abac-cb78-4922-8312-60fc6050d4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2024a724-e670-4081-aba6-179d0982df3f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_d551abac-cb78-4922-8312-60fc6050d4d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="fold-20210331.xsd#DescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#DescriptionofBusinessDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e9ed7b03-0ef5-4b39-b814-81bc724aa849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0055a8b6-b7cc-488a-bacd-b99c10d81ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e9ed7b03-0ef5-4b39-b814-81bc724aa849" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0055a8b6-b7cc-488a-bacd-b99c10d81ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_9b5e9157-7232-4c55-88d8-e741dba3a95b" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1d23d540-44e3-4860-8d2e-feb3d3f9e3ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_9b5e9157-7232-4c55-88d8-e741dba3a95b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1d23d540-44e3-4860-8d2e-feb3d3f9e3ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_655ce32e-0bc5-477e-a415-706bfab5a812" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_9b5e9157-7232-4c55-88d8-e741dba3a95b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_655ce32e-0bc5-477e-a415-706bfab5a812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cdbda186-0426-4edd-9c46-5b8c7fd69e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_9b5e9157-7232-4c55-88d8-e741dba3a95b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cdbda186-0426-4edd-9c46-5b8c7fd69e35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_f7eb7ed4-b0dc-49e9-9a4c-f62c4987c24d" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9c5ce494-9051-4ba0-b249-a052ea9f43db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_f7eb7ed4-b0dc-49e9-9a4c-f62c4987c24d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9c5ce494-9051-4ba0-b249-a052ea9f43db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8f4bd93-a14d-4660-8ff1-78bce92b39eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_f7eb7ed4-b0dc-49e9-9a4c-f62c4987c24d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8f4bd93-a14d-4660-8ff1-78bce92b39eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_11932867-a6b3-42ca-91b1-9bac5b7cdee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_f7eb7ed4-b0dc-49e9-9a4c-f62c4987c24d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_11932867-a6b3-42ca-91b1-9bac5b7cdee6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a059ab86-dc08-4932-ae47-ae32d0648374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4bd80c92-8d05-4e03-9303-50c564141b62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a059ab86-dc08-4932-ae47-ae32d0648374" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4bd80c92-8d05-4e03-9303-50c564141b62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_27330b34-109f-4106-a713-6b9b04984a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a059ab86-dc08-4932-ae47-ae32d0648374" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_27330b34-109f-4106-a713-6b9b04984a1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_630eed12-b6a3-4b97-a6bc-c38854cd6462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a059ab86-dc08-4932-ae47-ae32d0648374" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_630eed12-b6a3-4b97-a6bc-c38854cd6462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_213b2e0d-01a0-46d8-85b8-38d28732e674" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_30a7ec05-6f28-4eb9-bef9-5f5a782a7747" xlink:href="fold-20210331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_213b2e0d-01a0-46d8-85b8-38d28732e674" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_30a7ec05-6f28-4eb9-bef9-5f5a782a7747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_d4932abc-b56e-4484-869d-8370d7d787de" xlink:href="fold-20210331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_213b2e0d-01a0-46d8-85b8-38d28732e674" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_d4932abc-b56e-4484-869d-8370d7d787de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2e6cae1b-2eea-4b7f-9e93-1b552fab94b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_213b2e0d-01a0-46d8-85b8-38d28732e674" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2e6cae1b-2eea-4b7f-9e93-1b552fab94b7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_a9042373-19c5-4dfd-be57-40a341babf34" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b4cff390-9364-4d54-be0b-38190002f14d" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_a9042373-19c5-4dfd-be57-40a341babf34" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b4cff390-9364-4d54-be0b-38190002f14d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dc043128-c744-46f2-81a3-55c52d145dd5" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_a9042373-19c5-4dfd-be57-40a341babf34" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dc043128-c744-46f2-81a3-55c52d145dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_ba3f7120-d3d1-4948-82f5-066645f4184c" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_a9042373-19c5-4dfd-be57-40a341babf34" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_ba3f7120-d3d1-4948-82f5-066645f4184c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_c7f66673-3414-404e-915f-504a3430edb0" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_567d9147-d5b0-4382-b903-dbfc676f2fef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_c7f66673-3414-404e-915f-504a3430edb0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_567d9147-d5b0-4382-b903-dbfc676f2fef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_df8b3045-4b45-4470-9ec8-205b15f0abaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_c7f66673-3414-404e-915f-504a3430edb0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_df8b3045-4b45-4470-9ec8-205b15f0abaf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_015979c2-ecd4-4e90-830e-1e74f53541f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_646b87ef-5cc8-482a-9deb-693e63207282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_015979c2-ecd4-4e90-830e-1e74f53541f6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_646b87ef-5cc8-482a-9deb-693e63207282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_3b4b77d5-38cd-4e7b-b9fa-90fdc4ead297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_015979c2-ecd4-4e90-830e-1e74f53541f6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_3b4b77d5-38cd-4e7b-b9fa-90fdc4ead297" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:type="simple" xlink:href="fold-20210331.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="simple" xlink:href="fold-20210331.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ae9af8e2-6329-49ae-ba15-6f4a9641c9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_61987b4e-5ea3-4b05-a901-63d36a496db9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ae9af8e2-6329-49ae-ba15-6f4a9641c9c5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_61987b4e-5ea3-4b05-a901-63d36a496db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f7cbb704-14b8-41db-adda-512d0adc4fb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ae9af8e2-6329-49ae-ba15-6f4a9641c9c5" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f7cbb704-14b8-41db-adda-512d0adc4fb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8528163a-1638-4904-a890-3fb272e33f46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_ae9af8e2-6329-49ae-ba15-6f4a9641c9c5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_8528163a-1638-4904-a890-3fb272e33f46" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:type="simple" xlink:href="fold-20210331.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="simple" xlink:href="fold-20210331.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_63b905bc-fc26-4c4e-bbcb-06e3944e78bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5ff4c74f-a653-45c2-8be7-37dfbbefb55d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_63b905bc-fc26-4c4e-bbcb-06e3944e78bd" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5ff4c74f-a653-45c2-8be7-37dfbbefb55d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6ee995bc-44be-451d-8116-bc1512ea650d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_63b905bc-fc26-4c4e-bbcb-06e3944e78bd" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6ee995bc-44be-451d-8116-bc1512ea650d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_62fd577e-5ba8-485a-8be0-c8c99b1e5e45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_63b905bc-fc26-4c4e-bbcb-06e3944e78bd" xlink:to="loc_us-gaap_DeferredOfferingCosts_62fd577e-5ba8-485a-8be0-c8c99b1e5e45" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#DebtInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="fold-20210331.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#StockholdersEquityCommonStockandWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationExpenseSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e94c9f38-f211-4af4-badd-077de036dd92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a31146d0-41f2-4fd8-ab51-4837ae23eabe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e94c9f38-f211-4af4-badd-077de036dd92" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a31146d0-41f2-4fd8-ab51-4837ae23eabe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_586b2024-f784-4c77-9f74-595c5bd421e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e94c9f38-f211-4af4-badd-077de036dd92" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_586b2024-f784-4c77-9f74-595c5bd421e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="simple" xlink:href="fold-20210331.xsd#BasicandDilutedNetLossperCommonShare"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="simple" xlink:href="fold-20210331.xsd#BasicandDilutedNetLossperCommonShareTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>fold-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f3229f4b-7f57-4682-b4ab-77fd47b9060c,g:39b7c24e-a424-4896-93b0-dad319cae6ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="fold-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="extended" id="if5643b4867f2406d88d4d2119f4176e7_CoverPage"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="i4674972d49e44062a1a6dec950dde715_ConsolidatedBalanceSheetsUnaudited"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" id="id39ba4ced80c46c0b18b6fd1320de6ee_ConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofOperationsUnaudited"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited" xlink:type="extended" id="i86d8df21d6c54a018c0105ef2996af74_ConsolidatedStatementsofOperationsUnaudited"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended" id="i9ba407f2f81a48f1a8ed570ec7bbf854_ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical" xlink:type="extended" id="i65ae11087f964d159db3facdae822258_ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended" id="i1c035c21136d4a5e8aec636406f1cf10_ConsolidatedStatementsofChangesinStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d1594c99-076b-48e3-91c3-89540ea6f0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d1594c99-076b-48e3-91c3-89540ea6f0db" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_85f6598b-e89f-412f-9563-d5ef877303b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_85f6598b-e89f-412f-9563-d5ef877303b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d00d8723-90ae-495d-badc-508ecb919081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockholdersEquity_d00d8723-90ae-495d-badc-508ecb919081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f1e144a7-7a08-46de-91fc-20f7a9bf674e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f1e144a7-7a08-46de-91fc-20f7a9bf674e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c2b31c01-1ba2-4c78-ba97-fced25de9561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c2b31c01-1ba2-4c78-ba97-fced25de9561" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_eeb7fc7d-e785-414a-ba76-4d5b8839ec83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_eeb7fc7d-e785-414a-ba76-4d5b8839ec83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1320752d-911c-4a99-8f56-7526dac17310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1320752d-911c-4a99-8f56-7526dac17310" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666b6887-2f80-45ed-b83f-47938733af06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666b6887-2f80-45ed-b83f-47938733af06" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_1d8b4a09-fed0-4406-b3e0-8a8195164fe5" xlink:href="fold-20210331.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_1d8b4a09-fed0-4406-b3e0-8a8195164fe5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_8ca2a45e-1296-4ef5-98bf-98d7695820f7" xlink:href="fold-20210331.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_8ca2a45e-1296-4ef5-98bf-98d7695820f7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0c6fed2b-f68a-41f8-889b-68786731dc01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0c6fed2b-f68a-41f8-889b-68786731dc01" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_842296f1-20a5-4ec4-bf9d-98c154700e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_842296f1-20a5-4ec4-bf9d-98c154700e8f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7dcebbb2-3d58-4978-9817-3b349ae733fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7dcebbb2-3d58-4978-9817-3b349ae733fb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3152f23a-fba7-413b-85df-e7bb3753bda6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3152f23a-fba7-413b-85df-e7bb3753bda6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0bc928bf-2fea-4311-813e-1e972f6f86c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_NetIncomeLoss_0bc928bf-2fea-4311-813e-1e972f6f86c3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_67dc4710-0bad-4d07-b259-d0122c65efda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1b8963de-e411-4327-b8a3-13d52d7de77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c1d7dac6-25c1-4d26-9801-ce9a41ff16ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d1594c99-076b-48e3-91c3-89540ea6f0db" xlink:to="loc_us-gaap_StatementTable_c1d7dac6-25c1-4d26-9801-ce9a41ff16ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a78cb293-2ff8-4d5d-9df6-a4b60f1943b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c1d7dac6-25c1-4d26-9801-ce9a41ff16ee" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a78cb293-2ff8-4d5d-9df6-a4b60f1943b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a78cb293-2ff8-4d5d-9df6-a4b60f1943b7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a78cb293-2ff8-4d5d-9df6-a4b60f1943b7" xlink:to="loc_us-gaap_EquityComponentDomain_a78cb293-2ff8-4d5d-9df6-a4b60f1943b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a78cb293-2ff8-4d5d-9df6-a4b60f1943b7" xlink:to="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_34f99dbc-626a-4227-80d9-dfbd3cef2fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:to="loc_us-gaap_CommonStockMember_34f99dbc-626a-4227-80d9-dfbd3cef2fc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_373d02a7-bae9-44e6-94f4-be1191587e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_373d02a7-bae9-44e6-94f4-be1191587e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f193bdb9-c0c5-4828-8147-85ec36e280f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:to="loc_us-gaap_WarrantMember_f193bdb9-c0c5-4828-8147-85ec36e280f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_664fb65e-5d34-4414-aac2-d6dd575561ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_664fb65e-5d34-4414-aac2-d6dd575561ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_aa4ae434-6064-4f17-89a3-8f6d2b640be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:to="loc_us-gaap_RetainedEarningsMember_aa4ae434-6064-4f17-89a3-8f6d2b640be6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="i8489d757eb4d4f90a2b6b8e659529df0_ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="fold-20210331.xsd#DescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="extended" id="i3a127386f2664857b7a315bf1819c18c_DescriptionofBusiness"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="extended" id="ic987eb349c4a4b75ad78f304fd52b16c_DescriptionofBusinessDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="ib501d3ce5be549feb9479c501344cb0a_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="idfe4257a9ece401ca3b5d674df56ce82_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="id3f8659efb5c4305a2daf0466b092c8d_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i135b3c200ecc46de897818cea0a66118_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0b2135df-6e86-47e1-8955-1c681f745e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f2f41d1c-a608-4b94-aa65-a4124fe9ee88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0b2135df-6e86-47e1-8955-1c681f745e85" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f2f41d1c-a608-4b94-aa65-a4124fe9ee88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8551c31b-024d-4b9e-8f69-8a464df507f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0b2135df-6e86-47e1-8955-1c681f745e85" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8551c31b-024d-4b9e-8f69-8a464df507f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e3d43b9e-6d2d-4ecf-a18a-af04f9b7208c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8551c31b-024d-4b9e-8f69-8a464df507f8" xlink:to="loc_srt_StatementGeographicalAxis_e3d43b9e-6d2d-4ecf-a18a-af04f9b7208c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e3d43b9e-6d2d-4ecf-a18a-af04f9b7208c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e3d43b9e-6d2d-4ecf-a18a-af04f9b7208c" xlink:to="loc_srt_SegmentGeographicalDomain_e3d43b9e-6d2d-4ecf-a18a-af04f9b7208c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f48d0d3a-10e5-4be0-9a2a-84edb5593a97" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e3d43b9e-6d2d-4ecf-a18a-af04f9b7208c" xlink:to="loc_srt_SegmentGeographicalDomain_f48d0d3a-10e5-4be0-9a2a-84edb5593a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b275fc94-3109-4efd-978e-825f4031abbd" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f48d0d3a-10e5-4be0-9a2a-84edb5593a97" xlink:to="loc_country_US_b275fc94-3109-4efd-978e-825f4031abbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_eca7a11a-7ec0-4dad-a8bd-48d8cb6c8fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f48d0d3a-10e5-4be0-9a2a-84edb5593a97" xlink:to="loc_us-gaap_NonUsMember_eca7a11a-7ec0-4dad-a8bd-48d8cb6c8fa0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="extended" id="i567adb092b8a445fa73f4b19a671c74f_CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="extended" id="icaf422a500134a9aae31adbd27c3fc2e_CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="extended" id="ia2c82140b90e4bedafbb4ab2b29c1035_CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="extended" id="i2cfabb49a12a43a2893e6062699e182f_CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2fa21256-5f71-443e-b3f1-ba18e5c5f4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2fa21256-5f71-443e-b3f1-ba18e5c5f4c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_700fb877-80c0-4930-82a8-2efab6e7ee41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_700fb877-80c0-4930-82a8-2efab6e7ee41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_a61e6ba8-1862-4827-8a25-e4f517b8d4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_a61e6ba8-1862-4827-8a25-e4f517b8d4cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_67457fa2-d48a-44f0-887a-1757967016e1" xlink:href="fold-20210331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_67457fa2-d48a-44f0-887a-1757967016e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_982a20ff-6324-411d-99cb-014fa1a39172" xlink:href="fold-20210331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_982a20ff-6324-411d-99cb-014fa1a39172" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_91bbf0d9-7cb0-421f-80a8-66c7403a7aee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_91bbf0d9-7cb0-421f-80a8-66c7403a7aee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae1a178e-cb7f-4fd6-be10-eba51a64077e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae1a178e-cb7f-4fd6-be10-eba51a64077e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f17e27de-c8ad-406f-879f-dc672045a0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f17e27de-c8ad-406f-879f-dc672045a0bc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_329338b5-4724-43d5-a5c3-1a1795806934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_329338b5-4724-43d5-a5c3-1a1795806934" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56e42807-7d52-41b3-8d92-2c427c9b2e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56e42807-7d52-41b3-8d92-2c427c9b2e7e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_30d9a4d7-625f-4fe7-b077-c84ebfa50134" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_30d9a4d7-625f-4fe7-b077-c84ebfa50134" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_246c2dd0-c1cf-46ab-88c1-12bb4bba05bd" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_246c2dd0-c1cf-46ab-88c1-12bb4bba05bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_750b1d56-5e6d-4d16-bc0e-4f555756beb9" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_750b1d56-5e6d-4d16-bc0e-4f555756beb9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_8eb94c69-f540-44b9-a4e6-584942760923" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_8eb94c69-f540-44b9-a4e6-584942760923" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_38428fa1-ea67-4bcc-a631-fb79fa145c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_38428fa1-ea67-4bcc-a631-fb79fa145c0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_255f522b-0d62-463b-a655-4a64aeffe9ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_38428fa1-ea67-4bcc-a631-fb79fa145c0e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_255f522b-0d62-463b-a655-4a64aeffe9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_255f522b-0d62-463b-a655-4a64aeffe9ad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_255f522b-0d62-463b-a655-4a64aeffe9ad" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_255f522b-0d62-463b-a655-4a64aeffe9ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_255f522b-0d62-463b-a655-4a64aeffe9ad" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_686c4998-4d9f-4fe4-a4b7-183b3882c061" xlink:href="fold-20210331.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_686c4998-4d9f-4fe4-a4b7-183b3882c061" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_227f7461-427c-4e6e-aded-65d1a4dd63ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_227f7461-427c-4e6e-aded-65d1a4dd63ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_684c37d3-b4d8-4a64-add5-614216a44128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_684c37d3-b4d8-4a64-add5-614216a44128" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ec5ada10-c6da-449e-a127-239a34acff73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ec5ada10-c6da-449e-a127-239a34acff73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2eba277d-c3b4-48d0-b279-af65834c154e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2eba277d-c3b4-48d0-b279-af65834c154e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_530bd770-7df4-4546-8193-1258a1ef39fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_us-gaap_CertificatesOfDepositMember_530bd770-7df4-4546-8193-1258a1ef39fd" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" id="i02c865e6a82b4be4b3bd6ca989e0eab4_CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:type="simple" xlink:href="fold-20210331.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended" id="icfe8784a213b4710b39da2c9607b6341_Inventories"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="simple" xlink:href="fold-20210331.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended" id="i02fcae41992d4c6388672d31574c52c0_InventoriesTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#InventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended" id="i434c00e4b86443b2832370a8a3ae0c35_InventoriesDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:type="simple" xlink:href="fold-20210331.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended" id="i51b062b1bcf04a8c916fff1d11126945_Debt"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="simple" xlink:href="fold-20210331.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended" id="i3a9201f3c0984091bc90bffd78bb6766_DebtTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended" id="i9bef1ef9cc7c4ddaa66bc36cf668f68e_DebtSummaryofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d36718b1-9de2-4274-abd5-d613d27ab4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d36718b1-9de2-4274-abd5-d613d27ab4b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_31c957e4-341b-4e73-a87f-174c3ce73754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_31c957e4-341b-4e73-a87f-174c3ce73754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_fdc6dc5c-b29a-4b45-a393-1aecc8f339d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DeferredOfferingCosts_fdc6dc5c-b29a-4b45-a393-1aecc8f339d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a1503561-2a95-4b8b-8407-458209ed587e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_LongTermDebt_a1503561-2a95-4b8b-8407-458209ed587e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7bf901e4-5d61-4722-8fb1-e53e7405c23e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7bf901e4-5d61-4722-8fb1-e53e7405c23e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_45eccb4b-36d3-4eeb-aa7c-26b4730f5738" xlink:href="fold-20210331.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_45eccb4b-36d3-4eeb-aa7c-26b4730f5738" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_fd7e1586-da35-4ba9-867b-c4e5ac3987b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_fd7e1586-da35-4ba9-867b-c4e5ac3987b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_71240b04-6409-4099-9194-68fdf388069f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_71240b04-6409-4099-9194-68fdf388069f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_ce6a6800-8d57-4fa8-8422-5d020bedca01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_ce6a6800-8d57-4fa8-8422-5d020bedca01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ed82bac2-7ad6-436d-8423-b24b66a54961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ed82bac2-7ad6-436d-8423-b24b66a54961" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_36461fac-c10c-4417-b90a-1e96338c1015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtInstrumentTable_36461fac-c10c-4417-b90a-1e96338c1015" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_63280158-368e-4ea1-ab6a-ff46edd14448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_36461fac-c10c-4417-b90a-1e96338c1015" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_63280158-368e-4ea1-ab6a-ff46edd14448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_63280158-368e-4ea1-ab6a-ff46edd14448_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_63280158-368e-4ea1-ab6a-ff46edd14448" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_63280158-368e-4ea1-ab6a-ff46edd14448_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_52857866-a18e-4623-84da-90bcd8cadc05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_63280158-368e-4ea1-ab6a-ff46edd14448" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_52857866-a18e-4623-84da-90bcd8cadc05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_739ff4c5-591e-4087-ae1b-aeced18de19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_52857866-a18e-4623-84da-90bcd8cadc05" xlink:to="loc_us-gaap_SeniorLoansMember_739ff4c5-591e-4087-ae1b-aeced18de19d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_35c11691-2f67-49c2-936e-cff1cac3d1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_52857866-a18e-4623-84da-90bcd8cadc05" xlink:to="loc_us-gaap_ConvertibleDebtMember_35c11691-2f67-49c2-936e-cff1cac3d1d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_56af5320-aeaf-4f4d-8bc3-eab81f12ea02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_36461fac-c10c-4417-b90a-1e96338c1015" xlink:to="loc_us-gaap_DebtInstrumentAxis_56af5320-aeaf-4f4d-8bc3-eab81f12ea02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_56af5320-aeaf-4f4d-8bc3-eab81f12ea02_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_56af5320-aeaf-4f4d-8bc3-eab81f12ea02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_56af5320-aeaf-4f4d-8bc3-eab81f12ea02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_623c71ac-7b3c-411d-8fa7-a80cb04ced2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_56af5320-aeaf-4f4d-8bc3-eab81f12ea02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_623c71ac-7b3c-411d-8fa7-a80cb04ced2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_20d49e4e-14de-4a8c-bb21-f8038ac1611f" xlink:href="fold-20210331.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_623c71ac-7b3c-411d-8fa7-a80cb04ced2d" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_20d49e4e-14de-4a8c-bb21-f8038ac1611f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_932c2722-6b89-46ec-bd5e-40b9ff75f47a" xlink:href="fold-20210331.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_623c71ac-7b3c-411d-8fa7-a80cb04ced2d" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_932c2722-6b89-46ec-bd5e-40b9ff75f47a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#DebtInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended" id="ia369e2f43a6645bf93e41af59c052e54_DebtInterestExpenseDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="fold-20210331.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="extended" id="i553f15a85720447cbb91cc48d4d24fc1_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#StockholdersEquityCommonStockandWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="extended" id="i5ebd4211b75743ca95bdbad7b057ad40_StockholdersEquityCommonStockandWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c4309a3-039f-435e-83f1-9453c4b34107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6dff721-4552-4052-af9e-354addd9bdf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c4309a3-039f-435e-83f1-9453c4b34107" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6dff721-4552-4052-af9e-354addd9bdf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a56298c0-62f5-4b1d-b5f0-e88d342f1e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c4309a3-039f-435e-83f1-9453c4b34107" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a56298c0-62f5-4b1d-b5f0-e88d342f1e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_f5ef7af4-e736-4f73-bbab-eba5062428c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c4309a3-039f-435e-83f1-9453c4b34107" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_f5ef7af4-e736-4f73-bbab-eba5062428c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c4309a3-039f-435e-83f1-9453c4b34107" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_539026ec-e68e-4e82-a35f-6a3bc54ab3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_539026ec-e68e-4e82-a35f-6a3bc54ab3c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_539026ec-e68e-4e82-a35f-6a3bc54ab3c3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_539026ec-e68e-4e82-a35f-6a3bc54ab3c3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_539026ec-e68e-4e82-a35f-6a3bc54ab3c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d9b7e106-cee7-477e-914a-6f8d3bd9b095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_539026ec-e68e-4e82-a35f-6a3bc54ab3c3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d9b7e106-cee7-477e-914a-6f8d3bd9b095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4d6f42bc-1512-460f-bc36-3ffe5846a3eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d9b7e106-cee7-477e-914a-6f8d3bd9b095" xlink:to="loc_us-gaap_WarrantMember_4d6f42bc-1512-460f-bc36-3ffe5846a3eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_51709547-328c-4671-ae97-b6a0600d9ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_51709547-328c-4671-ae97-b6a0600d9ed6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_51709547-328c-4671-ae97-b6a0600d9ed6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_51709547-328c-4671-ae97-b6a0600d9ed6" xlink:to="loc_us-gaap_ClassOfStockDomain_51709547-328c-4671-ae97-b6a0600d9ed6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1bdc22d1-9fc5-4bf5-acc2-5dec9dd639a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_51709547-328c-4671-ae97-b6a0600d9ed6" xlink:to="loc_us-gaap_ClassOfStockDomain_1bdc22d1-9fc5-4bf5-acc2-5dec9dd639a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2e9accc9-5aac-4d58-9eee-36b3de86ce9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1bdc22d1-9fc5-4bf5-acc2-5dec9dd639a2" xlink:to="loc_us-gaap_CommonStockMember_2e9accc9-5aac-4d58-9eee-36b3de86ce9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f7c2bfce-2001-4185-954c-bf1d12969e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f7c2bfce-2001-4185-954c-bf1d12969e3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f7c2bfce-2001-4185-954c-bf1d12969e3b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f7c2bfce-2001-4185-954c-bf1d12969e3b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f7c2bfce-2001-4185-954c-bf1d12969e3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_876d32a9-d2ed-41e1-aa81-d8dd02a518f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f7c2bfce-2001-4185-954c-bf1d12969e3b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_876d32a9-d2ed-41e1-aa81-d8dd02a518f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt798Member_ae57f537-3e6e-44c9-9013-fa600e783b0c" xlink:href="fold-20210331.xsd#fold_StockExercisesAt798Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_876d32a9-d2ed-41e1-aa81-d8dd02a518f9" xlink:to="loc_fold_StockExercisesAt798Member_ae57f537-3e6e-44c9-9013-fa600e783b0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt706Member_cd9e2176-2c61-4dff-b1d4-34157953d946" xlink:href="fold-20210331.xsd#fold_StockExercisesAt706Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_876d32a9-d2ed-41e1-aa81-d8dd02a518f9" xlink:to="loc_fold_StockExercisesAt706Member_cd9e2176-2c61-4dff-b1d4-34157953d946" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="extended" id="i6fb1fdbb5efa403a98ddfb2154229e6d_ShareBasedCompensation"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended" id="i330acaa423904c9bbc4172497afe83c8_ShareBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended" id="i0c7eb2cabb4c4134a04d680d9177844d_ShareBasedCompensationWeightedaverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_017a3006-8c81-4360-81b2-db577d1f8222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_017a3006-8c81-4360-81b2-db577d1f8222" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e5fe2c8-f843-40e4-a579-fe803952624a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e5fe2c8-f843-40e4-a579-fe803952624a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_92c9033a-ab5e-4ff4-b7c8-0fcf35997569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_92c9033a-ab5e-4ff4-b7c8-0fcf35997569" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_117c7142-9f5d-46d7-807a-3df335249a79" xlink:href="fold-20210331.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_117c7142-9f5d-46d7-807a-3df335249a79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a831af4-1af5-467b-864b-6a9f8b1a651b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a831af4-1af5-467b-864b-6a9f8b1a651b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76a878f9-f03a-4f98-abaf-5f795d91bb9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a831af4-1af5-467b-864b-6a9f8b1a651b" xlink:to="loc_us-gaap_AwardTypeAxis_76a878f9-f03a-4f98-abaf-5f795d91bb9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76a878f9-f03a-4f98-abaf-5f795d91bb9f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_76a878f9-f03a-4f98-abaf-5f795d91bb9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_76a878f9-f03a-4f98-abaf-5f795d91bb9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c89a7de-573b-4fd3-8d2a-284420188c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_76a878f9-f03a-4f98-abaf-5f795d91bb9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c89a7de-573b-4fd3-8d2a-284420188c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_962bc83c-7b03-4efb-b23e-d5317391497c" xlink:href="fold-20210331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c89a7de-573b-4fd3-8d2a-284420188c98" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_962bc83c-7b03-4efb-b23e-d5317391497c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="iea11cfab39c5465ea29186a1fac1bab6_ShareBasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b5746b7-d94c-48d2-bc7e-b4151c5118b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b5746b7-d94c-48d2-bc7e-b4151c5118b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ada88a20-7f1a-49f3-a75b-ca7f4dca5b4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ada88a20-7f1a-49f3-a75b-ca7f4dca5b4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2e02629b-93c9-4c8d-872d-953926197234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2e02629b-93c9-4c8d-872d-953926197234" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1e0366e7-e4b5-448a-9274-a18c4f4b38fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1e0366e7-e4b5-448a-9274-a18c4f4b38fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ecc15ca-829c-47fd-a237-1c56a670ef90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6a805097-1268-4edb-a6de-718e9c3de2d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6a805097-1268-4edb-a6de-718e9c3de2d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7af0b29b-3e12-43a3-9871-f7a5e5f32f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7af0b29b-3e12-43a3-9871-f7a5e5f32f2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6575d7ed-de30-4001-bc8a-375b1a527ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6575d7ed-de30-4001-bc8a-375b1a527ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_557ca345-45e5-48f7-9801-a6fa02fd2b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_557ca345-45e5-48f7-9801-a6fa02fd2b92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d5a179e2-7deb-4c2f-a811-b95e30ba882d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d5a179e2-7deb-4c2f-a811-b95e30ba882d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_38b70a4c-fda4-4663-b054-a5607616daae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_38b70a4c-fda4-4663-b054-a5607616daae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76514556-d6ef-45b3-97b7-28ec8759da49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_764d62e9-a9d1-4ad4-8062-ad1d7ed6c3d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_764d62e9-a9d1-4ad4-8062-ad1d7ed6c3d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2d76ed3d-1ea5-405d-b875-ad4d5f612482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2d76ed3d-1ea5-405d-b875-ad4d5f612482" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ac695c79-08a1-4940-999b-b4440fb17a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ac695c79-08a1-4940-999b-b4440fb17a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c9a529f0-3aa2-409d-a244-47935cfb0e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c9a529f0-3aa2-409d-a244-47935cfb0e2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7fc90482-02c7-4d54-847c-dc579644e75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7fc90482-02c7-4d54-847c-dc579644e75f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_38cd3603-7f71-4eb2-93c6-c329eda818fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_38cd3603-7f71-4eb2-93c6-c329eda818fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_02f69df6-a6f2-43b6-a41e-0be8991083f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_02f69df6-a6f2-43b6-a41e-0be8991083f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_24c41d99-b922-4beb-aa85-9d052206ac99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_24c41d99-b922-4beb-aa85-9d052206ac99" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1289bc36-ea54-4c28-864f-220c1697463f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1289bc36-ea54-4c28-864f-220c1697463f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_58d534ba-eb92-43dd-b088-403fa044d29f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1289bc36-ea54-4c28-864f-220c1697463f" xlink:to="loc_us-gaap_AwardTypeAxis_58d534ba-eb92-43dd-b088-403fa044d29f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58d534ba-eb92-43dd-b088-403fa044d29f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_58d534ba-eb92-43dd-b088-403fa044d29f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58d534ba-eb92-43dd-b088-403fa044d29f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c42eee8b-379d-42fc-b2ca-17e50172c55b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_58d534ba-eb92-43dd-b088-403fa044d29f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c42eee8b-379d-42fc-b2ca-17e50172c55b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_c0dc7128-dc45-4a21-bb03-3066506c11d4" xlink:href="fold-20210331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c42eee8b-379d-42fc-b2ca-17e50172c55b" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_c0dc7128-dc45-4a21-bb03-3066506c11d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="i50891d13d6cc48358318f17d22d30157_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8e63dcd-8894-4f13-99b4-472522470468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1806d174-0855-45f6-902f-3d559d07bffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8e63dcd-8894-4f13-99b4-472522470468" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1806d174-0855-45f6-902f-3d559d07bffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_709a76fe-c30b-4365-b447-47f0f470a1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8e63dcd-8894-4f13-99b4-472522470468" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_709a76fe-c30b-4365-b447-47f0f470a1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2aa59aff-789f-4944-826f-da283f9651bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8e63dcd-8894-4f13-99b4-472522470468" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2aa59aff-789f-4944-826f-da283f9651bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78571c72-9603-4050-8452-46f06505e6b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8e63dcd-8894-4f13-99b4-472522470468" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78571c72-9603-4050-8452-46f06505e6b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2fe8337d-392b-4771-b567-8dd5233b058e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78571c72-9603-4050-8452-46f06505e6b4" xlink:to="loc_us-gaap_AwardTypeAxis_2fe8337d-392b-4771-b567-8dd5233b058e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fe8337d-392b-4771-b567-8dd5233b058e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2fe8337d-392b-4771-b567-8dd5233b058e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2fe8337d-392b-4771-b567-8dd5233b058e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7058509-24f8-466f-83b7-f5528d91feb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2fe8337d-392b-4771-b567-8dd5233b058e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7058509-24f8-466f-83b7-f5528d91feb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_025e72af-eb42-4b66-8a91-840188e1a542" xlink:href="fold-20210331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7058509-24f8-466f-83b7-f5528d91feb7" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_025e72af-eb42-4b66-8a91-840188e1a542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e2ab104b-a426-4e74-82d6-1836f4afb0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7058509-24f8-466f-83b7-f5528d91feb7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e2ab104b-a426-4e74-82d6-1836f4afb0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ced1e495-7355-4156-af7b-14b640d63ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78571c72-9603-4050-8452-46f06505e6b4" xlink:to="loc_us-gaap_PlanNameAxis_ced1e495-7355-4156-af7b-14b640d63ef3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ced1e495-7355-4156-af7b-14b640d63ef3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ced1e495-7355-4156-af7b-14b640d63ef3" xlink:to="loc_us-gaap_PlanNameDomain_ced1e495-7355-4156-af7b-14b640d63ef3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_84b4c1a7-cfa2-4655-bc4f-777cbdb77bba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ced1e495-7355-4156-af7b-14b640d63ef3" xlink:to="loc_us-gaap_PlanNameDomain_84b4c1a7-cfa2-4655-bc4f-777cbdb77bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_46728579-5727-44c8-a83a-90913a54e3d6" xlink:href="fold-20210331.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_84b4c1a7-cfa2-4655-bc4f-777cbdb77bba" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_46728579-5727-44c8-a83a-90913a54e3d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended" id="i581bb269aaf2470abda18f70afb66b9c_ShareBasedCompensationRSUsandPBRSUsSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65ec4c92-5e8f-4dc6-a631-9bcf70604bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65ec4c92-5e8f-4dc6-a631-9bcf70604bf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_61928468-00f2-4329-8fb3-e3479ef2bdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_61928468-00f2-4329-8fb3-e3479ef2bdbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f2272876-a148-4d86-bbb7-c0e0963d7858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f2272876-a148-4d86-bbb7-c0e0963d7858" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4080f717-6447-489c-9a5e-f46311e99daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4080f717-6447-489c-9a5e-f46311e99daf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2d94a8f9-e14d-40b2-9b4a-f8fb8b262451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2d94a8f9-e14d-40b2-9b4a-f8fb8b262451" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00ab0b92-3441-4bb2-bc00-17f479092257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65ec4c92-5e8f-4dc6-a631-9bcf70604bf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_00d40326-08f4-4e9f-afc6-4124efd649c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_00d40326-08f4-4e9f-afc6-4124efd649c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5dbdd61b-b47e-4418-8fd0-68d70478c8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5dbdd61b-b47e-4418-8fd0-68d70478c8f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ba6c71d6-cf8a-4787-a83a-e26dc57f01fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ba6c71d6-cf8a-4787-a83a-e26dc57f01fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6985619c-c047-49b6-bd01-0a88fa0dbda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6985619c-c047-49b6-bd01-0a88fa0dbda3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2333a1e3-61d6-421e-8755-c23628ef899f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_52276b83-a181-4e74-bf3e-eb72c6a97138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65ec4c92-5e8f-4dc6-a631-9bcf70604bf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_52276b83-a181-4e74-bf3e-eb72c6a97138" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d953dda3-4cfb-4928-b806-2307041f6b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_52276b83-a181-4e74-bf3e-eb72c6a97138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d953dda3-4cfb-4928-b806-2307041f6b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b32047dd-ab9f-43aa-8eba-74ca3e248239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_52276b83-a181-4e74-bf3e-eb72c6a97138" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b32047dd-ab9f-43aa-8eba-74ca3e248239" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d26c015-0b34-47c5-98f3-d92e96ccd58d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65ec4c92-5e8f-4dc6-a631-9bcf70604bf7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d26c015-0b34-47c5-98f3-d92e96ccd58d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d127b17b-8396-4696-ad30-720878261992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d26c015-0b34-47c5-98f3-d92e96ccd58d" xlink:to="loc_us-gaap_AwardTypeAxis_d127b17b-8396-4696-ad30-720878261992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d127b17b-8396-4696-ad30-720878261992_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d127b17b-8396-4696-ad30-720878261992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d127b17b-8396-4696-ad30-720878261992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1f06b0b-37c7-432c-93ff-647888f829ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d127b17b-8396-4696-ad30-720878261992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1f06b0b-37c7-432c-93ff-647888f829ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9d8626d5-7d79-4437-962d-f8e1537b767d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1f06b0b-37c7-432c-93ff-647888f829ac" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9d8626d5-7d79-4437-962d-f8e1537b767d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bce66f21-baf0-4808-a592-e30732c32c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d26c015-0b34-47c5-98f3-d92e96ccd58d" xlink:to="loc_us-gaap_PlanNameAxis_bce66f21-baf0-4808-a592-e30732c32c7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bce66f21-baf0-4808-a592-e30732c32c7e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_bce66f21-baf0-4808-a592-e30732c32c7e" xlink:to="loc_us-gaap_PlanNameDomain_bce66f21-baf0-4808-a592-e30732c32c7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c90d0935-7922-43e1-946f-41cf382b8a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_bce66f21-baf0-4808-a592-e30732c32c7e" xlink:to="loc_us-gaap_PlanNameDomain_c90d0935-7922-43e1-946f-41cf382b8a7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_3ef31339-7dd3-486a-b473-6ba07129d2e8" xlink:href="fold-20210331.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c90d0935-7922-43e1-946f-41cf382b8a7f" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_3ef31339-7dd3-486a-b473-6ba07129d2e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationExpenseSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended" id="ib3246ad2458e4806a2abde670c7c4cef_ShareBasedCompensationExpenseSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_889e4589-3fa4-4e4b-880c-d9b120b5cef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3d121a7a-9630-499c-8b81-44df944ccde2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_889e4589-3fa4-4e4b-880c-d9b120b5cef5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3d121a7a-9630-499c-8b81-44df944ccde2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb48f675-e565-4e9f-a4ce-1e4036e93455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_889e4589-3fa4-4e4b-880c-d9b120b5cef5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb48f675-e565-4e9f-a4ce-1e4036e93455" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c59055e5-2b24-4693-b45d-615a98ca3323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb48f675-e565-4e9f-a4ce-1e4036e93455" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c59055e5-2b24-4693-b45d-615a98ca3323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c59055e5-2b24-4693-b45d-615a98ca3323_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c59055e5-2b24-4693-b45d-615a98ca3323" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c59055e5-2b24-4693-b45d-615a98ca3323_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_472b698d-3149-400d-910f-a97bffbc01a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c59055e5-2b24-4693-b45d-615a98ca3323" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_472b698d-3149-400d-910f-a97bffbc01a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6790ceee-1ba3-484d-be55-65ec58eeca28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_472b698d-3149-400d-910f-a97bffbc01a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6790ceee-1ba3-484d-be55-65ec58eeca28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4168c9e8-3cf5-4756-be0f-2e0fb8859ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_472b698d-3149-400d-910f-a97bffbc01a6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4168c9e8-3cf5-4756-be0f-2e0fb8859ee0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="extended" id="ie076bc22a25946da81f0f4f2e5492f7a_AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="extended" id="ie6901276021a42b5b5bfe40d055f4051_AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="extended" id="i164e05e03c374c0cae783f9a699742b5_AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae53acd4-8239-4d95-94f6-14ad19bdaf1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1017c02d-b002-42b8-a99e-455800e07b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae53acd4-8239-4d95-94f6-14ad19bdaf1a" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1017c02d-b002-42b8-a99e-455800e07b18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b6ba6754-948f-4509-b1c7-dd6b751a13dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1017c02d-b002-42b8-a99e-455800e07b18" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b6ba6754-948f-4509-b1c7-dd6b751a13dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa5c0648-704b-41b8-b59b-27c31b8d498f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae53acd4-8239-4d95-94f6-14ad19bdaf1a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa5c0648-704b-41b8-b59b-27c31b8d498f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_50add501-469f-4dcf-8abb-643d9e4b0cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa5c0648-704b-41b8-b59b-27c31b8d498f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_50add501-469f-4dcf-8abb-643d9e4b0cce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_dbe811ce-aef3-4280-afc8-979fa46e936f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa5c0648-704b-41b8-b59b-27c31b8d498f" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_dbe811ce-aef3-4280-afc8-979fa46e936f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_84c5ea72-a6fe-44e3-a1e5-1e5d1cde2c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa5c0648-704b-41b8-b59b-27c31b8d498f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_84c5ea72-a6fe-44e3-a1e5-1e5d1cde2c97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_f679174a-69da-40dc-8d5f-e122d8e518ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae53acd4-8239-4d95-94f6-14ad19bdaf1a" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_f679174a-69da-40dc-8d5f-e122d8e518ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4859ebe-07dd-476c-a605-90cd324f40ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae53acd4-8239-4d95-94f6-14ad19bdaf1a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4859ebe-07dd-476c-a605-90cd324f40ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fe5d3de-801d-42e3-b543-ae551b0387f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4859ebe-07dd-476c-a605-90cd324f40ce" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fe5d3de-801d-42e3-b543-ae551b0387f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fe5d3de-801d-42e3-b543-ae551b0387f1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fe5d3de-801d-42e3-b543-ae551b0387f1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fe5d3de-801d-42e3-b543-ae551b0387f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d5d6c65-3979-4090-94df-8cc66908cb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fe5d3de-801d-42e3-b543-ae551b0387f1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d5d6c65-3979-4090-94df-8cc66908cb53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cf28f1d6-8543-4e96-817e-951310821455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d5d6c65-3979-4090-94df-8cc66908cb53" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cf28f1d6-8543-4e96-817e-951310821455" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f83aa562-12cc-4598-8172-d146321c375c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d5d6c65-3979-4090-94df-8cc66908cb53" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f83aa562-12cc-4598-8172-d146321c375c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ff1d949b-3d26-45ca-a2fb-1e9ca0f403ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4859ebe-07dd-476c-a605-90cd324f40ce" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ff1d949b-3d26-45ca-a2fb-1e9ca0f403ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff1d949b-3d26-45ca-a2fb-1e9ca0f403ce_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ff1d949b-3d26-45ca-a2fb-1e9ca0f403ce" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ff1d949b-3d26-45ca-a2fb-1e9ca0f403ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ff1d949b-3d26-45ca-a2fb-1e9ca0f403ce" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_bcf794af-5b34-4ee8-8293-d71e5e35b139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_bcf794af-5b34-4ee8-8293-d71e5e35b139" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8242a2eb-082e-4d06-86b2-3d67723dc7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_8242a2eb-082e-4d06-86b2-3d67723dc7a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_17b3d91f-821a-4ecd-b148-17c54eaa899f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_17b3d91f-821a-4ecd-b148-17c54eaa899f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_aa8255b3-95ea-4880-b341-4cb9550ab6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_aa8255b3-95ea-4880-b341-4cb9550ab6f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b2c0f697-738c-433a-b04b-0df34882d425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b2c0f697-738c-433a-b04b-0df34882d425" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="extended" id="icf68e2e52dba47ccb100bff0e37c048e_AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b843afed-f277-40c7-9660-18ee8b8317df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_b7dc1b9b-afc8-44e2-ae41-3403158422ec" xlink:href="fold-20210331.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b843afed-f277-40c7-9660-18ee8b8317df" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_b7dc1b9b-afc8-44e2-ae41-3403158422ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a8e725a8-4375-4453-a974-3c6764cc77e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b843afed-f277-40c7-9660-18ee8b8317df" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a8e725a8-4375-4453-a974-3c6764cc77e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b843afed-f277-40c7-9660-18ee8b8317df" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_53562160-723f-48d5-a8d5-5df55c62a8be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_53562160-723f-48d5-a8d5-5df55c62a8be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53562160-723f-48d5-a8d5-5df55c62a8be_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_53562160-723f-48d5-a8d5-5df55c62a8be" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_53562160-723f-48d5-a8d5-5df55c62a8be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4107348-a2cc-4119-96f8-7dd9470da7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_53562160-723f-48d5-a8d5-5df55c62a8be" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4107348-a2cc-4119-96f8-7dd9470da7ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember_213fa74d-18cb-47a2-a994-0844a78f8abd" xlink:href="fold-20210331.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4107348-a2cc-4119-96f8-7dd9470da7ac" xlink:to="loc_fold_CallidusBiopharmaIncMember_213fa74d-18cb-47a2-a994-0844a78f8abd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_6ab54e58-1ac5-464f-a69a-72f9940b783f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_6ab54e58-1ac5-464f-a69a-72f9940b783f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_6ab54e58-1ac5-464f-a69a-72f9940b783f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_6ab54e58-1ac5-464f-a69a-72f9940b783f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_6ab54e58-1ac5-464f-a69a-72f9940b783f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_cd0b7376-dc36-46d4-91ce-5cc68c9f5995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_6ab54e58-1ac5-464f-a69a-72f9940b783f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_cd0b7376-dc36-46d4-91ce-5cc68c9f5995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_502e28ab-effd-427b-88d4-c0315b6545d5" xlink:href="fold-20210331.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd0b7376-dc36-46d4-91ce-5cc68c9f5995" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_502e28ab-effd-427b-88d4-c0315b6545d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2c434998-935f-4670-825b-d5df0c4164ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2c434998-935f-4670-825b-d5df0c4164ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c434998-935f-4670-825b-d5df0c4164ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2c434998-935f-4670-825b-d5df0c4164ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c434998-935f-4670-825b-d5df0c4164ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_adb5878e-1b27-4484-8b48-dcb92f0eb53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2c434998-935f-4670-825b-d5df0c4164ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_adb5878e-1b27-4484-8b48-dcb92f0eb53f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7babff44-5830-4266-862b-f1d137b12623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_adb5878e-1b27-4484-8b48-dcb92f0eb53f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7babff44-5830-4266-862b-f1d137b12623" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_04e4a05b-c096-4430-8d20-9414db9bc554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_04e4a05b-c096-4430-8d20-9414db9bc554" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_04e4a05b-c096-4430-8d20-9414db9bc554_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_04e4a05b-c096-4430-8d20-9414db9bc554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_04e4a05b-c096-4430-8d20-9414db9bc554_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_98ba235e-21aa-4eeb-a5fe-74a1d18d2327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_04e4a05b-c096-4430-8d20-9414db9bc554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_98ba235e-21aa-4eeb-a5fe-74a1d18d2327" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_f44b8aa8-83dd-4133-86da-fa8bce526dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_98ba235e-21aa-4eeb-a5fe-74a1d18d2327" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_f44b8aa8-83dd-4133-86da-fa8bce526dbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_f34f536d-8176-47cb-bf18-750a1e62f731" xlink:href="fold-20210331.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_98ba235e-21aa-4eeb-a5fe-74a1d18d2327" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_f34f536d-8176-47cb-bf18-750a1e62f731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5ccd6886-b686-4488-a050-ec4ccbd8c8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5ccd6886-b686-4488-a050-ec4ccbd8c8c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ccd6886-b686-4488-a050-ec4ccbd8c8c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5ccd6886-b686-4488-a050-ec4ccbd8c8c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ccd6886-b686-4488-a050-ec4ccbd8c8c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b60b65ee-d71f-4949-861f-bbdd0d79c8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5ccd6886-b686-4488-a050-ec4ccbd8c8c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b60b65ee-d71f-4949-861f-bbdd0d79c8a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ATB200PompeProgramMember_d619173d-b41a-4679-9b49-18e3deae562d" xlink:href="fold-20210331.xsd#fold_ATB200PompeProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b60b65ee-d71f-4949-861f-bbdd0d79c8a2" xlink:to="loc_fold_ATB200PompeProgramMember_d619173d-b41a-4679-9b49-18e3deae562d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_7cc92afb-3c2a-497e-b60c-b36b80046fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_ValuationTechniqueAxis_7cc92afb-3c2a-497e-b60c-b36b80046fde" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7cc92afb-3c2a-497e-b60c-b36b80046fde_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7cc92afb-3c2a-497e-b60c-b36b80046fde" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7cc92afb-3c2a-497e-b60c-b36b80046fde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_b28a7e66-37cf-4f66-ac30-e7eaf9f586f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7cc92afb-3c2a-497e-b60c-b36b80046fde" xlink:to="loc_us-gaap_ValuationTechniqueDomain_b28a7e66-37cf-4f66-ac30-e7eaf9f586f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_5ad283d9-8ebc-4bb6-8391-72879f7d9616" xlink:href="fold-20210331.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_b28a7e66-37cf-4f66-ac30-e7eaf9f586f5" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_5ad283d9-8ebc-4bb6-8391-72879f7d9616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87758f0b-41c6-4dda-a7c9-3ebd9457de17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_srt_RangeAxis_87758f0b-41c6-4dda-a7c9-3ebd9457de17" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_87758f0b-41c6-4dda-a7c9-3ebd9457de17_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_87758f0b-41c6-4dda-a7c9-3ebd9457de17" xlink:to="loc_srt_RangeMember_87758f0b-41c6-4dda-a7c9-3ebd9457de17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d8a97ab9-743b-4205-bfef-c451444ad673" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_87758f0b-41c6-4dda-a7c9-3ebd9457de17" xlink:to="loc_srt_RangeMember_d8a97ab9-743b-4205-bfef-c451444ad673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_59602a46-175c-4a51-a168-57d1197ac321" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d8a97ab9-743b-4205-bfef-c451444ad673" xlink:to="loc_srt_MinimumMember_59602a46-175c-4a51-a168-57d1197ac321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_375e5c1b-b001-4acb-a739-64871dc3a88d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d8a97ab9-743b-4205-bfef-c451444ad673" xlink:to="loc_srt_MaximumMember_375e5c1b-b001-4acb-a739-64871dc3a88d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails" xlink:type="extended" id="i817bf71ae01d43fbbd0f13c01a62dc33_AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="simple" xlink:href="fold-20210331.xsd#BasicandDilutedNetLossperCommonShare"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="extended" id="i4269c272a0d542c5b5122563e76af2b9_BasicandDilutedNetLossperCommonShare"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="simple" xlink:href="fold-20210331.xsd#BasicandDilutedNetLossperCommonShareTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="extended" id="i569239966539498f80788f4effe4c9da_BasicandDilutedNetLossperCommonShareTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended" id="i6effacb971d2424fa76a1c0fa9a14880_BasicandDilutedNetLossperCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d04f127c-29ba-446e-aa57-a33e41bc6902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_71030383-0752-48ab-88a3-33e751eda82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d04f127c-29ba-446e-aa57-a33e41bc6902" xlink:to="loc_us-gaap_NetIncomeLossAbstract_71030383-0752-48ab-88a3-33e751eda82a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c09c9256-3db6-4873-b7ef-75e6964f165a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_71030383-0752-48ab-88a3-33e751eda82a" xlink:to="loc_us-gaap_NetIncomeLoss_c09c9256-3db6-4873-b7ef-75e6964f165a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_82942943-16f2-403c-9bea-c63ee5872dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d04f127c-29ba-446e-aa57-a33e41bc6902" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_82942943-16f2-403c-9bea-c63ee5872dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_04a279c7-54f7-4589-976c-b32f6a6eabba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_82942943-16f2-403c-9bea-c63ee5872dc9" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_04a279c7-54f7-4589-976c-b32f6a6eabba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ebcabff2-2be2-47e6-9f46-9bce0da94ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d04f127c-29ba-446e-aa57-a33e41bc6902" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ebcabff2-2be2-47e6-9f46-9bce0da94ebd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c08873d6-15d0-43af-9d3f-f96affd616d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d04f127c-29ba-446e-aa57-a33e41bc6902" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c08873d6-15d0-43af-9d3f-f96affd616d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9f00f0-b991-48c2-b8ae-7b5037ba61b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c08873d6-15d0-43af-9d3f-f96affd616d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9f00f0-b991-48c2-b8ae-7b5037ba61b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a9f00f0-b991-48c2-b8ae-7b5037ba61b1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9f00f0-b991-48c2-b8ae-7b5037ba61b1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9a9f00f0-b991-48c2-b8ae-7b5037ba61b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9f00f0-b991-48c2-b8ae-7b5037ba61b1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_98a4a59f-c807-4c6a-b8b6-bddd5d656384" xlink:href="fold-20210331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_98a4a59f-c807-4c6a-b8b6-bddd5d656384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_c923a8a9-9d71-4e81-90d9-f6cc88711920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_c923a8a9-9d71-4e81-90d9-f6cc88711920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c9eb9fcd-bd74-4a00-8c76-d3f42c388153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:to="loc_us-gaap_WarrantMember_c9eb9fcd-bd74-4a00-8c76-d3f42c388153" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f21d2ea4-544b-4fee-9d16-574cfcf7f697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f21d2ea4-544b-4fee-9d16-574cfcf7f697" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>fold-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f3229f4b-7f57-4682-b4ab-77fd47b9060c,g:39b7c24e-a424-4896-93b0-dad319cae6ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_LongTermDebt_f9029d34-880e-4621-ad81-3cb5845ce9c6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_87047668-ee7d-42f3-8b4d-83df23fc1b58_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_081073c7-7088-42d2-b1b0-636bda6fc483_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_70894de4-4ac5-4627-8e6a-37524f359cbf_terseLabel_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2026</link:label>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_label_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2026 [Member]</link:label>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2026Member_documentation_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member" xlink:href="fold-20210331.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_SeniorSecuredTermLoanDue2026Member" xlink:to="lab_fold_SeniorSecuredTermLoanDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_bfb08de1-24f6-4f53-9891-c02352b5338b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_aed823a4-92e8-4f1c-9ba9-107a046e88b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_48ef1952-15d5-4fca-a27a-933939e2b992_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_d3d2309f-d70a-4991-bb94-45bb6d3856a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4bb8c02a-ec2a-4b60-900a-82522107f27d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_1d97ab7b-7297-4b99-94da-5ba750ef4b71_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_4590f548-f856-4da6-9b27-f4fbb75eaa0b_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_967ef53b-8f53-46b2-9393-88aad615729d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d65f5c07-196c-45f1-afb4-5974a9fde88f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_73246081-41a9-4ae5-8e44-b00187a61ce0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0035b7a4-59ad-43dc-89d3-f8a736123793_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_eab8f4f7-acd9-4e9f-8bc2-9751c1436738_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_ec29af3c-6249-4e57-9fea-9cd3200fdab0_terseLabel_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_documentation_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember" xlink:href="fold-20210331.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShortTermCorporateDebtSecuritiesMember" xlink:to="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_7318cc1a-6936-41d0-a327-4c00d90e98a2_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents Stock issued from exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="fold-20210331.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3eda40f1-f18b-44d0-ac5d-8aba3fc359d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_a9ff28b5-66c0-4ee0-a717-0ea16085a9d5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dc3c3acc-4a9c-4e35-8d4b-91427441700a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9f673d8b-638d-46b0-82f0-0095b52bfc39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_df1dad27-9427-4525-a7e4-cbc542748221_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1e59ce17-e859-4ad7-ba57-036f5ed9b5eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_b93bab1b-ae0c-4a35-89db-2af7600048e1_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, measurement input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_label_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput" xlink:href="fold-20210331.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationMeasurementInput" xlink:to="lab_fold_ContingentConsiderationMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_2b84ebdb-120e-4cf1-a89a-638a30b75745_terseLabel_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability weighted discounted cash flow</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_label_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability Weighted Discounted Cash Flow [Member]</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_documentation_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to valuation technique of probability weighted discounted cash flow.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:href="fold-20210331.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:to="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_f7453a0b-62bf-43f2-b5be-f9dadb4bbaa7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_238e2547-d4ec-4c4d-a4d6-48fcc82083b6_negatedLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, Cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0b533ec3-01d7-4c90-928f-603c93d83ca3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_87ae13d5-2e32-44a7-b1d9-9555a1bc8b99_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f039226d-4c23-4980-bdb3-6120b24ac0fc_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d2546594-6ecc-4936-843e-309ddd24e0a7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_26d193fd-0193-4e31-9b85-0b1eaadd0be2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5fe673c1-d9cb-4a2d-b1dc-5e20d7bce146_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_08a2b962-f02d-474a-b573-68513c404ae8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_371573aa-dc84-4c3d-bc72-5048f2925917_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f7b5d750-d4b6-4393-9773-6684b1cc5f2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_d4ec21b9-699b-47ed-9603-664186e1f763_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ff5fe59b-e205-4161-8b39-e8cc0e6f3299_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_b2366899-e149-476b-aa46-a234194ec60d_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_f69e568e-ab15-4cd9-b4cf-7977825f0d91_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of the convertible notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_93da74ae-0fe9-4a31-aa9b-ad57edbc8770_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_26dfdd8c-f594-47c8-b9f4-50c55586cb69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_c7253fad-2cd8-4294-83e0-3bc7ce048de9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ab10ba22-5e70-4918-b2b9-3d461587dbe7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_63404a7a-fc31-4b04-bb1b-b55e1e49488c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_49ea93c5-b48b-41b5-8668-1e8b600b6e7d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ba8bcdcf-6b1e-4d6d-8cc8-6e55fcd1c07d_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research&#160;&amp; development</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b12fd5cf-fe16-4a97-9828-a438edbf90da_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_78e36327-7515-4869-9b90-ce7353ff320f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2b41baa5-ad49-42d7-8941-d2c478d67e7d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e5873e10-58a7-45fa-a3dc-0950b51ee81c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_44e1cfdf-bc1a-497b-acdb-770d44922efc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ATB200PompeProgramMember_94274e98-3d35-4cb2-af41-39b638bc4de8_terseLabel_en-US" xlink:label="lab_fold_ATB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATB200 Pompe Program</link:label>
    <link:label id="lab_fold_ATB200PompeProgramMember_label_en-US" xlink:label="lab_fold_ATB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATB200 Pompe Program [Member]</link:label>
    <link:label id="lab_fold_ATB200PompeProgramMember_documentation_en-US" xlink:label="lab_fold_ATB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to ATB-200 Pompe program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ATB200PompeProgramMember" xlink:href="fold-20210331.xsd#fold_ATB200PompeProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ATB200PompeProgramMember" xlink:to="lab_fold_ATB200PompeProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_a4fc3109-40e3-40ec-a911-feb0d8ade8c3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_d0ac938e-1fb7-4979-9bb5-562668398594_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_9791e868-8f0b-4a00-9d98-55a2ce296c47_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_0ee2b6db-d5df-4019-a890-8442193cde61_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_90e550dc-3b3e-411e-bd58-737092edd822_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_b4142e59-64cc-47d8-8d94-ed3ca5c4098b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b01720a3-746e-4f40-9e58-7379e1cdc435_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_753d202b-a50f-4cee-a0fc-d06cc284a123_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3c0b4d8e-31d0-43b3-bffc-a210931cee03_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_480c3754-a4d6-4ea6-898f-46fd57ad1763_terseLabel_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_label_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Deferred Financing Costs</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_documentation_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts" xlink:href="fold-20210331.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AmortizationDeferredFinancingCosts" xlink:to="lab_fold_AmortizationDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_7cd738ad-c845-4e0f-96fd-587bdffb35ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_6dcd4ab4-2674-4355-a7a9-7f7ad80fce9f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock tax vesting</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b43210a4-8e79-4602-9585-0c7e2df04b18_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_033d62c1-8cc5-4739-9f92-328845011d60_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6cd5b207-9a90-4d2a-b9dc-635c5179d7c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160; Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2e68c653-c5a5-4902-abcd-1a3de0355e8b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_dafe3036-0402-48a3-a342-769aa8ebc0ff_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash changes in the fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6b1e2559-5d12-4140-bc2a-e65ca6b323c6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_066bb7fe-d16e-41fb-8dd1-b9c91f3718bd_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6b0bbcb6-5570-4e17-8ef6-06adcd9e92a5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_311cd8a7-15ff-4717-801b-93fd8fa09fcd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e31058f4-2090-441f-8f12-bd9878536814_terseLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain, Cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c22ef087-7d91-4eb6-b050-5659b90eb621_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d5b8aa78-e6c4-4282-8920-37366fd95f09_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8a871a8d-0b44-41bf-9cb8-76169e481c01_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, less accumulated amortization of $7,499 and $7,574 at March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_61e6b60b-817c-4976-bc8e-2fc3e08c2b01_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3624e4da-4fb0-49b6-853f-3246ff622823_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_41979959-6d73-4e2f-b00c-49ceebd4ae0e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_aef3ae06-dd61-4224-ad50-39f1f8500b76_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of liability components of long term debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_41e74421-c40c-4354-8654-8addec901fd3_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_e9ecfdf1-c9b3-43a3-a0dc-cdd16d4e89c3_terseLabel_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of achievement of milestones</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_label_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_documentation_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:href="fold-20210331.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:to="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7af3f597-a522-4a83-baef-df07374d4558_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_63f3346b-029b-4864-b27e-6509fb2b073e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_98937b52-dc02-4623-ba2f-241a7b1291a8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5214830c-c8de-49a2-9dc6-ef97d7cea6b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_11413869-e74b-4088-8959-40ae074a6938_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_758a9bdf-d8b2-4779-b3de-bc647bbb5a57_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4c799ea4-3f1c-4edd-92f2-4cd11c5e4627_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_b1015aae-0ab4-42a7-afc3-b32b7b25b740_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_d92b3a13-1705-48fe-a499-72e6c78fe135_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_db7e07f3-a60a-48de-9041-6e34df917f59_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment gain, net of tax impact of $132 and $1,536, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_150b53db-b920-4e99-8254-d232bbc8a987_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1d9e2c37-f30c-4c59-8ea2-82a6d340f8b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_1f19e4c5-c51e-4e69-b594-1df0a6e66c51_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c59b0e9a-5fa4-4428-98f8-834c2e9aec05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Money Market Funds, and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_bc51bcaa-3c89-4b60-83d7-e6a7bffae553_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_40ec97b5-09bb-4b57-81d1-47c8f709f2d5_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_4e993a2d-abf6-4f85-85b3-5c02f99479f8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8ec1d44a-72cb-421c-b508-84512c16dd93_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_a8f123df-03a2-4d4d-a9d8-a3b8a9240960_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and regulatory milestones</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to clinical and regulatory contingent consideration milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:href="fold-20210331.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:to="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_acfca912-08e2-4b40-90bf-026c55d22600_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_cba7764a-35aa-4c8c-a077-fbd524929d54_negatedTerseLabel_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, Gross Unrealized Loss</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="fold-20210331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7052c1dd-80b0-402a-b616-91905c525768_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_e161be46-5313-43c4-8213-08d58f4dbecb_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_f6e88147-c81f-4989-8079-48ca4165dc2c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b6f1cb3d-afda-46a2-8ea6-6e4db32f9489_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_6767a89f-e6a1-48ed-ade5-f2c30d0422fe_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_c93f1c5d-d108-491c-b1df-2fa34343dc7d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_8bb16082-aed1-427d-9dfc-0cfadc03b77b_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_508939f9-741f-43a9-84e3-5f4802d7340a_netLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding warrants, convertible to common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_6133f777-80c6-4487-a82a-782d4b08ef92_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding warrants, convertible to common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_bc894676-43fd-487e-bc3e-8c8d04259beb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_8bf12be6-090b-46ea-9b09-d802bfa28806_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain (loss) on debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_9cf33017-18d2-4f6c-b3de-305d1780abf5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_b3e934f1-3682-420d-9cc4-dca70a50f79b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3622f403-6def-491b-a35f-a040e66b5076_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_794b04b6-f3a2-49db-92c3-a3b1126001c2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_21f96e8a-2ed3-46e4-ab06-51ea4a2bd98a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_36757d15-5bee-43d9-9aa7-03a25b277b80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3559d0a5-763a-405f-b773-77df1243caeb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_068b2b91-a034-4778-afdb-f8499e3e2d9d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_84188ccc-34fb-4017-b5a0-df5b43162115_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_1591f6a5-88b3-45da-afa8-d276b5aecde8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_d9a035ad-3e88-4762-a545-7ea39a400bee_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2e955353-77bc-4f28-94e8-36e75d53d6ce_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_71341e14-7f30-4016-b50d-b85044251886_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_3a8adcf7-bdfe-4440-8045-5d1ad173a042_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f193780c-52a8-4d4e-b797-2f22c88059b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_2d451464-53ea-4276-9226-ea44f4468620_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_82e21615-cb17-433e-89c9-2e053bee6d6b_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_d07aa853-a63b-43b0-aae3-aecfddf38a6f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_57e98e44-f9c8-4fcd-9708-2b41965a518d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_b6c28a53-2760-4ae4-9a4f-402b774dd2e4_terseLabel_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets and liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_label_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Operating Liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_documentation_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:href="fold-20210331.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:to="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b29b5dc8-c280-42c9-affb-c21586899117_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6d2c9157-c6d7-46fd-8bd6-1ea7d0949d78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and unvested expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b165adb9-3c9a-43b6-bc51-afe000d2b116_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_aabf2dd5-3f9a-4a5c-b63d-382f5140a366_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities subject to fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_f1d34d46-7a14-43c4-aa53-0d7776421340_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dca3aa6c-ed0c-49ff-aa56-165cef830737_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2ebb1f92-0fda-47a6-93c3-78c21b29b1a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c4a5b179-ef63-4c72-a2c6-ac5b9a53b6a8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6660a8d7-ba55-4592-9084-60325a502033_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_dd8f25b0-15a2-479c-9c05-29e58e208ba7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b96ab6a1-2a5d-46e2-9474-6424c97aaff7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_02776869-e7cd-4896-ba36-95cd4af47f03_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_8e018db0-aa33-4875-9246-91d4af2d5de9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_054b7896-26cf-42b8-b769-44fc80b681a8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_67d7b7db-7f3a-4fdb-935c-8b3c2b32bb07_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents Stock issued from exercise of warrants (in shares).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="fold-20210331.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3b205d0f-01f1-4778-8f99-07800783b659_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_886fba64-011a-42ce-a939-1630706cc459_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_847b57f2-4aa9-4513-a018-4a7c8ca4c92c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and deferred financing</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2a7dda70-7e60-4be5-892c-a84b0bcc46f5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_cebf9d7f-ab99-4d91-8493-7031f8d05d68_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_82731b0d-e8dd-4f90-8548-a5b6407ec66c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_62da0b26-f7b1-4e82-ad5b-d860f70cfde8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e9b48c06-9871-4b87-813c-43aa70c05995_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_8306ad9d-cefb-40bc-8a02-a4a8fe4d5654_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7822b9b1-3283-4f9c-9ae8-a10ee4e7e015_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_eabd4180-9163-4333-8049-ab439bdd11c2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 500,000,000 shares authorized, 266,007,718 and 262,063,461 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_134e4542-6697-4840-bfb9-3108d65011f0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_0589a946-33cd-4ce9-9dc4-b7ffd59c24c1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9b3dfa50-0737-47a7-928e-ddd22aed4b25_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9648b2bc-e286-4c84-a998-eba3a39bb677_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_cf7f5dd9-ab01-404d-b573-dd17bdf506be_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c95ae89a-e2d2-442d-b6e1-50973bc09995_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_2123c13d-98ca-4066-adba-22033115f154_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7c1896a-12ca-4a0b-a632-5be47bf9f0cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c3213f59-287d-4739-ba53-e32fce249fd9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5e8cac1e-d61e-4c53-9307-2a9a9d528b04_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_7a6c73f9-eca8-463c-84c6-7c3c41344400_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value during the period, included in the Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2fc61483-303b-46d5-8f90-82b88f7e1779_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_54e12b37-d04b-40b1-bd1b-a4fadeb50565_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9037c0fe-e02f-4a72-b225-9282c82b7f22_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and redemption of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d9457050-8cb6-4176-96e4-7f74bdedfed7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e2137884-3e94-4286-9b76-7b10021f7b85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_255f6d1e-9881-4ffa-965c-fcfed65916a6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_12b3a329-a63e-4f8c-b4bc-a00a856c46e7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Instruments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d6ebc51e-113c-4675-b069-2e6efd6c203f_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b0dc3fb6-076e-4dc8-a340-8168de1045cc_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_c398d717-b368-4085-86d7-1c89304f3c83_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e333919b-e125-49af-94ff-4e03615d26cb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_e2181df8-ac0a-4b7f-b082-956c3a6f6a0f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23acc935-d119-40ca-bf02-7aa42a68fefd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_cf8a5751-f8f9-4447-943a-d1aa66a4091e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a05c9a67-b2f6-4bf4-b1a1-982ce471626d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_eee5ba30-8a78-4a71-97d0-e67d9265c2f1_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases_0c90c754-8575-445c-a3f5-5b668d91e159_terseLabel_en-US" xlink:label="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization on finance and operating lease right-of-use leases</link:label>
    <link:label id="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases_label_en-US" xlink:label="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation And Amortization, Finance And Operating Right-Of-Use Leases</link:label>
    <link:label id="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases_documentation_en-US" xlink:label="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation And Amortization, Finance And Operating Right-Of-Use Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:href="fold-20210331.xsd#fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:to="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2fafca2e-a198-4eb2-bcb5-0a916ee955b8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6ca5ede9-918d-496b-8f8a-b3feddfdc582_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_63b30cfe-4943-450e-8e53-8194b3d23f59_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f633bd9b-3734-40f6-a5b1-b7b2026a8d12_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c1f915cd-0b73-443d-8678-4bf82ffadfcf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_cdb3b543-bf16-45b8-94b7-467f5abe840a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_652b0f7c-d933-4840-91d4-3473e6c8a589_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f047fc1b-852b-4ad4-9ffa-878efb058998_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_15651f27-582d-478a-9a3b-0ff6a7d4eb90_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ac8329ae-3781-49e3-baf7-fc0b6f6ebc10_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c77af7eb-0e07-4b71-9a3e-9ce7f5a6c8e4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_23214d94-76fd-4323-8b1d-c3df231461f6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7a53cdaf-d64b-48e1-9495-6d9c05207956_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures unpaid at the end of period</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8e0b08cf-0f6d-45d4-a37a-2bc11d11428d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a3114261-5f52-4836-b921-8a3c96b5ae19_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_2b72d927-1161-4452-8b3c-d4e3b3cee48b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_66a7603b-ad90-4de2-8f51-210f28592f2d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_be97ad8d-0a0a-44b7-b460-e8e0ad9416a8_terseLabel_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes 2016, Due 2023</link:label>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_label_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes2016 Due2023 [Member]</link:label>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_documentation_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:href="fold-20210331.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:to="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_404efe36-c658-42fd-a7d5-1b302b7edb85_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_08626876-a9c9-4618-a540-2e3a496951aa_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b255e057-3ea1-4388-9ef8-e7aca5c8da1d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a9195358-fc24-423f-a6a6-e515ed2f06d7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_77aa9d58-8739-46d4-be70-98524935818a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_358610ed-707f-42f1-a514-3e6aa3a98222_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_81a4b82a-4a3e-4cca-bba7-b8d04dbc8f25_terseLabel_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_c7b1ba53-c570-4e4c-88f5-96b73b8d6286_verboseLabel_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_label_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Directors Stock Options [Member]</link:label>
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_documentation_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember" xlink:href="fold-20210331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_EmployeeAndDirectorsStockOptionsMember" xlink:to="lab_fold_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_d07e2246-bc0b-4520-b9a8-2303a01fb259_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested RSU Activity under the Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_53e35771-25bf-4dd3-b8f0-780c570714b7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements paid through lease incentives</link:label>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForTenantImprovements" xlink:to="lab_us-gaap_PaymentsForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_6fe81c60-f676-4cf9-afae-103bffed238f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_12777ebc-ce89-4535-b94d-aaa47602e179_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_692b56ec-6696-4b04-8e8d-e08b1437989e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4d186053-2a60-4365-97ed-745b9d7a3df7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_33defb8d-10d8-44e2-a0d5-cc56a5efadbf_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeMember" xlink:to="lab_us-gaap_ComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_0cb6b899-ac7d-4b14-98eb-5f03a259add2_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ec051d1c-5764-4831-a660-94799fe870d5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5d72f4e5-2841-4497-a15f-9fa0f4f0d0e3_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, less accumulated depreciation of $15,961 and $14,487 at March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_37165b88-2b0b-40a8-849b-692d6eee5c45_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e69e26c5-cb05-4dc8-be66-6d6eaf2dde04_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8dd46acc-d3af-4683-a972-221d138e5c2f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d6f0795e-8feb-4cfe-87af-884f0c4865c1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8230f6cf-0cbe-4d6e-90e2-b69b3e5d1fa6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1083adb5-eafd-45e6-b668-3d9d8deb5b66_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_14ef1b6c-7151-467f-a679-53895cfce0f0_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_620aede9-2252-4e9c-a53b-276106c7b8fa_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8e57bb37-f254-4cc8-967c-39549282e218_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_c2e24bb8-8b7c-4966-8aae-686a50b22471_negatedTerseLabel_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of vested restricted stock units</link:label>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_label_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Repurchase Of Restricted Stock Units</link:label>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_documentation_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow to reacquire restricted stock units during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:href="fold-20210331.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:to="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_211d5a15-5444-4bcd-94b5-fd6f48dbb492_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments, Convertible, Threshold Trading Days</link:label>
    <link:label id="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_documentation_en-US" xlink:label="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:href="fold-20210331.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:to="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e6716566-a553-4779-b9af-7f8f26e21ad9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c2c79fff-e893-4b8e-a8bb-53a2e7cbc256_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_b334a232-bbfa-4509-aee2-91af1e0e4819_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_e4822005-2b52-4a0d-802c-03a21868ea43_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_7119de7b-aa44-443d-896c-ae62febc48c1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1dfd1544-d1f7-4ccf-9b0e-8599091cb7c1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Cash balances</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_912a5fb9-c2aa-46d5-9f4b-64963be563cb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock tax vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e05d5c74-8733-4b3b-9d0a-f64f873c3488_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_97b2054b-7693-4c44-bab9-b222f8fcfd92_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4f08972e-e33a-46a3-a2f2-0082d8489752_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e52d7817-804a-43a5-991f-b86a252cdb00_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_a826d468-1dde-465a-81f0-bac57ccd6e01_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1a529897-fdc0-4a9a-b959-2a1a8001b905_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3e89469a-fa4c-46b9-8f57-b210ff46d9a2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_780b15ad-8756-4c6e-b3ea-84557e12ffea_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ac34fdaa-6630-44df-bb43-76d05cf701bc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c6411be3-2832-4dbc-be95-16fefb5217d3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_7a2f43b7-924e-488b-9351-ef751301b289_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, shares issued</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0d8b1f65-238b-469e-af43-e53ee7d47478_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fa33686a-bfba-4b97-91b8-144196cde151_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_28ec0302-e199-4f31-85ce-0cfe6fac4824_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_13f3b381-6ddb-4518-bd00-000d65cf2190_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6d57cff0-8466-4323-b082-ffa14ef0e4ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1bf0d9bf-8136-4749-902d-d8b339655437_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_986399cb-7838-4b8e-a16e-40a211940fc8_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_73beeb67-9dbb-498a-a263-3a6b83192e93_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy_99f1110d-9cb1-4969-93da-44d2c93165d4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories and Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy_label_en-US" xlink:label="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Costs for Contracts or Programs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCostsForContractsOrProgramsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:to="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_445932e2-f219-406c-8088-f7d598737567_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a363dc7f-e6e2-4316-b123-b2836b374fc9_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_6e057f88-afc8-4695-9ab2-69076116a578_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, Cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockExercisesAt798Member_99cffc4b-5b32-48fa-8463-40c4afad0df8_terseLabel_en-US" xlink:label="lab_fold_StockExercisesAt798Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.98</link:label>
    <link:label id="lab_fold_StockExercisesAt798Member_label_en-US" xlink:label="lab_fold_StockExercisesAt798Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.98 [Member]</link:label>
    <link:label id="lab_fold_StockExercisesAt798Member_documentation_en-US" xlink:label="lab_fold_StockExercisesAt798Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.98</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt798Member" xlink:href="fold-20210331.xsd#fold_StockExercisesAt798Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockExercisesAt798Member" xlink:to="lab_fold_StockExercisesAt798Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_6848f92f-7e89-4dc9-a533-55a72b1ba3a3_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f2bc6fae-abbb-4a1f-93bb-8724ba9c7def_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_9a251753-88b7-4693-a3c5-5b19a970bedf_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_69b068a4-9959-4b98-a8dc-97d796335a74_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_62d41426-a75c-439b-86a8-61e0968e2ef5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs, period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_0fecf63c-7cef-4a28-92da-618e9fd2f473_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_31fa2887-1098-420d-866d-a7feec14853c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_1130dccf-48c7-4d29-b5c7-67f4ea31a3c1_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ex-U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_93fde3ae-c3fc-47fb-b6e1-391220708b3e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, options vested and unvested expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_be6fcde8-86a4-4583-afa0-82f10e819a99_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4acdcc48-15ee-4627-94ad-4e54890c56d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Compensation Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_a20af164-da7d-46d8-8c06-f783c9dda1eb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of available-for-sale debt securities in unrealized loss positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f9ea8996-a383-4575-a984-67aa1036d3ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_5bc010b6-7d31-4f98-a24d-bb21ddfba05a_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_4a9fae83-fd9c-4986-83ff-6a9348b81ecf_terseLabel_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, Gross Unrealized Gain</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="fold-20210331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_f15ae074-1d69-4476-ba97-44a21461651e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_40f31c85-9c74-46fd-8fc6-5daf17129493_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_a07dde63-cbaa-4e36-883b-cd571ed4c737_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: deferred financing</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1c7ef5b1-bfae-4ee3-873c-2f2f716d75b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockExercisesAt706Member_ba43340b-8705-48d6-84d4-29586d55e80d_terseLabel_en-US" xlink:label="lab_fold_StockExercisesAt706Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.06</link:label>
    <link:label id="lab_fold_StockExercisesAt706Member_label_en-US" xlink:label="lab_fold_StockExercisesAt706Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.06 [Member]</link:label>
    <link:label id="lab_fold_StockExercisesAt706Member_documentation_en-US" xlink:label="lab_fold_StockExercisesAt706Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Exercises at $7.06</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt706Member" xlink:href="fold-20210331.xsd#fold_StockExercisesAt706Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockExercisesAt706Member" xlink:to="lab_fold_StockExercisesAt706Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a02eb001-9610-4340-bda2-f29a61be3106_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_470c5c3c-9244-473b-854e-22a69c9948fa_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dd8413ce-270d-4f8e-a7f1-6b00913055ff_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued from equity financing (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_36ac6357-4d89-469d-9a67-d2103b157ead_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ff29ced5-c578-411c-a93a-c0ba2069dacd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d673669f-1e76-4b7b-a6a2-6b7f1410a1e2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of the convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3999daf7-9aa9-44b3-8e83-bcbe305d0698_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_67e4d2ca-3ea6-4c1c-90a8-dec5d4527fd8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_cf563cbd-7924-4fc9-9fca-f860ccddb3fc_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_8bdccc36-e8e7-4a97-8c09-a2283792925b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_2bdba307-de77-4229-b9c4-9df071457228_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4074831e-7331-42b4-ae26-de00c8c41a71_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5c59de57-5a1f-4aed-b63e-770c328fec3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and unvested expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_105880fc-2eb7-4420-9744-bde845ca30bc_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7d559ad3-00a3-4c93-a480-a898161e1fca_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued from exercise of stock options, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6b879372-4b12-4ed2-9fa2-38088712aac5_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_88f9f775-d998-4ee0-8e57-9ab210012498_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase(decrease) in cash, cash equivalents, and restricted cash at the end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_89278c8c-c9f0-4288-a3ca-5117d2cbd01a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on available-for-sale securities, net of tax impact of $0 and $(56), respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_8612ed54-09b9-4f34-b861-998cce2a9c3e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding loss on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_187688e0-759b-4f91-8ff1-52e89f2b2a40_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_986274dc-ac1c-4a07-b395-034610da6d7d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2bed80d2-bc0e-4995-bd8f-d8d5e0d89693_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_08af2969-6ee0-4398-aba4-d39595ef796b_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_29171610-0c91-438a-83d8-d56817b097f0_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_a65f3cfc-4815-4e67-ba9d-6a1acc73958c_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_635a0206-55d0-478e-a9c7-aaf16df6b16a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3e488cdd-f973-4974-860b-8d7b2ff65a39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_998bae55-ab90-43fe-97f7-51e209bed848_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_601559d8-53f0-45fc-929a-77edc89e8d81_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4cca0311-b6c4-4fa8-a8af-c49220c578c4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7bfd5145-f54d-4aab-b3f5-deb6952dab3b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_10f61a32-16f5-42a4-aaa0-d872420ed5fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_3750776c-918c-46db-8957-cafc24c7c80e_terseLabel_en-US" xlink:label="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan Amended Restated 2007 Equity Incentive Plan</link:label>
    <link:label id="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_label_en-US" xlink:label="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan Amended Restated2007 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the Company's Amended and Restated 2007 Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:href="fold-20210331.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:to="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0e1019ec-7ab7-493d-a5ad-2c61f8b71369_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_295b12aa-4576-4312-9feb-eb4dabc480f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_252fe487-9df8-49f1-869f-ff474980ea45_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_4535d914-37b2-450c-acd9-25344fce39f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment, tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_14553b3d-bbd7-42a8-b7e6-d8307f2acdb5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8428ffb9-69e8-437d-bd7f-69770a7ff59a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4d1e5333-81b2-4d55-916d-612601e16cf8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_95572c4a-4f9d-4ffb-83ae-8164eb0347c0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_65860f7d-6b98-4272-b820-02a5aee8b760_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_1f5caab2-9d16-459a-be3b-ad3cb7263703_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual dividend per share (in dollars per share)</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:href="fold-20210331.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_3b63dad3-36ae-4236-9a43-ac64945fe704_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_c5c00803-30d6-4e4c-9716-870b0078f424_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorLoansMember_23e35631-170e-4644-b882-d76cee813475_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Loans</link:label>
    <link:label id="lab_us-gaap_SeniorLoansMember_label_en-US" xlink:label="lab_us-gaap_SeniorLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLoansMember" xlink:to="lab_us-gaap_SeniorLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23f7c6f8-cf38-42a6-9ee4-e7958fa63844_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d2227e37-10be-4369-a12f-a76a37fcc931_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at the end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ebfd4846-93c2-43fb-ab5f-a2ec981c88d8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1ee20699-f154-434b-bfdb-e44ac11f8747_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_0ef6e3b4-22f7-435e-9aa4-cb9214e5b5eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_132a07c2-d083-4b50-a3b7-c843b648f3d5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_aca212e9-7543-41ea-a78e-b3936b9c7ca8_terseLabel_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Callidus Biopharma Inc</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_label_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Callidus Biopharma Inc [Member]</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_documentation_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Callidus Biopharma, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember" xlink:href="fold-20210331.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CallidusBiopharmaIncMember" xlink:to="lab_fold_CallidusBiopharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_bb6fea70-0b7e-40a9-95fe-e65eaa3994ad_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_b3757aab-26dc-4521-9630-0cf9a5a06d6f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_464655d3-13a7-429c-a12e-4415fb008fa5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7148a6cf-11fb-4d6b-aeba-e6997e78aedc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_bd634a77-8beb-4780-aa43-8fc9405d7f5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e9a88335-af3e-44fa-9407-99290aea7ffd_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_0a31ec72-99f3-43c3-9cef-a5da75396522_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e9ecd679-4d5b-4bd6-b804-851e4daf3d54_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_388ac15b-eeaa-44d9-9b25-10b258d600f5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e5608208-7e61-4a97-ae70-c0140f6cfc6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_bbf19d75-1c19-4b15-b5af-71cd77bbf19e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_a94c458b-cf61-49a0-86d1-ef294496a9ba_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9a6fd312-2d8a-4d34-8b1a-29cb7429aaab_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a9bcce46-1623-4a93-9239-c100dc44592e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e980c730-4fd2-418d-85cf-172167eb246d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued from exercise of stock options, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_5e427442-a353-4369-a674-018844018b7e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c8c7cb39-86aa-431d-a458-a0dae07995d2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_383a535f-62fb-4422-9a92-4a1a54ce5985_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c06647ef-697d-4e05-a89e-77556c4869f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_43b3d5d2-52ee-49fe-8c23-2eab1d3605eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_78e45f9b-49d4-40cb-a6d7-b128e0dc5c6c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2efd7628-aa18-4c7a-8a8d-d28f432847cc_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_333d78f4-6ffc-47de-8315-ad2d1b3def66_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_dde8c07b-d0d1-4c8c-926c-3221ed513442_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_30e52ac3-5b65-45bd-b8d1-7b3a0e4d0bd1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_35926f20-ad50-4934-b85a-bb0cd8448f8a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_11ebfb4a-834f-46db-b576-cf3afe8140dd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_cc6c8d7d-f529-4f59-9b39-86f797b59f76_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_11853160-4da2-40e1-bb97-fcd340ae7ef6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities subject to fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7ad6b84a-03ab-48bb-9bd2-7df5259ea890_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a4bad838-4857-4390-b55f-307019efbafb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c3e191f8-024f-4773-b591-0e0ed01d2b48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3f1ab90f-b68e-4956-ac34-85b200b9d259_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_61225070-5ed8-4366-bb2e-5058dd959cfc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_eae7a55a-4cbd-4f52-a13c-83835cf81103_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_1def1ac3-2f25-480b-9797-55b3c8dd592a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_f7d0c374-dbdb-483a-a4c3-7ac1cc755124_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_245d737b-649b-4f71-b493-fbfba522b8b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_9e4d9d44-102d-42f8-9443-c7fe5f906a38_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_6f13ca55-4351-4169-8485-382f7519242b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_73344152-dd84-49b7-b0e7-03c7c0c3e734_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_914fe96a-549a-44f0-a98b-3042e5124dbc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_dfabecde-3077-4d60-80ff-0014efe4e389_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories for the period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_205328b8-885b-42c3-ac1c-51a6cda0a631_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units, weighted average remaining years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c9c5fa16-6b62-44f8-97a9-f0c80547bf8d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_f0b082c6-40ed-4305-a66f-487a703dbbac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_e7ec7c49-70ac-43ee-a9bc-8e8e11beb881_negatedLabel_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency remeasurement loss</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_label_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_documentation_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:href="fold-20210331.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:to="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4498a2c2-92b4-4faa-904c-277a013bfa5b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_850c7ee6-b1ae-4668-b911-7243d8a0c781_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86cabea1-c595-4ddd-ad62-31e759a983db_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_6b4a06ba-8371-4f34-8e2c-7bc7523fee23_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_59784c4e-95d4-46b7-99bf-f0588cd67d71_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_debbc0d5-f8b8-4905-94ed-25c6942f8176_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ca30e69c-549e-4e67-8fbb-973b64ea4a39_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9d240d5b-f40e-4dce-aa11-719662ba71d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1feab0b4-148d-4e56-b34a-b049d239d26e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and unvested expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_12705077-acd8-4d02-b573-e68e75321fac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5f16439d-3001-46bb-a27a-547d0ae28925_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Developments</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_c31d117d-ba89-4b47-8c1b-7c5b41f5f469_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_6a21cd6c-58de-4413-9b0f-5a93d8bdaafe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>fold-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:f3229f4b-7f57-4682-b4ab-77fd47b9060c,g:39b7c24e-a424-4896-93b0-dad319cae6ae-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="fold-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_24bd9147-e327-4180-aeea-1408c960844b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_DocumentType_24bd9147-e327-4180-aeea-1408c960844b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_1cd76ec2-de42-42cb-bd9e-b393e2847ca0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_DocumentQuarterlyReport_1cd76ec2-de42-42cb-bd9e-b393e2847ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_257bcdba-ea51-4297-9b22-b3d8699d5918" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_DocumentPeriodEndDate_257bcdba-ea51-4297-9b22-b3d8699d5918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7c2642f2-7837-40c1-9907-09013428a80a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_DocumentTransitionReport_7c2642f2-7837-40c1-9907-09013428a80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ce551c97-e072-496f-aa8d-699533fcec29" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityFileNumber_ce551c97-e072-496f-aa8d-699533fcec29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_822bfceb-d742-49c7-ab06-04645316ac82" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityRegistrantName_822bfceb-d742-49c7-ab06-04645316ac82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2f879ed8-3c21-400e-99e8-fe6c31ac1c3d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2f879ed8-3c21-400e-99e8-fe6c31ac1c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_730b05b8-4604-4c20-b82f-719a5b7a5dcc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityTaxIdentificationNumber_730b05b8-4604-4c20-b82f-719a5b7a5dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_258a814b-5dd3-4fe3-aad7-145c0185047a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityAddressAddressLine1_258a814b-5dd3-4fe3-aad7-145c0185047a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4d26ba3d-88d0-460a-9748-78ec872a7f5b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityAddressCityOrTown_4d26ba3d-88d0-460a-9748-78ec872a7f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e773169d-3f38-4023-8f9d-07d3f83ff114" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityAddressStateOrProvince_e773169d-3f38-4023-8f9d-07d3f83ff114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_87a7aced-1859-47cd-b16c-ca1b189ba799" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityAddressPostalZipCode_87a7aced-1859-47cd-b16c-ca1b189ba799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_708a5856-489e-42b5-9108-e6927145e625" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_CityAreaCode_708a5856-489e-42b5-9108-e6927145e625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5335f615-d202-4fd4-9cbe-7d17942bc9e6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_LocalPhoneNumber_5335f615-d202-4fd4-9cbe-7d17942bc9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_87ae4557-1a4f-49c0-b0a8-5b47d361c606" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_Security12bTitle_87ae4557-1a4f-49c0-b0a8-5b47d361c606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_754c1689-5149-4ae6-9aba-3d02a3aca7a6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_TradingSymbol_754c1689-5149-4ae6-9aba-3d02a3aca7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_44bc6c51-c27d-48c4-90b7-61b80ade2313" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_SecurityExchangeName_44bc6c51-c27d-48c4-90b7-61b80ade2313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d2790c06-7a94-4b1d-8ea4-41fa2e3ac542" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityCurrentReportingStatus_d2790c06-7a94-4b1d-8ea4-41fa2e3ac542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c964691d-56cd-464a-acd8-e962a0abf1cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityInteractiveDataCurrent_c964691d-56cd-464a-acd8-e962a0abf1cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_077dd8c1-ec79-4583-9d9c-84586476cdd5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityFilerCategory_077dd8c1-ec79-4583-9d9c-84586476cdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b12430ed-abc9-47cb-be8c-8439dc8ec5de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntitySmallBusiness_b12430ed-abc9-47cb-be8c-8439dc8ec5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_39455d2d-2c92-4bed-a378-a140aae69bda" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityEmergingGrowthCompany_39455d2d-2c92-4bed-a378-a140aae69bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4798c330-a551-41c1-b055-23660f0e693e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityShellCompany_4798c330-a551-41c1-b055-23660f0e693e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_622ff903-dd83-4985-80e5-ff028b1ae8cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_622ff903-dd83-4985-80e5-ff028b1ae8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2ffe91d5-82fa-491d-9fa6-d150f2ab7deb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_EntityCentralIndexKey_2ffe91d5-82fa-491d-9fa6-d150f2ab7deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a1826e4d-49d9-4449-9bf2-cdd471120f75" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_CurrentFiscalYearEndDate_a1826e4d-49d9-4449-9bf2-cdd471120f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_29125adf-7db5-41d7-a8a4-0a7e24914636" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_DocumentFiscalYearFocus_29125adf-7db5-41d7-a8a4-0a7e24914636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c83bbac4-4b8a-4762-b65e-a940ab14cecc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c83bbac4-4b8a-4762-b65e-a940ab14cecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e2836d40-bfc8-4ce8-9a5a-b105c2300323" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_672415d6-c836-4548-8ed0-ca93b1ddb946" xlink:to="loc_dei_AmendmentFlag_e2836d40-bfc8-4ce8-9a5a-b105c2300323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c32c5942-22d7-47be-9182-f27700e382fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1ae8a433-58b4-45df-a798-d54beee90ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c32c5942-22d7-47be-9182-f27700e382fe" xlink:to="loc_us-gaap_AssetsAbstract_1ae8a433-58b4-45df-a798-d54beee90ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_778287a6-e21b-4384-b5d4-a4907f35de65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ae8a433-58b4-45df-a798-d54beee90ddb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_778287a6-e21b-4384-b5d4-a4907f35de65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f97e8e05-9688-479b-af25-a5599136c1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_778287a6-e21b-4384-b5d4-a4907f35de65" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f97e8e05-9688-479b-af25-a5599136c1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_eb743674-4652-4765-a8dd-c098ef655a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_778287a6-e21b-4384-b5d4-a4907f35de65" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_eb743674-4652-4765-a8dd-c098ef655a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_899b397c-45e9-4df1-aa3a-23cee8da5e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_778287a6-e21b-4384-b5d4-a4907f35de65" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_899b397c-45e9-4df1-aa3a-23cee8da5e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3e8f1249-9eb0-495b-897d-f0acdf359814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_778287a6-e21b-4384-b5d4-a4907f35de65" xlink:to="loc_us-gaap_InventoryNet_3e8f1249-9eb0-495b-897d-f0acdf359814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a19f2741-c40c-4127-a0b9-a80d4dae9569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_778287a6-e21b-4384-b5d4-a4907f35de65" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a19f2741-c40c-4127-a0b9-a80d4dae9569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_22157ad4-33d5-4f38-8bad-c68c49b03dac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_778287a6-e21b-4384-b5d4-a4907f35de65" xlink:to="loc_us-gaap_AssetsCurrent_22157ad4-33d5-4f38-8bad-c68c49b03dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_67d5de84-31e3-42c7-b16a-f73558ba3bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ae8a433-58b4-45df-a798-d54beee90ddb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_67d5de84-31e3-42c7-b16a-f73558ba3bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f8ca6493-4f48-4b6a-883f-d63872b38eb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ae8a433-58b4-45df-a798-d54beee90ddb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f8ca6493-4f48-4b6a-883f-d63872b38eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b2830fd4-ca4d-4181-a687-90a5965bc0c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ae8a433-58b4-45df-a798-d54beee90ddb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b2830fd4-ca4d-4181-a687-90a5965bc0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_95d2e545-d093-45dc-8e55-630da56904af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ae8a433-58b4-45df-a798-d54beee90ddb" xlink:to="loc_us-gaap_Goodwill_95d2e545-d093-45dc-8e55-630da56904af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_55c238b5-e96c-460b-9411-72b2ccd3815d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ae8a433-58b4-45df-a798-d54beee90ddb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_55c238b5-e96c-460b-9411-72b2ccd3815d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d759fb16-3f12-43b3-9f4d-385743cb7000" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1ae8a433-58b4-45df-a798-d54beee90ddb" xlink:to="loc_us-gaap_Assets_d759fb16-3f12-43b3-9f4d-385743cb7000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c32c5942-22d7-47be-9182-f27700e382fe" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4f37f0ba-9594-482b-a685-f08f2367a09e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4f37f0ba-9594-482b-a685-f08f2367a09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4e6ffc82-90d4-4eeb-b71e-b31957dff51d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4f37f0ba-9594-482b-a685-f08f2367a09e" xlink:to="loc_us-gaap_AccountsPayableCurrent_4e6ffc82-90d4-4eeb-b71e-b31957dff51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_188fb5a5-9a64-4214-abcf-299ed19bdf03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4f37f0ba-9594-482b-a685-f08f2367a09e" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_188fb5a5-9a64-4214-abcf-299ed19bdf03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_17ec34be-585b-4724-9f30-29b29d5ced24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4f37f0ba-9594-482b-a685-f08f2367a09e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_17ec34be-585b-4724-9f30-29b29d5ced24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1a3076f2-eb04-400f-9f64-7274127e2def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4f37f0ba-9594-482b-a685-f08f2367a09e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1a3076f2-eb04-400f-9f64-7274127e2def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b178a681-aaf5-49e4-8f31-32b154241332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4f37f0ba-9594-482b-a685-f08f2367a09e" xlink:to="loc_us-gaap_LiabilitiesCurrent_b178a681-aaf5-49e4-8f31-32b154241332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_ce51e524-61f2-4cb5-9074-092c2766eb8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_ce51e524-61f2-4cb5-9074-092c2766eb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9ef867f6-80c4-4a91-9ce3-815784f3deaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_LongTermDebt_9ef867f6-80c4-4a91-9ce3-815784f3deaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5080d4d3-5ed7-4f1f-9699-4ef667dfc3bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5080d4d3-5ed7-4f1f-9699-4ef667dfc3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_15aec8a5-1a75-485d-b632-63850e85f3d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_15aec8a5-1a75-485d-b632-63850e85f3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f8e66b15-7c5a-45c6-b8f7-f2d8c0cb4c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f8e66b15-7c5a-45c6-b8f7-f2d8c0cb4c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bf56817d-e1b1-4278-821d-9a7d734b1ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bf56817d-e1b1-4278-821d-9a7d734b1ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d2479506-baa2-407f-a3fb-b9f30ffe0554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_Liabilities_d2479506-baa2-407f-a3fb-b9f30ffe0554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2c0b9d38-d744-4f97-9b0b-282ac1c4ca81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2c0b9d38-d744-4f97-9b0b-282ac1c4ca81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_759f02a7-1b03-4f73-8fdc-07e3b8cd034c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_759f02a7-1b03-4f73-8fdc-07e3b8cd034c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7706688f-d41c-413a-9f45-244d0cbbbace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_759f02a7-1b03-4f73-8fdc-07e3b8cd034c" xlink:to="loc_us-gaap_CommonStockValue_7706688f-d41c-413a-9f45-244d0cbbbace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5a9514f7-7dc8-4841-ad45-ed23b747da4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_759f02a7-1b03-4f73-8fdc-07e3b8cd034c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5a9514f7-7dc8-4841-ad45-ed23b747da4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_f204de52-16df-46d9-af00-52d0f12aded2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_759f02a7-1b03-4f73-8fdc-07e3b8cd034c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_f204de52-16df-46d9-af00-52d0f12aded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_e179e090-6555-4cab-9253-34e5087947ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_f204de52-16df-46d9-af00-52d0f12aded2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_e179e090-6555-4cab-9253-34e5087947ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_62c38505-d5b7-4bbc-a445-182b316d741b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_f204de52-16df-46d9-af00-52d0f12aded2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_62c38505-d5b7-4bbc-a445-182b316d741b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_7c2e8778-8ef7-46dc-afcb-cde159d0951c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_759f02a7-1b03-4f73-8fdc-07e3b8cd034c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_7c2e8778-8ef7-46dc-afcb-cde159d0951c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e537c45a-4626-4f48-b51d-a790cbcecf60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_759f02a7-1b03-4f73-8fdc-07e3b8cd034c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e537c45a-4626-4f48-b51d-a790cbcecf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3d738017-39f1-4550-93cc-2e228d64120b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_759f02a7-1b03-4f73-8fdc-07e3b8cd034c" xlink:to="loc_us-gaap_StockholdersEquity_3d738017-39f1-4550-93cc-2e228d64120b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_86afc48e-7e01-4a1a-ae3c-8447c29d89cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dd52cfab-791e-4c03-aebf-dec76461fcf3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_86afc48e-7e01-4a1a-ae3c-8447c29d89cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0a9bcbba-3f35-485f-8457-ace76a692c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases_1037590b-feec-4f27-b3c2-72388ceba4fe" xlink:href="fold-20210331.xsd#fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0a9bcbba-3f35-485f-8457-ace76a692c29" xlink:to="loc_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases_1037590b-feec-4f27-b3c2-72388ceba4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_af7c7691-345c-4d52-982e-fdeb9fbd09dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0a9bcbba-3f35-485f-8457-ace76a692c29" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_af7c7691-345c-4d52-982e-fdeb9fbd09dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c6f63186-a1c1-48f4-89a8-cb02427c8d72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0a9bcbba-3f35-485f-8457-ace76a692c29" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c6f63186-a1c1-48f4-89a8-cb02427c8d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4bafeed4-3008-4999-9cd7-8f2d6cc0e249" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0a9bcbba-3f35-485f-8457-ace76a692c29" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4bafeed4-3008-4999-9cd7-8f2d6cc0e249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4aac5d45-e2a5-42df-9f79-4bb66d0c3f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0a9bcbba-3f35-485f-8457-ace76a692c29" xlink:to="loc_us-gaap_CommonStockSharesIssued_4aac5d45-e2a5-42df-9f79-4bb66d0c3f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_22975e65-cee5-49f2-b576-8dd89dfe53e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0a9bcbba-3f35-485f-8457-ace76a692c29" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_22975e65-cee5-49f2-b576-8dd89dfe53e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6643f6e1-bade-4aa2-9147-254dd1b85ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d4fe8f25-bc9e-47fb-baa2-c93641b2c26e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6643f6e1-bade-4aa2-9147-254dd1b85ab5" xlink:to="loc_us-gaap_RevenuesAbstract_d4fe8f25-bc9e-47fb-baa2-c93641b2c26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_aa45f187-8b93-4100-9b60-3eb1651e9fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d4fe8f25-bc9e-47fb-baa2-c93641b2c26e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_aa45f187-8b93-4100-9b60-3eb1651e9fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fce77204-daed-48c3-8bb1-475ffd3c8143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d4fe8f25-bc9e-47fb-baa2-c93641b2c26e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fce77204-daed-48c3-8bb1-475ffd3c8143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_60859fc1-6298-424e-8d89-13f2e3240bd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d4fe8f25-bc9e-47fb-baa2-c93641b2c26e" xlink:to="loc_us-gaap_GrossProfit_60859fc1-6298-424e-8d89-13f2e3240bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_989ff9e9-4740-49b1-b11f-8eb2231326ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6643f6e1-bade-4aa2-9147-254dd1b85ab5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_989ff9e9-4740-49b1-b11f-8eb2231326ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_16520e8b-4dd9-4dff-9690-b0c9b0afd21b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_989ff9e9-4740-49b1-b11f-8eb2231326ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_16520e8b-4dd9-4dff-9690-b0c9b0afd21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_93a0dcd1-95c2-4642-bf2b-235440e5c82d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_989ff9e9-4740-49b1-b11f-8eb2231326ac" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_93a0dcd1-95c2-4642-bf2b-235440e5c82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9d681539-363d-4fb8-a28e-3f45ac7f6b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_989ff9e9-4740-49b1-b11f-8eb2231326ac" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9d681539-363d-4fb8-a28e-3f45ac7f6b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37c59e2d-1b50-44f2-b4e5-b0ec754669bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_989ff9e9-4740-49b1-b11f-8eb2231326ac" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37c59e2d-1b50-44f2-b4e5-b0ec754669bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6b078592-5261-4da2-b576-61437c89cbfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_989ff9e9-4740-49b1-b11f-8eb2231326ac" xlink:to="loc_us-gaap_OperatingExpenses_6b078592-5261-4da2-b576-61437c89cbfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_db9aedbc-9b61-4725-a070-eafc08166827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6643f6e1-bade-4aa2-9147-254dd1b85ab5" xlink:to="loc_us-gaap_OperatingIncomeLoss_db9aedbc-9b61-4725-a070-eafc08166827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0464c259-5149-471a-a484-6d9c162cf1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6643f6e1-bade-4aa2-9147-254dd1b85ab5" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0464c259-5149-471a-a484-6d9c162cf1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_44512107-4277-4f18-a0bc-f74448e1211e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0464c259-5149-471a-a484-6d9c162cf1dd" xlink:to="loc_us-gaap_InvestmentIncomeInterest_44512107-4277-4f18-a0bc-f74448e1211e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e8c0bfbb-8cbd-4d36-b369-38f168c72240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0464c259-5149-471a-a484-6d9c162cf1dd" xlink:to="loc_us-gaap_InterestExpense_e8c0bfbb-8cbd-4d36-b369-38f168c72240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a7e8f932-9faf-4f17-8ce7-4706890fb91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0464c259-5149-471a-a484-6d9c162cf1dd" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a7e8f932-9faf-4f17-8ce7-4706890fb91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8cacf792-a8da-4120-a6a2-8a08d9a3d9cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6643f6e1-bade-4aa2-9147-254dd1b85ab5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8cacf792-a8da-4120-a6a2-8a08d9a3d9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ceaed4f6-7976-49b1-8170-1c22e11e1a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6643f6e1-bade-4aa2-9147-254dd1b85ab5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ceaed4f6-7976-49b1-8170-1c22e11e1a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_908db7b4-caf8-46ad-9517-d0acbfabf360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6643f6e1-bade-4aa2-9147-254dd1b85ab5" xlink:to="loc_us-gaap_NetIncomeLoss_908db7b4-caf8-46ad-9517-d0acbfabf360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_03bb22f2-ba83-4f0e-83ea-14afdec7b6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6643f6e1-bade-4aa2-9147-254dd1b85ab5" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_03bb22f2-ba83-4f0e-83ea-14afdec7b6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b3b1f379-7945-4e4e-9310-d30d826fb31a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6643f6e1-bade-4aa2-9147-254dd1b85ab5" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_b3b1f379-7945-4e4e-9310-d30d826fb31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fea48274-2651-4d35-b289-727ba2d90dc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_629f47e9-1e59-43da-a867-9df737b12766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fea48274-2651-4d35-b289-727ba2d90dc4" xlink:to="loc_us-gaap_NetIncomeLoss_629f47e9-1e59-43da-a867-9df737b12766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a9e686cc-e0e5-4a8d-a646-5bb7b1ea8de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fea48274-2651-4d35-b289-727ba2d90dc4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a9e686cc-e0e5-4a8d-a646-5bb7b1ea8de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d2c0d3af-6a55-4722-ae5a-f3d5e59770c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a9e686cc-e0e5-4a8d-a646-5bb7b1ea8de6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d2c0d3af-6a55-4722-ae5a-f3d5e59770c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b9ccac16-a4a6-4469-a08d-7a70b29506f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a9e686cc-e0e5-4a8d-a646-5bb7b1ea8de6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b9ccac16-a4a6-4469-a08d-7a70b29506f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_009cc5e5-66ad-498a-8f66-23917e2f442b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a9e686cc-e0e5-4a8d-a646-5bb7b1ea8de6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_009cc5e5-66ad-498a-8f66-23917e2f442b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_8ec32278-7163-406e-addc-5b7af8d66f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_fea48274-2651-4d35-b289-727ba2d90dc4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_8ec32278-7163-406e-addc-5b7af8d66f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_afbab2b0-81b9-4c57-8f57-f2414677bae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_c674ac02-0107-4231-a501-5e7f151ff5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_afbab2b0-81b9-4c57-8f57-f2414677bae3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_c674ac02-0107-4231-a501-5e7f151ff5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_67d7744e-6b6c-4431-87f8-41bb44f0dbea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_afbab2b0-81b9-4c57-8f57-f2414677bae3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_67d7744e-6b6c-4431-87f8-41bb44f0dbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_66e63778-b8e9-462f-8328-103bdfaaf3d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c1d7dac6-25c1-4d26-9801-ce9a41ff16ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_66e63778-b8e9-462f-8328-103bdfaaf3d9" xlink:to="loc_us-gaap_StatementTable_c1d7dac6-25c1-4d26-9801-ce9a41ff16ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a78cb293-2ff8-4d5d-9df6-a4b60f1943b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c1d7dac6-25c1-4d26-9801-ce9a41ff16ee" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a78cb293-2ff8-4d5d-9df6-a4b60f1943b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a78cb293-2ff8-4d5d-9df6-a4b60f1943b7" xlink:to="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_34f99dbc-626a-4227-80d9-dfbd3cef2fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:to="loc_us-gaap_CommonStockMember_34f99dbc-626a-4227-80d9-dfbd3cef2fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_373d02a7-bae9-44e6-94f4-be1191587e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_373d02a7-bae9-44e6-94f4-be1191587e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_f193bdb9-c0c5-4828-8147-85ec36e280f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:to="loc_us-gaap_WarrantMember_f193bdb9-c0c5-4828-8147-85ec36e280f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_664fb65e-5d34-4414-aac2-d6dd575561ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_664fb65e-5d34-4414-aac2-d6dd575561ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_aa4ae434-6064-4f17-89a3-8f6d2b640be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bd744525-9116-4770-9e90-1a2a1151ce90" xlink:to="loc_us-gaap_RetainedEarningsMember_aa4ae434-6064-4f17-89a3-8f6d2b640be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d1594c99-076b-48e3-91c3-89540ea6f0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c1d7dac6-25c1-4d26-9801-ce9a41ff16ee" xlink:to="loc_us-gaap_StatementLineItems_d1594c99-076b-48e3-91c3-89540ea6f0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d1594c99-076b-48e3-91c3-89540ea6f0db" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_85f6598b-e89f-412f-9563-d5ef877303b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_85f6598b-e89f-412f-9563-d5ef877303b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d00d8723-90ae-495d-badc-508ecb919081" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockholdersEquity_d00d8723-90ae-495d-badc-508ecb919081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f1e144a7-7a08-46de-91fc-20f7a9bf674e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f1e144a7-7a08-46de-91fc-20f7a9bf674e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c2b31c01-1ba2-4c78-ba97-fced25de9561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c2b31c01-1ba2-4c78-ba97-fced25de9561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_eeb7fc7d-e785-414a-ba76-4d5b8839ec83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_eeb7fc7d-e785-414a-ba76-4d5b8839ec83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1320752d-911c-4a99-8f56-7526dac17310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1320752d-911c-4a99-8f56-7526dac17310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666b6887-2f80-45ed-b83f-47938733af06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_666b6887-2f80-45ed-b83f-47938733af06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_1d8b4a09-fed0-4406-b3e0-8a8195164fe5" xlink:href="fold-20210331.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_1d8b4a09-fed0-4406-b3e0-8a8195164fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_8ca2a45e-1296-4ef5-98bf-98d7695820f7" xlink:href="fold-20210331.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_8ca2a45e-1296-4ef5-98bf-98d7695820f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0c6fed2b-f68a-41f8-889b-68786731dc01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0c6fed2b-f68a-41f8-889b-68786731dc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_842296f1-20a5-4ec4-bf9d-98c154700e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_842296f1-20a5-4ec4-bf9d-98c154700e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7dcebbb2-3d58-4978-9817-3b349ae733fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_7dcebbb2-3d58-4978-9817-3b349ae733fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3152f23a-fba7-413b-85df-e7bb3753bda6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3152f23a-fba7-413b-85df-e7bb3753bda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0bc928bf-2fea-4311-813e-1e972f6f86c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_NetIncomeLoss_0bc928bf-2fea-4311-813e-1e972f6f86c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_67dc4710-0bad-4d07-b259-d0122c65efda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_67dc4710-0bad-4d07-b259-d0122c65efda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1b8963de-e411-4327-b8a3-13d52d7de77c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f4a6b95d-9748-4a78-9541-f81f478013fe" xlink:to="loc_us-gaap_StockholdersEquity_1b8963de-e411-4327-b8a3-13d52d7de77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="fold-20210331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bb01b174-c17b-4243-a8f7-341292920712" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ba7c5e19-b58d-4d4f-9b2e-7976b527e87b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bb01b174-c17b-4243-a8f7-341292920712" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ba7c5e19-b58d-4d4f-9b2e-7976b527e87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_074b6fe4-23f9-4393-b09a-af1db12f3190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ba7c5e19-b58d-4d4f-9b2e-7976b527e87b" xlink:to="loc_us-gaap_ProfitLoss_074b6fe4-23f9-4393-b09a-af1db12f3190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8f2e9ec-7be0-434d-afff-c4697a40e5a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ba7c5e19-b58d-4d4f-9b2e-7976b527e87b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8f2e9ec-7be0-434d-afff-c4697a40e5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_01fd51a3-710f-4391-b366-71091d15e889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8f2e9ec-7be0-434d-afff-c4697a40e5a9" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_01fd51a3-710f-4391-b366-71091d15e889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_40615082-e86b-4d16-9a23-0c876ac3626a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8f2e9ec-7be0-434d-afff-c4697a40e5a9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_40615082-e86b-4d16-9a23-0c876ac3626a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9f3318a0-b851-40ae-803c-f7f71bf34bcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8f2e9ec-7be0-434d-afff-c4697a40e5a9" xlink:to="loc_us-gaap_ShareBasedCompensation_9f3318a0-b851-40ae-803c-f7f71bf34bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3ecc9450-27ae-446a-9b45-bb5a55e519ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8f2e9ec-7be0-434d-afff-c4697a40e5a9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3ecc9450-27ae-446a-9b45-bb5a55e519ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_5bfde42d-3c03-4257-b732-0a02f23905eb" xlink:href="fold-20210331.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8f2e9ec-7be0-434d-afff-c4697a40e5a9" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_5bfde42d-3c03-4257-b732-0a02f23905eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f511627-8e81-4a9a-af1a-a838285de5bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d8f2e9ec-7be0-434d-afff-c4697a40e5a9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f511627-8e81-4a9a-af1a-a838285de5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_aa7d04f1-d403-40c1-b57c-195353de9d1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f511627-8e81-4a9a-af1a-a838285de5bb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_aa7d04f1-d403-40c1-b57c-195353de9d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1b590ae8-c765-40ab-bedc-50283a66d76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f511627-8e81-4a9a-af1a-a838285de5bb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1b590ae8-c765-40ab-bedc-50283a66d76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f426d27c-082a-48c7-bfea-189916489ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f511627-8e81-4a9a-af1a-a838285de5bb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f426d27c-082a-48c7-bfea-189916489ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bdcff954-d09f-411d-8979-dc55222e2c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f511627-8e81-4a9a-af1a-a838285de5bb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bdcff954-d09f-411d-8979-dc55222e2c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_04c61965-f5c1-4f8b-aea2-61fbc91af0cb" xlink:href="fold-20210331.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9f511627-8e81-4a9a-af1a-a838285de5bb" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_04c61965-f5c1-4f8b-aea2-61fbc91af0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_897fd2b1-6ec5-4ce8-8936-3430f3cbd360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ba7c5e19-b58d-4d4f-9b2e-7976b527e87b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_897fd2b1-6ec5-4ce8-8936-3430f3cbd360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ece40315-73fe-4be1-9350-28f421b30118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bb01b174-c17b-4243-a8f7-341292920712" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ece40315-73fe-4be1-9350-28f421b30118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2009d160-c9e5-446b-b31c-6eb2605f7b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ece40315-73fe-4be1-9350-28f421b30118" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2009d160-c9e5-446b-b31c-6eb2605f7b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d31e57a4-5d53-40d8-a5f1-ae8182935897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ece40315-73fe-4be1-9350-28f421b30118" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d31e57a4-5d53-40d8-a5f1-ae8182935897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6593d791-40bc-4802-88ec-571496dcefd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ece40315-73fe-4be1-9350-28f421b30118" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6593d791-40bc-4802-88ec-571496dcefd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca997cf0-b8b1-4a1c-91e2-e033045ea87e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ece40315-73fe-4be1-9350-28f421b30118" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ca997cf0-b8b1-4a1c-91e2-e033045ea87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cf258371-5a0f-4534-a778-9caf8c7e6bcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bb01b174-c17b-4243-a8f7-341292920712" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cf258371-5a0f-4534-a778-9caf8c7e6bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_d898fb17-59c5-4e41-b043-0cf5e688928b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cf258371-5a0f-4534-a778-9caf8c7e6bcc" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_d898fb17-59c5-4e41-b043-0cf5e688928b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_88e8e668-7a9c-4473-bf06-f4166d5ec9e7" xlink:href="fold-20210331.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cf258371-5a0f-4534-a778-9caf8c7e6bcc" xlink:to="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_88e8e668-7a9c-4473-bf06-f4166d5ec9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c2d143b3-903a-4135-aded-bad6f9784e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cf258371-5a0f-4534-a778-9caf8c7e6bcc" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c2d143b3-903a-4135-aded-bad6f9784e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8f585e32-37fc-4c2b-b7e4-076d894764e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cf258371-5a0f-4534-a778-9caf8c7e6bcc" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_8f585e32-37fc-4c2b-b7e4-076d894764e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_689621b9-2889-4000-9db1-38cdd03745d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cf258371-5a0f-4534-a778-9caf8c7e6bcc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_689621b9-2889-4000-9db1-38cdd03745d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52f1eefe-bb88-4529-90e0-2c0cd750e314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bb01b174-c17b-4243-a8f7-341292920712" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52f1eefe-bb88-4529-90e0-2c0cd750e314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a230168e-09ec-4713-a51d-e681b82a1473" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bb01b174-c17b-4243-a8f7-341292920712" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a230168e-09ec-4713-a51d-e681b82a1473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c34b1bc2-89c6-4a16-af17-42153d0daa22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bb01b174-c17b-4243-a8f7-341292920712" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c34b1bc2-89c6-4a16-af17-42153d0daa22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1a8bb386-923d-4b76-98fb-59c24077635e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bb01b174-c17b-4243-a8f7-341292920712" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1a8bb386-923d-4b76-98fb-59c24077635e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_8200abb3-1c15-44a2-8b40-f9e9b63df4f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bb01b174-c17b-4243-a8f7-341292920712" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_8200abb3-1c15-44a2-8b40-f9e9b63df4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_1d04aaeb-b2dd-46b3-8995-9026825f7396" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8200abb3-1c15-44a2-8b40-f9e9b63df4f1" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_1d04aaeb-b2dd-46b3-8995-9026825f7396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4e07e307-c370-41b9-9f80-8bdaedc2d3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8200abb3-1c15-44a2-8b40-f9e9b63df4f1" xlink:to="loc_us-gaap_InterestPaidNet_4e07e307-c370-41b9-9f80-8bdaedc2d3c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_346f37ae-b07d-4bfb-bfd0-a2f490497642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8200abb3-1c15-44a2-8b40-f9e9b63df4f1" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_346f37ae-b07d-4bfb-bfd0-a2f490497642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_283417d4-31ac-4da8-b62c-fabee51ec9c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8200abb3-1c15-44a2-8b40-f9e9b63df4f1" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_283417d4-31ac-4da8-b62c-fabee51ec9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="fold-20210331.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3513d28f-e281-483b-9e3d-01be690ceba8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dc6d8304-e17d-4611-9811-d7e2f6e7727e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3513d28f-e281-483b-9e3d-01be690ceba8" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_dc6d8304-e17d-4611-9811-d7e2f6e7727e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2702d97d-e652-41c5-b454-882d2f4bb176" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4ad61bfb-b5c3-4a5f-bf4a-dc4b97284029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2702d97d-e652-41c5-b454-882d2f4bb176" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4ad61bfb-b5c3-4a5f-bf4a-dc4b97284029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_35034698-0b4c-44ef-b2d3-420842f05219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cdff1245-0042-490c-907f-35af06b94fb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35034698-0b4c-44ef-b2d3-420842f05219" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cdff1245-0042-490c-907f-35af06b94fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_22787375-2131-4785-9b84-ab6fb07c39f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_22787375-2131-4785-9b84-ab6fb07c39f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_7869513c-3890-46d5-a1a4-472425d99ec5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_7869513c-3890-46d5-a1a4-472425d99ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e7a3877e-aee2-4bdb-9a56-b65cb865f2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e7a3877e-aee2-4bdb-9a56-b65cb865f2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d13ed98e-6b07-40eb-9a65-aeb7502e5df7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:to="loc_us-gaap_UseOfEstimates_d13ed98e-6b07-40eb-9a65-aeb7502e5df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a87f2116-d8f4-443c-8255-0b77e7b6f2ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a87f2116-d8f4-443c-8255-0b77e7b6f2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_adde819b-98eb-40a2-8360-76b4e8ab86ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_adde819b-98eb-40a2-8360-76b4e8ab86ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7b4a2821-a639-41c9-b077-ebe2cfa88422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7b4a2821-a639-41c9-b077-ebe2cfa88422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy_82262103-a83c-44e2-8ba6-fd47c24b0fe1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryCostsForContractsOrProgramsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:to="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy_82262103-a83c-44e2-8ba6-fd47c24b0fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_db0f89dd-24b5-435b-887b-1e730c73a11e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_db0f89dd-24b5-435b-887b-1e730c73a11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6570f403-7767-489a-af8e-3c72027fc047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1cb11213-52a2-48d9-88fd-d94b18ad4295" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6570f403-7767-489a-af8e-3c72027fc047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8152ce3d-7f76-455a-a6c4-46ca6116f304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_227ab491-e8b7-46ad-b6ce-e007994dd003" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8152ce3d-7f76-455a-a6c4-46ca6116f304" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_227ab491-e8b7-46ad-b6ce-e007994dd003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0036b6b7-246f-4e4d-a3fd-6fbe44943b78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_4122ea31-3241-4a8e-877b-4d5ed43f6a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0036b6b7-246f-4e4d-a3fd-6fbe44943b78" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_4122ea31-3241-4a8e-877b-4d5ed43f6a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8551c31b-024d-4b9e-8f69-8a464df507f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0036b6b7-246f-4e4d-a3fd-6fbe44943b78" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8551c31b-024d-4b9e-8f69-8a464df507f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e3d43b9e-6d2d-4ecf-a18a-af04f9b7208c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8551c31b-024d-4b9e-8f69-8a464df507f8" xlink:to="loc_srt_StatementGeographicalAxis_e3d43b9e-6d2d-4ecf-a18a-af04f9b7208c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f48d0d3a-10e5-4be0-9a2a-84edb5593a97" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e3d43b9e-6d2d-4ecf-a18a-af04f9b7208c" xlink:to="loc_srt_SegmentGeographicalDomain_f48d0d3a-10e5-4be0-9a2a-84edb5593a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b275fc94-3109-4efd-978e-825f4031abbd" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f48d0d3a-10e5-4be0-9a2a-84edb5593a97" xlink:to="loc_country_US_b275fc94-3109-4efd-978e-825f4031abbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_eca7a11a-7ec0-4dad-a8bd-48d8cb6c8fa0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f48d0d3a-10e5-4be0-9a2a-84edb5593a97" xlink:to="loc_us-gaap_NonUsMember_eca7a11a-7ec0-4dad-a8bd-48d8cb6c8fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0b2135df-6e86-47e1-8955-1c681f745e85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8551c31b-024d-4b9e-8f69-8a464df507f8" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0b2135df-6e86-47e1-8955-1c681f745e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f2f41d1c-a608-4b94-aa65-a4124fe9ee88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0b2135df-6e86-47e1-8955-1c681f745e85" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f2f41d1c-a608-4b94-aa65-a4124fe9ee88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_7e4cf775-724c-45f8-959c-6ec9c1ff3b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_de65a687-491f-4249-a189-a804324e5381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_7e4cf775-724c-45f8-959c-6ec9c1ff3b3b" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_de65a687-491f-4249-a189-a804324e5381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_eb9a650e-0bb8-47a8-ae02-0970fda08006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_98659ae7-ed05-43dd-bcf0-362f08b0845a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_eb9a650e-0bb8-47a8-ae02-0970fda08006" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_98659ae7-ed05-43dd-bcf0-362f08b0845a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_dc4dad64-e153-462e-846c-67feaf6c808c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_eb9a650e-0bb8-47a8-ae02-0970fda08006" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_dc4dad64-e153-462e-846c-67feaf6c808c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_32444bd5-54e9-4777-a4ea-a3fcfd2b1750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5160a616-b0ea-4f9b-a87e-595d7d33334c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_32444bd5-54e9-4777-a4ea-a3fcfd2b1750" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5160a616-b0ea-4f9b-a87e-595d7d33334c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2bc367db-4f24-4dd1-b605-e1b8ff193ddd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_32444bd5-54e9-4777-a4ea-a3fcfd2b1750" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2bc367db-4f24-4dd1-b605-e1b8ff193ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_2b627fc9-ff12-4d6a-8824-3444cf0b376f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_32444bd5-54e9-4777-a4ea-a3fcfd2b1750" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_2b627fc9-ff12-4d6a-8824-3444cf0b376f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_27cf3594-0b2a-46a6-91a6-8dab2a4f9311" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_32444bd5-54e9-4777-a4ea-a3fcfd2b1750" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_27cf3594-0b2a-46a6-91a6-8dab2a4f9311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_2633a481-aba7-4afa-a6e0-76288f268f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_38428fa1-ea67-4bcc-a631-fb79fa145c0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_2633a481-aba7-4afa-a6e0-76288f268f7a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_38428fa1-ea67-4bcc-a631-fb79fa145c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_255f522b-0d62-463b-a655-4a64aeffe9ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_38428fa1-ea67-4bcc-a631-fb79fa145c0e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_255f522b-0d62-463b-a655-4a64aeffe9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_255f522b-0d62-463b-a655-4a64aeffe9ad" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_686c4998-4d9f-4fe4-a4b7-183b3882c061" xlink:href="fold-20210331.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_686c4998-4d9f-4fe4-a4b7-183b3882c061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_227f7461-427c-4e6e-aded-65d1a4dd63ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_227f7461-427c-4e6e-aded-65d1a4dd63ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_684c37d3-b4d8-4a64-add5-614216a44128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_684c37d3-b4d8-4a64-add5-614216a44128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ec5ada10-c6da-449e-a127-239a34acff73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ec5ada10-c6da-449e-a127-239a34acff73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2eba277d-c3b4-48d0-b279-af65834c154e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2eba277d-c3b4-48d0-b279-af65834c154e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_530bd770-7df4-4546-8193-1258a1ef39fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_834008e9-df5d-4667-a9f8-6efbee990558" xlink:to="loc_us-gaap_CertificatesOfDepositMember_530bd770-7df4-4546-8193-1258a1ef39fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_38428fa1-ea67-4bcc-a631-fb79fa145c0e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2fa21256-5f71-443e-b3f1-ba18e5c5f4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2fa21256-5f71-443e-b3f1-ba18e5c5f4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_700fb877-80c0-4930-82a8-2efab6e7ee41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_700fb877-80c0-4930-82a8-2efab6e7ee41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_a61e6ba8-1862-4827-8a25-e4f517b8d4cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_a61e6ba8-1862-4827-8a25-e4f517b8d4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_67457fa2-d48a-44f0-887a-1757967016e1" xlink:href="fold-20210331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_67457fa2-d48a-44f0-887a-1757967016e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_982a20ff-6324-411d-99cb-014fa1a39172" xlink:href="fold-20210331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_982a20ff-6324-411d-99cb-014fa1a39172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_91bbf0d9-7cb0-421f-80a8-66c7403a7aee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_91bbf0d9-7cb0-421f-80a8-66c7403a7aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae1a178e-cb7f-4fd6-be10-eba51a64077e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae1a178e-cb7f-4fd6-be10-eba51a64077e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f17e27de-c8ad-406f-879f-dc672045a0bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f17e27de-c8ad-406f-879f-dc672045a0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_329338b5-4724-43d5-a5c3-1a1795806934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_329338b5-4724-43d5-a5c3-1a1795806934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56e42807-7d52-41b3-8d92-2c427c9b2e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_56e42807-7d52-41b3-8d92-2c427c9b2e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_30d9a4d7-625f-4fe7-b077-c84ebfa50134" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_30d9a4d7-625f-4fe7-b077-c84ebfa50134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_246c2dd0-c1cf-46ab-88c1-12bb4bba05bd" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_246c2dd0-c1cf-46ab-88c1-12bb4bba05bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_750b1d56-5e6d-4d16-bc0e-4f555756beb9" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_750b1d56-5e6d-4d16-bc0e-4f555756beb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_8eb94c69-f540-44b9-a4e6-584942760923" xlink:href="fold-20210331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa02c944-aa93-4429-893a-b523c253b5d7" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_8eb94c69-f540-44b9-a4e6-584942760923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_b4e244e1-3da7-4097-9925-26ba1c5e2753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b44373b1-36d5-46d7-a73b-b03113d134f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_b4e244e1-3da7-4097-9925-26ba1c5e2753" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b44373b1-36d5-46d7-a73b-b03113d134f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_ae9f92eb-5223-4737-a75d-b91bc0b168dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_b4e244e1-3da7-4097-9925-26ba1c5e2753" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_ae9f92eb-5223-4737-a75d-b91bc0b168dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4db4854-ce49-4e94-b2fb-23885c7091f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_b4e244e1-3da7-4097-9925-26ba1c5e2753" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e4db4854-ce49-4e94-b2fb-23885c7091f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:type="simple" xlink:href="fold-20210331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4e1c7edd-b8ee-4fd5-b674-fc70acdb06bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_235eb1f2-5a64-4ec8-b456-7c1f16f1350f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4e1c7edd-b8ee-4fd5-b674-fc70acdb06bd" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_235eb1f2-5a64-4ec8-b456-7c1f16f1350f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="simple" xlink:href="fold-20210331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f567edba-27f8-4513-8344-b0660742ad15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_28c0913c-2dc5-412b-a34a-8387fa0ff350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f567edba-27f8-4513-8344-b0660742ad15" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_28c0913c-2dc5-412b-a34a-8387fa0ff350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_60b099c7-b4f2-4158-a75c-4e10a452ecf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_90be738e-0cf7-44aa-834f-83eb965cb240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_60b099c7-b4f2-4158-a75c-4e10a452ecf4" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_90be738e-0cf7-44aa-834f-83eb965cb240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_81a1d7f7-5c00-448b-bdef-a3041fba5cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_60b099c7-b4f2-4158-a75c-4e10a452ecf4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_81a1d7f7-5c00-448b-bdef-a3041fba5cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c8b505ae-9cba-45f3-9b7d-70981e4380f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_60b099c7-b4f2-4158-a75c-4e10a452ecf4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c8b505ae-9cba-45f3-9b7d-70981e4380f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_082b6aaf-d854-4887-9fb9-d502c4cf2fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_60b099c7-b4f2-4158-a75c-4e10a452ecf4" xlink:to="loc_us-gaap_InventoryNet_082b6aaf-d854-4887-9fb9-d502c4cf2fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_30765c00-0f8f-4785-9bab-04503b517415" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_60b099c7-b4f2-4158-a75c-4e10a452ecf4" xlink:to="loc_us-gaap_InventoryValuationReserves_30765c00-0f8f-4785-9bab-04503b517415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:type="simple" xlink:href="fold-20210331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_027d79bc-da44-4cf3-a084-caf10330bcd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_01c31322-24f9-4366-905b-517e5a15db08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_027d79bc-da44-4cf3-a084-caf10330bcd8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_01c31322-24f9-4366-905b-517e5a15db08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="simple" xlink:href="fold-20210331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1d63eb5c-957a-4c9d-8f20-e804f54004c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_bc51e06a-078b-4c41-9b94-1bcfe262b145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1d63eb5c-957a-4c9d-8f20-e804f54004c3" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_bc51e06a-078b-4c41-9b94-1bcfe262b145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_bb137df1-42d4-426e-b374-607db7a35e24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1d63eb5c-957a-4c9d-8f20-e804f54004c3" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_bb137df1-42d4-426e-b374-607db7a35e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_db39d162-33e6-4fd7-b821-8691ed5ac11f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_36461fac-c10c-4417-b90a-1e96338c1015" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_db39d162-33e6-4fd7-b821-8691ed5ac11f" xlink:to="loc_us-gaap_DebtInstrumentTable_36461fac-c10c-4417-b90a-1e96338c1015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_63280158-368e-4ea1-ab6a-ff46edd14448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_36461fac-c10c-4417-b90a-1e96338c1015" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_63280158-368e-4ea1-ab6a-ff46edd14448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_52857866-a18e-4623-84da-90bcd8cadc05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_63280158-368e-4ea1-ab6a-ff46edd14448" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_52857866-a18e-4623-84da-90bcd8cadc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_739ff4c5-591e-4087-ae1b-aeced18de19d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_52857866-a18e-4623-84da-90bcd8cadc05" xlink:to="loc_us-gaap_SeniorLoansMember_739ff4c5-591e-4087-ae1b-aeced18de19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_35c11691-2f67-49c2-936e-cff1cac3d1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_52857866-a18e-4623-84da-90bcd8cadc05" xlink:to="loc_us-gaap_ConvertibleDebtMember_35c11691-2f67-49c2-936e-cff1cac3d1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_56af5320-aeaf-4f4d-8bc3-eab81f12ea02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_36461fac-c10c-4417-b90a-1e96338c1015" xlink:to="loc_us-gaap_DebtInstrumentAxis_56af5320-aeaf-4f4d-8bc3-eab81f12ea02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_623c71ac-7b3c-411d-8fa7-a80cb04ced2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_56af5320-aeaf-4f4d-8bc3-eab81f12ea02" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_623c71ac-7b3c-411d-8fa7-a80cb04ced2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2026Member_20d49e4e-14de-4a8c-bb21-f8038ac1611f" xlink:href="fold-20210331.xsd#fold_SeniorSecuredTermLoanDue2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_623c71ac-7b3c-411d-8fa7-a80cb04ced2d" xlink:to="loc_fold_SeniorSecuredTermLoanDue2026Member_20d49e4e-14de-4a8c-bb21-f8038ac1611f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_932c2722-6b89-46ec-bd5e-40b9ff75f47a" xlink:href="fold-20210331.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_623c71ac-7b3c-411d-8fa7-a80cb04ced2d" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_932c2722-6b89-46ec-bd5e-40b9ff75f47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_36461fac-c10c-4417-b90a-1e96338c1015" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d36718b1-9de2-4274-abd5-d613d27ab4b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d36718b1-9de2-4274-abd5-d613d27ab4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_31c957e4-341b-4e73-a87f-174c3ce73754" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_31c957e4-341b-4e73-a87f-174c3ce73754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_fdc6dc5c-b29a-4b45-a393-1aecc8f339d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DeferredOfferingCosts_fdc6dc5c-b29a-4b45-a393-1aecc8f339d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a1503561-2a95-4b8b-8407-458209ed587e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_LongTermDebt_a1503561-2a95-4b8b-8407-458209ed587e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7bf901e4-5d61-4722-8fb1-e53e7405c23e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_7bf901e4-5d61-4722-8fb1-e53e7405c23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_45eccb4b-36d3-4eeb-aa7c-26b4730f5738" xlink:href="fold-20210331.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_45eccb4b-36d3-4eeb-aa7c-26b4730f5738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_fd7e1586-da35-4ba9-867b-c4e5ac3987b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_fd7e1586-da35-4ba9-867b-c4e5ac3987b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_71240b04-6409-4099-9194-68fdf388069f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_71240b04-6409-4099-9194-68fdf388069f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_ce6a6800-8d57-4fa8-8422-5d020bedca01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_ce6a6800-8d57-4fa8-8422-5d020bedca01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ed82bac2-7ad6-436d-8423-b24b66a54961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a90441af-b2a5-40e5-9131-05290a9e119b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ed82bac2-7ad6-436d-8423-b24b66a54961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9674851e-14cc-4aff-bb39-b2c47a3c3b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_dfde47ee-6a82-4ecc-aee3-98c9b9031a29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9674851e-14cc-4aff-bb39-b2c47a3c3b58" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_dfde47ee-6a82-4ecc-aee3-98c9b9031a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_43d5a1a8-bd32-4cb9-a3d8-e2c0ada52ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9674851e-14cc-4aff-bb39-b2c47a3c3b58" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_43d5a1a8-bd32-4cb9-a3d8-e2c0ada52ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts_6b69e2ff-26f0-4c1a-93fe-24c13cc06a20" xlink:href="fold-20210331.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9674851e-14cc-4aff-bb39-b2c47a3c3b58" xlink:to="loc_fold_AmortizationDeferredFinancingCosts_6b69e2ff-26f0-4c1a-93fe-24c13cc06a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="fold-20210331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_359c893a-fa2f-4149-bd15-f5bb01802d57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7fcb446a-b9a0-4e0b-9012-7f1eea430591" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_359c893a-fa2f-4149-bd15-f5bb01802d57" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7fcb446a-b9a0-4e0b-9012-7f1eea430591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#StockholdersEquityCommonStockandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6af2f770-7063-4dd9-8fd9-ae01c3582fb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6af2f770-7063-4dd9-8fd9-ae01c3582fb0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_539026ec-e68e-4e82-a35f-6a3bc54ab3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_539026ec-e68e-4e82-a35f-6a3bc54ab3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d9b7e106-cee7-477e-914a-6f8d3bd9b095" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_539026ec-e68e-4e82-a35f-6a3bc54ab3c3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d9b7e106-cee7-477e-914a-6f8d3bd9b095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4d6f42bc-1512-460f-bc36-3ffe5846a3eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d9b7e106-cee7-477e-914a-6f8d3bd9b095" xlink:to="loc_us-gaap_WarrantMember_4d6f42bc-1512-460f-bc36-3ffe5846a3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_51709547-328c-4671-ae97-b6a0600d9ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_51709547-328c-4671-ae97-b6a0600d9ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1bdc22d1-9fc5-4bf5-acc2-5dec9dd639a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_51709547-328c-4671-ae97-b6a0600d9ed6" xlink:to="loc_us-gaap_ClassOfStockDomain_1bdc22d1-9fc5-4bf5-acc2-5dec9dd639a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2e9accc9-5aac-4d58-9eee-36b3de86ce9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1bdc22d1-9fc5-4bf5-acc2-5dec9dd639a2" xlink:to="loc_us-gaap_CommonStockMember_2e9accc9-5aac-4d58-9eee-36b3de86ce9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_f7c2bfce-2001-4185-954c-bf1d12969e3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_f7c2bfce-2001-4185-954c-bf1d12969e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_876d32a9-d2ed-41e1-aa81-d8dd02a518f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_f7c2bfce-2001-4185-954c-bf1d12969e3b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_876d32a9-d2ed-41e1-aa81-d8dd02a518f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt798Member_ae57f537-3e6e-44c9-9013-fa600e783b0c" xlink:href="fold-20210331.xsd#fold_StockExercisesAt798Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_876d32a9-d2ed-41e1-aa81-d8dd02a518f9" xlink:to="loc_fold_StockExercisesAt798Member_ae57f537-3e6e-44c9-9013-fa600e783b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockExercisesAt706Member_cd9e2176-2c61-4dff-b1d4-34157953d946" xlink:href="fold-20210331.xsd#fold_StockExercisesAt706Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_876d32a9-d2ed-41e1-aa81-d8dd02a518f9" xlink:to="loc_fold_StockExercisesAt706Member_cd9e2176-2c61-4dff-b1d4-34157953d946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c4309a3-039f-435e-83f1-9453c4b34107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ccb85047-e7d9-4704-96a3-d8ddd29f340b" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c4309a3-039f-435e-83f1-9453c4b34107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6dff721-4552-4052-af9e-354addd9bdf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c4309a3-039f-435e-83f1-9453c4b34107" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e6dff721-4552-4052-af9e-354addd9bdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a56298c0-62f5-4b1d-b5f0-e88d342f1e7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c4309a3-039f-435e-83f1-9453c4b34107" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a56298c0-62f5-4b1d-b5f0-e88d342f1e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_f5ef7af4-e736-4f73-bbab-eba5062428c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8c4309a3-039f-435e-83f1-9453c4b34107" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_f5ef7af4-e736-4f73-bbab-eba5062428c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b49f93f-c5a6-4145-b521-3f7d78be273e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_deef9438-3d2c-4cda-87fe-422d8b111384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3b49f93f-c5a6-4145-b521-3f7d78be273e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_deef9438-3d2c-4cda-87fe-422d8b111384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b04c3147-e3a1-4dbc-8faa-a0ed968c8faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ccc78c2d-1cb5-4d48-8ad6-d97fba47c3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b04c3147-e3a1-4dbc-8faa-a0ed968c8faf" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ccc78c2d-1cb5-4d48-8ad6-d97fba47c3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_67c6fe8a-59e2-4234-b7e7-b0253190c3f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b04c3147-e3a1-4dbc-8faa-a0ed968c8faf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_67c6fe8a-59e2-4234-b7e7-b0253190c3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_e35fe54b-3469-4190-b057-ea965ed3e31b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b04c3147-e3a1-4dbc-8faa-a0ed968c8faf" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_e35fe54b-3469-4190-b057-ea965ed3e31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e95af54a-64f4-4e25-b8db-d3dafd3d7610" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b04c3147-e3a1-4dbc-8faa-a0ed968c8faf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_e95af54a-64f4-4e25-b8db-d3dafd3d7610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d94e33e4-3aa6-41d1-ba41-13f7a19beed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a831af4-1af5-467b-864b-6a9f8b1a651b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d94e33e4-3aa6-41d1-ba41-13f7a19beed6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a831af4-1af5-467b-864b-6a9f8b1a651b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_76a878f9-f03a-4f98-abaf-5f795d91bb9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a831af4-1af5-467b-864b-6a9f8b1a651b" xlink:to="loc_us-gaap_AwardTypeAxis_76a878f9-f03a-4f98-abaf-5f795d91bb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c89a7de-573b-4fd3-8d2a-284420188c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_76a878f9-f03a-4f98-abaf-5f795d91bb9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c89a7de-573b-4fd3-8d2a-284420188c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_962bc83c-7b03-4efb-b23e-d5317391497c" xlink:href="fold-20210331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c89a7de-573b-4fd3-8d2a-284420188c98" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_962bc83c-7b03-4efb-b23e-d5317391497c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7a831af4-1af5-467b-864b-6a9f8b1a651b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_017a3006-8c81-4360-81b2-db577d1f8222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_017a3006-8c81-4360-81b2-db577d1f8222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e5fe2c8-f843-40e4-a579-fe803952624a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6e5fe2c8-f843-40e4-a579-fe803952624a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_92c9033a-ab5e-4ff4-b7c8-0fcf35997569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_92c9033a-ab5e-4ff4-b7c8-0fcf35997569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_117c7142-9f5d-46d7-807a-3df335249a79" xlink:href="fold-20210331.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cdf87571-1dc8-4045-a790-1518ecae82bc" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_117c7142-9f5d-46d7-807a-3df335249a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4521efc7-a7c2-40d2-974a-45847bf938d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1289bc36-ea54-4c28-864f-220c1697463f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4521efc7-a7c2-40d2-974a-45847bf938d2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1289bc36-ea54-4c28-864f-220c1697463f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_58d534ba-eb92-43dd-b088-403fa044d29f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1289bc36-ea54-4c28-864f-220c1697463f" xlink:to="loc_us-gaap_AwardTypeAxis_58d534ba-eb92-43dd-b088-403fa044d29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c42eee8b-379d-42fc-b2ca-17e50172c55b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_58d534ba-eb92-43dd-b088-403fa044d29f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c42eee8b-379d-42fc-b2ca-17e50172c55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_c0dc7128-dc45-4a21-bb03-3066506c11d4" xlink:href="fold-20210331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c42eee8b-379d-42fc-b2ca-17e50172c55b" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_c0dc7128-dc45-4a21-bb03-3066506c11d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1289bc36-ea54-4c28-864f-220c1697463f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b5746b7-d94c-48d2-bc7e-b4151c5118b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b5746b7-d94c-48d2-bc7e-b4151c5118b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ada88a20-7f1a-49f3-a75b-ca7f4dca5b4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ada88a20-7f1a-49f3-a75b-ca7f4dca5b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2e02629b-93c9-4c8d-872d-953926197234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2e02629b-93c9-4c8d-872d-953926197234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1e0366e7-e4b5-448a-9274-a18c4f4b38fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1e0366e7-e4b5-448a-9274-a18c4f4b38fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ecc15ca-829c-47fd-a237-1c56a670ef90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57d7c9e3-3948-4b68-b00e-b92acfeda1a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1ecc15ca-829c-47fd-a237-1c56a670ef90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6a805097-1268-4edb-a6de-718e9c3de2d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_6a805097-1268-4edb-a6de-718e9c3de2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7af0b29b-3e12-43a3-9871-f7a5e5f32f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7af0b29b-3e12-43a3-9871-f7a5e5f32f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6575d7ed-de30-4001-bc8a-375b1a527ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6575d7ed-de30-4001-bc8a-375b1a527ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_557ca345-45e5-48f7-9801-a6fa02fd2b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_557ca345-45e5-48f7-9801-a6fa02fd2b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d5a179e2-7deb-4c2f-a811-b95e30ba882d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d5a179e2-7deb-4c2f-a811-b95e30ba882d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_38b70a4c-fda4-4663-b054-a5607616daae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_38b70a4c-fda4-4663-b054-a5607616daae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76514556-d6ef-45b3-97b7-28ec8759da49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4ba4779b-961b-467b-914d-395f1a8c2209" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76514556-d6ef-45b3-97b7-28ec8759da49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_764d62e9-a9d1-4ad4-8062-ad1d7ed6c3d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_764d62e9-a9d1-4ad4-8062-ad1d7ed6c3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2d76ed3d-1ea5-405d-b875-ad4d5f612482" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2d76ed3d-1ea5-405d-b875-ad4d5f612482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bfe70b50-e296-49e5-8760-6c5571152680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ac695c79-08a1-4940-999b-b4440fb17a2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ac695c79-08a1-4940-999b-b4440fb17a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c9a529f0-3aa2-409d-a244-47935cfb0e2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c9a529f0-3aa2-409d-a244-47935cfb0e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7fc90482-02c7-4d54-847c-dc579644e75f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7fc90482-02c7-4d54-847c-dc579644e75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_38cd3603-7f71-4eb2-93c6-c329eda818fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_38cd3603-7f71-4eb2-93c6-c329eda818fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_02f69df6-a6f2-43b6-a41e-0be8991083f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_02f69df6-a6f2-43b6-a41e-0be8991083f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_24c41d99-b922-4beb-aa85-9d052206ac99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_49ee2cab-4690-430f-83f1-80546f20a2c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_24c41d99-b922-4beb-aa85-9d052206ac99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8c0a46f-b88a-4a84-b0d5-b172b3113baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78571c72-9603-4050-8452-46f06505e6b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8c0a46f-b88a-4a84-b0d5-b172b3113baf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78571c72-9603-4050-8452-46f06505e6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2fe8337d-392b-4771-b567-8dd5233b058e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78571c72-9603-4050-8452-46f06505e6b4" xlink:to="loc_us-gaap_AwardTypeAxis_2fe8337d-392b-4771-b567-8dd5233b058e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7058509-24f8-466f-83b7-f5528d91feb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2fe8337d-392b-4771-b567-8dd5233b058e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7058509-24f8-466f-83b7-f5528d91feb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_025e72af-eb42-4b66-8a91-840188e1a542" xlink:href="fold-20210331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7058509-24f8-466f-83b7-f5528d91feb7" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_025e72af-eb42-4b66-8a91-840188e1a542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e2ab104b-a426-4e74-82d6-1836f4afb0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7058509-24f8-466f-83b7-f5528d91feb7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e2ab104b-a426-4e74-82d6-1836f4afb0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ced1e495-7355-4156-af7b-14b640d63ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78571c72-9603-4050-8452-46f06505e6b4" xlink:to="loc_us-gaap_PlanNameAxis_ced1e495-7355-4156-af7b-14b640d63ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_84b4c1a7-cfa2-4655-bc4f-777cbdb77bba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ced1e495-7355-4156-af7b-14b640d63ef3" xlink:to="loc_us-gaap_PlanNameDomain_84b4c1a7-cfa2-4655-bc4f-777cbdb77bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_46728579-5727-44c8-a83a-90913a54e3d6" xlink:href="fold-20210331.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_84b4c1a7-cfa2-4655-bc4f-777cbdb77bba" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_46728579-5727-44c8-a83a-90913a54e3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8e63dcd-8894-4f13-99b4-472522470468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_78571c72-9603-4050-8452-46f06505e6b4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8e63dcd-8894-4f13-99b4-472522470468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1806d174-0855-45f6-902f-3d559d07bffd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8e63dcd-8894-4f13-99b4-472522470468" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1806d174-0855-45f6-902f-3d559d07bffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_709a76fe-c30b-4365-b447-47f0f470a1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8e63dcd-8894-4f13-99b4-472522470468" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_709a76fe-c30b-4365-b447-47f0f470a1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2aa59aff-789f-4944-826f-da283f9651bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8e63dcd-8894-4f13-99b4-472522470468" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2aa59aff-789f-4944-826f-da283f9651bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd6d20e-b12a-4c49-89ff-274d7d49e077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d26c015-0b34-47c5-98f3-d92e96ccd58d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2dd6d20e-b12a-4c49-89ff-274d7d49e077" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d26c015-0b34-47c5-98f3-d92e96ccd58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d127b17b-8396-4696-ad30-720878261992" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d26c015-0b34-47c5-98f3-d92e96ccd58d" xlink:to="loc_us-gaap_AwardTypeAxis_d127b17b-8396-4696-ad30-720878261992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1f06b0b-37c7-432c-93ff-647888f829ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d127b17b-8396-4696-ad30-720878261992" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1f06b0b-37c7-432c-93ff-647888f829ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9d8626d5-7d79-4437-962d-f8e1537b767d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1f06b0b-37c7-432c-93ff-647888f829ac" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9d8626d5-7d79-4437-962d-f8e1537b767d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bce66f21-baf0-4808-a592-e30732c32c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d26c015-0b34-47c5-98f3-d92e96ccd58d" xlink:to="loc_us-gaap_PlanNameAxis_bce66f21-baf0-4808-a592-e30732c32c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c90d0935-7922-43e1-946f-41cf382b8a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_bce66f21-baf0-4808-a592-e30732c32c7e" xlink:to="loc_us-gaap_PlanNameDomain_c90d0935-7922-43e1-946f-41cf382b8a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_3ef31339-7dd3-486a-b473-6ba07129d2e8" xlink:href="fold-20210331.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c90d0935-7922-43e1-946f-41cf382b8a7f" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_3ef31339-7dd3-486a-b473-6ba07129d2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65ec4c92-5e8f-4dc6-a631-9bcf70604bf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6d26c015-0b34-47c5-98f3-d92e96ccd58d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65ec4c92-5e8f-4dc6-a631-9bcf70604bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65ec4c92-5e8f-4dc6-a631-9bcf70604bf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_61928468-00f2-4329-8fb3-e3479ef2bdbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_61928468-00f2-4329-8fb3-e3479ef2bdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f2272876-a148-4d86-bbb7-c0e0963d7858" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f2272876-a148-4d86-bbb7-c0e0963d7858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4080f717-6447-489c-9a5e-f46311e99daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4080f717-6447-489c-9a5e-f46311e99daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2d94a8f9-e14d-40b2-9b4a-f8fb8b262451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2d94a8f9-e14d-40b2-9b4a-f8fb8b262451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00ab0b92-3441-4bb2-bc00-17f479092257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5c8b4f1f-8a61-4818-a27a-32a60486444c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_00ab0b92-3441-4bb2-bc00-17f479092257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65ec4c92-5e8f-4dc6-a631-9bcf70604bf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_00d40326-08f4-4e9f-afc6-4124efd649c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_00d40326-08f4-4e9f-afc6-4124efd649c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5dbdd61b-b47e-4418-8fd0-68d70478c8f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5dbdd61b-b47e-4418-8fd0-68d70478c8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ba6c71d6-cf8a-4787-a83a-e26dc57f01fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ba6c71d6-cf8a-4787-a83a-e26dc57f01fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6985619c-c047-49b6-bd01-0a88fa0dbda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6985619c-c047-49b6-bd01-0a88fa0dbda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2333a1e3-61d6-421e-8755-c23628ef899f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a225d852-7f2f-4421-a26c-0d5c93cf9ec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2333a1e3-61d6-421e-8755-c23628ef899f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_52276b83-a181-4e74-bf3e-eb72c6a97138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_65ec4c92-5e8f-4dc6-a631-9bcf70604bf7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_52276b83-a181-4e74-bf3e-eb72c6a97138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d953dda3-4cfb-4928-b806-2307041f6b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_52276b83-a181-4e74-bf3e-eb72c6a97138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_d953dda3-4cfb-4928-b806-2307041f6b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b32047dd-ab9f-43aa-8eba-74ca3e248239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_52276b83-a181-4e74-bf3e-eb72c6a97138" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_b32047dd-ab9f-43aa-8eba-74ca3e248239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#ShareBasedCompensationExpenseSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0030f75c-33c1-4c82-b157-a639220f6149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb48f675-e565-4e9f-a4ce-1e4036e93455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0030f75c-33c1-4c82-b157-a639220f6149" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb48f675-e565-4e9f-a4ce-1e4036e93455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_c59055e5-2b24-4693-b45d-615a98ca3323" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb48f675-e565-4e9f-a4ce-1e4036e93455" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_c59055e5-2b24-4693-b45d-615a98ca3323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_472b698d-3149-400d-910f-a97bffbc01a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_c59055e5-2b24-4693-b45d-615a98ca3323" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_472b698d-3149-400d-910f-a97bffbc01a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6790ceee-1ba3-484d-be55-65ec58eeca28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_472b698d-3149-400d-910f-a97bffbc01a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6790ceee-1ba3-484d-be55-65ec58eeca28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4168c9e8-3cf5-4756-be0f-2e0fb8859ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_472b698d-3149-400d-910f-a97bffbc01a6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4168c9e8-3cf5-4756-be0f-2e0fb8859ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_889e4589-3fa4-4e4b-880c-d9b120b5cef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fb48f675-e565-4e9f-a4ce-1e4036e93455" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_889e4589-3fa4-4e4b-880c-d9b120b5cef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3d121a7a-9630-499c-8b81-44df944ccde2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_889e4589-3fa4-4e4b-880c-d9b120b5cef5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3d121a7a-9630-499c-8b81-44df944ccde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f26c6c80-1f01-4ca1-95cd-92b11620b594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_96ed0250-8b9a-4a58-bb43-09b9e02505a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f26c6c80-1f01-4ca1-95cd-92b11620b594" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_96ed0250-8b9a-4a58-bb43-09b9e02505a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7296ac31-ec59-4194-b70d-6ca846914d89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_480e6c75-dd8f-44b2-bda6-1e61e647724b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7296ac31-ec59-4194-b70d-6ca846914d89" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_480e6c75-dd8f-44b2-bda6-1e61e647724b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ecf6086f-5b9e-4450-b41f-877b0d225540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7296ac31-ec59-4194-b70d-6ca846914d89" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ecf6086f-5b9e-4450-b41f-877b0d225540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_40f4fa2d-e987-4106-99c1-18b32a0907e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7296ac31-ec59-4194-b70d-6ca846914d89" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_40f4fa2d-e987-4106-99c1-18b32a0907e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e33af2f6-a487-4e36-9da2-2c1687a5d21f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4859ebe-07dd-476c-a605-90cd324f40ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e33af2f6-a487-4e36-9da2-2c1687a5d21f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4859ebe-07dd-476c-a605-90cd324f40ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fe5d3de-801d-42e3-b543-ae551b0387f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4859ebe-07dd-476c-a605-90cd324f40ce" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fe5d3de-801d-42e3-b543-ae551b0387f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d5d6c65-3979-4090-94df-8cc66908cb53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0fe5d3de-801d-42e3-b543-ae551b0387f1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d5d6c65-3979-4090-94df-8cc66908cb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_cf28f1d6-8543-4e96-817e-951310821455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d5d6c65-3979-4090-94df-8cc66908cb53" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_cf28f1d6-8543-4e96-817e-951310821455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f83aa562-12cc-4598-8172-d146321c375c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2d5d6c65-3979-4090-94df-8cc66908cb53" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f83aa562-12cc-4598-8172-d146321c375c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ff1d949b-3d26-45ca-a2fb-1e9ca0f403ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4859ebe-07dd-476c-a605-90cd324f40ce" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ff1d949b-3d26-45ca-a2fb-1e9ca0f403ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ff1d949b-3d26-45ca-a2fb-1e9ca0f403ce" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_bcf794af-5b34-4ee8-8293-d71e5e35b139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_bcf794af-5b34-4ee8-8293-d71e5e35b139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_8242a2eb-082e-4d06-86b2-3d67723dc7a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_8242a2eb-082e-4d06-86b2-3d67723dc7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_17b3d91f-821a-4ecd-b148-17c54eaa899f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_17b3d91f-821a-4ecd-b148-17c54eaa899f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_aa8255b3-95ea-4880-b341-4cb9550ab6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_aa8255b3-95ea-4880-b341-4cb9550ab6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b2c0f697-738c-433a-b04b-0df34882d425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1ce031c7-4c8c-4ee4-9088-41ba8788cd12" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b2c0f697-738c-433a-b04b-0df34882d425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae53acd4-8239-4d95-94f6-14ad19bdaf1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4859ebe-07dd-476c-a605-90cd324f40ce" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae53acd4-8239-4d95-94f6-14ad19bdaf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1017c02d-b002-42b8-a99e-455800e07b18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae53acd4-8239-4d95-94f6-14ad19bdaf1a" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1017c02d-b002-42b8-a99e-455800e07b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b6ba6754-948f-4509-b1c7-dd6b751a13dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1017c02d-b002-42b8-a99e-455800e07b18" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_b6ba6754-948f-4509-b1c7-dd6b751a13dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa5c0648-704b-41b8-b59b-27c31b8d498f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae53acd4-8239-4d95-94f6-14ad19bdaf1a" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa5c0648-704b-41b8-b59b-27c31b8d498f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_50add501-469f-4dcf-8abb-643d9e4b0cce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa5c0648-704b-41b8-b59b-27c31b8d498f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_50add501-469f-4dcf-8abb-643d9e4b0cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_dbe811ce-aef3-4280-afc8-979fa46e936f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa5c0648-704b-41b8-b59b-27c31b8d498f" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_dbe811ce-aef3-4280-afc8-979fa46e936f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_84c5ea72-a6fe-44e3-a1e5-1e5d1cde2c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_aa5c0648-704b-41b8-b59b-27c31b8d498f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_84c5ea72-a6fe-44e3-a1e5-1e5d1cde2c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_f679174a-69da-40dc-8d5f-e122d8e518ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae53acd4-8239-4d95-94f6-14ad19bdaf1a" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_f679174a-69da-40dc-8d5f-e122d8e518ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_717dadc0-7a39-466c-9824-418314295678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_717dadc0-7a39-466c-9824-418314295678" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_53562160-723f-48d5-a8d5-5df55c62a8be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_53562160-723f-48d5-a8d5-5df55c62a8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4107348-a2cc-4119-96f8-7dd9470da7ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_53562160-723f-48d5-a8d5-5df55c62a8be" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4107348-a2cc-4119-96f8-7dd9470da7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember_213fa74d-18cb-47a2-a994-0844a78f8abd" xlink:href="fold-20210331.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a4107348-a2cc-4119-96f8-7dd9470da7ac" xlink:to="loc_fold_CallidusBiopharmaIncMember_213fa74d-18cb-47a2-a994-0844a78f8abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_6ab54e58-1ac5-464f-a69a-72f9940b783f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_6ab54e58-1ac5-464f-a69a-72f9940b783f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_cd0b7376-dc36-46d4-91ce-5cc68c9f5995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_6ab54e58-1ac5-464f-a69a-72f9940b783f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_cd0b7376-dc36-46d4-91ce-5cc68c9f5995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_502e28ab-effd-427b-88d4-c0315b6545d5" xlink:href="fold-20210331.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_cd0b7376-dc36-46d4-91ce-5cc68c9f5995" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_502e28ab-effd-427b-88d4-c0315b6545d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2c434998-935f-4670-825b-d5df0c4164ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2c434998-935f-4670-825b-d5df0c4164ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_adb5878e-1b27-4484-8b48-dcb92f0eb53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2c434998-935f-4670-825b-d5df0c4164ec" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_adb5878e-1b27-4484-8b48-dcb92f0eb53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7babff44-5830-4266-862b-f1d137b12623" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_adb5878e-1b27-4484-8b48-dcb92f0eb53f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7babff44-5830-4266-862b-f1d137b12623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_04e4a05b-c096-4430-8d20-9414db9bc554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_04e4a05b-c096-4430-8d20-9414db9bc554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_98ba235e-21aa-4eeb-a5fe-74a1d18d2327" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_04e4a05b-c096-4430-8d20-9414db9bc554" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_98ba235e-21aa-4eeb-a5fe-74a1d18d2327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_f44b8aa8-83dd-4133-86da-fa8bce526dbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_98ba235e-21aa-4eeb-a5fe-74a1d18d2327" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_f44b8aa8-83dd-4133-86da-fa8bce526dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_f34f536d-8176-47cb-bf18-750a1e62f731" xlink:href="fold-20210331.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_98ba235e-21aa-4eeb-a5fe-74a1d18d2327" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_f34f536d-8176-47cb-bf18-750a1e62f731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5ccd6886-b686-4488-a050-ec4ccbd8c8c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5ccd6886-b686-4488-a050-ec4ccbd8c8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b60b65ee-d71f-4949-861f-bbdd0d79c8a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5ccd6886-b686-4488-a050-ec4ccbd8c8c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b60b65ee-d71f-4949-861f-bbdd0d79c8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ATB200PompeProgramMember_d619173d-b41a-4679-9b49-18e3deae562d" xlink:href="fold-20210331.xsd#fold_ATB200PompeProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b60b65ee-d71f-4949-861f-bbdd0d79c8a2" xlink:to="loc_fold_ATB200PompeProgramMember_d619173d-b41a-4679-9b49-18e3deae562d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_7cc92afb-3c2a-497e-b60c-b36b80046fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_ValuationTechniqueAxis_7cc92afb-3c2a-497e-b60c-b36b80046fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_b28a7e66-37cf-4f66-ac30-e7eaf9f586f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7cc92afb-3c2a-497e-b60c-b36b80046fde" xlink:to="loc_us-gaap_ValuationTechniqueDomain_b28a7e66-37cf-4f66-ac30-e7eaf9f586f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_5ad283d9-8ebc-4bb6-8391-72879f7d9616" xlink:href="fold-20210331.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_b28a7e66-37cf-4f66-ac30-e7eaf9f586f5" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_5ad283d9-8ebc-4bb6-8391-72879f7d9616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_87758f0b-41c6-4dda-a7c9-3ebd9457de17" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_srt_RangeAxis_87758f0b-41c6-4dda-a7c9-3ebd9457de17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d8a97ab9-743b-4205-bfef-c451444ad673" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_87758f0b-41c6-4dda-a7c9-3ebd9457de17" xlink:to="loc_srt_RangeMember_d8a97ab9-743b-4205-bfef-c451444ad673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_59602a46-175c-4a51-a168-57d1197ac321" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d8a97ab9-743b-4205-bfef-c451444ad673" xlink:to="loc_srt_MinimumMember_59602a46-175c-4a51-a168-57d1197ac321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_375e5c1b-b001-4acb-a739-64871dc3a88d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d8a97ab9-743b-4205-bfef-c451444ad673" xlink:to="loc_srt_MaximumMember_375e5c1b-b001-4acb-a739-64871dc3a88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b843afed-f277-40c7-9660-18ee8b8317df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_b3cd201c-c151-448b-9434-f0d02c380ae3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b843afed-f277-40c7-9660-18ee8b8317df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_b7dc1b9b-afc8-44e2-ae41-3403158422ec" xlink:href="fold-20210331.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b843afed-f277-40c7-9660-18ee8b8317df" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_b7dc1b9b-afc8-44e2-ae41-3403158422ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a8e725a8-4375-4453-a974-3c6764cc77e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_b843afed-f277-40c7-9660-18ee8b8317df" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a8e725a8-4375-4453-a974-3c6764cc77e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_01ad52e2-11e9-47aa-a0de-16524dababb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09a2e08a-5fd1-49e5-bb08-af55c94548f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_01ad52e2-11e9-47aa-a0de-16524dababb1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09a2e08a-5fd1-49e5-bb08-af55c94548f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_dcc9f4ae-5df1-4d36-ac60-3c0f64aa4ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09a2e08a-5fd1-49e5-bb08-af55c94548f0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_dcc9f4ae-5df1-4d36-ac60-3c0f64aa4ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4620428e-dcf1-444f-a216-2c3797c3b1f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09a2e08a-5fd1-49e5-bb08-af55c94548f0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4620428e-dcf1-444f-a216-2c3797c3b1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_451d039c-1862-4102-b37d-10eab969a555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_09a2e08a-5fd1-49e5-bb08-af55c94548f0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_451d039c-1862-4102-b37d-10eab969a555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="simple" xlink:href="fold-20210331.xsd#BasicandDilutedNetLossperCommonShare"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2c5f110a-1460-4bde-b5a7-32b0cdc09541" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9c258374-f76b-4654-8fd3-089a07d40bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2c5f110a-1460-4bde-b5a7-32b0cdc09541" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9c258374-f76b-4654-8fd3-089a07d40bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="simple" xlink:href="fold-20210331.xsd#BasicandDilutedNetLossperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a93275b1-e8d6-4663-aeb7-8d12c46d2682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_59c9a76b-6236-4d3e-a7b4-c816fef78fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a93275b1-e8d6-4663-aeb7-8d12c46d2682" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_59c9a76b-6236-4d3e-a7b4-c816fef78fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_becfb136-0627-4fa9-9fc1-82269b5cc65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a93275b1-e8d6-4663-aeb7-8d12c46d2682" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_becfb136-0627-4fa9-9fc1-82269b5cc65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20210331.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1e4393e2-75a2-488e-8478-8e09e6319d02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c08873d6-15d0-43af-9d3f-f96affd616d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1e4393e2-75a2-488e-8478-8e09e6319d02" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c08873d6-15d0-43af-9d3f-f96affd616d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9f00f0-b991-48c2-b8ae-7b5037ba61b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c08873d6-15d0-43af-9d3f-f96affd616d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9f00f0-b991-48c2-b8ae-7b5037ba61b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9a9f00f0-b991-48c2-b8ae-7b5037ba61b1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_98a4a59f-c807-4c6a-b8b6-bddd5d656384" xlink:href="fold-20210331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_98a4a59f-c807-4c6a-b8b6-bddd5d656384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_c923a8a9-9d71-4e81-90d9-f6cc88711920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_c923a8a9-9d71-4e81-90d9-f6cc88711920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c9eb9fcd-bd74-4a00-8c76-d3f42c388153" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:to="loc_us-gaap_WarrantMember_c9eb9fcd-bd74-4a00-8c76-d3f42c388153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f21d2ea4-544b-4fee-9d16-574cfcf7f697" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_df6fbb1d-c44c-417b-b5fa-a1ca4e250e50" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f21d2ea4-544b-4fee-9d16-574cfcf7f697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d04f127c-29ba-446e-aa57-a33e41bc6902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c08873d6-15d0-43af-9d3f-f96affd616d8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d04f127c-29ba-446e-aa57-a33e41bc6902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_71030383-0752-48ab-88a3-33e751eda82a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d04f127c-29ba-446e-aa57-a33e41bc6902" xlink:to="loc_us-gaap_NetIncomeLossAbstract_71030383-0752-48ab-88a3-33e751eda82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c09c9256-3db6-4873-b7ef-75e6964f165a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_71030383-0752-48ab-88a3-33e751eda82a" xlink:to="loc_us-gaap_NetIncomeLoss_c09c9256-3db6-4873-b7ef-75e6964f165a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_82942943-16f2-403c-9bea-c63ee5872dc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d04f127c-29ba-446e-aa57-a33e41bc6902" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_82942943-16f2-403c-9bea-c63ee5872dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_04a279c7-54f7-4589-976c-b32f6a6eabba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_82942943-16f2-403c-9bea-c63ee5872dc9" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_04a279c7-54f7-4589-976c-b32f6a6eabba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ebcabff2-2be2-47e6-9f46-9bce0da94ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d04f127c-29ba-446e-aa57-a33e41bc6902" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ebcabff2-2be2-47e6-9f46-9bce0da94ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>fold-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:fold="http://www.amicustherapeutics.com/20210331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fold-20210331.xsd" xlink:type="simple"/>
    <context id="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if28eb188bd19434e8fa22bdbc05ce6ed_I20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2021-04-26</instant>
        </period>
    </context>
    <context id="i085324ad68f040cab6d186478f2dac9f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i01cf5118ba1646a0a3dfd406beed48c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4106d82d54f040ab8a176e31e97e485d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id288f022ad3e4df48660873a6e9fea15_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46ce59af193c4c868c341c26afa4148b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2fa2ef2f3d8442d9b9a0ada40c1530dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia8fc939cca8b43d0920b98c1049e39f3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i03da422e5e5b41988fb9336c36774604_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i32ad9c5f70914438a056f21590c29a77_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i58b1a856d6014eafa34817652747a42b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6a64d12323e541d285585950b069b321_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iec56b4d95a9040f691ae98d1932ff45b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i97fd1af684a34d1a9cebb50ef794c543_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3e9a645c33e64a77841416360656deb9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2b4a5c424f2945d7bd2f559c6b986d5b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibd1b47a0c9e8402fbff7bffee12db9fd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i517fd281a28749d78656d0a3c7970477_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8c7e2aad59ba4f578e5e314f37acb879_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if21cdcddb1bf4bc0beb5bdf9f9bc15d0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18c0cf87387948d38739af8f77a6b421_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7e38b37ec5484f9da915405503e03bd6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia75e14a1366d45c3b7e75e7e9a700855_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i91e38d29dead4f2785069422f620c2d0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i43f99be30a2947fca4d5d0dc3b99d26b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i020ee144910d46a2aec0495b12e94578_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i843e6fbfc6d34a439da0268c8c325cf1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2d77582b16b44d15a065c048a584eeb0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icc16447402d44046a7451c1acd97ace7_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idd32f0ef41fb4c0eb71b5ff4f53781b9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i91abb571e5b04f10ab1bb7976314f183_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0db45e1d6c1c4528adbb181b99592123_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ice1b8156e8124fb381e0a08494f81a37_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie422fb8df9cc41a8898b1ecdbc54b0ba_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7d4f9bae82114ff29db94ce7ce943250_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8ef534e19d7042548a667fe11fe7f8df_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7d172b37766a4bff90df25277ccbedb9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i806c5d2d5f15482c81c841bd96d6e68a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia838f9184beb47c297d0a9b6544f7d24_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i62fb03830de7497887830162220ec3d7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i86075c190d2342278bca860d772e4fc9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i69afd1d0068b46408516b4e05dbea56d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i52a446687d324ec99e46667ddf742275_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e96be861b404667ab8e185f54dce138_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90263ef14b3e490f92f545e8f1abec6d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7a9bf8271f74640842b35661ede6ee6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i471af39f23494beca4b65d011f8a7d44_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide7d1fdcbabf448182fada4f80efd849_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96b2d9a6834748be93f41e359fed6f91_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1859eeb446e743c997733b443de3f5c8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i64bce1e96a6b41f88ce6934c6afe246c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec32650d30684749839221747f88aa14_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3ec6a6de4b2d49b0a233b7ac18dc5fc0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99f52dc175e143b393b832e43be95df1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iac3a273d2c644f5780e23dc81b7297ff_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i3e22a2bd23524e7ab906f08199397062_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="idc272117737541f1b41cbaf126872267_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f487fde288f4011b4b648177324c5df_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt798Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7a5a6bdf179e45b4aa77d6a3a56433ed_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i70e0a9292cfa42c8845f33beb7296ef3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">fold:StockExercisesAt706Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i383d26a8b8bd42e3ac89f235894e1cbf_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if040fef71ada406393452b0b39e0a2e1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i27a30ae4c9ce4d2e910e5d6a3b595381_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18b0bfea8fa64c228509348665fc54c8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iafc0c4bbc6714c919e4c4906d4cbc02d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0abd1fb5725a4bedad2d8202c502b854_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0cdf6bb18bf446948b40dfbf1cb8cf1e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i290692dfef66483bbda493456b3bc22a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic0570ee1bbea436e8e48eef0fd3bd67c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic314dbac744e4ddea724b9e8a9812eef_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6eb20145e2874e789ae1c2623304be15_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7e6bf707c01a42f88c4ac502aa81d78f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2dca0209b8ee4d85a4cfb8abbdde80a1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9312ad97e83344808a753c2777b9f467_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6936379467174bf0b8d397139372390d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id8d80b53cc024638bae2f43fb6d44a08_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie3072184bd964b5c80a501c985ee8879_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0595419a51734a4191e082d87b615eb2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4936c29e819c4df1803afec2e7346d1f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6bf8b70d9e4c47a798d27a71f86e9dc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93bf63ec6fe74e25acfb12d7d93c414a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6283b4e42587498eb64b1d806d8e10e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ebe9d99985f4e54a4e7b34d261a0b63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id4887cc5b8ad47438f6ddb6830f15cc0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i525ca3a76a74424385c3cfcd34a9894d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia39206c7064840cc993f0d99c3d83ac6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i925eb208debe4acf8dbeded140f69103_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i037b121761ef436aabc14ae0bdc430a2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iba028b38e31b4ee9b5ccfc7c44f23b30_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i505945357e0a4dc4b3ca2122d1d0441f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic95386b7dca242ae8b4eb32c56d32799_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6f0863e5d54c41c88117aaf4a26aba0d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i534dddc6b1d74accbbb4df2865f0432a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0adf3d441ca04bac95b5ee95c7459225_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iafbfc7637aea4b6b9a703e4bdfd9e9c6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6d4d9cbe713d437ba0d38b04a1e4b8db_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d2ae022e9674e9889a69b4ecabc8ec5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>fold:day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80L2ZyYWc6NGY1ODJjM2E1YWYyNDdiM2E4OWQ2MjgzZWJkMjNjODEvdGFibGU6NjU1NWNmNTUzMWI3NDQzZDgwN2Y5MzI1YmQzY2RmNTcvdGFibGVyYW5nZTo2NTU1Y2Y1NTMxYjc0NDNkODA3ZjkzMjViZDNjZGY1N18zLTEtMS0xLTA_f25afaad-0abb-4918-8853-e11b51db57e0">0001178879</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80L2ZyYWc6NGY1ODJjM2E1YWYyNDdiM2E4OWQ2MjgzZWJkMjNjODEvdGFibGU6NjU1NWNmNTUzMWI3NDQzZDgwN2Y5MzI1YmQzY2RmNTcvdGFibGVyYW5nZTo2NTU1Y2Y1NTMxYjc0NDNkODA3ZjkzMjViZDNjZGY1N180LTEtMS0xLTA_b3d7c21d-e675-423d-8b14-e408fcb74a0d">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80L2ZyYWc6NGY1ODJjM2E1YWYyNDdiM2E4OWQ2MjgzZWJkMjNjODEvdGFibGU6NjU1NWNmNTUzMWI3NDQzZDgwN2Y5MzI1YmQzY2RmNTcvdGFibGVyYW5nZTo2NTU1Y2Y1NTMxYjc0NDNkODA3ZjkzMjViZDNjZGY1N181LTEtMS0xLTA_ceff687a-4c7e-41bf-86f4-80e9eb72f43a">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80L2ZyYWc6NGY1ODJjM2E1YWYyNDdiM2E4OWQ2MjgzZWJkMjNjODEvdGFibGU6NjU1NWNmNTUzMWI3NDQzZDgwN2Y5MzI1YmQzY2RmNTcvdGFibGVyYW5nZTo2NTU1Y2Y1NTMxYjc0NDNkODA3ZjkzMjViZDNjZGY1N182LTEtMS0xLTA_ee96168e-c21b-477c-bca4-01a276c85041">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80L2ZyYWc6NGY1ODJjM2E1YWYyNDdiM2E4OWQ2MjgzZWJkMjNjODEvdGFibGU6NjU1NWNmNTUzMWI3NDQzZDgwN2Y5MzI1YmQzY2RmNTcvdGFibGVyYW5nZTo2NTU1Y2Y1NTMxYjc0NDNkODA3ZjkzMjViZDNjZGY1N183LTEtMS0xLTA_ceaf6b50-b3b1-4b1b-adcd-1dc7ae412653">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMDk1_7f7e9c36-f438-4c7a-a9a1-a9681961a346">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMDk2_d5726fa8-f3eb-4808-a050-b605c7bb0ccb">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMzI_7910f314-23ff-4c60-a887-e94a8999fc56">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMDk3_b12b7ddf-5daf-49b6-9aab-115e3c8248e5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMDk5_01e07766-89e5-4382-964c-994171a4d3af">001-33497</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMTAw_49290a89-aeed-4b29-810a-edd3ce3004be">Amicus Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF8wLTAtMS0xLTA_aea655d0-3911-4787-9d2a-5ceed876af46">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF8wLTQtMS0xLTA_69e13589-3537-4758-ae72-08bc13af399c">71-0869350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF80LTAtMS0xLTA_e31144a3-dfe5-43c7-903a-cadf20309790">3675 Market Street,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF80LTEtMS0xLTA_6dd7f8bf-4497-45f5-b307-6a1b4be693f3">Philadelphia,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF80LTItMS0xLTA_8a1d9bc0-1f5e-4456-ae89-30adc79c6b23">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF80LTQtMS0xLTA_1bb2f9fe-e15d-4ed8-8885-3735d6972cff">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF83LTAtMS0xLTA_34fd571a-56f7-4c45-8d91-4fa80fe14204">(215)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6OGUxMjM3OWIwNDNhNGJkNmI0ZDBlMzcwMDk2OTY1MmQvdGFibGVyYW5nZTo4ZTEyMzc5YjA0M2E0YmQ2YjRkMGUzNzAwOTY5NjUyZF83LTMtMS0xLTA_4512853a-107d-477d-8da4-2a7855dcb8d6">921-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6NTJmZjdiZjk4ODMyNDI5OTgyYmU3ZjQ4OTVkMGZkNzcvdGFibGVyYW5nZTo1MmZmN2JmOTg4MzI0Mjk5ODJiZTdmNDg5NWQwZmQ3N18xLTAtMS0xLTA_28a98f89-fb28-4b7f-9a55-40442cae4bbe">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6NTJmZjdiZjk4ODMyNDI5OTgyYmU3ZjQ4OTVkMGZkNzcvdGFibGVyYW5nZTo1MmZmN2JmOTg4MzI0Mjk5ODJiZTdmNDg5NWQwZmQ3N18xLTEtMS0xLTA_0dee00ff-42a6-45d1-b2e3-accd5feb012d">FOLD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6NTJmZjdiZjk4ODMyNDI5OTgyYmU3ZjQ4OTVkMGZkNzcvdGFibGVyYW5nZTo1MmZmN2JmOTg4MzI0Mjk5ODJiZTdmNDg5NWQwZmQ3N18xLTItMS0xLTA_eedcebdd-dcfd-4b31-b4c6-04f7b9db98da">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMTAx_96be524d-1905-477e-b904-8b48385122ce">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMDk4_a7d3b581-5407-49e8-9db2-f713efec94f7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6ZGUwMWQ0YmRiNDgxNDJkNTk0MDU0YWM2MjJmNzJlZjQvdGFibGVyYW5nZTpkZTAxZDRiZGI0ODE0MmQ1OTQwNTRhYzYyMmY3MmVmNF8wLTAtMS0xLTA_681a1dda-f082-4fd7-912e-0555592692a2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6ZGUwMWQ0YmRiNDgxNDJkNTk0MDU0YWM2MjJmNzJlZjQvdGFibGVyYW5nZTpkZTAxZDRiZGI0ODE0MmQ1OTQwNTRhYzYyMmY3MmVmNF8xLTQtMS0xLTA_5684f6b9-b417-4979-948c-04a73bfe752d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGFibGU6ZGUwMWQ0YmRiNDgxNDJkNTk0MDU0YWM2MjJmNzJlZjQvdGFibGVyYW5nZTpkZTAxZDRiZGI0ODE0MmQ1OTQwNTRhYzYyMmY3MmVmNF8yLTQtMS0xLTA_6ad109d3-beb8-412a-abb1-ae3548e8acbc">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF8yMTAy_26a4b2c5-610b-4ed4-9b59-99babc27ffcd">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if28eb188bd19434e8fa22bdbc05ce6ed_I20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xL2ZyYWc6YjE5NTRlNzI4ZWU0NDc3MmI1NjA0NzcyMmE5MGYzMzgvdGV4dHJlZ2lvbjpiMTk1NGU3MjhlZTQ0NzcyYjU2MDQ3NzIyYTkwZjMzOF84MjQ2MzM3MjEwNDY2_085d893b-97ed-4371-92ab-4983eac1f022"
      unitRef="shares">266060455</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMy0xLTEtMS0w_9ae2b5e8-6846-4a67-801e-e1fa20a56b2e"
      unitRef="usd">184833000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMy0zLTEtMS0w_3da8df3c-288d-43c3-a1fc-71d01f5da96f"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNC0xLTEtMS0w_2fb6982e-0d3e-44f3-90b5-d0a636645695"
      unitRef="usd">232596000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNC0zLTEtMS0w_f6365976-d568-4ad5-8319-56245acbb13b"
      unitRef="usd">320029000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNS0xLTEtMS0w_32adc6b9-cf63-407e-87da-d2328bdf6b7d"
      unitRef="usd">44931000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNS0zLTEtMS0w_c38b02ca-25bc-42fb-9bbb-40dfa481c97a"
      unitRef="usd">46923000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNi0xLTEtMS0w_98ac7570-fda6-479f-8101-ecd4c536cbdc"
      unitRef="usd">18801000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNi0zLTEtMS0w_67c0b3c9-56b3-4d16-aab8-6d8728154f62"
      unitRef="usd">19556000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNy0xLTEtMS0w_9d6a6b9c-4aea-493e-ab88-693bb41a4052"
      unitRef="usd">21730000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfNy0zLTEtMS0w_e1ccb7d5-4282-41c7-bd04-815fcee50cdf"
      unitRef="usd">29721000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOC0xLTEtMS0w_be27f0cc-2718-40bd-96dc-9c445fef8800"
      unitRef="usd">502891000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOC0zLTEtMS0w_18691d04-f890-4130-9321-a4710a34ed16"
      unitRef="usd">579469000</us-gaap:AssetsCurrent>
    <fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOS0wLTEtMS0wL3RleHRyZWdpb246MGRiMThlY2RiOWIxNDhiZWFhYTQ3MDQ3YzNkNmRhN2JfNzQ_e7fa2f76-14f7-485e-8154-e9884008d61a"
      unitRef="usd">7499000</fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases>
    <fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOS0wLTEtMS0wL3RleHRyZWdpb246MGRiMThlY2RiOWIxNDhiZWFhYTQ3MDQ3YzNkNmRhN2JfODE_57693e23-c5b9-4825-949b-8617fb08fd2e"
      unitRef="usd">7574000</fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOS0xLTEtMS0w_cfb7eb44-e66e-4cab-8219-a72eeb7d8d91"
      unitRef="usd">22363000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfOS0zLTEtMS0w_08402797-4f58-4afc-91f4-e7d50c3751ed"
      unitRef="usd">23296000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjNiMzRhOTdmMWQyNTRkNTg4ZmE3NTU5MGQyZDRlM2ZkXzYx_6b58a70b-04ca-40c5-95cf-a54cb2257ad0"
      unitRef="usd">15961000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjNiMzRhOTdmMWQyNTRkNTg4ZmE3NTU5MGQyZDRlM2ZkXzY4_f3a3633d-dd47-49dc-9a82-31e3cf428298"
      unitRef="usd">14487000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTAtMS0xLTEtMA_33891be6-4709-421b-9498-5fc7c59796c6"
      unitRef="usd">43445000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTAtMy0xLTEtMA_34d70851-0882-42b2-8094-e037852d7f19"
      unitRef="usd">43863000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTEtMS0xLTEtMA_04c70b50-535e-4af1-ad22-d94a4b49a77c"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTEtMy0xLTEtMA_2f60e2f9-b89a-4f03-b45e-5138a28eee55"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTItMS0xLTEtMA_16843b8e-6a01-4391-9ef7-b927108bbb15"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTItMy0xLTEtMA_453c55e0-d326-45a7-9854-591b740470f7"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTMtMS0xLTEtMA_66911bc9-3f43-4a77-940e-a646fd25feb3"
      unitRef="usd">20538000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTMtMy0xLTEtMA_001c6bab-f0a4-4db3-8197-838ee2c1a413"
      unitRef="usd">19095000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTQtMS0xLTEtMA_f545df7e-3bf4-4174-ab0b-f955a54339fd"
      unitRef="usd">810034000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTQtMy0xLTEtMA_07169d3e-0dd7-4b33-a5f1-4985d69cb934"
      unitRef="usd">886520000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTctMS0xLTEtMA_a8d5cf14-cd93-45d1-9461-4448dacf8a88"
      unitRef="usd">16110000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTctMy0xLTEtMA_e0a1535b-ad82-493b-b704-1c451cbce3a1"
      unitRef="usd">17063000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTgtMS0xLTEtMA_40b25a3c-5aff-49e3-9776-4d1dbdf92869"
      unitRef="usd">57178000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTgtMy0xLTEtMA_19f550e5-c417-4763-8444-71229cd8b5f5"
      unitRef="usd">96841000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTktMS0xLTEtMjA_39241c57-5e11-419f-adeb-4da339da3fe3"
      unitRef="usd">19600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTktMy0xLTEtMjA_cac1911f-ff5f-427c-8884-6c26f415a5e8"
      unitRef="usd">8900000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTktMS0xLTEtMA_87042762-e302-4de7-b92d-ef716a63bd73"
      unitRef="usd">6764000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMTktMy0xLTEtMA_e0832aa1-c9e6-4a8d-85b1-284999066f5c"
      unitRef="usd">6872000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjAtMS0xLTEtMA_24390a86-e6a0-42ca-9f5a-cb56620aa84c"
      unitRef="usd">99652000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjAtMy0xLTEtMA_3e09d0c7-d09c-4fa4-b0d5-9cbdec09dc36"
      unitRef="usd">129676000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjEtMS0xLTEtMA_848f3c5a-de83-4689-b6f8-aa3d1d93bcd9"
      unitRef="usd">7406000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjEtMy0xLTEtMA_c51484bd-79a9-4d3e-9708-06b5a1c33c86"
      unitRef="usd">7406000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjItMS0xLTEtMA_f4409d2f-89d2-4c6b-aab5-37cb32c40d6f"
      unitRef="usd">389789000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjItMy0xLTEtMA_29035a85-7520-4970-8629-b5664cd63add"
      unitRef="usd">389254000</us-gaap:LongTermDebt>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjMtMS0xLTEtMA_0288da33-a236-4aeb-8e8e-76cb287263b4"
      unitRef="usd">6696000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjMtMy0xLTEtMA_8abc1578-b078-4268-8e72-87a413056c8e"
      unitRef="usd">16925000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjQtMS0xLTEtMA_45f1826c-979c-4eae-89a1-acc5b83f5702"
      unitRef="usd">4896000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjQtMy0xLTEtMA_f6b54e96-faca-47ce-ad8c-1105bf8886a0"
      unitRef="usd">4896000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjUtMS0xLTEtMA_f54283f0-8c94-441d-8fc1-2b4dd5c2f45d"
      unitRef="usd">44431000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjUtMy0xLTEtMA_7019aff6-90bd-49a3-a0ae-43d03d28a12b"
      unitRef="usd">45604000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjYtMS0xLTEtMA_1da41f8c-ffb4-48c7-bd38-e1e0028b7d1b"
      unitRef="usd">6268000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjYtMy0xLTEtMA_ac8a0fbe-3124-4eba-bc68-2c97023a67d0"
      unitRef="usd">6379000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjctMS0xLTEtMA_7a404ae6-2e0c-43ea-b987-de4f735e9ad3"
      unitRef="usd">559138000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjctMy0xLTEtMA_006a9fbc-76db-4cb4-a69e-71bdfbb11aa5"
      unitRef="usd">600140000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjgtMS0xLTEtMA_6d4512c6-bc06-4f51-aee6-cc0154256bb2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMjgtMy0xLTEtMA_b5f28fd4-45c8-4c68-9cf9-4e742da4818e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzE4_0fdea5d7-3b08-49a1-9a6e-1953ce95b4a5"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzE4_3a1a6499-fa00-44bb-ae6e-7baff1e9b82f"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzMy_4a328cc2-d467-4c19-9607-f6a5e0ce5259"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzMy_84dc2e9a-e8ef-49fd-aed2-81e823329461"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzU0_22616a65-034d-49b4-b1bc-c0da86d5b504"
      unitRef="shares">266007718</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzU0_7409f339-1d58-4bb4-a676-2d97fbc0e0ce"
      unitRef="shares">266007718</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzYx_c519862e-1000-419e-b9c6-e5712aee09a9"
      unitRef="shares">262063461</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOjM1NjI1ZDI3MTBkNzRjYTM4YThjYTk5Yzc5ZTFmMDRlXzYx_f0dae3d1-1d43-4e2d-8887-588ae0e736b6"
      unitRef="shares">262063461</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMS0xLTEtMA_5b4d1d17-0d39-43fc-bece-6332506dd697"
      unitRef="usd">2680000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzAtMy0xLTEtMA_07a7e486-69c8-431c-b6eb-105f0a46617a"
      unitRef="usd">2650000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzEtMS0xLTEtMA_90c5e636-3ad0-42e9-9e26-38f166d8b97b"
      unitRef="usd">2350507000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzEtMy0xLTEtMA_42f0ba87-5e9d-4593-8ddb-33a6cb0b4ece"
      unitRef="usd">2308578000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzMtMS0xLTEtMA_d897edd4-ab73-4890-98fe-f303bd889331"
      unitRef="usd">9020000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzMtMy0xLTEtMA_b9360e3e-7801-40b4-8d5e-864ba56d2d77"
      unitRef="usd">8412000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzQtMS0xLTEtMA_2bc7608c-9f33-407a-ace9-72482383a7ed"
      unitRef="usd">-185000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzQtMy0xLTEtMA_af50069c-8b0d-481d-ad96-1dc7f601ed40"
      unitRef="usd">-185000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzUtMS0xLTEtMA_b6e53e7c-2414-4618-9fb4-26201b68146b"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzUtMy0xLTEtMA_8e51a7e5-52bd-4113-8b4f-f66217a83bd0"
      unitRef="usd">12387000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzYtMS0xLTEtMA_0940f0dc-bf0b-4874-821c-492e2f1d486b"
      unitRef="usd">-2111126000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzYtMy0xLTEtMA_57c55a75-63ef-426f-9e44-28f20da1c89f"
      unitRef="usd">-2045462000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzctMS0xLTEtMA_c7d5ddd1-bde0-406c-acb9-004faf2ae5ca"
      unitRef="usd">250896000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzctMy0xLTEtMA_2fdbe114-24db-48c9-a284-a67495bf8af5"
      unitRef="usd">286380000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzgtMS0xLTEtMA_e1993128-76c4-4c88-b63b-7d3066ec05b8"
      unitRef="usd">810034000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xOS9mcmFnOjI4MGU1ZWY5ODY3MjQ0NzU4NTU3NThhMTZkYjhmMDU4L3RhYmxlOjIyOTk5NmQyMTE2ZjQwZWJhN2M5NGRhNDRiNzg1MDRiL3RhYmxlcmFuZ2U6MjI5OTk2ZDIxMTZmNDBlYmE3Yzk0ZGE0NGI3ODUwNGJfMzgtMy0xLTEtMA_112d67ad-2cb1-41b2-83e3-e013fa6399fb"
      unitRef="usd">886520000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMi0xLTEtMS0w_3276787a-fd3c-44e1-92d0-a795c58c086e"
      unitRef="usd">66402000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMi0zLTEtMS0w_f2813100-ba71-4052-8db7-71d6e5ce55a4"
      unitRef="usd">60525000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMy0xLTEtMS0w_949b4fe6-3690-4d13-8f9d-f78ed965e742"
      unitRef="usd">6539000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMy0zLTEtMS0w_6ab137d5-642e-41d1-91f8-9ab9dff17a8f"
      unitRef="usd">6552000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNC0xLTEtMS0w_d00bdede-0e6f-4772-b957-1eb1d642fe57"
      unitRef="usd">59863000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNC0zLTEtMS0w_d6825172-07b7-4ae0-a1ed-6a635f3b05d8"
      unitRef="usd">53973000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNi0xLTEtMS0w_04bcad7d-0275-4da6-a384-7f1830a7c15c"
      unitRef="usd">64117000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNi0zLTEtMS0w_3c321447-a74e-4714-8697-68b660e2bbf9"
      unitRef="usd">89120000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNy0xLTEtMS0w_10939f4c-5be1-4ec5-919b-a5b9253fa7c6"
      unitRef="usd">46726000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfNy0zLTEtMS0w_b7059dc4-0464-479e-ae0a-c78f0fc431b7"
      unitRef="usd">40215000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfOC0xLTEtMS0w_eeab55d7-c431-4029-baf8-8f7fe8c069a3"
      unitRef="usd">-471000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfOC0zLTEtMS0w_00064d62-66c3-4cde-b6b6-ce7be4f95969"
      unitRef="usd">-931000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfOS0xLTEtMS0w_522b0989-f6b9-4ed5-8673-9653c8ad67fc"
      unitRef="usd">1604000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfOS0zLTEtMS0w_a3008857-a45b-43fb-98cb-26be8fad84ab"
      unitRef="usd">1764000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTAtMS0xLTEtMA_5fc5c718-df00-48a2-bb9e-832ccfd6ccc5"
      unitRef="usd">112918000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTAtMy0xLTEtMA_ef1d52a3-3685-43b4-92fb-9b7f8bb51d4e"
      unitRef="usd">132030000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTEtMS0xLTEtMA_5861042d-d5de-4566-b77b-bcc2b2286a72"
      unitRef="usd">-53055000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTEtMy0xLTEtMA_5c5963f1-a420-4cae-8502-4945023bb095"
      unitRef="usd">-78057000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTMtMS0xLTEtMA_29576be5-0d99-4c68-a51d-3b2ddc87931c"
      unitRef="usd">165000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTMtMy0xLTEtMA_45ba6187-89e8-4dc6-b65e-83ad187706af"
      unitRef="usd">1515000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTQtMS0xLTEtMA_aa49743d-d448-4eb3-b75b-f38f7f33d25d"
      unitRef="usd">7992000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTQtMy0xLTEtMA_328c52f3-83c0-41b6-b28c-e29eb20c9f49"
      unitRef="usd">3729000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTctMS0xLTEtMA_4a8c3ab7-9ebf-4b44-bd59-feaea6c201c8"
      unitRef="usd">-3200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTctMy0xLTEtMA_a8155ff7-6960-44aa-a77a-d4cd9a198a32"
      unitRef="usd">-8316000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTgtMS0xLTEtMA_dce3594c-3d01-4b7b-bb4f-000b790a9fdc"
      unitRef="usd">-64082000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTgtMy0xLTEtMA_2f746a37-2ab3-4ffc-8daa-1ca52580009d"
      unitRef="usd">-88587000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTktMS0xLTEtMA_6b18883f-d21e-490e-bcb3-d59fc364b805"
      unitRef="usd">1582000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMTktMy0xLTEtMA_2194eaec-247d-432f-b08e-291a01bf28f6"
      unitRef="usd">361000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjAtMS0xLTEtMA_9ee2bff2-eac4-483f-99ad-6bc9c723bb13"
      unitRef="usd">-65664000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjAtMy0xLTEtMA_dbba8de3-573e-4684-8ea7-0a5893545276"
      unitRef="usd">-88948000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjEtMS0xLTEtMA_6c310874-5e21-4859-85ba-29126ce2f110"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjEtMy0xLTEtMA_9bf3d4b4-87e2-4950-a004-436228d82080"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjItMS0xLTEtMA_5e793483-030a-4816-98d9-b79d4733e5c2"
      unitRef="shares">264369317</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yMi9mcmFnOmM4YmU1NmRiNDJmNTQ2ZGNhODQ2NTUxZDVjYWExYmNiL3RhYmxlOjUzNjYxMGNlZGYyODQ0ZjM5NzhmMDI5YzEwMWMwODc1L3RhYmxlcmFuZ2U6NTM2NjEwY2VkZjI4NDRmMzk3OGYwMjljMTAxYzA4NzVfMjItMy0xLTEtMA_f44dda7f-2ec4-45ed-a58e-5e1d35d73afb"
      unitRef="shares">256968248</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfMi0xLTEtMS0w_049656ea-f0bf-43a6-959a-772e48a06b3a"
      unitRef="usd">-65664000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfMi0zLTEtMS0w_446d0d1c-a22e-44d0-975b-339a412b44f6"
      unitRef="usd">-88948000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNC0wLTEtMS0wL3RleHRyZWdpb246ZTc5MjdiN2VjNDNmNDY3N2FkMWUxMzhmNGNhZmUyNjBfNzg_43521081-dd62-4faf-aa2a-f534c8561171"
      unitRef="usd">132000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNC0wLTEtMS0wL3RleHRyZWdpb246ZTc5MjdiN2VjNDNmNDY3N2FkMWUxMzhmNGNhZmUyNjBfODI_1c551c12-f7d6-432d-88d0-17f06f7e2b08"
      unitRef="usd">1536000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNC0xLTEtMS0w_e7d13c89-357d-4fdc-b2ac-1ff159fa5ed1"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNC0zLTEtMS0w_2930ed06-4b77-4ff1-8962-a998dd10447d"
      unitRef="usd">4196000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNS0wLTEtMS0wL3RleHRyZWdpb246ZjVkOWEyZDlhYzMyNGI5NDgyMGVlYmI5NjRiYWM2YmRfMTY0OTI2NzQ0MTgxOQ_6dc841ad-3e2c-42ed-968f-0dca2db8c2ab"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNS0wLTEtMS0wL3RleHRyZWdpb246ZjVkOWEyZDlhYzMyNGI5NDgyMGVlYmI5NjRiYWM2YmRfODY_60da962e-967c-4320-9ab6-d8ca5734b727"
      unitRef="usd">-56000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNS0xLTEtMS0w_b1452619-11a1-4453-ba8d-d330cd1f5b9e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNS0zLTEtMS0w_25feab05-4503-411f-b320-4eac3bdbe10a"
      unitRef="usd">-209000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNi0xLTEtMS0w_65dd3e42-d323-46df-aaf3-27e0cd1f34d5"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNi0zLTEtMS0w_f72fd76c-4d1a-45c3-a579-ca79559b496f"
      unitRef="usd">3987000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNy0xLTEtMS0w_768435dc-c7ac-4337-976d-81d19a159197"
      unitRef="usd">-65056000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8yNS9mcmFnOjA0YmZkN2JkMjBhOTRlMmZiZDFlMzM3NTYzMmU3YjNiL3RhYmxlOjk3MTUwNjUxNDU3MjRhZGE4NDA2OWUyNDNiYzRhNTBiL3RhYmxlcmFuZ2U6OTcxNTA2NTE0NTcyNGFkYTg0MDY5ZTI0M2JjNGE1MGJfNy0zLTEtMS0w_91ce5da0-6fae-4b10-ba7c-f6db61cc19d0"
      unitRef="usd">-84961000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4106d82d54f040ab8a176e31e97e485d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTEtMS0xLTc2NA_14dabdb8-c129-4fa9-b3d0-b42a8de0ebde"
      unitRef="shares">262063461</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4106d82d54f040ab8a176e31e97e485d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTMtMS0xLTc2NA_dab49069-f49f-46e0-a218-77ca7ae85b69"
      unitRef="usd">2650000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id288f022ad3e4df48660873a6e9fea15_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTUtMS0xLTc2NA_9eff1b16-55d9-478d-8186-161a31e52d4d"
      unitRef="usd">2308578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i46ce59af193c4c868c341c26afa4148b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTctMS0xLTc2NA_fc008ead-08fe-422f-a4c6-1923c5114f15"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2fa2ef2f3d8442d9b9a0ada40c1530dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTktMS0xLTc2NA_d0724703-7fde-4b89-a655-5797a7f46e2e"
      unitRef="usd">8227000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8fc939cca8b43d0920b98c1049e39f3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTExLTEtMS03NjQ_9af77ef2-ca70-4926-90e0-d691d246d32b"
      unitRef="usd">-2045462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF80LTEzLTEtMS0xNjYy_c7da0822-b722-4c2a-aa6d-dd0685ec07b0"
      unitRef="usd">286380000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF81LTEtMS0xLTc2NA_036d842e-4b7e-4630-8b29-884df8ecdc00"
      unitRef="shares">488111</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF81LTMtMS0xLTc2NA_1713c8b5-0ff8-4d0d-98b8-4dc777e37b5e"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i03da422e5e5b41988fb9336c36774604_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF81LTUtMS0xLTc2NA_512ee23d-169a-4795-a820-00abeb319521"
      unitRef="usd">4157000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF81LTEzLTEtMS0xNjYy_4bbfbfe6-b938-4dd9-961c-695e68180a96"
      unitRef="usd">4161000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF82LTEtMS0xLTc2NA_bc1acd10-0576-442c-925a-1f7059fd177e"
      unitRef="shares">897063</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i03da422e5e5b41988fb9336c36774604_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF82LTUtMS0xLTc2NA_631cf983-3f57-4cd7-9211-d23bd608a17b"
      unitRef="usd">14194000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF82LTEzLTEtMS0xNjYy_e3bfdce0-950c-4a01-a6f7-4d37aa600d7f"
      unitRef="usd">14194000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i03da422e5e5b41988fb9336c36774604_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF83LTUtMS0xLTc2NA_e56dca7b-7d7d-41c4-84bf-effdefd98185"
      unitRef="usd">20354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF83LTEzLTEtMS0xNjYy_0175557f-93d0-440e-a06c-507f2c78c0c7"
      unitRef="usd">20354000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <fold:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF84LTEtMS0xLTc2NA_cf5ad971-bc02-4af5-8935-1a1c18b9a5a9"
      unitRef="shares">2554999</fold:StockIssuedDuringPeriodSharesWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF84LTMtMS0xLTc2NA_0c96211d-679b-4ffe-9343-5b8cbf0e31e6"
      unitRef="usd">26000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i03da422e5e5b41988fb9336c36774604_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF84LTUtMS0xLTc2NA_cf2bdc01-2d13-47f5-a609-937efac08743"
      unitRef="usd">31591000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i32ad9c5f70914438a056f21590c29a77_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF84LTctMS0xLTc2NA_88c4a6d4-e4e1-4960-9647-2b32527568a7"
      unitRef="usd">-12387000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF84LTEzLTEtMS0xNjY0_0a9700d9-e482-4a03-918f-5dbebbaedef8"
      unitRef="usd">19230000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF85LTEtMS0xLTc2NA_08a5790b-a41c-4a9e-ba90-e5215a04c7cd"
      unitRef="shares">4084</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i2a9d2bafbcb54b98a2f51d749db6f292_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF85LTMtMS0xLTc2NA_17f02eb6-f28b-4f20-adf6-1f33946d2a54"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i03da422e5e5b41988fb9336c36774604_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF85LTUtMS0xLTc2NA_789bb3fd-83ce-409d-a1e9-b7494358ae78"
      unitRef="usd">21000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF85LTEzLTEtMS0xNjY0_27228108-bd50-4d31-8a7e-ff31ec376822"
      unitRef="usd">21000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i58b1a856d6014eafa34817652747a42b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMS05LTEtMS03NjQ_15672dc7-5949-45ca-b5cb-00763adb3e80"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMC0xMy0xLTEtMTY1OQ_7f4adf40-75f1-4922-ab04-4bf1cc3b3e36"
      unitRef="usd">608000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i6a64d12323e541d285585950b069b321_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMi0xMS0xLTEtNzY0_415b2feb-37c9-4200-ba64-7baf4920d5f8"
      unitRef="usd">-65664000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMS0xMy0xLTEtMTY1OQ_12e21369-0e48-46ea-9fbc-1782f979eadf"
      unitRef="usd">-65664000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iec56b4d95a9040f691ae98d1932ff45b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy0xLTEtMS03NjQ_4fae13ca-fe41-4163-928c-fb0fb5a0e949"
      unitRef="shares">266007718</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iec56b4d95a9040f691ae98d1932ff45b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy0zLTEtMS03NjQ_bac5f123-5645-49b5-9abd-cda497162777"
      unitRef="usd">2680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97fd1af684a34d1a9cebb50ef794c543_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy01LTEtMS03NjQ_0cce762f-bff4-485b-a759-bd53431c1732"
      unitRef="usd">2350507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e9a645c33e64a77841416360656deb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy03LTEtMS03NjQ_04413473-ac32-4430-9052-ef102301b350"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b4a5c424f2945d7bd2f559c6b986d5b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy05LTEtMS03NjQ_2243c152-9157-4144-ad9e-97058c35bd45"
      unitRef="usd">8835000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibd1b47a0c9e8402fbff7bffee12db9fd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMy0xMS0xLTEtNzY0_b890edf3-cc4d-4a00-9efb-5b865bb809b9"
      unitRef="usd">-2111126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YzRhOGQzYjRhOTdmNGRkNDk2ZjhlMTNiOWJlNzM2MjAvdGFibGVyYW5nZTpjNGE4ZDNiNGE5N2Y0ZGQ0OTZmOGUxM2I5YmU3MzYyMF8xMi0xMy0xLTEtMTY1OQ_291ad9de-4037-4e11-8716-c974a8548d6d"
      unitRef="usd">250896000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i517fd281a28749d78656d0a3c7970477_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTEtMS0xLTc2NA_8a9f0f47-41b3-4ff6-8f2b-572dd604e022"
      unitRef="shares">255417869</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i517fd281a28749d78656d0a3c7970477_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTMtMS0xLTc2NA_4750ee0b-38ee-4b3f-ae0e-6e1b75cb72c1"
      unitRef="usd">2598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8c7e2aad59ba4f578e5e314f37acb879_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTUtMS0xLTc2NA_e9c7f5b3-8797-43ae-b90c-1f1e7fcf27f9"
      unitRef="usd">2227225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if21cdcddb1bf4bc0beb5bdf9f9bc15d0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTctMS0xLTc2NA_da9b789a-e09a-4ba5-b143-f566d0558ec7"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i18c0cf87387948d38739af8f77a6b421_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTktMS0xLTc2NA_3573d85d-bd40-46f2-b4ca-c8939e880fa0"
      unitRef="usd">2825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e38b37ec5484f9da915405503e03bd6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTExLTEtMS03NjQ_1a7767bd-4550-45ce-a1af-a76b71915ffa"
      unitRef="usd">-1768610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia75e14a1366d45c3b7e75e7e9a700855_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF80LTEzLTEtMS0xNjU2_b21f31f1-28fd-42c2-a303-96e417641bb9"
      unitRef="usd">476425000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i91e38d29dead4f2785069422f620c2d0_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF81LTEtMS0xLTc2NA_0367373f-9e96-4f30-a188-03385241dd6f"
      unitRef="shares">958947</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i91e38d29dead4f2785069422f620c2d0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF81LTMtMS0xLTc2NA_04c61c19-39ae-425c-bf99-d09839d8bba8"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i43f99be30a2947fca4d5d0dc3b99d26b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF81LTUtMS0xLTc2NA_719704d2-934b-485f-bce6-e02f459c0f50"
      unitRef="usd">6068000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF81LTEzLTEtMS0xNjUw_186704c2-6d0b-4308-8028-86950be1f8aa"
      unitRef="usd">6077000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i91e38d29dead4f2785069422f620c2d0_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF82LTEtMS0xLTc2NA_238f5ae6-1f3d-44cc-a305-c5748c891a6a"
      unitRef="shares">1073139</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i43f99be30a2947fca4d5d0dc3b99d26b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF82LTUtMS0xLTc2NA_cb64785d-cd75-403b-afa9-f922eccbb1fd"
      unitRef="usd">7543000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF82LTEzLTEtMS0xNjUw_2ae57707-8a94-448e-b286-68252f575f66"
      unitRef="usd">7543000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i43f99be30a2947fca4d5d0dc3b99d26b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF83LTUtMS0xLTc2NA_db20be3e-f75f-4f01-8fb3-a98bf673be9d"
      unitRef="usd">12596000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF83LTEzLTEtMS0xNjUw_66648505-9faa-442b-a2af-b00e80d01c7a"
      unitRef="usd">12596000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i020ee144910d46a2aec0495b12e94578_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF84LTktMS0xLTc2NA_ac6f8763-17b3-48d4-9ba6-fe0d08c291d4"
      unitRef="usd">-209000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF84LTEzLTEtMS0xNjUw_7cf6cbc6-5bd9-411c-9db3-ed968b5eca7d"
      unitRef="usd">-209000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i020ee144910d46a2aec0495b12e94578_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF85LTktMS0xLTc2NA_4e26b44b-af0a-4ace-9ea0-fe8cb486143f"
      unitRef="usd">4196000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF85LTEzLTEtMS0xNjUw_2b17c4d5-a61e-476d-83ae-e91de4052a4c"
      unitRef="usd">4196000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i843e6fbfc6d34a439da0268c8c325cf1_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMC0xMS0xLTEtNzY0_605fcfe7-ee07-453d-bf13-4b16272b45ec"
      unitRef="usd">-88948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMC0xMy0xLTEtMTY1MA_4bb379b0-71d2-48f6-a7f0-710a081a55b0"
      unitRef="usd">-88948000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2d77582b16b44d15a065c048a584eeb0_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS0xLTEtMS0xNjUw_4d80674d-544c-4013-b3e9-ef6f0fff0aab"
      unitRef="shares">257449955</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2d77582b16b44d15a065c048a584eeb0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS0zLTEtMS0xNjUw_18c11f4a-1d2d-437a-a6d1-f206250d83f2"
      unitRef="usd">2607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icc16447402d44046a7451c1acd97ace7_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS01LTEtMS0xNjUw_47682436-28e9-426d-b24d-c311fb2dcb51"
      unitRef="usd">2238346000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd32f0ef41fb4c0eb71b5ff4f53781b9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS03LTEtMS0xNjUw_13646c40-645f-411b-a98d-8149adb96516"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i91abb571e5b04f10ab1bb7976314f183_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS05LTEtMS0xNjUw_15fd4a39-d0dc-4bce-b8e4-962ceef8261b"
      unitRef="usd">6812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0db45e1d6c1c4528adbb181b99592123_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS0xMS0xLTEtMTY1MA_cf66f606-f59e-4dbe-93c6-ac42b59e26a3"
      unitRef="usd">-1857558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDk5L2ZyYWc6NThjY2IxNThiOGNiNGU3Mjg0ZDAwMjcxNzU1YTIzNTUvdGFibGU6YmE2M2E0NDk1MDQwNDlmNThjNzVjZjU0ZmMxNzQzZTQvdGFibGVyYW5nZTpiYTYzYTQ0OTUwNDA0OWY1OGM3NWNmNTRmYzE3NDNlNF8xMS0xMy0xLTEtMTY1MA_08090089-ad7b-4ad0-9c06-e27b6e3e0646"
      unitRef="usd">402594000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMy0xLTEtMS0w_0db932b6-9b80-4fc7-8103-90bbf1a7f536"
      unitRef="usd">-65664000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMy0zLTEtMS0w_289c5a46-b361-4e0b-a974-6cde48d761de"
      unitRef="usd">-88948000</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNS0xLTEtMS0w_d17ba9ca-fc87-4523-b903-7fda7a063d07"
      unitRef="usd">555000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNS0zLTEtMS0w_13ed75eb-802f-4f20-bd9c-5be172caaacf"
      unitRef="usd">231000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNi0xLTEtMS0w_83b81a87-38eb-4f90-8534-e6e8f39bc2a0"
      unitRef="usd">1604000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNi0zLTEtMS0w_88647100-4e90-4db4-bb09-5dec9ade1a99"
      unitRef="usd">1764000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNy0xLTEtMS0w_da7a80fd-94b8-4568-a38c-0ba4b2766d9b"
      unitRef="usd">20354000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNy0zLTEtMS0w_dca5fbce-a453-40dc-977a-7199ef0bae6b"
      unitRef="usd">12596000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTAtMS0xLTEtMA_b2efb9b1-0e84-4234-aae7-15a5f7a71a87"
      unitRef="usd">471000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTAtMy0xLTEtMA_2416dbc6-49bc-4196-bc1c-ea92f4bc5f6b"
      unitRef="usd">931000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTEtMS0xLTEtMA_3403772e-b106-4cc4-badc-08bba760461d"
      unitRef="usd">-2846000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTEtMy0xLTEtMA_90210497-3e99-476d-80a3-787c23b20be3"
      unitRef="usd">-10662000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTQtMS0xLTEtMA_d1c305ed-0ad0-41f3-9585-97a57aafcf5d"
      unitRef="usd">-839000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTQtMy0xLTEtMA_1e85133e-66d7-4eff-aaa9-5993302f8362"
      unitRef="usd">8358000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTUtMS0xLTEtMA_f423ce9e-6507-49dd-8bce-9f6bee088817"
      unitRef="usd">-741000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTUtMy0xLTEtMA_c5fe1a60-0e8f-496f-bb77-33d8a7f00b3d"
      unitRef="usd">251000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTYtMS0xLTEtMA_f2384cc6-df2e-4c9d-b934-c2142272db50"
      unitRef="usd">-7669000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTYtMy0xLTEtMA_c37a010e-a1b7-4dc2-b50f-341d9a73d228"
      unitRef="usd">-4016000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTctMS0xLTEtMA_d0b35a84-41ff-45c4-b200-1b97b7b77633"
      unitRef="usd">-40191000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTctMy0xLTEtMA_ca6154b4-4f18-4052-bc53-b6399ac28e4d"
      unitRef="usd">-35251000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTgtMS0xLTEtMA_78fdb4f4-6c79-43ef-9154-2e3fc300d80e"
      unitRef="usd">-1578000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMTgtMy0xLTEtMA_d56b6f02-a5c1-4a36-9df5-0b93f32f8e7e"
      unitRef="usd">-5334000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjAtMS0xLTEtMA_8a452f99-76ff-4a0f-ab2a-60bd7d6accc5"
      unitRef="usd">-72354000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjAtMy0xLTEtMA_1501855e-6914-4391-8e62-5423d39df6b7"
      unitRef="usd">-107942000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjItMS0xLTEtMA_006133aa-1def-4870-a93e-0252cf528167"
      unitRef="usd">163680000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjItMy0xLTEtMA_69a12296-39d9-42cf-a8f5-5109ad23785d"
      unitRef="usd">106140000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjMtMS0xLTEtMA_b0281a00-ce39-4ffa-beb7-533bc48e130f"
      unitRef="usd">76247000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjMtMy0xLTEtMA_0078c9d0-5079-444f-8709-bdec1dd0b114"
      unitRef="usd">12088000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjQtMS0xLTEtMA_b9421d1a-5104-4bd9-a6d8-1ee618e09f43"
      unitRef="usd">868000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjQtMy0xLTEtMA_47692ac9-1c32-4ba1-b654-f58aff6ac100"
      unitRef="usd">806000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjUtMS0xLTEtMA_8cf814d9-7069-475e-8614-779cb08610be"
      unitRef="usd">86565000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMjUtMy0xLTEtMA_8c873ab6-f91c-4f1a-8b65-090f9ec31c37"
      unitRef="usd">93246000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzAtMS0xLTEtMA_8756eb6f-c02f-49d5-a7e0-6a4afc23536b"
      unitRef="usd">368000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzAtMy0xLTEtMA_90469e3d-30c2-4166-bcf8-4c404fc504b6"
      unitRef="usd">21000</us-gaap:FinanceLeasePrincipalPayments>
    <fold:PaymentsForRepurchaseOfRestrictedStockUnits
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzEtMS0xLTEtMA_b52a2c14-9fd5-4ef6-98b4-ff0883d4848e"
      unitRef="usd">14194000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
    <fold:PaymentsForRepurchaseOfRestrictedStockUnits
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzEtMy0xLTEtMA_70466892-588f-4e28-88c6-0d7748ee2383"
      unitRef="usd">7543000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzMtMS0xLTEtMA_b16344b4-68b5-44b8-b173-65b22704e349"
      unitRef="usd">4161000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzMtMy0xLTEtMA_7b94d8e7-ae40-45d7-bb95-65145cc3935e"
      unitRef="usd">6077000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzQtMS0xLTEtMA_dca9b241-328b-4c94-a12f-a0f3ea8e439d"
      unitRef="usd">19230000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzQtMy0xLTEtMA_a1b82dca-49a3-4d48-b7ce-cbbec4fe62d8"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzUtMS0xLTEtMA_786a4dc9-964a-4b77-bbea-7be541a68202"
      unitRef="usd">8829000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzUtMy0xLTEtMA_7e1e87a1-e1f0-4811-9b58-8f3aeda0a725"
      unitRef="usd">-1487000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzYtMS0xLTEtMA_de907722-add9-461e-a266-34eb7e31af0c"
      unitRef="usd">-1153000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzYtMy0xLTEtMA_9a104765-4d87-4b99-a50c-a4aae1e34084"
      unitRef="usd">-4265000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzctMS0xLTEtMA_7b8feea3-daf5-48ea-85c7-546f736a0c91"
      unitRef="usd">21887000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzctMy0xLTEtMA_3d30ad3b-c233-4d4f-99e4-d1adff0c89dd"
      unitRef="usd">-20448000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzgtMS0xLTEtMA_483cfaaa-7bc3-4f55-842c-b2695f7a2a41"
      unitRef="usd">166162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia75e14a1366d45c3b7e75e7e9a700855_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzgtMy0xLTEtMA_6e9fdf11-159d-4e16-8db8-7f489b44af92"
      unitRef="usd">146341000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzktMS0xLTEtMA_e36f89ad-c262-4590-988f-7a82de687d22"
      unitRef="usd">188049000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzktMy0xLTEtMA_1851b618-11d0-478b-9f56-d2e3f226e694"
      unitRef="usd">125893000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDEtMS0xLTEtMA_cd16219d-1e65-46d6-8fa1-c0560113a0e6"
      unitRef="usd">0</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDEtMy0xLTEtMA_ee91dc8c-ee69-4f71-a4bd-b844736988d6"
      unitRef="usd">254000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:InterestPaidNet
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDItMS0xLTEtMA_3edbe02f-d25c-44ef-9a8a-a7b20c442e28"
      unitRef="usd">7513000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDItMy0xLTEtMA_23048ca6-8bf8-4639-ad5e-fe86c77563f6"
      unitRef="usd">3693000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDQtMS0xLTEtMA_725b71e5-8941-450f-b401-1010c51d9adc"
      unitRef="usd">188000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfNDQtMy0xLTEtMA_867ffa2f-6c58-4ebc-b360-fd42d4d03d59"
      unitRef="usd">589000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzctMS0xLTEtODQ3_033fa676-6214-4d79-8953-9ba68f54d977"
      unitRef="usd">2472000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zMS9mcmFnOmRiNTE3NDdjYWJmOTQ2NGVhOWZlNmM4ZTZjZjkyYzhhL3RhYmxlOjJmMDEyM2Q4Nzg5ZDQ3ZDM4ZjI3MmViODNmNGVkZjUyL3RhYmxlcmFuZ2U6MmYwMTIzZDg3ODlkNDdkMzhmMjcyZWI4M2Y0ZWRmNTJfMzctMy0xLTEtODQ3_8a2c2f8f-95e6-4b1a-a0a3-258748008fe1"
      unitRef="usd">1627000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zNy9mcmFnOjhlNjYyNDA3ODljODQ3NTViMjgzNzZmMTFhNWRlZGQ0L3RleHRyZWdpb246OGU2NjI0MDc4OWM4NDc1NWIyODM3NmYxMWE1ZGVkZDRfNTY1Nw_00f7b62b-3fb2-4fb7-bebb-c9b987daed1d">Description of Business&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities led by the first, oral monotherapy for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease, and an industry leading rare disease gene therapy portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cornerstone of the Company's portfolio is Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several other geographies around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late-onset Pompe disease. The Company initiated the rolling Biologic License Application ("BLA") submission to the FDA in the fourth quarter of 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("Nationwide Children's") and a research collaboration with the University of Pennsylvania ("Penn"). The Company's pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Mucopolysaccharidosis Type IIIB ("MPS IIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPS IIIA"). This research collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. In the first quarter of 2020, the FDA granted Fast Track designation to the CLN3 Batten disease gene therapy, AT-GTX-502, for the treatment of pediatric patients less than 18 years of age. In September 2020 and February 2021, the European Medicines Agency granted Priority Medicines designation and the FDA granted Fast Track Designation, respectively, to the CLN6 Batten disease gene therapy, AT-GTX-501, for the treatment of patients with variant late infantile neuronal ceroid lipofuscinosis 6 ("vLINCL6").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operations have not been significantly impacted from the novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic thus far. However, the Company continued to observe increased lag times between patient identification and Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; initiation due to the resurgence of COVID-19 into 2021. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, and maintained the operational integrity of its clinical trials, with minimal disruption. The Company believes its ability to continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had an accumulated deficit of $2.1 billion as of March 31, 2021 and anticipates incurring losses through the fiscal year ending December 31, 2021 and beyond. The Company has historically funded its operations through stock offerings, debt issuances, Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues, collaborations, and other financing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on current operating models, the Company believes that the current cash position, which includes expected revenues, is sufficient to fund the Company's operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8zNy9mcmFnOjhlNjYyNDA3ODljODQ3NTViMjgzNzZmMTFhNWRlZGQ0L3RleHRyZWdpb246OGU2NjI0MDc4OWM4NDc1NWIyODM3NmYxMWE1ZGVkZDRfNDg5NQ_eb0c590b-8649-43c5-9e33-adfb248749ce"
      unitRef="usd">-2100000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMjc_55aac8cc-28dc-4f3c-8676-f6645fa0ea1b">Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2021 and through the issuance of this report. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company's accounts receivable at March 31, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of March 31, 2021, the Company recorded an allowance for doubtful accounts of $0.1 million.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net product sales consist of sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are generally received from distributors and pharmacies with the ultimate payor often a government authority. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's net product sales from Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.619%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ex-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Developments - Guidance Adopted in 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2019-12 - In December 2019, the Financial Accounting Standard Board issued Accounting Standard Update ("ASU")  2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following applies in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#x2019; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance prospectively on January 1, 2021. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Developments - Guidance Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNjE_874f6b8f-4e07-4b94-8d62-fcafae181291">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.&lt;/span&gt;&lt;/div&gt;The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMTM_be808e65-95d8-4638-9676-6e471adf786c">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMjg_5786c6c7-fcac-4180-9f74-6d4e749ffb9b">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMzg_3c1c1034-4db6-4806-acd6-318e8905c889">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2021 and through the issuance of this report. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNDI_bfb0feef-430e-4d76-ad5b-931ca62ec9a1">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.&lt;/span&gt;&lt;/div&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNTY_c9416b91-2095-4fe8-be47-a7ebf16a20c0">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;. The Company's accounts receivable at March 31, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfNTE4MA_b666fb50-ae85-4e83-aa38-fa679f9e8bc2"
      unitRef="usd">100000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNzE_8cd427d0-6bc3-44b7-9867-86ca241a2c67">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net product sales consist of sales of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are generally received from distributors and pharmacies with the ultimate payor often a government authority. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMzk_61cb9813-4d31-4bc3-950f-5afea9d194b6">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's net product sales from Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.619%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.862%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ex-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ice1b8156e8124fb381e0a08494f81a37_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfMi0yLTEtMS0w_a87a5fea-f1ae-4af8-8ffc-4509c65226ec"
      unitRef="usd">20853000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ie422fb8df9cc41a8898b1ecdbc54b0ba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfMi00LTEtMS0w_12e99f31-2d77-4a8d-9bd6-2c1407f056a4"
      unitRef="usd">17772000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7d4f9bae82114ff29db94ce7ce943250_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfMy0yLTEtMS0w_7a32669c-8ac4-4a97-a60a-b650e814a13a"
      unitRef="usd">45549000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i8ef534e19d7042548a667fe11fe7f8df_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfMy00LTEtMS0w_efa6129c-e34c-404a-a261-81462580bc8a"
      unitRef="usd">42753000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfNC0yLTEtMS0w_20ebc0c5-5751-4533-93a5-3c6980c5e6f0"
      unitRef="usd">66402000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RhYmxlOjk3YzRjN2RiMzMwYTQxZWU5OTA0NzFlYTk2MmQyMTJjL3RhYmxlcmFuZ2U6OTdjNGM3ZGIzMzBhNDFlZTk5MDQ3MWVhOTYyZDIxMmNfNC00LTEtMS0w_5e5f1341-96e4-4fb8-b7b5-311ed2750a62"
      unitRef="usd">60525000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:InventoryCostsForContractsOrProgramsPolicy
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNjc_7ba83e0c-6803-4a3a-9bd7-5535c1df63bd">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</us-gaap:InventoryCostsForContractsOrProgramsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyMzM_6fb7d642-5e51-4fc4-9d51-16484ab70434">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. &lt;/span&gt;&lt;/div&gt;Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80MC9mcmFnOjNkYzQzNTc0Zjk4YjQzNWU4YzgzNmYzNzc2MTgzZTJjL3RleHRyZWdpb246M2RjNDM1NzRmOThiNDM1ZThjODM2ZjM3NzYxODNlMmNfMTUyNTg_d60672f2-39d3-4841-b155-88642216264a">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Developments - Guidance Adopted in 2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2019-12 - In December 2019, the Financial Accounting Standard Board issued Accounting Standard Update ("ASU")  2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following applies in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#x2019; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance prospectively on January 1, 2021. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Developments - Guidance Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjk4Nw_9fcf2440-a61d-4c06-9343-ee8b5ab8a61e">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2021, the Company held $184.8 million in cash and cash equivalents and $232.6 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#x2019;s fair value is determined to less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320,029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021 there were no realized gains or losses. For the fiscal year ended December 31, 2020, there were nominal realized gains. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized loss positions in the marketable securities as of March 31, 2021 and December 31, 2020 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive gain (loss). The fair value of these marketable securities in unrealized loss positions was $114.5 million and $124.9 million as of March 31, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMTA3_1d9b6c3e-1f9b-43b6-b331-9b8f303fbe21"
      unitRef="usd">184800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMTQz_88c9639e-dc9d-4da0-93b7-e3eabf28935b"
      unitRef="usd">232600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjk4MQ_ce87a4f6-3623-4f46-a622-2181d985807f">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;163,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Included in marketable securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320,029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;483,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMi0yLTEtMS0w_0c2fffa4-da7e-4a35-a31d-e43b4233ab73"
      unitRef="usd">184833000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMi04LTEtMS0w_f832b650-874e-4768-9fe5-7fbfd12ddbf0"
      unitRef="usd">184833000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i7d172b37766a4bff90df25277ccbedb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMy0yLTEtMS0w_95290d4e-e78d-4d0c-b460-f7bf204b4452"
      unitRef="usd">20936000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i7d172b37766a4bff90df25277ccbedb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMy00LTEtMS0w_25deb000-184c-48af-87de-4c16f70a344a"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i7d172b37766a4bff90df25277ccbedb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMy02LTEtMS0w_ab98bbbd-f410-45a8-8b80-11d87bc3a0c5"
      unitRef="usd">4000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7d172b37766a4bff90df25277ccbedb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMy04LTEtMS0w_82f9a076-9ebe-42d7-964c-0e36aed17ce0"
      unitRef="usd">20932000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i806c5d2d5f15482c81c841bd96d6e68a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNC0yLTEtMS0w_d2c2b76a-d38f-49b9-83e6-bdadebd51315"
      unitRef="usd">151300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i806c5d2d5f15482c81c841bd96d6e68a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNC00LTEtMS0w_6d079d3f-3ccd-48e9-9a88-17084912e2aa"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i806c5d2d5f15482c81c841bd96d6e68a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNC02LTEtMS0w_1564a365-79f4-4168-b342-10c0933d9e94"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i806c5d2d5f15482c81c841bd96d6e68a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNC04LTEtMS0w_72f2aa7a-b3eb-4770-be02-7717df1c344d"
      unitRef="usd">151307000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ia838f9184beb47c297d0a9b6544f7d24_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNS0yLTEtMS0w_1c35ab79-1915-46d6-a05e-9cd017819b7a"
      unitRef="usd">13718000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ia838f9184beb47c297d0a9b6544f7d24_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNS00LTEtMS0w_98624b99-b887-4a8a-9bab-c3062378704b"
      unitRef="usd">1000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ia838f9184beb47c297d0a9b6544f7d24_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNS02LTEtMS0w_f7e988f2-e322-43a8-84a7-3d42c21e5555"
      unitRef="usd">3000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia838f9184beb47c297d0a9b6544f7d24_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNS04LTEtMS0w_59cede09-cb09-4cc8-a2ca-545b7a232117"
      unitRef="usd">13716000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i62fb03830de7497887830162220ec3d7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNi0yLTEtMS0w_ff40464e-46b0-475c-8031-1f9e5a4e4f57"
      unitRef="usd">46228000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i62fb03830de7497887830162220ec3d7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNi00LTEtMS0w_1f7b756c-bad6-4320-95d4-eaaa3a656f34"
      unitRef="usd">12000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i62fb03830de7497887830162220ec3d7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNi02LTEtMS0w_6e68f46e-3390-4828-a44b-baad75cd0f08"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i62fb03830de7497887830162220ec3d7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNi04LTEtMS0w_d99cd6b8-1164-4cdd-a2f2-36ca9cf2a7e1"
      unitRef="usd">46240000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i86075c190d2342278bca860d772e4fc9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNy0yLTEtMS0w_ac3ed16f-4fe4-48fe-ab41-e5faa32eb9f3"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i86075c190d2342278bca860d772e4fc9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNy00LTEtMS0w_309490fc-52be-4abe-be1c-53d9d055dcfc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i86075c190d2342278bca860d772e4fc9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNy02LTEtMS0w_406662bc-c64a-47fe-96e4-b158d2684a8b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86075c190d2342278bca860d772e4fc9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfNy04LTEtMS0w_d0333769-64db-4a4b-bb9f-ceffe9ef9cd3"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i69afd1d0068b46408516b4e05dbea56d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOC0yLTEtMS0w_e2226788-00e6-45ed-b668-69d3cce1b430"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i69afd1d0068b46408516b4e05dbea56d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOC00LTEtMS0w_9f808826-d80d-4597-8658-43f152df5e9c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i69afd1d0068b46408516b4e05dbea56d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOC02LTEtMS0w_2afe5248-1066-4cce-aa05-0f2f5e80ab62"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69afd1d0068b46408516b4e05dbea56d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOC04LTEtMS0w_4c81ce48-c00b-442c-8992-7e67d3a5830e"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOS0yLTEtMS0w_641ca937-5d29-4f98-ab9d-70020ee19eca"
      unitRef="usd">417416000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOS00LTEtMS0w_aa3d07ff-ec14-4c2c-96bb-411ef91df266"
      unitRef="usd">23000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOS02LTEtMS0w_2d6f3ab3-1bce-47c5-b51f-4fef0b4b9bdc"
      unitRef="usd">10000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfOS04LTEtMS0w_9a266152-648b-4685-a3a5-e93231156061"
      unitRef="usd">417429000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTAtMi0xLTEtMA_c6b8a59b-9cb2-40f9-b70e-72e45aa02350"
      unitRef="usd">184833000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTAtOC0xLTEtMA_64a9e202-72d5-46d0-b0c2-bb0870486dfc"
      unitRef="usd">184833000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTEtMi0xLTEtMA_4e80f047-1128-4ffb-a673-6237f3c1101a"
      unitRef="usd">232583000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTEtNC0xLTEtMA_56de3b7d-97b3-4873-9edd-70347a8296e4"
      unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTEtNi0xLTEtMA_236fee50-8189-4019-bed8-037119d02472"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTEtOC0xLTEtMA_72b362ca-6c2a-468a-b20c-3bc0d50020d2"
      unitRef="usd">232596000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTItMi0xLTEtMA_e035d252-eed8-4674-9a0e-90a33b1a084f"
      unitRef="usd">417416000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTItNC0xLTEtMA_713d5167-4b40-4161-8c66-49df1bcb49c5"
      unitRef="usd">23000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTItNi0xLTEtMA_5b663968-80a8-47bc-91a8-9f00258fa380"
      unitRef="usd">10000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjQ5NTI4YzhhYzBmNTRmNjliNjc3MWI3MDU5YjMzM2Q2L3RhYmxlcmFuZ2U6NDk1MjhjOGFjMGY1NGY2OWI2NzcxYjcwNTliMzMzZDZfMTItOC0xLTEtMA_6249551f-5e4b-4697-892b-badfb70591f7"
      unitRef="usd">417429000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMi0yLTEtMS0w_95849177-2b8a-48b9-94c5-c7999c1ed45d"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMi04LTEtMS0w_14430206-ae35-450c-b188-08cf8bf0facc"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i52a446687d324ec99e46667ddf742275_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMy0yLTEtMS0w_cedd7323-e22b-4c4d-8a68-20dcc64c4390"
      unitRef="usd">39525000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i52a446687d324ec99e46667ddf742275_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMy00LTEtMS0w_0a4340c5-7573-442c-b2d8-7c89333f72f8"
      unitRef="usd">4000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i52a446687d324ec99e46667ddf742275_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMy02LTEtMS0w_6810f838-5953-4fa1-adec-07e3ef92bb38"
      unitRef="usd">16000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i52a446687d324ec99e46667ddf742275_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMy04LTEtMS0w_c1b96c13-64e0-44c4-8e2f-25f08bb05a0e"
      unitRef="usd">39513000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1e96be861b404667ab8e185f54dce138_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNC0yLTEtMS0w_278fa737-8122-4b5c-9ee7-188022e8cb44"
      unitRef="usd">217087000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1e96be861b404667ab8e185f54dce138_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNC00LTEtMS0w_f8c4917f-c6a1-49cd-824a-5b44a06327e2"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1e96be861b404667ab8e185f54dce138_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNC02LTEtMS0w_c4c47054-8ede-47c3-9184-473d02bc0fce"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e96be861b404667ab8e185f54dce138_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNC04LTEtMS0w_246b51e7-a83f-4487-967b-661341f24882"
      unitRef="usd">217095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i90263ef14b3e490f92f545e8f1abec6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNS0yLTEtMS0w_ca269bd2-bdd6-41ee-880f-7ce9aa755b0c"
      unitRef="usd">9420000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i90263ef14b3e490f92f545e8f1abec6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNS00LTEtMS0w_8bf99e52-f054-4c9d-abd0-0e98367c49c3"
      unitRef="usd">18000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i90263ef14b3e490f92f545e8f1abec6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNS02LTEtMS0w_3659dfd7-22a5-4e50-9eba-ef34fa0e3eac"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i90263ef14b3e490f92f545e8f1abec6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNS04LTEtMS0w_b1e9f601-b7fe-4002-963b-7805b45056dc"
      unitRef="usd">9438000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ie7a9bf8271f74640842b35661ede6ee6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNi0yLTEtMS0w_e1880b2b-c5c8-43a5-b9bc-4bc1210d2999"
      unitRef="usd">53583000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ie7a9bf8271f74640842b35661ede6ee6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNi00LTEtMS0w_a1b40156-061e-4932-8c7b-433d45e876a8"
      unitRef="usd">3000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ie7a9bf8271f74640842b35661ede6ee6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNi02LTEtMS0w_92ca6bcd-f45f-4547-8636-2e2de292822a"
      unitRef="usd">4000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie7a9bf8271f74640842b35661ede6ee6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNi04LTEtMS0w_08187738-bf61-4cdc-b915-5a5ec6239268"
      unitRef="usd">53582000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i471af39f23494beca4b65d011f8a7d44_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNy0yLTEtMS0w_a7fe0bb0-a6ff-416a-9847-7709de6f2da6"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i471af39f23494beca4b65d011f8a7d44_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNy00LTEtMS0w_f6378ae4-cd6e-47fd-aebb-f1dcefb9d3ba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i471af39f23494beca4b65d011f8a7d44_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNy02LTEtMS0w_a7aaf8fa-6855-402b-8f7b-67f483d2c7d1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i471af39f23494beca4b65d011f8a7d44_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfNy04LTEtMS0w_0f08a099-d1c3-4823-8fd6-4a1b6a35ba88"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ide7d1fdcbabf448182fada4f80efd849_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOC0yLTEtMS0w_88e74c53-a5cd-4a6f-a06b-89807b706f83"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ide7d1fdcbabf448182fada4f80efd849_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOC00LTEtMS0w_cca6aa95-c61c-4782-99d0-0328530bf5e8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ide7d1fdcbabf448182fada4f80efd849_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOC02LTEtMS0w_1004ff36-356b-4f17-a6cc-465edbacaffb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide7d1fdcbabf448182fada4f80efd849_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOC04LTEtMS0w_0a4d4862-1a6b-4ad1-9ccc-115e553b3bbb"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOS0yLTEtMS0w_db063da9-2257-4895-8126-7d9ecb55c3a7"
      unitRef="usd">483256000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOS00LTEtMS0w_9615a10e-93bc-4183-9475-c1c2c207585f"
      unitRef="usd">39000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOS02LTEtMS0w_8ea67ad3-e0de-4423-9032-8bcfc0654586"
      unitRef="usd">26000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfOS04LTEtMS0w_c5cf462e-42e2-433d-a006-3b3b190a7643"
      unitRef="usd">483269000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTAtMi0xLTEtMA_03395f72-08ad-414d-9b36-4e406fe3cb07"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTAtOC0xLTEtMA_fd761b2a-b74e-4724-b44c-af0f8c364568"
      unitRef="usd">163240000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTEtMi0xLTEtMA_109cd009-7c1f-4f3b-bce3-3367fb09ad4f"
      unitRef="usd">320016000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTEtNC0xLTEtMA_78109cd6-3480-4591-938d-8335ec46f01f"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTEtNi0xLTEtMA_fbc28328-90e1-4ab8-826a-00a2ab82d429"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTEtOC0xLTEtMA_2f35da32-f953-428c-9ea2-847af7a94802"
      unitRef="usd">320029000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTItMi0xLTEtMA_a080b98d-896d-4c95-9fde-5a847b8e3806"
      unitRef="usd">483256000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTItNC0xLTEtMA_93cdcf4d-73c8-4aa5-ac35-5ce72460e431"
      unitRef="usd">39000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTItNi0xLTEtMA_df009d89-f6bc-4c47-a9af-5e45304f4e71"
      unitRef="usd">26000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOjJjYWE0YmY3N2QyNTQ4NDFhMjcxNDM3MjkwZjhhNjRhL3RhYmxlcmFuZ2U6MmNhYTRiZjc3ZDI1NDg0MWEyNzE0MzcyOTBmOGE2NGFfMTItOC0xLTEtMA_4226f493-9337-4948-aff6-55aeb54b1c3f"
      unitRef="usd">483269000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjA4MA_dd142e08-9276-4d7b-9921-ce64da98472c"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="i96b2d9a6834748be93f41e359fed6f91_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjE0NQ_da61772f-4507-45f3-b1bf-99f8ee13a557"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjY5Mw_1ffc2a88-d2bc-458b-819f-91677536f65a"
      unitRef="usd">114500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjcwMA_8512064b-1f63-406a-a088-5e2139b9d213"
      unitRef="usd">124900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RleHRyZWdpb246YTZmZDQ2NzkzYzIxNDQ4MTllMDJiZjk4MjVhNGRhMmVfMjk5Mw_72f76721-c43d-4a7d-ad98-6a388b1ef61a">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMS0yLTEtMS0w_1becf21d-bc7a-4ebf-9d68-6a0179a687a0"
      unitRef="usd">184833000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMS00LTEtMS0w_bdec9cbb-bc6c-43fd-9035-6b54801490d2"
      unitRef="usd">123231000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMi0yLTEtMS0w_5f64b4bf-0858-431f-9ade-1c3caa2b1fda"
      unitRef="usd">3216000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMi00LTEtMS0w_36790ad5-ee7e-4d21-8478-48c9397c4406"
      unitRef="usd">2662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMy0yLTEtMS0w_af8e926b-f8cf-4323-89df-c9a7ef264443"
      unitRef="usd">188049000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80My9mcmFnOmE2ZmQ0Njc5M2MyMTQ0ODE5ZTAyYmY5ODI1YTRkYTJlL3RhYmxlOmE3ZWMyZTllNTU1MzQwMTY5NDhhMjI4YmUwYzkyOTg2L3RhYmxlcmFuZ2U6YTdlYzJlOWU1NTUzNDAxNjk0OGEyMjhiZTBjOTI5ODZfMy00LTEtMS0w_129dfae6-eb45-404f-a18a-5913fc8366b2"
      unitRef="usd">125893000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RleHRyZWdpb246YjRlODBmMGY0MThkNGQ3NjhkZDVmZjVmNjg5NTE0ZTJfMzAx_4de71de3-91d1-476e-849e-2aec49f3e85b">Inventories&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of raw materials, work-in-process, and finished goods related to the manufacture of Galafold&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The following table summarizes the components of inventories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a reserve for inventory of $0.2 million and $0.1 million as of March 31, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RleHRyZWdpb246YjRlODBmMGY0MThkNGQ3NjhkZDVmZjVmNjg5NTE0ZTJfMzAw_e027d567-989d-451f-9c4b-76cca6c6d52e">The following table summarizes the components of inventories: &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMS0yLTEtMS0w_dc5acca2-4eb5-405a-92f9-2220e12bb2b6"
      unitRef="usd">3709000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMS00LTEtMS0w_297682c1-5ae9-4745-9f4e-c3f31bd8d354"
      unitRef="usd">5547000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMi0yLTEtMS0w_5467cf72-2544-4da6-b1df-5fa8c3701323"
      unitRef="usd">10023000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMi00LTEtMS0w_21f0e2b4-91d7-441c-8924-282cc52b950a"
      unitRef="usd">7693000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMy0yLTEtMS0w_bf69e2b5-50d2-48cd-a89c-d0923bcc7aba"
      unitRef="usd">5069000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfMy00LTEtMS0w_8334af8c-d2b3-4ef9-8dd5-eb716b40e303"
      unitRef="usd">6316000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfNC0yLTEtMS0w_79780e74-72f1-489f-8bb9-99a6fe8220a5"
      unitRef="usd">18801000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RhYmxlOjVkNmY5YTdjZmE1MDRlOTk5MzNjMGQ5YjcxNDY5MTg0L3RhYmxlcmFuZ2U6NWQ2ZjlhN2NmYTUwNGU5OTkzM2MwZDliNzE0NjkxODRfNC00LTEtMS0w_95c3b662-8903-4f97-a161-79ed4864c11d"
      unitRef="usd">19556000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RleHRyZWdpb246YjRlODBmMGY0MThkNGQ3NjhkZDVmZjVmNjg5NTE0ZTJfMjUz_597e5af2-add9-49d1-a413-27c7cef89249"
      unitRef="usd">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80Ni9mcmFnOmI0ZTgwZjBmNDE4ZDRkNzY4ZGQ1ZmY1ZjY4OTUxNGUyL3RleHRyZWdpb246YjRlODBmMGY0MThkNGQ3NjhkZDVmZjVmNjg5NTE0ZTJfMjYw_922d8386-5f18-4c19-81ff-5d00f16a5a0f"
      unitRef="usd">100000</us-gaap:InventoryValuationReserves>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNTA2NQ_9f239d4b-422b-443b-b9c8-ea62dfbec96b">Debt &lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's debt consists of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Term Loan due 2026:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of the Senior Secured Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;387,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Convertible Notes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of the Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net carrying value of Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The Convertible Notes are currently convertible as the last reported sale price of the Company's common stock was equal to or more than 130% of the conversion price for at least 20 trading days of the 30 consecutive trading days ending on the last day of the quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; In the first quarter of 2021, the Company exchanged an aggregate principal amount of $25.0&#160;thousand of Convertible Notes in exchange for an aggregate of approximately 4.1&#160;thousand shares of Company common stock, par value $0.01 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth interest expense recognized related to the Company's debt for the three months ended March 31, 2021 and 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNTA1Mw_1edfc126-b82f-46f4-b3fb-da5ed54f8909">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's debt consists of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Term Loan due 2026:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,592)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of the Senior Secured Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;387,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;386,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Convertible Notes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Principal&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: debt discount &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: deferred financing &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net carrying value of the Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net carrying value of Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;389,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; The Convertible Notes are currently convertible as the last reported sale price of the Company's common stock was equal to or more than 130% of the conversion price for at least 20 trading days of the 30 consecutive trading days ending on the last day of the quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; In the first quarter of 2021, the Company exchanged an aggregate principal amount of $25.0&#160;thousand of Convertible Notes in exchange for an aggregate of approximately 4.1&#160;thousand shares of Company common stock, par value $0.01 per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1859eeb446e743c997733b443de3f5c8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMi0yLTEtMS0w_46c39037-5ee0-406e-bd69-2d6fe1b37591"
      unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i64bce1e96a6b41f88ce6934c6afe246c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMi00LTEtMS0w_feaa65fb-93e6-4e51-ad5e-8158864703d5"
      unitRef="usd">400000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i1859eeb446e743c997733b443de3f5c8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMy0yLTEtMS0w_1061be5c-28f2-4d62-8fe2-2889c1d0d675"
      unitRef="usd">7139000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i64bce1e96a6b41f88ce6934c6afe246c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMy00LTEtMS0w_87e101d0-1890-4ac9-b86f-7d06c7300c34"
      unitRef="usd">7434000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="i1859eeb446e743c997733b443de3f5c8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfNC0yLTEtMS0w_adc9950a-a4d4-40bf-927d-ae1cf0ca5760"
      unitRef="usd">5371000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i64bce1e96a6b41f88ce6934c6afe246c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfNC00LTEtMS0w_2607716d-cf82-4780-8c5e-ea78e1a88172"
      unitRef="usd">5592000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LongTermDebt
      contextRef="i1859eeb446e743c997733b443de3f5c8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfNS0yLTEtMS0w_075fb91f-22c5-4b17-8cce-5ec6f24058c6"
      unitRef="usd">387490000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i64bce1e96a6b41f88ce6934c6afe246c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfNS00LTEtMS0w_6f655714-1ba2-41cc-8acf-8882a07234ca"
      unitRef="usd">386974000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iec32650d30684749839221747f88aa14_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTQtMi0xLTEtMA_4878928b-22d9-4440-ac25-76c6b398c62a"
      unitRef="usd">2800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3ec6a6de4b2d49b0a233b7ac18dc5fc0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTQtNC0xLTEtMA_c025e15d-524e-4747-a7a4-6569b9d37cde"
      unitRef="usd">2825000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="iec32650d30684749839221747f88aa14_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTUtMi0xLTEtMA_9c7bf4f8-04ea-4cc0-a87b-6374fc0e7589"
      unitRef="usd">476000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i3ec6a6de4b2d49b0a233b7ac18dc5fc0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTUtNC0xLTEtMA_4c786a18-63e5-4703-adab-9338c7e025be"
      unitRef="usd">518000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="iec32650d30684749839221747f88aa14_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTYtMi0xLTEtMA_a118f0c9-cc21-4a0e-b861-df3689db6dfb"
      unitRef="usd">25000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i3ec6a6de4b2d49b0a233b7ac18dc5fc0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTYtNC0xLTEtMA_6ed4790f-5ade-4267-9cbd-31de7326af1a"
      unitRef="usd">27000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LongTermDebt
      contextRef="iec32650d30684749839221747f88aa14_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTctMi0xLTEtMA_9bd9b38b-5ffb-4dad-a2b1-968a3aeaeb7b"
      unitRef="usd">2299000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3ec6a6de4b2d49b0a233b7ac18dc5fc0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTctNC0xLTEtMA_36fd1a99-a10f-40f8-8f62-3b179107896e"
      unitRef="usd">2280000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTktMi0xLTEtMA_ba0a50e7-91ac-41e6-b5b8-443cf6215234"
      unitRef="usd">389789000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOmExYzNjYjc0NTg0ZTQ4YzdhNDlhNzgzMWNiYTcyM2E0L3RhYmxlcmFuZ2U6YTFjM2NiNzQ1ODRlNDhjN2E0OWE3ODMxY2JhNzIzYTRfMTktNC0xLTEtMA_c63065b9-52a1-4caf-ac74-774d2184a4c6"
      unitRef="usd">389254000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i99f52dc175e143b393b832e43be95df1_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNjI5_a47b8687-7769-440c-9421-3b31dcb72b59"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <fold:DebtInstrumentsConvertibleThresholdTradingDays
      contextRef="i99f52dc175e143b393b832e43be95df1_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNjY5_379c2c2e-e6c3-4735-979a-b64b7e49cfa3">P20D</fold:DebtInstrumentsConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i99f52dc175e143b393b832e43be95df1_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNjky_2326d832-d5db-4ee5-bf80-33800437c7b7"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i99f52dc175e143b393b832e43be95df1_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfODI0NjMzNzIzMzQyOQ_be12b70b-c17a-4d68-8c30-432e0a3a0213"
      unitRef="usd">25000.0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfODI0NjMzNzIzMzQ0NQ_06a1c167-1cb4-42c1-bfef-9311c551ac08"
      unitRef="shares">4100</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfODI0NjMzNzIzMzQ2NQ_f9528a39-9fb6-47f7-b7f8-8eec2997cc6c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RleHRyZWdpb246ZjVjYjVkYjIwYzM1NDI3ZWI3MWQ4NDhhMGM1YzgzYWRfNTA2Mw_9c6fcef3-9e86-4b3b-b47a-e3ee9a90a9ce">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth interest expense recognized related to the Company's debt for the three months ended March 31, 2021 and 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfMi0yLTEtMS0w_dd586890-1340-42e6-8e95-2102696bbeb3"
      unitRef="usd">7521000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfMi00LTEtMS0w_51d5f6ea-177f-4b7c-bf72-74359d723f3d"
      unitRef="usd">3585000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfMy0yLTEtMS0w_8977ba96-848b-424a-8e14-b2d0ccc9e86d"
      unitRef="usd">332000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfMy00LTEtMS0w_d42d7dfb-85f0-402e-877e-3a1a09fb0ac8"
      unitRef="usd">206000</us-gaap:AmortizationOfDebtDiscountPremium>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfNC0yLTEtMS0w_5ecf2152-9ec3-4ad6-bde2-dbee5c23b56a"
      unitRef="usd">223000</fold:AmortizationDeferredFinancingCosts>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV80OS9mcmFnOmY1Y2I1ZGIyMGMzNTQyN2ViNzFkODQ4YTBjNWM4M2FkL3RhYmxlOjZmYTJiOGY2NjVmYjQ4MGM5NTcxNzg2NTg2YzZiM2ZkL3RhYmxlcmFuZ2U6NmZhMmI4ZjY2NWZiNDgwYzk1NzE3ODY1ODZjNmIzZmRfNC00LTEtMS0w_3a53349d-9351-4bca-aa21-bdd69a870295"
      unitRef="usd">25000</fold:AmortizationDeferredFinancingCosts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjk1_e2ff3400-1927-463a-99a9-87dc2344f171">Stockholders' Equity In February 2021, 1,050,000 warrants were exercised at $7.06 per share of common stock resulting in gross cash proceeds of $7.4&#160;million. Additionally, in March 2021, 1,294,999 warrants were exercised at $7.98 per share of common stock and 210,000 warrants were exercised at $7.06 per share of common stock resulting in gross cash proceeds of $11.8&#160;million.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iac3a273d2c644f5780e23dc81b7297ff_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjE1_c9ae4ae3-a2ca-4048-b959-dfc6d954a2d9"
      unitRef="shares">1050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3e22a2bd23524e7ab906f08199397062_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjI2_4a058717-262d-4c63-ba4c-1a42806e67d3"
      unitRef="usdPerShare">7.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="iac3a273d2c644f5780e23dc81b7297ff_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjMz_45692f1c-a6cd-4394-97c1-c6df793dd017"
      unitRef="usd">7400000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="idc272117737541f1b41cbaf126872267_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjYy_48b62f80-125b-4f57-aca9-3f7b381f5f9a"
      unitRef="shares">1294999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2f487fde288f4011b4b648177324c5df_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjcz_d34fb602-f312-46d2-8b43-1a8fffc8fa7d"
      unitRef="usdPerShare">7.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7a5a6bdf179e45b4aa77d6a3a56433ed_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjg3_d7443df3-608f-42c5-8183-363fb991e6cd"
      unitRef="shares">210000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i70e0a9292cfa42c8845f33beb7296ef3_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjgw_821b38cf-d51b-47a5-a9a6-d3cd3bf57061"
      unitRef="usdPerShare">7.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i383d26a8b8bd42e3ac89f235894e1cbf_D20210301-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV8xMDU3L2ZyYWc6ZmY3YzVlYjA2ZjE3NDVkMjljYzNhMzhhMDExOGY0YmUvdGV4dHJlZ2lvbjpmZjdjNWViMDZmMTc0NWQyOWNjM2EzOGEwMTE4ZjRiZV84MjQ2MzM3MjEyMjQ3_811aac7f-2519-4ac4-b2b4-13a93d8c30f9"
      unitRef="usd">11800000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjQ2Mw_2c20428f-8fb3-4dda-89be-476675468437">Share-Based Compensation&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Option Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected life of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's stock options for the three months ended March 31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise&#160;&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining &lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and unvested expected to vest, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, nominal stock options expired at a weighted average exercise price of $15.36. As of March 31, 2021, the total unrecognized compensation cost related to non-vested stock options granted was $38.7 million and is expected to be recognized over a weighted average period of three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;and Performance-Based Restricted Stock Units (collectively "RSUs")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Grant  &lt;br/&gt;Date Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;br/&gt;Average&lt;br/&gt;Remaining&#160;&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All non-vested units are expected to vest over their normal term. As of March 31, 2021, there was $64.5 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation Expense Related to Equity Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity compensation expense recognized in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjQ2NA_d12e6cd9-bab6-4b1c-af98-85e55b2222a5">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected life of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfMi0xLTEtMS0w_70cdd1ad-3aa9-45db-ad9e-467770ef4b23"
      unitRef="number">0.667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if040fef71ada406393452b0b39e0a2e1_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfMi0zLTEtMS0w_82c6863d-4aed-4a30-ba72-c4242e2a931c"
      unitRef="number">0.752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfMy0xLTEtMS0w_bebde379-303c-416a-bf6e-808bec8e2efe"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if040fef71ada406393452b0b39e0a2e1_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfMy0zLTEtMS0w_59bcb3b4-6478-4bcc-ac95-060c52959333"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfNC0xLTEtMS0w_11f1dc1f-e358-4653-b107-5f7201112a84">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if040fef71ada406393452b0b39e0a2e1_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfNC0zLTEtMS0w_49ecd5d7-83cf-4503-bf9d-b2da8352c5ae">P5Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfNS0xLTEtMS0w_199c0090-d1af-4c0c-a86a-4e1fd6bc42fa"
      unitRef="usdPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="if040fef71ada406393452b0b39e0a2e1_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNhNDgzN2ZkOGJlZDQ3YzY4ZDVhMDg2ZDIzNTE5M2M3L3RhYmxlcmFuZ2U6Y2E0ODM3ZmQ4YmVkNDdjNjhkNWEwODZkMjM1MTkzYzdfNS0zLTEtMS0w_0efda38b-f834-4c63-8343-e6315b46a211"
      unitRef="usdPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjQ2Nw_9e9503d0-db8b-46ee-8d02-20804d728e1f">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company's stock options for the three months ended March 31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise&#160;&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining &lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options outstanding, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested and unvested expected to vest, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i27a30ae4c9ce4d2e910e5d6a3b595381_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfMi0xLTEtMS0w_7defbfe4-3c71-40cf-871d-a952a3f36837"
      unitRef="shares">14032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i27a30ae4c9ce4d2e910e5d6a3b595381_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfMi0zLTEtMS0w_907e2f1e-8d19-40de-b8da-f10ae187eac6"
      unitRef="usdPerShare">9.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfMy0xLTEtMS0w_6557659e-79be-4cd1-b5a4-b10c32c70811"
      unitRef="shares">1818000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfMy0zLTEtMS0w_7ffd7c30-4558-44e1-bc3e-9955ea71cdee"
      unitRef="usdPerShare">21.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNC0xLTEtMS0w_1e2d0bb3-075b-4c98-b0b8-39a99ecfba97"
      unitRef="shares">493000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNC0zLTEtMS0w_4712d9a8-ee18-4ada-835c-2e42031ea30f"
      unitRef="usdPerShare">8.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNS0xLTEtMS0w_ff0e93f4-9077-4991-8955-30cab2a83f66"
      unitRef="shares">273000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNS0zLTEtMS0w_b9c91acc-b75a-4cd2-9b4b-a724b0e1e829"
      unitRef="usdPerShare">12.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNy0xLTEtMS0w_b01273dc-f493-4c6b-b56a-8404ddac6aca"
      unitRef="shares">15084000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNy0zLTEtMS0w_eec70055-5548-40eb-b691-2f58b99d0f82"
      unitRef="usdPerShare">10.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNy01LTEtMS0w_7c2befe4-df74-43d1-916f-983c8eaedd7b">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfNy03LTEtMS0w_23df34c8-8a4b-4f81-b71a-96a4898cb624"
      unitRef="usd">18500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOC0xLTEtMS0w_7d6eeebb-a4fd-41d6-bf5b-ae208d2d0c67"
      unitRef="shares">13643000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOC0zLTEtMS0w_0ed9a991-fc2d-4477-ab6c-371c122c6c79"
      unitRef="usdPerShare">10.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOC01LTEtMS0w_ef5146dc-8519-4504-b754-521c5aa0f37f">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOC03LTEtMS0w_9cbc6563-ceba-41b6-a089-bd7fc3e2f379"
      unitRef="usd">18300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOS0xLTEtMS0w_43210368-98e9-49f1-bfa4-a7ce11e74818"
      unitRef="shares">8962000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOS0zLTEtMS0w_a08a7ca6-6d5c-471b-8278-758875145b58"
      unitRef="usdPerShare">9.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOS01LTEtMS0w_0db83895-07ef-40ed-b5e6-9838d44bd87e">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmJkNjExNzI0NTVlZjQ2YzA5Zjk4NDg1MWY2MmQ3ZGYzL3RhYmxlcmFuZ2U6YmQ2MTE3MjQ1NWVmNDZjMDlmOTg0ODUxZjYyZDdkZjNfOS03LTEtMS0w_15750c6e-48ab-48bb-a191-5fb23b3d9c5c"
      unitRef="usd">17700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfODI0NjMzNzIxMTQwMw_ef350ac2-5b0e-4cf9-907c-ad40a64eeb5e"
      unitRef="usdPerShare">15.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i18b0bfea8fa64c228509348665fc54c8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMTI0NA_59ea03ad-4b46-499a-8218-34c4e3ec9c15"
      unitRef="usd">38700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMTMxNA_408093b3-9689-43e8-b43b-30e0943480ba">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjQ3Mg_d783d193-632c-435f-be14-80c8df07b811">A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2021 is as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.338%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.390%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Grant  &lt;br/&gt;Date Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;br/&gt;Average&lt;br/&gt;Remaining&#160;&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested units as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iafc0c4bbc6714c919e4c4906d4cbc02d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfMi0xLTEtMS0w_53ab8794-c451-4e2b-9829-adddd523b0ec"
      unitRef="shares">7080000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iafc0c4bbc6714c919e4c4906d4cbc02d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfMi0zLTEtMS0w_a163bf95-9552-4eb0-92e9-ae701a3be51d"
      unitRef="usdPerShare">11.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfMy0xLTEtMS0w_c9cc7cda-6559-4d9b-a335-f708be72b017"
      unitRef="shares">2131000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfMy0zLTEtMS0w_3cd50e89-92a4-40a2-aa19-b362b55b0756"
      unitRef="usdPerShare">20.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNC0xLTEtMS0w_d72fdf10-47db-48c4-b5c8-948f239e6cf2"
      unitRef="shares">1435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNC0zLTEtMS0w_ad661ae9-788e-4d89-a409-c5dcf9ecae87"
      unitRef="usdPerShare">17.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNS0xLTEtMS0w_928f51a9-1dff-42df-8991-94ad51d1e562"
      unitRef="shares">310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNS0zLTEtMS0w_8930a1a4-55fb-4082-8f55-07bf9206e6a7"
      unitRef="usdPerShare">13.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0abd1fb5725a4bedad2d8202c502b854_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNi0xLTEtMS0w_404e6c81-92f9-4ecb-8fd3-ad3199f8249f"
      unitRef="shares">7466000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0abd1fb5725a4bedad2d8202c502b854_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNi0zLTEtMS0w_dcafd2ca-f2de-4028-aa7a-336dcc7eee5f"
      unitRef="usdPerShare">14.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNi01LTEtMS0w_70e9dad6-dafe-46b1-b28e-3402ef8e758f">P2Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i0abd1fb5725a4bedad2d8202c502b854_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOmNlNzYwZTM3MmFjMDQ3MWRhZGIwYjk0YjU1YzIxMGE5L3RhYmxlcmFuZ2U6Y2U3NjBlMzcyYWMwNDcxZGFkYjBiOTRiNTVjMjEwYTlfNi03LTEtMS0w_74957fd6-af9e-42f6-bd2e-e8fd245361cb"
      unitRef="usd">73800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i0abd1fb5725a4bedad2d8202c502b854_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjA1Nw_1aba0c23-918c-4854-abbc-93662400bace"
      unitRef="usd">64500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i11474ef81e8f44e5871c1a1225d56edf_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjI0MA_ba34db2f-f17a-480e-80d6-07f68af0cd62">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RleHRyZWdpb246OTViMThjYWFhZGY2NDk1ZWExNWI5ZjA4YzQxNTk5N2RfMjQ2OA_5c395d79-6d40-4b86-8dbd-d027662acc50">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity compensation expense recognized in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total equity compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0cdf6bb18bf446948b40dfbf1cb8cf1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfMy0yLTEtMS0w_ff0722b3-9b86-4d6e-8624-e7c012860058"
      unitRef="usd">6305000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i290692dfef66483bbda493456b3bc22a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfMy00LTEtMS0w_27309864-fb10-43e6-9b26-7cffd139c9aa"
      unitRef="usd">5253000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic0570ee1bbea436e8e48eef0fd3bd67c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfNC0yLTEtMS0w_2cb41a5d-1813-46a9-8311-997bce015573"
      unitRef="usd">14049000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic314dbac744e4ddea724b9e8a9812eef_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfNC00LTEtMS0w_e38c818a-0d20-4b0e-95a2-ccd51b72522b"
      unitRef="usd">7343000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfNS0yLTEtMS0w_15902fac-e93c-426d-b61e-345536ce9a34"
      unitRef="usd">20354000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81NS9mcmFnOjk1YjE4Y2FhYWRmNjQ5NWVhMTViOWYwOGM0MTU5OTdkL3RhYmxlOjA3OTU1ZmUzNjA5MzQ0ZmJhYTZkNmFjMjM3YTEwMWEwL3RhYmxlcmFuZ2U6MDc5NTVmZTM2MDkzNDRmYmFhNmQ2YWMyMzdhMTAxYTBfNS00LTEtMS0w_bb81fb9c-3ebb-44c7-90ff-1f3acee3589e"
      unitRef="usd">12596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RleHRyZWdpb246YjI3ZWQzNDdmODNhNDYzNmFmMDI1YzQ4MTQzMzUzMzVfNDI1MQ_55abd219-671f-4a15-88fb-5befdb6691c0">Assets and Liabilities Measured at Fair Value&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs that are unobservable for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of March 31, 2021 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2020 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Convertible Notes fall into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the Convertible Notes at March 31, 2021 was $4.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 approximates the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets as of March 31, 2021 or December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Money Market Funds, and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market.&#160;If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:20pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent&#160;Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&#160;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&#160;Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75% - 78%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021 - 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the change in the balance of contingent consideration payable for the three months ended March 31, 2021 and March 31, 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RleHRyZWdpb246YjI3ZWQzNDdmODNhNDYzNmFmMDI1YzQ4MTQzMzUzMzVfNDI1Mg_9fa87310-02c2-46cd-8ec7-387218782acb">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of March 31, 2021 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2020 are identified in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.776%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.210%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6eb20145e2874e789ae1c2623304be15_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfMi0yLTEtMS0w_751c6195-e4bc-43d7-90a0-8df59c1d4bac"
      unitRef="usd">151307000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i806c5d2d5f15482c81c841bd96d6e68a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfMi00LTEtMS0w_9c144585-317c-4dfa-875f-9424efb4f878"
      unitRef="usd">151307000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7e6bf707c01a42f88c4ac502aa81d78f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfMy0yLTEtMS0w_3748778f-4782-4f25-97f7-89d3061a1049"
      unitRef="usd">13716000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia838f9184beb47c297d0a9b6544f7d24_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfMy00LTEtMS0w_325e6e7b-73b0-4af6-94c6-e4c6a2a643ef"
      unitRef="usd">13716000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2dca0209b8ee4d85a4cfb8abbdde80a1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNC0yLTEtMS0w_b6822c24-5e83-45e1-9cf3-af31b0ced5df"
      unitRef="usd">20932000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9312ad97e83344808a753c2777b9f467_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNC00LTEtMS0w_71a580e5-af6b-4181-8352-a116c54557d4"
      unitRef="usd">20932000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6936379467174bf0b8d397139372390d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNS0yLTEtMS0w_41ed8e2b-01ba-4952-9492-cdc490eda808"
      unitRef="usd">46240000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i62fb03830de7497887830162220ec3d7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNS00LTEtMS0w_26fc9a02-2b24-41e8-a878-99cc9a02333c"
      unitRef="usd">46240000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id8d80b53cc024638bae2f43fb6d44a08_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNi0yLTEtMS0w_eea8ed1b-aa58-4c6c-94cc-9be96f153c74"
      unitRef="usd">4296000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i86075c190d2342278bca860d772e4fc9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNi00LTEtMS0w_bd4004ee-c761-47c1-9049-61d0de4730b7"
      unitRef="usd">4296000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNy0yLTEtMS0w_7632ae1f-8d48-4bcb-a9b8-324a8738c5d6"
      unitRef="usd">236491000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNGYwZWRjNjU1YjQ4Y2RiOTc2MTQ3ZGQ3ZDAyNjIwL3RhYmxlcmFuZ2U6MDI0ZjBlZGM2NTViNDhjZGI5NzYxNDdkZDdkMDI2MjBfNy00LTEtMS0w_36445904-9ef8-4ba2-bab1-f064251b5ed4"
      unitRef="usd">236491000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMi0yLTEtMS0w_531094e3-390a-438b-a4dc-633b69f6ec53"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie3072184bd964b5c80a501c985ee8879_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMi00LTEtMS0w_e842fdcf-39bb-40b8-9485-2d0425430048"
      unitRef="usd">26296000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMi02LTEtMS0w_87b35a1c-01b8-4db8-81b9-796ab9add651"
      unitRef="usd">26296000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMy0yLTEtMS0w_f7ed8f61-3fa5-4817-a742-cef93fff9054"
      unitRef="usd">3946000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="ie3072184bd964b5c80a501c985ee8879_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMy00LTEtMS0w_c19469f3-8349-4f37-b60c-af5429456834"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfMy02LTEtMS0w_4d1fa104-3bea-4c99-975e-2ab8db5a1c47"
      unitRef="usd">3946000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfNC0yLTEtMS0w_2c8620db-8904-47a2-9d73-0aac36a29b32"
      unitRef="usd">3946000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ie3072184bd964b5c80a501c985ee8879_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfNC00LTEtMS0w_201a5804-11e4-4e08-8fb6-0669d5ed7be8"
      unitRef="usd">26296000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAwODlkYjkxMmMyNzRjYzJiZmY5NWNhOGFmNTIyYTg3L3RhYmxlcmFuZ2U6MDA4OWRiOTEyYzI3NGNjMmJmZjk1Y2E4YWY1MjJhODdfNC02LTEtMS0w_c0a62a95-b9fb-40bd-b4eb-132fa323e74f"
      unitRef="usd">30242000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0595419a51734a4191e082d87b615eb2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfMi0yLTEtMS0w_cc22e45c-80e7-48e6-ab0e-2763ab503735"
      unitRef="usd">217095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1e96be861b404667ab8e185f54dce138_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfMi00LTEtMS0w_807de469-b199-49b1-9c72-40e68e85eaa8"
      unitRef="usd">217095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4936c29e819c4df1803afec2e7346d1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfMy0yLTEtMS0w_5a758398-96ec-4660-bac3-132f110cd807"
      unitRef="usd">9438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i90263ef14b3e490f92f545e8f1abec6d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfMy00LTEtMS0w_3e76ae44-3ebd-4398-a026-0794bb3b62de"
      unitRef="usd">9438000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6bf8b70d9e4c47a798d27a71f86e9dc9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNC0yLTEtMS0w_c2382887-79b8-400b-ab41-12dcdd24f655"
      unitRef="usd">39513000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i93bf63ec6fe74e25acfb12d7d93c414a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNC00LTEtMS0w_0391f12e-062c-4552-b5fc-ba27cfa209b2"
      unitRef="usd">39513000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6283b4e42587498eb64b1d806d8e10e6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNS0yLTEtMS0w_88aef05e-8019-4e68-933d-b464cc2d9e30"
      unitRef="usd">53582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie7a9bf8271f74640842b35661ede6ee6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNS00LTEtMS0w_d4b54680-0a30-471a-8c86-ecbd6b045ad2"
      unitRef="usd">53582000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5ebe9d99985f4e54a4e7b34d261a0b63_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNi0yLTEtMS0w_44b515fe-41d2-41ec-a6e4-2515ee675e1e"
      unitRef="usd">4427000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i471af39f23494beca4b65d011f8a7d44_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNi00LTEtMS0w_ef75f02a-a04d-4912-9373-6b1a8593dd24"
      unitRef="usd">4427000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id4887cc5b8ad47438f6ddb6830f15cc0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNy0yLTEtMS0w_ed9802ec-e4e1-4d1e-b16e-45e11b7a356f"
      unitRef="usd">324055000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOmM4ZGYzYWRmNmVlZTRkOWU4ZjUxNjgyYmY2ZTJmNGE3L3RhYmxlcmFuZ2U6YzhkZjNhZGY2ZWVlNGQ5ZThmNTE2ODJiZjZlMmY0YTdfNy00LTEtMS0w_4bd70d1c-c340-4ee1-8714-77c2588c7912"
      unitRef="usd">324055000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id4887cc5b8ad47438f6ddb6830f15cc0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMi0yLTEtMS0w_bc0d1b23-fb87-4cbd-b774-5c998891e2c7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i525ca3a76a74424385c3cfcd34a9894d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMi00LTEtMS0w_98a25fd5-38e3-46ba-9e9d-04906c457395"
      unitRef="usd">25825000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMi02LTEtMS0w_77fad046-771d-4b0b-9e93-a10d328f570e"
      unitRef="usd">25825000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="id4887cc5b8ad47438f6ddb6830f15cc0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMy0yLTEtMS0w_79642156-1243-430d-9826-7e528ec09baf"
      unitRef="usd">4078000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i525ca3a76a74424385c3cfcd34a9894d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMy00LTEtMS0w_1b4f9bc9-9378-48d3-b544-fb8278ce844a"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfMy02LTEtMS0w_6aa9a253-c9d7-4373-98b4-0ca91be7ac04"
      unitRef="usd">4078000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id4887cc5b8ad47438f6ddb6830f15cc0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfNC0yLTEtMS0w_11ab2a5a-41e5-49f0-bab0-2f6a8ce93067"
      unitRef="usd">4078000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i525ca3a76a74424385c3cfcd34a9894d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfNC00LTEtMS0w_2c4da609-abad-49c0-90ca-1ce28c480cfc"
      unitRef="usd">25825000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjZiZmFiNmM4Y2JlNDRjOTNhNzNjZGMzMGU0ODA4YTM2L3RhYmxlcmFuZ2U6NmJmYWI2YzhjYmU0NGM5M2E3M2NkYzMwZTQ4MDhhMzZfNC02LTEtMS0w_c67f906f-f9d4-4512-9b75-c68c93ee7ed7"
      unitRef="usd">29903000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i75abaa6d7b8a455b9235e26f5f52b9cd_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RleHRyZWdpb246YjI3ZWQzNDdmODNhNDYzNmFmMDI1YzQ4MTQzMzUzMzVfMTI0NA_f317bc8b-fb96-4dda-9726-c1553a2820df"
      unitRef="usd">4500000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RleHRyZWdpb246YjI3ZWQzNDdmODNhNDYzNmFmMDI1YzQ4MTQzMzUzMzVfNDI0Mw_7cdeb0b6-4ad4-4298-9b43-20f6c8bee303">&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:20pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent&#160;Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value as of March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation&#160;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&#160;Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75% - 78%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021 - 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="ia39206c7064840cc993f0d99c3d83ac6_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNzFiMTdmZmQ0MzRhMDhhNzc4MzFiYzI2YmY4NTJhL3RhYmxlcmFuZ2U6MDI3MWIxN2ZmZDQzNGEwOGE3NzgzMWJjMjZiZjg1MmFfMy04LTEtMS0w_f943dcb1-81d7-460c-a53a-6dfc7fc77716"
      unitRef="number">0.075</fold:ContingentConsiderationMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i925eb208debe4acf8dbeded140f69103_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNzFiMTdmZmQ0MzRhMDhhNzc4MzFiYzI2YmY4NTJhL3RhYmxlcmFuZ2U6MDI3MWIxN2ZmZDQzNGEwOGE3NzgzMWJjMjZiZjg1MmFfNS0yLTEtMS0w_c860671f-7b59-454f-a5ed-435aeed48318"
      unitRef="usd">25559000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="i037b121761ef436aabc14ae0bdc430a2_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNzFiMTdmZmQ0MzRhMDhhNzc4MzFiYzI2YmY4NTJhL3RhYmxlcmFuZ2U6MDI3MWIxN2ZmZDQzNGEwOGE3NzgzMWJjMjZiZjg1MmFfNS04LTEtMS0wL3RleHRyZWdpb246ZjBhMzk0MjUwNTM5NGQ5YWEzNzRkNGNlZjc1YzYyYmJfMTY0OTI2NzQ0MTY4MA_9124de8d-624a-424f-a421-175531caa86f"
      unitRef="number">0.75</fold:ContingentConsiderationMeasurementInput>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="iba028b38e31b4ee9b5ccfc7c44f23b30_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjAyNzFiMTdmZmQ0MzRhMDhhNzc4MzFiYzI2YmY4NTJhL3RhYmxlcmFuZ2U6MDI3MWIxN2ZmZDQzNGEwOGE3NzgzMWJjMjZiZjg1MmFfNS04LTEtMS0wL3RleHRyZWdpb246ZjBhMzk0MjUwNTM5NGQ5YWEzNzRkNGNlZjc1YzYyYmJfMTY0OTI2NzQ0MTY5MA_41e12a54-a8b9-4941-b954-ecc5690fdd4a"
      unitRef="number">0.78</fold:ContingentConsiderationMeasurementInput>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RleHRyZWdpb246YjI3ZWQzNDdmODNhNDYzNmFmMDI1YzQ4MTQzMzUzMzVfNDI0OQ_6fc8019d-e45b-4e42-8861-76853313cb78">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the change in the balance of contingent consideration payable for the three months ended March 31, 2021 and March 31, 2020, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i01cf5118ba1646a0a3dfd406beed48c6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfMi0yLTEtMS0w_6267013e-facf-4bf5-8527-0956ced3796f"
      unitRef="usd">25825000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia75e14a1366d45c3b7e75e7e9a700855_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfMi00LTEtMS0w_be39ea91-e1ba-42c7-bd2e-eaa21e66af10"
      unitRef="usd">22681000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfMy0yLTEtMS0w_b7806453-cbd3-4217-bf2d-964c61c9d8a0"
      unitRef="usd">-471000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfMy00LTEtMS0w_69b7aa93-1ce9-4e7e-af20-e87d95b12877"
      unitRef="usd">-931000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i085324ad68f040cab6d186478f2dac9f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfNS0yLTEtMS0w_aa9d9a70-8e2b-43b1-a4a9-abd2a70a55b0"
      unitRef="usd">26296000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie87ab55a5443407b8d90c3bfdb7cbb71_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV81OC9mcmFnOmIyN2VkMzQ3ZjgzYTQ2MzZhZjAyNWM0ODE0MzM1MzM1L3RhYmxlOjc2OGIwNmQxYWZlMDRhMjNiOTExNTNiMWQ3OGNkZTk0L3RhYmxlcmFuZ2U6NzY4YjA2ZDFhZmUwNGEyM2I5MTE1M2IxZDc4Y2RlOTRfNS00LTEtMS0w_6cc0da4f-4018-4fdc-a6d0-1ff50a53ed6c"
      unitRef="usd">23612000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RleHRyZWdpb246ZTBjZTM0YWZhYTNmNGMyZmJmMDU2MTI3YmE3MTBhMGZfNzM2_84479c92-6205-4cc1-bff4-a856aebacf24">Basic and Diluted Net Loss per Common Share&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,369,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256,968,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs, and warrants for common stock equivalents.&#160;Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding warrants, convertible to common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RleHRyZWdpb246ZTBjZTM0YWZhYTNmNGMyZmJmMDU2MTI3YmE3MTBhMGZfNzI3_3058042d-8f4b-4ea3-824b-f1c1949f66e3">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.584%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(88,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,369,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256,968,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOjA1OGZhNmIzODc3ODRlZTE5N2FmMzVmOGJiMDY3MmY1L3RhYmxlcmFuZ2U6MDU4ZmE2YjM4Nzc4NGVlMTk3YWYzNWY4YmIwNjcyZjVfMy0yLTEtMS0w_84401a78-5f38-4ea7-a719-eb43bfe692c5"
      unitRef="usd">-65664000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOjA1OGZhNmIzODc3ODRlZTE5N2FmMzVmOGJiMDY3MmY1L3RhYmxlcmFuZ2U6MDU4ZmE2YjM4Nzc4NGVlMTk3YWYzNWY4YmIwNjcyZjVfMy00LTEtMS0w_587773fb-c33a-4de9-91ff-434b03483c4c"
      unitRef="usd">-88948000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOjA1OGZhNmIzODc3ODRlZTE5N2FmMzVmOGJiMDY3MmY1L3RhYmxlcmFuZ2U6MDU4ZmE2YjM4Nzc4NGVlMTk3YWYzNWY4YmIwNjcyZjVfNS0yLTEtMS0w_dcfb938b-19df-4857-b815-ed6afc260ff4"
      unitRef="shares">264369317</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOjA1OGZhNmIzODc3ODRlZTE5N2FmMzVmOGJiMDY3MmY1L3RhYmxlcmFuZ2U6MDU4ZmE2YjM4Nzc4NGVlMTk3YWYzNWY4YmIwNjcyZjVfNS00LTEtMS0w_915fa291-7932-4991-b87c-67c832213f83"
      unitRef="shares">256968248</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RleHRyZWdpb246ZTBjZTM0YWZhYTNmNGMyZmJmMDU2MTI3YmE3MTBhMGZfNzMw_29e2e186-1a6a-401b-8610-aba0ef2d79d6">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;thousands)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding warrants, convertible to common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i505945357e0a4dc4b3ca2122d1d0441f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfMi0yLTEtMS0w_dd722aa0-18f4-4d09-8bc1-277ed8746592"
      unitRef="shares">15084000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic95386b7dca242ae8b4eb32c56d32799_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfMi00LTEtMS0w_a4f1de1c-daa0-435b-9d0f-2481e2f3047f"
      unitRef="shares">19086000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6f0863e5d54c41c88117aaf4a26aba0d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfMy0yLTEtMS0w_616b58ec-f4e9-4c3a-9d96-5448c649f0c2"
      unitRef="shares">458000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i534dddc6b1d74accbbb4df2865f0432a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfMy00LTEtMS0w_cce48800-47c5-4d93-a2bf-bac1e885d27e"
      unitRef="shares">462000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0adf3d441ca04bac95b5ee95c7459225_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNC0yLTEtMS0w_0cd00392-25ac-48fd-aa8e-a4e2f11b5336"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iafbfc7637aea4b6b9a703e4bdfd9e9c6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNC00LTEtMS0w_9ba05257-002c-4ade-bde6-6d4f88095467"
      unitRef="shares">2554000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6d4d9cbe713d437ba0d38b04a1e4b8db_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNS0yLTEtMS0w_dc0cd6eb-4bc3-4dc3-93b9-7b561aec8a92"
      unitRef="shares">7466000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6d2ae022e9674e9889a69b4ecabc8ec5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNS00LTEtMS0w_f4a44db0-c800-4a87-a02b-03b050046a19"
      unitRef="shares">7562000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNi0yLTEtMS0w_7e54c26c-d1fb-44a3-b654-35f3975a6c7f"
      unitRef="shares">23008000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if5fc18c3373746cb8e84f8a411d340a9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFiYzY3YzUwOGJiNTQwNzNhZjIwNzlhN2QzNmJkNzQ5L3NlYzoxYmM2N2M1MDhiYjU0MDczYWYyMDc5YTdkMzZiZDc0OV82NC9mcmFnOmUwY2UzNGFmYWEzZjRjMmZiZjA1NjEyN2JhNzEwYTBmL3RhYmxlOmQxNmE3ODRlM2M1NTQzZTdiNGViMjJjODcyYWJhMmJiL3RhYmxlcmFuZ2U6ZDE2YTc4NGUzYzU1NDNlN2I0ZWIyMmM4NzJhYmEyYmJfNi00LTEtMS0w_83fcb081-e00a-4e96-bd29-4ca9e1686e9a"
      unitRef="shares">29664000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682513441704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amicus Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">71-0869350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">921-7600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FOLD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,060,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682509205272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184,833<span></span>
</td>
<td class="nump">$ 163,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="nump">232,596<span></span>
</td>
<td class="nump">320,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">44,931<span></span>
</td>
<td class="nump">46,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">18,801<span></span>
</td>
<td class="nump">19,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">21,730<span></span>
</td>
<td class="nump">29,721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">502,891<span></span>
</td>
<td class="nump">579,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, less accumulated amortization of $7,499 and $7,574 at March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">22,363<span></span>
</td>
<td class="nump">23,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, less accumulated depreciation of $15,961 and $14,487 at March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">43,445<span></span>
</td>
<td class="nump">43,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research&#160;&amp; development</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="nump">197,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">20,538<span></span>
</td>
<td class="nump">19,095<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">810,034<span></span>
</td>
<td class="nump">886,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16,110<span></span>
</td>
<td class="nump">17,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">57,178<span></span>
</td>
<td class="nump">96,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration payable</a></td>
<td class="nump">19,600<span></span>
</td>
<td class="nump">8,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">6,764<span></span>
</td>
<td class="nump">6,872<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">99,652<span></span>
</td>
<td class="nump">129,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="nump">7,406<span></span>
</td>
<td class="nump">7,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">389,789<span></span>
</td>
<td class="nump">389,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">6,696<span></span>
</td>
<td class="nump">16,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">4,896<span></span>
</td>
<td class="nump">4,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">44,431<span></span>
</td>
<td class="nump">45,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">6,268<span></span>
</td>
<td class="nump">6,379<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">559,138<span></span>
</td>
<td class="nump">600,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 500,000,000 shares authorized, 266,007,718 and 262,063,461 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">2,680<span></span>
</td>
<td class="nump">2,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,350,507<span></span>
</td>
<td class="nump">2,308,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">9,020<span></span>
</td>
<td class="nump">8,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,111,126)<span></span>
</td>
<td class="num">(2,045,462)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">250,896<span></span>
</td>
<td class="nump">286,380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 810,034<span></span>
</td>
<td class="nump">$ 886,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=116690757&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682514018776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases', window );">Accumulated depreciation and amortization on finance and operating lease right-of-use leases</a></td>
<td class="nump">$ 7,499<span></span>
</td>
<td class="nump">$ 7,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation of property and equipment</a></td>
<td class="nump">$ 15,961<span></span>
</td>
<td class="nump">$ 14,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">266,007,718<span></span>
</td>
<td class="nump">262,063,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">266,007,718<span></span>
</td>
<td class="nump">262,063,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated Depreciation And Amortization, Finance And Operating Right-Of-Use Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682514200808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 66,402<span></span>
</td>
<td class="nump">$ 60,525<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">6,539<span></span>
</td>
<td class="nump">6,552<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">59,863<span></span>
</td>
<td class="nump">53,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">64,117<span></span>
</td>
<td class="nump">89,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">46,726<span></span>
</td>
<td class="nump">40,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">112,918<span></span>
</td>
<td class="nump">132,030<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(53,055)<span></span>
</td>
<td class="num">(78,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7,992)<span></span>
</td>
<td class="num">(3,729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(3,200)<span></span>
</td>
<td class="num">(8,316)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(64,082)<span></span>
</td>
<td class="num">(88,587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(1,582)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (65,664)<span></span>
</td>
<td class="num">$ (88,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">264,369,317<span></span>
</td>
<td class="nump">256,968,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682508340536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (65,664)<span></span>
</td>
<td class="num">$ (88,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment gain, net of tax impact of $132 and $1,536, respectively</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">4,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized loss on available-for-sale securities, net of tax impact of $0 and $(56), respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">608<span></span>
</td>
<td class="nump">3,987<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (65,056)<span></span>
</td>
<td class="num">$ (84,961)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682508500888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Unaudited) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, tax impact</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 1,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Available-for-sale securities, tax impact</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (56)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682505551720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,417,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 476,425<span></span>
</td>
<td class="nump">$ 2,598<span></span>
</td>
<td class="nump">$ 2,227,225<span></span>
</td>
<td class="nump">$ 12,387<span></span>
</td>
<td class="nump">$ 2,825<span></span>
</td>
<td class="num">$ (1,768,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued from exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued from exercise of stock options, net</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">6,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock tax vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,073,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock tax vesting</a></td>
<td class="num">(7,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding loss on available-for-sale securities</a></td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">4,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(88,948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,948)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,449,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 402,594<span></span>
</td>
<td class="nump">$ 2,607<span></span>
</td>
<td class="nump">2,238,346<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">6,812<span></span>
</td>
<td class="num">(1,857,558)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">262,063,461<span></span>
</td>
<td class="nump">262,063,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 286,380<span></span>
</td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">2,308,578<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">8,227<span></span>
</td>
<td class="num">(2,045,462)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued from exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued from exercise of stock options, net</a></td>
<td class="nump">4,161<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">4,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock tax vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock tax vesting</a></td>
<td class="num">(14,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,554,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">19,230<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">31,591<span></span>
</td>
<td class="num">(12,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Equity component of the convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of the convertible notes</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding loss on available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (65,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,664)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">266,007,718<span></span>
</td>
<td class="nump">266,007,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 250,896<span></span>
</td>
<td class="nump">$ 2,680<span></span>
</td>
<td class="nump">$ 2,350,507<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,835<span></span>
</td>
<td class="num">$ (2,111,126)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants (in shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682509759688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (65,664)<span></span>
</td>
<td class="num">$ (88,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and deferred financing</a></td>
<td class="nump">555<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,604<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">20,354<span></span>
</td>
<td class="nump">12,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Non-cash changes in the fair value of contingent consideration payable</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax', window );">Foreign currency remeasurement loss</a></td>
<td class="nump">2,846<span></span>
</td>
<td class="nump">10,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">839<span></span>
</td>
<td class="num">(8,358)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">741<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,669<span></span>
</td>
<td class="nump">4,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(40,191)<span></span>
</td>
<td class="num">(35,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities', window );">Other non-current assets and liabilities</a></td>
<td class="num">(1,578)<span></span>
</td>
<td class="num">(5,334)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(72,354)<span></span>
</td>
<td class="num">(107,942)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sale and redemption of marketable securities</a></td>
<td class="nump">163,680<span></span>
</td>
<td class="nump">106,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(76,247)<span></span>
</td>
<td class="num">(12,088)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(868)<span></span>
</td>
<td class="num">(806)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">86,565<span></span>
</td>
<td class="nump">93,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance leases</a></td>
<td class="num">(368)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentsForRepurchaseOfRestrictedStockUnits', window );">Purchase of vested restricted stock units</a></td>
<td class="num">(14,194)<span></span>
</td>
<td class="num">(7,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4,161<span></span>
</td>
<td class="nump">6,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">19,230<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">8,829<span></span>
</td>
<td class="num">(1,487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(1,153)<span></span>
</td>
<td class="num">(4,265)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase(decrease) in cash, cash equivalents, and restricted cash at the end of the period</a></td>
<td class="nump">21,887<span></span>
</td>
<td class="num">(20,448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">166,162<span></span>
</td>
<td class="nump">146,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at the end of period</a></td>
<td class="nump">188,049<span></span>
</td>
<td class="nump">125,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvements paid through lease incentives</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">7,513<span></span>
</td>
<td class="nump">3,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures unpaid at the end of period</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">$ 2,472<span></span>
</td>
<td class="nump">$ 1,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Remeasurement Gain (Loss), Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ForeignCurrencyRemeasurementGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInNoncurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentsForRepurchaseOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire restricted stock units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentsForRepurchaseOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682507066312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities led by the first, oral monotherapy for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease, and an industry leading rare disease gene therapy portfolio. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cornerstone of the Company's portfolio is Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several other geographies around the world. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221, or cipaglucosidase alfa/miglustat), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late-onset Pompe disease. The Company initiated the rolling Biologic License Application ("BLA") submission to the FDA in the fourth quarter of 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("Nationwide Children's") and a research collaboration with the University of Pennsylvania ("Penn"). The Company's pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Mucopolysaccharidosis Type IIIB ("MPS IIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPS IIIA"). This research collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. In the first quarter of 2020, the FDA granted Fast Track designation to the CLN3 Batten disease gene therapy, AT-GTX-502, for the treatment of pediatric patients less than 18 years of age. In September 2020 and February 2021, the European Medicines Agency granted Priority Medicines designation and the FDA granted Fast Track Designation, respectively, to the CLN6 Batten disease gene therapy, AT-GTX-501, for the treatment of patients with variant late infantile neuronal ceroid lipofuscinosis 6 ("vLINCL6").</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations have not been significantly impacted from the novel coronavirus (&#8220;COVID-19&#8221;) pandemic thus far. However, the Company continued to observe increased lag times between patient identification and Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initiation due to the resurgence of COVID-19 into 2021. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, and maintained the operational integrity of its clinical trials, with minimal disruption. The Company believes its ability to continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had an accumulated deficit of $2.1 billion as of March 31, 2021 and anticipates incurring losses through the fiscal year ending December 31, 2021 and beyond. The Company has historically funded its operations through stock offerings, debt issuances, Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues, collaborations, and other financing arrangements. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on current operating models, the Company believes that the current cash position, which includes expected revenues, is sufficient to fund the Company's operations and ongoing research programs to achieve self-sustainability. Potential impacts of the COVID-19 pandemic, business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682508668248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2021 and through the issuance of this report. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's accounts receivable at March 31, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of March 31, 2021, the Company recorded an allowance for doubtful accounts of $0.1 million.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net product sales consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies with the ultimate payor often a government authority. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's net product sales from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by geographic area:</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.619%"><tr><td style="width:1.0%"/><td style="width:69.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.605%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,753&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,525&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments - Guidance Adopted in 2021</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2019-12 - In December 2019, the Financial Accounting Standard Board issued Accounting Standard Update ("ASU")  2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following applies in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance prospectively on January 1, 2021. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments - Guidance Not Yet Adopted</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682507043576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company held $184.8 million in cash and cash equivalents and $232.6 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#8217;s fair value is determined to less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,833&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,833&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320,029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 there were no realized gains or losses. For the fiscal year ended December 31, 2020, there were nominal realized gains. The cost of securities sold is based on the specific identification method.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss positions in the marketable securities as of March 31, 2021 and December 31, 2020 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive gain (loss). The fair value of these marketable securities in unrealized loss positions was $114.5 million and $124.9 million as of March 31, 2021 and December 31, 2020, respectively.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,662&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682506816680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of raw materials, work-in-process, and finished goods related to the manufacture of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following table summarizes the components of inventories: </span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,801&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,556&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a reserve for inventory of $0.2 million and $0.1 million as of March 31, 2021 and December 31, 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682506988616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,371)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,592)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Senior Secured Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,254&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Convertible Notes are currently convertible as the last reported sale price of the Company's common stock was equal to or more than 130% of the conversion price for at least 20 trading days of the 30 consecutive trading days ending on the last day of the quarter. </span></div><div style="margin-bottom:15pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In the first quarter of 2021, the Company exchanged an aggregate principal amount of $25.0&#160;thousand of Convertible Notes in exchange for an aggregate of approximately 4.1&#160;thousand shares of Company common stock, par value $0.01 per share.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the three months ended March 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682507147288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity In February 2021, 1,050,000 warrants were exercised at $7.06 per share of common stock resulting in gross cash proceeds of $7.4&#160;million. Additionally, in March 2021, 1,294,999 warrants were exercised at $7.98 per share of common stock and 210,000 warrants were exercised at $7.06 per share of common stock resulting in gross cash proceeds of $11.8&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682507003000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Amended and Restated 2007 Equity Incentive Plan (the "Plan") provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Grants</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.67</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock options for the three months ended March 31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise&#160;<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining <br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,643&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, nominal stock options expired at a weighted average exercise price of $15.36. As of March 31, 2021, the total unrecognized compensation cost related to non-vested stock options granted was $38.7 million and is expected to be recognized over a weighted average period of three years.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2021 is as follows:</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:38.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.890%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant  <br/>Date Fair <br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;<br/>Average<br/>Remaining&#160;<br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All non-vested units are expected to vest over their normal term. As of March 31, 2021, there was $64.5 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of three years.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense Related to Equity Awards</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation expense recognized in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,354&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682506988616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text">Assets and Liabilities Measured at Fair Value<div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs that are unobservable for the asset or liability.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of March 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,242&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2020 are identified in the following tables:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:62.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,903&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Convertible Notes fall into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the Convertible Notes at March 31, 2021 was $4.5 million.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Senior Secured Term Loan due 2026 falls into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan due 2026 approximates the fair value.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets as of March 31, 2021 or December 31, 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Money Market Funds, and Marketable Securities</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Payable</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market.&#160;If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: </span></div><div style="margin-bottom:20pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent&#160;Consideration</span></div><div style="margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation&#160;Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable&#160;Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75% - 78%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 - 2022</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the three months ended March 31, 2021 and March 31, 2020, respectively:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, end of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682509508888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text">Basic and Diluted Net Loss per Common Share<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.330%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,664)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88,948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,369,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256,968,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs, and warrants for common stock equivalents.&#160;Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,008&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682524731752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with the U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.</span></div>The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2021 and through the issuance of this report. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, Marketable Securities and Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div>Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in other current assets and other non-current assets on the Company's Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>. The Company's accounts receivable at March 31, 2021 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net product sales consist of sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are generally received from distributors and pharmacies with the ultimate payor often a government authority. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenue from the sale of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryCostsForContractsOrProgramsPolicy', window );">Inventories and Cost of Goods Sold</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and Cost of Goods Sold</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div>Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease term for all of the Company's leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div>Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Developments</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments - Guidance Adopted in 2021</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2019-12 - In December 2019, the Financial Accounting Standard Board issued Accounting Standard Update ("ASU")  2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following applies in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this guidance prospectively on January 1, 2021. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Developments - Guidance Not Yet Adopted</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated recent accounting pronouncements and believes that none of them will have a material effect on the Company's Consolidated Financial Statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryCostsForContractsOrProgramsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for costs relating to long-term contracts or programs. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average). Elements of costs in inventory may include retained costs representing the excess of manufacturing or production costs over the amounts charged to cost of sales or delivered or in-process units, initial tooling or other deferred startup costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryCostsForContractsOrProgramsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682514050872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's net product sales from Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by geographic area:</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:89.619%"><tr><td style="width:1.0%"/><td style="width:69.862%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.615%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.605%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ex-U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,549&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,753&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,525&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682507012248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash, cash equivalents and marketable securities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,416&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,833&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,833&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417,429&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,240&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in marketable securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320,029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,269&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of cash, cash equivalents, and restricted cash</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,662&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,893&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682509508888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories for the period</a></td>
<td class="text">The following table summarizes the components of inventories: <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,547&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,801&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,556&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682507131128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of liability components of long term debt</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's debt consists of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Term Loan due 2026:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,139)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,371)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,592)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Senior Secured Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">387,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">386,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Convertible Notes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: debt discount </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(476)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(518)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: deferred financing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net carrying value of the Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value of Long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389,254&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in the Consolidated Balance Sheets within long-term debt and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Convertible Notes are currently convertible as the last reported sale price of the Company's common stock was equal to or more than 130% of the conversion price for at least 20 trading days of the 30 consecutive trading days ending on the last day of the quarter. </span></div><div style="margin-bottom:15pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In the first quarter of 2021, the Company exchanged an aggregate principal amount of $25.0&#160;thousand of Convertible Notes in exchange for an aggregate of approximately 4.1&#160;thousand shares of Company common stock, par value $0.01 per share.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of total interest expense</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth interest expense recognized related to the Company's debt for the three months ended March 31, 2021 and 2020, respectively:</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682509908792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Options</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected stock price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.67</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected annual dividend per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company's stock options for the three months ended March 31, 2021 were as follows:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise&#160;<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining <br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options outstanding, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and unvested expected to vest, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,643&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Non-Vested RSU Activity under the Plan</a></td>
<td class="text">A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2021 is as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:38.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.890%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average Grant  <br/>Date Fair <br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;<br/>Average<br/>Remaining&#160;<br/>Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(310)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested units as of March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,466&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity Compensation Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation expense recognized in:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,354&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,596&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682513895112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of assets and liabilities subject to fair value measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of March 31, 2021 are identified in the following tables:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236,491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:58.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.384%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,296&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,242&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2020 are identified in the following tables:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:62.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.210%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,903&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: </span></div><div style="margin-bottom:20pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent&#160;Consideration</span></div><div style="margin-bottom:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Liability</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value as of March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation&#160;Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable&#160;Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75% - 78%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021 - 2022</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of changes in contingent consideration payable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the change in the balance of contingent consideration payable for the three months ended March 31, 2021 and March 31, 2020, respectively:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value during the period, included in the Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, end of the period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682507034648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="margin-bottom:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.584%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.330%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65,664)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88,948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,369,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256,968,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="margin-bottom:15pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,086&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,008&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682507126904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 2,111,126<span></span>
</td>
<td class="nump">$ 2,045,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682512480280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">66,402<span></span>
</td>
<td class="nump">$ 60,525<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">20,853<span></span>
</td>
<td class="nump">17,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Ex-U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 45,549<span></span>
</td>
<td class="nump">$ 42,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682514044104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184,833,000<span></span>
</td>
<td class="nump">$ 163,240,000<span></span>
</td>
<td class="nump">$ 123,231,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">232,596,000<span></span>
</td>
<td class="nump">320,029,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Realized gain (loss) on debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of available-for-sale debt securities in unrealized loss positions</a></td>
<td class="nump">$ 114,500,000<span></span>
</td>
<td class="nump">$ 124,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682505692024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184,833<span></span>
</td>
<td class="nump">$ 163,240<span></span>
</td>
<td class="nump">$ 123,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value, Cash balances</a></td>
<td class="nump">184,833<span></span>
</td>
<td class="nump">163,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">232,583<span></span>
</td>
<td class="nump">320,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">232,596<span></span>
</td>
<td class="nump">320,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities', window );">Cost, Cash balances and available-for-sale securities</a></td>
<td class="nump">417,416<span></span>
</td>
<td class="nump">483,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, Cash balances and available-for-sale securities</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, Cash balances and available-for-sale securities</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure', window );">Fair value, Cash balances and available-for-sale securities</a></td>
<td class="nump">417,429<span></span>
</td>
<td class="nump">483,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, Cost</a></td>
<td class="nump">20,936<span></span>
</td>
<td class="nump">39,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Loss</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, Fair Value</a></td>
<td class="nump">20,932<span></span>
</td>
<td class="nump">39,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">151,300<span></span>
</td>
<td class="nump">217,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">151,307<span></span>
</td>
<td class="nump">217,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, Cost</a></td>
<td class="nump">13,718<span></span>
</td>
<td class="nump">9,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Gain</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, Fair Value</a></td>
<td class="nump">13,716<span></span>
</td>
<td class="nump">9,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, Cost</a></td>
<td class="nump">46,228<span></span>
</td>
<td class="nump">53,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Gain</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, Fair Value</a></td>
<td class="nump">46,240<span></span>
</td>
<td class="nump">53,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale debt securities</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682510373256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 184,833<span></span>
</td>
<td class="nump">$ 163,240<span></span>
</td>
<td class="nump">$ 123,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">3,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 188,049<span></span>
</td>
<td class="nump">$ 166,162<span></span>
</td>
<td class="nump">$ 125,893<span></span>
</td>
<td class="nump">$ 146,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682514066504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,709<span></span>
</td>
<td class="nump">$ 5,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">10,023<span></span>
</td>
<td class="nump">7,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">5,069<span></span>
</td>
<td class="nump">6,316<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">18,801<span></span>
</td>
<td class="nump">19,556<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for inventory</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682510174200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Summary of Long Term Debt (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="nump">$ 389,789<span></span>
</td>
<td class="nump">$ 389,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued | shares</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember', window );">Senior Loans | Senior Secured Term Loan due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="num">(7,139)<span></span>
</td>
<td class="num">(7,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Less: deferred financing</a></td>
<td class="num">(5,371)<span></span>
</td>
<td class="num">(5,592)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="nump">387,490<span></span>
</td>
<td class="nump">386,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | Convertible Senior Notes 2016, Due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="num">(476)<span></span>
</td>
<td class="num">(518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Less: deferred financing</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="nump">$ 2,299<span></span>
</td>
<td class="nump">$ 2,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentsConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentsConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682517899560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 7,521<span></span>
</td>
<td class="nump">$ 3,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AmortizationDeferredFinancingCosts', window );">Amortization of deferred financing</a></td>
<td class="nump">$ 223<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AmortizationDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AmortizationDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682510123496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock and Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,230<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 11,800<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock | Stock Exercises at $7.98</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="nump">1,294,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock | Stock Exercises at $7.06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued from equity financing (in shares)</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock | Common Stock | Stock Exercises at $7.98</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock | Common Stock | Stock Exercises at $7.06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt798Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt798Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt706Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=fold_StockExercisesAt706Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682506901816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted-average Assumptions (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">66.70%<span></span>
</td>
<td class="nump">75.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare', window );">Expected annual dividend per share (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682510128232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (Details) - Options to purchase common stock<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">14,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted (in shares) | shares</a></td>
<td class="nump">1,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares) | shares</a></td>
<td class="num">(493)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares) | shares</a></td>
<td class="num">(273)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">15,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and unvested expected to vest (in shares) | shares</a></td>
<td class="nump">13,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable (in shares) | shares</a></td>
<td class="nump">8,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise&#160; Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">21.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">8.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">12.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">10.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, Vested and unvested expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">10.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options, Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, options outstanding</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, options vested and unvested expected to vest</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, options exercisable</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding | $</a></td>
<td class="nump">$ 18.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and unvested expected to vest | $</a></td>
<td class="nump">18.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, exercisable | $</a></td>
<td class="nump">$ 17.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682525947512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, expired (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 38.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | Stock Option Plan Amended Restated 2007 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 64.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682513901016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - RSUs and PBRSUs Summary (Details) - Unvested restricted stock units - Stock Option Plan Amended Restated 2007 Equity Incentive Plan<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units (in shares) | shares</a></td>
<td class="nump">7,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,435)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units (in shares) | shares</a></td>
<td class="nump">7,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">20.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">17.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">13.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 14.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Non-vested units, weighted average remaining years</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Non-vested units, aggregate intrinsic value | $</a></td>
<td class="nump">$ 73.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682513984712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Expense Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 20,354<span></span>
</td>
<td class="nump">$ 12,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">6,305<span></span>
</td>
<td class="nump">5,253<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 14,049<span></span>
</td>
<td class="nump">$ 7,343<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682511841976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">$ 236,491<span></span>
</td>
<td class="nump">$ 324,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">26,296<span></span>
</td>
<td class="nump">25,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">3,946<span></span>
</td>
<td class="nump">4,078<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">30,242<span></span>
</td>
<td class="nump">29,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">151,307<span></span>
</td>
<td class="nump">217,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">13,716<span></span>
</td>
<td class="nump">9,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">20,932<span></span>
</td>
<td class="nump">39,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">46,240<span></span>
</td>
<td class="nump">53,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">4,296<span></span>
</td>
<td class="nump">4,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">236,491<span></span>
</td>
<td class="nump">324,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">3,946<span></span>
</td>
<td class="nump">4,078<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">3,946<span></span>
</td>
<td class="nump">4,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of the Convertible Notes</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">151,307<span></span>
</td>
<td class="nump">217,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">13,716<span></span>
</td>
<td class="nump">9,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">20,932<span></span>
</td>
<td class="nump">39,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">46,240<span></span>
</td>
<td class="nump">53,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">4,296<span></span>
</td>
<td class="nump">4,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">26,296<span></span>
</td>
<td class="nump">25,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">$ 26,296<span></span>
</td>
<td class="nump">$ 25,825<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682535218504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">$ 26,296<span></span>
</td>
<td class="nump">$ 25,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">26,296<span></span>
</td>
<td class="nump">$ 25,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus Biopharma Inc | Clinical and regulatory milestones | ATB200 Pompe Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">$ 25,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus Biopharma Inc | Clinical and regulatory milestones | Probability of achievement of milestones | ATB200 Pompe Program | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus Biopharma Inc | Clinical and regulatory milestones | Probability of achievement of milestones | ATB200 Pompe Program | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="nump">0.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember', window );">Callidus Biopharma Inc | Clinical and regulatory milestones | Level&#160;3 | Discount rate | ATB200 Pompe Program | Probability weighted discounted cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Contingent consideration, measurement input</a></td>
<td class="nump">0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_ATB200PompeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_ATB200PompeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682510356696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of the period</a></td>
<td class="nump">$ 25,825<span></span>
</td>
<td class="nump">$ 22,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value during the period, included in the Consolidated Statements of Operations</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of the period</a></td>
<td class="nump">$ 26,296<span></span>
</td>
<td class="nump">$ 23,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139682509755144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (65,664)<span></span>
</td>
<td class="num">$ (88,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">264,369,317<span></span>
</td>
<td class="nump">256,968,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">23,008,000<span></span>
</td>
<td class="nump">29,664,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">15,084,000<span></span>
</td>
<td class="nump">19,086,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">458,000<span></span>
</td>
<td class="nump">462,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,554,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">7,466,000<span></span>
</td>
<td class="nump">7,562,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M*+$BWC2\+UH$CDY!Y\7&EG6@8K\O([Y=FI5[7-75:D]Q7NRD.?7CY88D+"?
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MNM-.=SJI^W=I6/D"B:GS\B@@:3:,K<<LR6#@_2*S3F0V*?+7'5?,B/H!E1S
M@I0ER$IN5@W<'#0OX9&&J.=Y4S5EFW-9)941?[,6:G*#+I)EF&7MP,!EE(2(
M&00Y,]]V2;-]"'F05_<P<,^Y< D+0N]XB\7RR1>=S!T:0N-AJO%849*-3#P<
M])P)9J8>E![*/+7B;5+<V;SC"4C!H1[)11\0'"VS^-#I"QPNPS3Y?B$YBCY+
M #0,HT%,O&9I/)(G\ E\\4RF6.V4S&T(0"FW77KU XZ#]Z]8M7L/H0#=L@V4
M5SSV#%40#%?DK-FY^!Z<F$R*_U'*XE&4I5<:\:2O),F2H;99NW-Q/8/Q-(1_
M;9-:+>O5?-8XNCH+4!#1=*C5-<-9D$4C4GL(XVD*'Y+;S;@\EZ,I#@(:#O5Y
M[-(X(F,#W0,71R\JD4K![D795@53=1+N.8FG0=FA?,>>QCB./2",,78FN<<L
M"497: ],/$U,D*@:/DG,D[!X.^ 2,4IPXLPNURR+TW $G+@G)YY&)Q3XEDE6
M: ZUOBA:2$%JG8JY"TB<Q6YB<<W2;#2O]!C%_XRC<_%U@14GL;,X/%9I0OQ:
M24\U,DVU\\)D1BEQ*9)EL$ '4CUF& "<C""8]+0AT[3YR#<<A!; &E'=-TKS
M:FQ;0EQF)&$P+/#GK,YUGNS(IL'RBZP?5H:K"@!X[R4?<;%!TRQ)LZ% KQV)
MPA&)/5[(S![O7ZPJXO(CCIU-D\<*PY9DA#*DIPR9IDPW^*+.9<618=]&9JF+
MD3!U9<Y8G:OL44.F-W?_<.T3WRXO='9Y/K,H#L9F0<\O,LTOM\B8T^M2*B;Q
M$ 4^*YJ,[$Y(CS(RC;)#KII3Z*%5E&&G&/+8 2#PV(D$Z7E%YGA55>)X)M$>
MHCROM'Q,\:0_>PSZ3N]8SJ\6.UMCJSU?7"/?N=-W<'3>YYYX))LLL.Z,S+]N
M90E91+_Z(85M]?MVBV2>)L^C>DK1:4K9F$)NTO8U2W01O TP)"J%]JQL^!)%
M0; ,#C](;YFR54YCME*)OWD!.ZDXAD?),L%I.R(D)DNHK)8A;,J.YD)K6R2U
MM5%CM($+NX:_VS:-NDB$93.L1[Q6T<B,I#TVZ30V;XI"V-P.B\<>GJQ$C7*V
M$["8O%)]NZTHB(+AUL=K&*31265X+KCG)YT^TKPYV4T?2U59P9S=VM/W/7\F
MP.M2:OUF<H:=''E.\_"3A)KBH3Y60OD3,HK5NCPPD17_:P['C-Z N<#+ N*,
MK6L%Q?%(_49[*M)I*GZI%6>EG>?(1@-9M7LF2LOPU4:JE6:SIZ'41>$*I\,C
MA#FK\P[TP*33P/R3*8CTR-FRBSTGK*X))C0=V7[3GHQT=F=W<J"S$;GPC[U+
MNA7!\(\,ZPVO91!&83PV!WHNTI=P48_F8*]PSS%G%+AEDL\NC6DZEI1Z3-*7
MG(C^TL.\3:T^D/QGO!.I\U7!>[#@L_,=+*Q//D/9;X"0^Q]$K:&4VT##X&T"
M85"'SVJ'&R-W[9>I>VF,K-K++6<@WAK \XV4YOG&?NSJ/FY>_Q]02P,$%
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MX$<#5=8 YW,IS4O'GDO=9\C\'U!+ P04    " # @*I2<#J5OMT$  #K$
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MXI@=2.= Q@ZK&0>O<_ :HBVRAM87JNAF+?@)"6T-T?1%DYO&&]CDE7Z-STK
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MNH%/-SB3[D^J?4&WU781M6?J/5V!;Z>]=)BF@W&X/=2GQ2S+\D'6F+T!-FR
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M\()9+&!J:: KL@;4',:JHL(HW8VM$;XJ8^#\4;)5P<GV LXG3)-IB9;G3%Q
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M^P*\IOIKHO[%R(.[:;F5QLC6/>XYJ[FR O#[5DKS]&(G.%W67?T/4$L#!!0
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MYA@?2D1Y U:@;#!BI4(\UO8X@V,#W*9D),($E<"#NJP?YL@$1"0NU,JWZ 7
M\;-?4EB2 \6%<PG:I6]+L<A1^#3Q;DR^O%@NP%F]"\YPVN=8 =*RZH! 0*J@
M2]MO.+M;8@-2(8'"VJ3XZA4%R 8A= P7HA,ZT'27DC0Q#N<_"?#.&/+V6<\%
M5SI#QZ+$8AL3=/X5*1S:5:T#9Q54H>TPI _DPK4>4?<%<$1$"_1!W3MY2(<
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M($8*[**?'A^M"VFF3RDY=&Q#YT,7 NF^@UJ/XCC0F >3$X%,T*WV8T(?9OT
M>AAD8['J;YJZ#HVKX"&R0RL.RR3?YB:TM04ZJ7 B'\ <;8'C6HZK#(,X*T2-
M6^9:>#!I<V!UEQ!8SH.&5U]:[3N'/79#-]VY*06)EWP?S"?8F"Y-AU^'*^=%
MNFG=+D_WU<B14EMJ?0IL/9G\_'R46M;^);J&[UU7+D97\R/X!!TF+<#WP@'I
M[H4.&"[B3_\+4$L#!!0    ( ," JE(3N=*U!1(  %<R   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;+5;;9/;-I+^*ZC9U*Y=)6E>/(X3OU6-)TXV
M=YN-;\;.W=75?8!(2$*&)!B '(WVU^_3W0!(2AK[<I6M2CF22#3ZO9]N8%YO
MG;\+&V,Z]5!737ASLNFZ]N7I:2@VIM9AX5K3X,G*^5IW^.K7IZ'U1I>\J*Y.
M+\[.OCZMM6U.WK[FWS[XMZ]=WU6V,1^\"GU=:[][9RJW?7-R?I)^N+'K34<_
MG+Y]W>JUN37=I_:#Q[?33*6TM6F"=8WR9O7FY.K\Y;M+>I]?^,6:;1A]5B3)
MTKD[^O)C^>;DC!@RE2DZHJ#QOWMS;:J*"(&-WR+-D[PE+1Q_3M2_9]DARU('
M<^VJ_[1EMWES\LV)*LU*]U5WX[9_-5&>YT2O<%7@?]56WKU\=J**/G2NCHO!
M06T;^;]^B'H8+?CF[)$%%W'!!?,M&S&7W^E.OWWMW59Y>AO4Z .+RJO!G&W(
M*+>=QU.+==W;6S&&<BMU:]>-7=E"-YVZ*@K7-YUMUNJ#JVQA37A]VF$_6G5:
M1-KOA/;%([2?J9]<TVV">M^4IIRN/P6?F=F+Q.R[B\\2_$G[A7IV/E,79Q?G
MGZ'W+ O_C.D]>X3>$2G5_UPM0^?A+/_[F0TN\P:7O,'EOT2[?Q1M]4X'&^C%
M#]X$TW2: ^+CQJAK5[>ZV:F-#@I!W6IO2M7A@089?D2$^D;WI>WPZ-HU 51+
M35^^MXUN"JLK=0N2!J':!64;7NM+/#)PYF[#]#XM;A=J;1KC=57MZ!73$@T]
ML-MZ"VIM!8:?G/#[/UQ=?3AYJI!Z0+8SWM9JE?>TC:0DCNVF'+:R#0S8<] '
MU3E%T:O.S^;_P:]=^<X6E:$?SLY))S=FW5="YG;^7PM6H"_!4+6;$;V=*IUJ
M7 >Z1=674$U5T3K9:LI#:4-1N=!#S<A8O_66U+G<J2P-RT*:K4QG1L*$K,"%
M^K%AVJZU#='%5K5ND"#I\>QSQCE&CA(G94#F6I>_(J/P[S.UW=ABDX5R#:S2
MD# 5EA2]]T1[LJ QA0F!7 Y*;<63U$I;CY7=X$M_"9\WUH(=[__M7Z1F;RI^
M 5:!HL/&]174;!15)7+ PC6_]HVD_>P6 WM']71(%R$!0AT*FV&J4R)73=.#
MPHUIG>^@ONQF_\XVII=7\ :\LC/:*T,I4'T'%=9+XU,2.UO0,J4'ERA-*+QM
MNVCYZ9[C8(FQ/5-8AZI$=@9=6(:6_%',#>88$L:7$X!X5'+4GGZ<BL+*MO@Y
M],M@2ZL])"''A]L4Z96TE-Y%0FZ"CB&-'*5,95$,F0FQ]\ FJQ3%N%'7\&+3
M%#OU<;R<I%A%[P#G17J)%%.[T!VJ?17IC;E52*AXRWI5N6)$1@S:N&;.,3]9
MTFUTET7A1'F4$0>Z9"/=#)FS=%6E_0P^&4S4267UTE:V(\JD$B8L_HMMA%JG
MO"97ADCFH0#%M:&'1':I*\[0 OW(GF0 :-\P=?, V >W0E36Q^BS=>^1S4$Q
MZ2=O(9LF3VN1"UR)Q#HD$WAK &PB1UYY5_-KB?[(\X\&ZJ/F 5#U6FR,!.3&
MBHM.\\">60Y[E@@YSXX4=VT,Y_FD!5J%;(AZ((X&I^SK7I0@9B)W]69#*/7>
MQ*4PDPI42_$>O^ :,@7( \X5=QM7E<:'OR@J$!T\YA/TC(?O0V=KUARYJ%3C
MS-A158CK4V8%'<ET0Z6)]2>,J@>EAUK?01-Y*Y8R )*WL5Z2C^K5BDH&:<AS
M"B&;USF2CSNAE*:A M*;E#]A9-KZ,<^5;<C_/F?UF:2!1QCRYMXT?90F>FY0
M9<\U;%C$>9.=,5"9[WJN=>2(E.FIAI1V15DT^H<+(TV1_Z)&<:Q&9#"D,\B&
M_X1!B]^@O.N??_GQN_GYMPIOE*:V!6.L#0H4#$JY;^2NQ/8@=6))LVS O"C3
M"?1&-7C7KR/8@>TXCEEY-D11%V-T]^<_?7-Q_N(5[:.K'4'!K0ZQ) L^8;6#
M:V&EL!YN#N6#+K/!*&AK8-.[QFV;5&4B>=K+AJ@$=C/*QQ8^_HA&:DV \YY
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MX'^SL7MYM],5ZQP5G\)DH?Y&,"A,,MV IZE'\7'N+>=!HXYZQ9!A174SM+I
ML)'%6CE/)&;NS8;.1&/&JV0CKOJH3WQ"QR!V!@75[&E2\F1FFD\0VPP?@,C-
M=B95(P)=P4YIVKX'YW+L!P'A\ 9/*9B1#>&V)%.7:S9M:UHY[XE&!YN1=7*F
M\7C T]6,N5O-:7SPY.3FYT\G3R<30Z8^GANZ(YZV/Q0 F40$-26>ATYK F\<
M>WV&. SF9-RO*9A:.L7KJ+OW-"9-WT8(02 -[R.=2RI;%/ VGE,<"O 81P/0
MRX<!LCBV*X&;F\G!3"7X^WI :6"]1UV"1=GQF3=),_=F)TWFN.6PT\,_R6,2
M@ZP@]ID262/.=[."F%($B722UE$FDE9P.(-'TF@<S=>7\+H5(5?F7$:*3&Z/
MU8GECIVDC?-0)^T![,[.R%/87"@D;8N:XUQQM:].RO^#&CD"IL[?!R.C$7BL
M9%%J1)SW@CK\P8Z32P>YHSG**?268BMIXPO\QCPS\#^.(UI?XW$O?"8+3+UO
M)P-:FF3:F/+%AX<M?DFH]\#UCAW296L=<?7=Y)@N&BUR&N,$WR1=\:6*P?VE
MYW0365E<&A26GV<RCX5^5TE*+P==DP2-G*Y2NL]G5I/@$[7M;<_)?"_A'3;'
M!S5 H'M,U?$I83'7S.5;/J?,5T,F)UQI), I*##@;]99.<,A)S]'<![DAP(Z
M63MO)U6&PR&O.3C9C>E\4K5YEDMYN!*_'V7#3+6M^L#3/)V/[/)$CP&9@,PX
M!-!#9FI38I32I9[P63YG\%RZGHZC>:.[::JCS*L#=EP28(C3;29((X9@>,RG
MF]^_5:P@U8"/Z73(^0P,Y.B&^EU+25)4"[6<7QR<*'F3YZ7<8OY?JMTCC:(P
MEVX+Q#E.R"""!RQTGXXK,/M\G+%\*2UJ0"ZY-$'=)MUV83S_1=^Z,314'U^#
M^PXXNG*MQ,%<_=!;N9MV5;HVAC"W45>WG_#A_-LY-#8G,)\OQ-"O M*'&R^C
M#1#O3:G1^;]S]"\=R8+LL1<^M9R6GYQ@KY.G:;=9NGCQ43_0Y;>/KD4Y>W%Y
M]O2ENF54L-JE]#VB2LJ>+CP9B4 C*3Z7!113ZR0S$K>CN74 =J=VG2'I -QH
MASBH&E_'@X8R3VASNN'Z38Q)/@N(CNW7&JZ1(0:?.?^#YT'Q7LNXITY6YI'
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M*$L'\'YI<%-J%R2@^XY\]Q]02P,$%     @ P("J4B[2+$O9 @  *P8  !D
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M<!'RPP(W3S)L@.^91@YV+[Q ?Y>]^!=02P,$%     @ P("J4D"H4&MI @
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M'K85S5<T/H#\&ZW=WO )^HF]^ E02P,$%     @ P("J4C7_5M"3!P  VA(
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MDN)OK-JZKQ=+9:VJW.6&T)LT;\#Z2N&MJ;WA _K/6=?_ 5!+ P04    " #
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M8^$?K%JZ?PEFREI5N=M"<*PW#<#WN4+#%QY(0?NWT>7O4$L#!!0    ( ,"
MJE*<G&DN% 0  &X)   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;+56
M;6_;-A#^*P=M&!I M6Q95A3/-I"7#ANPMD'2K!^&?:"DLT6$(E62BI-_WR,E
MRW90!]N'?9%(ZEZ>NWN.I\56Z4=3(5IXKH4TRZ"RMIE'D2DJK)D9J08E?5DK
M73-+6[V)3*.1E5ZI%E$\'J=1S;@,5@M_=JM7"]5:P27>:C!M73/]<H5";9?!
M)-@=W/%-9=U!M%HT;(/W:!^:6TV[:+!2\AJEX4J"QO4RN)S,KQ(G[P7^XK@U
M!VMPD>1*/;K-'^4R&#M *+"PS@*CUQ->HQ#.$,'XUML,!I=.\7"]L_Z;CYUB
MR9G!:R6^\M)6RR +H,0U:X6]4]O?L8]GYNP52AC_A&TGFR0!%*VQJNZ5"4'-
M9?=FSWT>#A2R\0F%N%>(/>[.D4=YPRQ;+;3:@G;29,TM?*A>F\!QZ8IR;S5]
MY:1G5U?,\ *8+.&&B]9B"9^("7\J8Z!!#=>JKBEW]Q73N(@L.71J4=$;O^J,
MQR>,3^&CDK8R\$&66![K1P1T0!OOT%[%;QK\R/0(II,0XG$\></>=(A^ZNU-
M3]C[P+3D<F/@EF+U0<+?E[FQFLCRSQOVD\%^XNTG_T]VWS3NVG5N&E;@,J!^
M-*B?,/@O'N%+A;!6@OJ2<@"6Y0*AT>J)EVB 4<L52A9<<.;[1ZW!DH)L:]3,
M*NV=E"@5L=+O6T/>N(1"U4UKG<E\ %/V8"2!$0X,LU;SO.V<6N64'##B>_%8
M*5&B[@#OSAW@.2'6B$>D J)$47E.O"/?ME*M(8<F!'PNL+'>B-<&5JM66G/F
MR>,>8_BT"V;NT_2OD?T,[])9F*;)F5MF67B19&=PLT_&'+[Z^X  LB=RL<&C
M2 S0_6@L 75I^N6G+)[$O_X@77&:A-/T(IQ.SB&>I>%%FH5QDG6UI=OL"!S@
MMY8_,8$4)-V%K7#5*$1;HB]<N=/!]9JN1%?/(VW5N#)3XJCJ!-ER%W^)N856
M<DOG=_</]'3PMDQKYKS04#@)802WRM*",R%>]MY/(T:J$17- 2YAK56]ATT'
MN&O5?4$/R>>0D"/WE:O20(X%(T+VK.6.K9:_?Y6#D6^!KM*YFT_@&\FA:7;8
MAX*]2I>MF#V%N>N KFV8<4<OG>@QB-;XOG,0:)Z:5K_TMFLD'I=SN/1N3S#\
MD,>?N]HYNC8M2=.8.D8[F87C+(')!;U2N@7V%984J(%DED&2QO#Y@):[*A\S
MXE5'#.2-P]DL@0<2-*Y<E#)JH\(M.SE/(C@/DS2EYXQ\?5&6TDOW24X5I3B;
M [IP8UI?EC[[\30<CS.(+US3P8]NYNA@!E)3;_RD-X25>KX;A\/I\#-QV<W0
MO7CW)T()WW#*IL UJ8Y'Y[, =#?=NXU5C9^HN;(TG_VRHA\BU$Z OJ\5A=)O
MG(/A%VOU'5!+ P04    " # @*I2GYEF@4\0  "R+P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6RU6FUS([>1_BLHIBK9K1(I4?OJ?:O2RFN?K^QX
ML_+Z[BJ5#^ ,2"*:&8R!&4G,K\_3W0!FAJ*XV3A7Y5J+)-#H]WZZ@3>WSE^'
MK3&=NJNK)KR=;;NN?75Z&HJMJ758N-8T^&7M?*T[?/2;T]!ZHTO>5%>GYV=G
MST]K;9O9NS?\W4?_[HWKN\HVYJ-7H:]K[7?O3>5NW\Z6L_3%)[O9=O3%Z;LW
MK=Z8*]-];C]Z?#K-5$I;FR98URAOUF]G%\M7[Y=/: .O^-6:VS#Z6Y$H*^>N
MZ<,/Y=O9&7%D*E-T1$+C?S?FTE0540(?OT6BLWPF;1S_G:A_Q\)#F)4.YM)5
M_V/+;OMV]G*F2K/6?=5]<K?_9:) SXA>X:K _ZI;6?O\^4P5?>A<'3>#@]HV
M\G]]%Q4QVO#R[($-YW'#.?,M!S&7W^I.OWOCW:WRM!K4Z \6E7>#.=N05:XZ
MCU\M]G7OKL0:RJW5E=TT=FT+W73JHBA<WW2VV:B/KK*%-4$]2G\]?G/:X6@B
M<%K$8][+,></'/-$_>2:;AO4AZ8TY73_*5C.?)\GOM^?'R7XD_8+]61YHL[/
MSI='Z#W)>GC"])X\0.^0P'^]6(7.PV_^=N2 I_F IWS TP<.>*^##:3FC]X$
MTW2:G/*0(O\-,NJ7K5&7KFYULU-;'10"M-7>E*K##QJB\4\D7-_HOK0=?KIT
M38"DI:8/W]E&-X75E;H"28.PZX*R#>_U)7XR\,MNR_0^+ZX6:F,:XW55[6B)
M:8F&'E38>@MJ;45>,^/UWU]<?)P]5D@C(-L9;VNUSF?:1M(+AVE3#D?9!@;H
M.7Z#ZIRB0%3+L_E?>-F%[VQ1&?KB;$DZ^60V?25DKN;_NV O]B48JG8G1&^G
M2J<:UX%N4?4E5%-5M$^.FO)0VE!4+O10,[+/;[TE=:YV*DO#LI!F*].9D3 A
M*W"A?FB8MFMM0W1Q5*T;)#OZ^>28<0Z1HR1(R8RYUN7?D1SX^Q-UN[7%-@OE
M&EBE(6$J;"EZ[XGV9$-C"A,"Q3V4VHHGJ;6V'CN[P9?^%(X;:W$D+I[EN'AV
MU*$'-WP@'KYB>XR#+_NU*"KIOZ<OHQND*"(7L/@Z]*M@2ZL]$@+9$]HHTI*T
ME=8B3S1!1T]%Z"E36:1K9@)Q5(S9/*:VYUEMSX_*C4A P6G4)<QKFF*G?ADQ
M<$B-OX,<JW7=-_P)JBS2(HJ VH5N3WEPFW6D-U:?0N+"*NM5Y8H1F06%-1RV
MF7-L3;9T6]UEW7)".LB( UU/BYLA0Y6NJK0_43H$$XU46;VRE>V(,MF("5=L
M(QPCU#KE\07[@[DK0'%CZ$<BN](59T*!2^1@Y!%P!\/4S1V@4D F@9\=HL_N
M=H.L"8I)/_D(.9042LM:Q)PKD<"&H$4H!R -"N6U=S4O2_1C;J&O#B:.!\T#
M<.>UV!B![L:*BUY\QZ%2#F>6R':>/3N>VAC.ITD+M M9!WE7/!]1TM>]*$',
M1/'CS9:0W8V)6V$F%:AF81TO< V9 N2!@(KKK:M*X\.?%"7B;G<L@%[D 'IQ
MU.,_PU(@_R%TMB;='XJ9KZ/ 82*5-ROGH#DD'U 6A2Q2[(:J$FM-&%4*2M*U
MOH8U\E&LZ0 HW<;:2'&BUVLJ#V0E<.$\^UV=T]OA0) R-%0[6@GNR-'HZ(>B
M1XZA&#CF>2>2&Q]@R)L;T_11FA@]094]UZMA$P,*#HA );WKN:Y1, 1PVE=4
MJR&Y3S[JPDA3%$,HJ9PO(@H8<CQDPW_"H,5W4-[ES[_^\.U\^8W"BM+4MF \
MM=5PWH8+PBADB.U!ZL229MF 3U&2$T"-:O"NWT1@ ]MQ+F'EV1!%78R1W!__
M\/)\^>(UG:.K'<&^6QUB^14LPFH'U\)*83U"#<H'76:#$<^M@4VO&W?;D!N-
MQ*>S;(A*8#>C(F419P]HI-8$+F\(8(S$_O_P2?X<O6/B',<"_V4._)?'$8,.
MVQ-%_ZH/"+4;78FGPF+7IM,K ,HK0DT#)Y\@H[<%@V9L.Y0I_H-'GAPZ<X+P
MDYT"(\$M^D[ MLJ",F7<&Y,J1MO#!S4Y..<8#0MV=,A.O,X;@^K-71G*#K#Z
MO;#6!6@&CAYRGA52,_%B!AD68QG"H#9F48#!VMYQ)> *,6;O %,;;W!TKN0C
M#DDG4CX>EI<=#NTK,4H3"HME@PX@(R!8J?I "06;P+-%*2_! 8D0./C"E$>J
M9D4%+T5C3)Z+;VZTK4C<.>)P'J"&4=E+#BY@6D%)/8?+M/I.$.K[""JN"%2
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MAC)6TAUULB,'7\E8SV>0J$'=UJO>DSL9[>.@+;#5-E[7ZM'L XW4%NIGSUB
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M&VE(M,XLZ)5$90/(GTEI]AM+T+V[L_]02P,$%     @ P("J4KQ1QF>A!
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MW;,)-C-97[OJ%RU*>]6)A,:+DYUF>%.ET@C@_Y40NGTQ#KJ[[_P?4$L#!!0
M   ( ," JE(H*OU7T0,  &D)   9    >&PO=V]R:W-H965T<R]S:&5E=#(U
M+GAM;,U6VV[C-A#]E8%:% F@C6Q94F37-I#+%BW0W0TVV>Y#T0=:&EM$*%(E
MJ3CY^QU2LM9N8R,O!?HBD=3<SLP9CN9;I1]-A6CAN1;2+(+*VF861::HL&;F
M0C4HZ<M:Z9I9VNI-9!J-K/1*M8CBT2B+:L9EL)S[LSN]G*O6"B[Q3H-IZYKI
MEVL4:KL(QL'NX#/?5-8=1,MYPS9XC_9+<Z=I%PU62EZC-%Q)T+A>!%?CV77J
MY+W 'QRW9F\-#LE*J4>W^:U<!",7$ HLK+/ Z/6$-RB$,T1A_-W;# :73G%_
MO;/^B\=.6%;,X(T27WEIJT60!U#BFK7"?E;;7[''XP,LE##^"=M>=A1 T1JK
MZEZ9(JBY[-[LN<_#6Q3B7B'V<7>.?)2WS++E7*LM:"=-UMS"0_7:%!R7KBCW
M5M-73GIV><T,+X#)$FZY:"V6\)&8\+LR!AK4<*/JFG)W7S&-</; 5@+-^3RR
MY-GI1T7OY;KS$A_Q,H$/2MK*P'M98GFH'U'$0]CQ+NSK^*3!#TQ?P&0<0CR*
MQR?L388T3+R]R1%[[YF67&X,W!'H#NV?5RMC-;'FKQ/VD\%^XNTG1^S?4S.5
MK4!0:Z)RH63!!6>>EW1B*P39UJB95=H7HT2IJ-I^WQJJ"I=0J+II+47I:-@7
MK>R+)JEH8E>THBN:<3!>J]7)4-TM,#,-*W 14)L;U$\8+!\HPK42U,+.OW4\
M@$:K)UZB ?;?0F+6:KYJ.Z=6#?"L*AXK)4K4_X8]@X=*(Q[0#H@T1>59<T:^
M;:5:0PY-"/A<8&.]$:\-K%:MM.;<T\L]1O!Q!V;F.^3-D?T(9UD:9EER[I9Y
M'DZ3_!QNOR=C!E_]U4$!LB=RL<$#) ;H*C66 G5I^NF'/!['/[^2KCA+PDDV
M#2?C2XC3+)QF>1@G.9P@;SJ0-WTS>1ME45K.Q!#=^@ VI959V"(ED;(J6I?W
MM5:U)T17[HXCS+BCETZ4D<EW'@E=T<0.3S)2L#1G3*M?>MLU4M'*URA]$L!Q
M2G>56[G1!/X+%?W_ '$&5][M$<;N\_)3XWP91[^F)6F:4(?1CM-PE"<PGM(K
MHPM=$LDL=[@E 360I#DD60R?]FBV95I3P-0:Q9[\/Q@^D#$.TS2!+R1H'!,I
M9=06A5MV<JWDE-;+,,DR>J;DZT%92B_=#RMJN7U6B1?@QK2^+'WVXTDX&N40
M3UT3O4KG:&_\49-N_) W%"OU<#<)A]/A/^*J&Y_?Q;N?$$KXAE,V!:Y)=71Q
M2<32W6#O-E8U?IBNE*71[)<5_0NA=@+T?:T(2K]Q#H:_J^4W4$L#!!0    (
M ," JE+U/HP +0(  )\$   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;(U4RV[;,!#\%4+((0%24P_;+0)9@!\(VD-1(V[:0]$#+:TL(A2IDI25]NN[
MI&3!!>R@/EA<<F=V9K54VBG]8BH 2UYK(<TBJ*QM'B@U>04U,Q/5@,234NF:
M60SU@9I& RL\J!8T#L,YK1F709;ZO:W.4M5:P25L-3%M73/]>P5"=8L@"DX;
M3_Q06;=!L[1A!]B!?6ZV&B,ZLA2\!FFXDD1#N0B6T<,Z<?D^X1N'SIRMB7.R
M5^K%!9^*11 Z02 @MXZ!X>,(:Q#"$:&,7P-G,)9TP//UB?W1>T<O>V9@K<1W
M7MAJ$7P(2 $E:X5]4MU'&/S,'%^NA/'_I!MRPX#DK;&J'L"HH.:R?[+7H0]G
M@&AZ!1 /@/A_ <D \)VCO3)O:\,LRU*M.J)=-K*YA>^-1Z,;+MU;W%F-IQQQ
M-MN R35O?$M525:MP01CR.T&+./"W)%WY'FW(;<W=^2&<$F^5JHU3!8FI1;K
M.Q::#[56?:WX2JW/3$]($MV3.(RC"_#UV_ -Y",\_!=.T?5H/1ZMQYXON<+W
M11^8Y'^8\WY/UDH:)7C!^NF2!=EJ," M._7FD4LF<\X$V>$FX"A;0WXL]\9J
M',:?;RA*1D6)5S2]HFB9YVW="B0OW"CRG-M+7>Y)YI[$W=)C%D?XB^<I/9ZW
M\T)>.)U-Y_&8UZND9^/CKBZ^IP.7A@@H$1E.WL\"HOOKT =6-7ZB]LKB?/IE
MA5\0T"X!STNE["EP0SI^D[*_4$L#!!0    ( ," JE+H"^*Z_P(  #<)   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;,U6WT_;,!#^5ZR(!Y"VYD>;
MMJ"V$BU,0QJHHF-[0'MPDVMCX=B=[;3LO]_9*2&4D$WBA9?6=NZ^^^ZSS^?1
M3JH'G0$8\IASH<=>9LSFS/=UDD%.=4=N0."7E50Y-3A5:U]O%-#4.>7<CX*@
M[^>4"6\R<FMS-1G)PG F8*Z(+O*<JC]3X'(W]D+O:>&6K3-C%_S):$/7L !S
MMYDKG/D52LIR$)I)012LQMYY>#8+(^O@+'XPV.G:F-A4EE(^V,E5.O8"RP@X
M),9"4/S;P@PXMTC(X_<>U*MB6L?Z^ G]BTL>DUE2#3/)?[+49&-OZ)$45K3@
MYE;NOL(^H=CB)9)K]TMVI>T C9-"&YGOG9%!SD3Y3Q_W0M0<$*?9(=H[1(<.
MO3<<NGN'KDNT9.;2NJ"&3D9*[HBRUHAF!TX;YXW9,&&W<6$4?F7H9R:+<ON(
M7)$%6PNV8@D5AIPGB2R$86)-YI*SA($FQQ=@*./ZA'PF=XL+<GQT0HX($^1[
M)@M-1:I'OD%*%MA/]N&G9?CHC?!=<BV%R32Y%"FD+_U]3*7*)WK*9QJU EY3
MU2'=\!.)@BALX#/[?_>@A4ZWDK?K\+IOX#7I>'^^U$;A^?W5$J!7!>BY +VW
M G L1"H2(%C2))7%TJP*CM7AXFJLM 38EBXY-&U.B=UWV+;@MY,PP+2W#83B
MBE#<FO$-5FX]:R4%CA/ TD<ZR'&64;$&>VY>F#&1L T'<O\- <F5@5RWZ=.O
MZ/1;];G!FW"C9%HDAFC*H?&,EA!Q389^OQ=$E1#ER>F_$JL?Q%'<+->@XC=H
MY7?7671:TAQ6,,./H/II1>?T_:J?OE(]"H9Q]T#UUU;A8#"(FE4/@^=K+VAE
M>/GX^1_2A[4K-/P(XH?1,Z'H_?+O,>KGN1?'O=,#_9O,HD%MFTJ.?JT%Y:#6
MKC-KXK(M;^]JM>K^YZ[G':Q/[:O M;9GF/))@7?SF@E-.*P0,N@,\%"HLDN7
M$R,WKM$MI<&VZ889OFQ 60/\OI+2/$UL@.JM-/D+4$L#!!0    ( ," JE)%
M2J->"0,  'X(   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;)56WV_:
M,!#^5ZQH#ZU4FI^$M@(D"JVVATH5J-O#M >3',2J$U/;@6Y__<Y.2&D)6?>2
MV,Y]=]]W/I\SW GYK#( 35YS7JB1DVF]N7%=E6204W4I-E#@EY60.=4XE6M7
M;230U()R[@:>%[LY984S'MJU1SD>BE)S5L"C)*K,<RI_WP(7NY'C._N%.5MG
MVBRXX^&&KF$!^FGS*''F-EY2ED.AF"B(A-7(F?@WLX&QMP;?&>S4P9@8)4LA
MGLWD6SIR/$,(."3:>*#XVL(4.#>.D,9+[=-I0AK@X7CO_=YJ1RU+JF J^ ^6
MZFSD7#DDA14MN9Z+W5>H]?2-OT1P99]D5]MZ#DE*I45>@Y%!SHKJ35_K/!P
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M%LXKMI0GB ?6J3/Q6]Q-6#YU4$?T)S7]R1G3O9&21>%Y<?@G!CT"QP2VO;#
M N5MQR! 3PNCUR<%7L&QJF-G5E@P76D!C[0>]DF,UW )GI$K-E!7LD MIQ"=
MG2ZOX0FR3KNCK*B<L>#4O/.[!DD+-3RAU#S;\8S*$YG>;%VK)B077'U K8'P
ME AV>*4&314,ZTA8%-";X';^6V!X,D*CCG'0"@C=$NA@7.;1@\ZCSZHT6%TP
MQ<U("A-".JAK_8-N 7P)];_5O96Z1=E(F[M-(;L26LL?=.N?@[U>]%DI6W1/
M31C49FW1O<D(X@[>6O?@*>%+$I:%$8W!CNY8YMHK:!5"W@7S%6FI0&ZIZ+EH
M16:)ARJT7GO66W (CKU@;!\$=+2Y<JO!:RU<D5G>#3VS83IR%^GRC]SE_[46
MKU4WC=QL+S)LF([T15IAT!D;LU]:OB++/BR?1.,V?1.73Z))1^E'6JR06ZP^
M",'D]9*&CRK^9PDPTK*"_$LFM-8$U%L3N@08F>4=XC$,VL-@PB8$=6R:D98!
MU%L&SM9?9)9ZV&9O@00=W+44H%-2\.L"C,R-C9G )J8C[E@K#G;O>WK++S:W
M+/ET::_7++ )P1TAQUJPL%NP'F[N;\"&'UB6)BR5@&Y8&CZ#)3>.')L=:&7!
M%SVW.SJXZ[D?Z$Y<;-9UXB/43EP+;(2/3YB:C+4"8+<"O$;F8HL&M!=R%DP7
M=UWZ<>]]RMF9B\T=27OI8(%<=RP=L)86W'O'<B)S+7L0WSC(G5M@^7Q!';RU
M-&&W-)4YE109Y$H9+1TXN&2JZK*/SSGZ>O%2#9M5'(^,X+M!S3-T7>Q)KT.N
M%[M S*+>=L ):=+719_T.M!Z.7US.V+0=T&:]+6DD/./KOHME8FY!3&GS@E0
MD[S6)7)"EU@FHW44JGHC %\KMCLN(E<"DZ-W.Y<\I2*Z^I/?\JJ&F-5\U%YG
MNC%-OKKBD\N\IB&GSZF<D"9]7?C)95[4$','8M!W09KTM<R0W_VBINK =TX<
M)Z:D/CSZ "#_7$-ER"9*!8C96AEY-V/E=U9^ 5'>2+XKO@E8<BEY4EQN&5VQ
M+ >HW]><RY\W^6<&]7<HL_\!4$L#!!0    ( ," JE*N+MS=P@(  ,H'   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;)5576^;,!3]*Q;:0RNE!0QA
M:460VB35^C"I:M;M8=J# S?!JK%3VTFZ?S_;4$92FF4OX(][SKW'QQ_I3LAG
M50)H]%HQKL9>J?7ZVO=57D)%U*58 S<S2R$KHDU7KGRUED *!ZJ8CX,@\2M"
MN9>E;NQ!9JG8:$8Y/$BD-E5%Y.];8&(W]D+O;>"1KDIM!_PL79,5S$$_K1^D
MZ?DM2T$KX(H*CB0LQ]Y->#T;VG@7\)W"3G7:R"I9"/%L._?%V ML0< @UY:!
MF-\6)L"8)3)EO#2<7IO2 KOM-_8[I]UH61 %$\%^T$*78V_DH0*69,/TH]A]
M@4:/*S 73+DOVC6Q@8?RC=*B:L"F@HKR^D]>FW7H ,+X P!N /A40-0 HE,!
M<0.(3P4,&X"3[M?:W<)-B299*L4.21MMV&S#K;Y#F_6BW.Z3N99FEAJ<SB9$
ME0-DOVCVLJ%;PH!K-4!?B7P&318,T!SRC:2:@ADFO$"/H+2DN8:BQEV@CTAN
M>J+/IH:6,G5N<$_S*3K[=(X^(<K1MU)LE.%7J:^-,%N>GS<B;FL1^ ,1IMA+
M%(4#A ,<]L GQ^%3R%MXT .?GIZ]#SX[.7MXM0_WC9FMH[AU%#N^Z#\=M=;-
M2R'UA099H7N^-<Y4=@[]O%D8D\R9_74D?]3FCUS^^$A^ERRW#?A;0I^O-57B
MJ.R5MLW"43R*HM3?=OWK"4LB' ?[8=.>,!SA*&S#]@3%K:#XJ*#.#K:2^F34
M!,-.X@B'R4%U[X-PDN#^VH9M;<-_+O;@W4K79LO]NI$JQ8[;DZ9+0!/!E6"T
M('9ZKLVOW@IB66^=._. ]#HV['%L%,17!X[UA"5)V)%;KTE/&!Z.K@[\G_6$
MQ4D4'QKK=^Y!^\J9D[FB7"$&2P,,+C\;'EF_''5'B[6[&A="FXO6-4OSV(*T
M 69^*81^Z]C;MGV^LS]02P,$%     @ P("J4KMAYX"& @  SP8  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&ULC57+;J,P%/T5"W712M/R"M!6!*E-
M5$T7(U5]3!>C63AP$ZP:F[&=T/[]V$ M&DAF-N#'/>>><[$O:</%FRP!%'JO
M*)-SIU2JOG9=F9=087G!:V!Z9\U%A96>BHTK:P&X:$$5=0//B]T*$^9D:;OV
M(+*4;Q4E#!X$DMNJPN+C%BAOYH[O?"X\DDVIS(*;I37>P!.HE_I!Z)EK60I2
M 9.$,R1@/7=N_.M%8N+;@)\$&CD8(^-DQ?F;F=P7<\<S@H!"K@P#UJ\=+(!2
M0Z1E_.DY'9O2 (?C3_:[UKOVLL(2%IR^DD*5<^?2006L\9:J1]Y\A]Y/9/AR
M3F7[1$T7.TL<E&^EXE4/U@HJPKHW?N_K, #XLP. H <$_PL(>T#8&NV4M;:6
M6.$L%;Q!PD1K-C-H:].BM1O"S%=\4D+O$HU3V3W; 5-<$)#H= D*$RK/T#EZ
M>5JBTY,S=(((0\\EWTK,"IFZ2N<T2#?O^6\[_N  _P\L+E#H?T.!%_@3\,5Q
M^!)R"_>^PEWMU-H-K-V@Y0O_8?<#+8G,*9=; >C7S4HJH0_4[R,90ILA;#/,
M#F1XQ(W^/@H$P72R7AT\;N'FCNVR,/&N4G<WK,HX*(IFB0WZHFQFE<V.*GO5
M]^F<L/-:\!SDI+:.(!JD]3TO"/?$C:.2^"J<%A=9<=%1<7>$$7V*"[3A?/J<
M1:.LD1?OUVT<%(=^/"TMMM+BH]*>N<)47P-[4:;4Q>/*75YZ_IZ\B:BK*#J@
M+['ZDN,G#B2('2#=TJW*CRF-R>A0Z5Z_IW <XP]B.GWNH-V85J_O^(8PB2BL
M-<J[2+1!T;7/;J)XW7:@%5>ZG[7#4O]Q0)@ O;_F7'U.3%.S_[#L+U!+ P04
M    " # @*I20%RIB5P$  #(#P  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6RU5U%OVS80_BN$T0$)X$0B)5MVX!AHX@T+T!9!G:P/Q1X8B;:$2*1'
MTG8#[,?O2"F2;$M,!K1^L$CQ[OC=\>ZC;K87\EFEC&GTH\BYNAZD6F^N/$_%
M*2NHNA0;QF%E)61!-4SEVE,;R6ABE8K<([X_]@J:\<%\9M_=R_E,;'6><78O
MD=H6!94O-RP7^^L!'KR^^)JM4VU>>//9AJ[9DNG'S;V$F5=;2;*"<94)CB1;
M70\^XJM;0HR"E?@K8WO5&B/CRI,0SV9REUP/?(.(Y2S6Q@2%QX[=LCPWE@#'
M/Y710;VG46R/7ZW_89T'9YZH8K<B_Y8E.KT>3 8H82NZS?57L?^350Z-C+U8
MY,K^HWTI&TT'*-XJ+8I*&1 4&2^?]$<5B)9"Z/<HD$J!'"D$N$<AJ!0"ZVB)
MS+JUH)K.9U+LD3328,T,;&RL-GB3<7.,2RUA-0,]/5^P)XTNT+(\1216Z)/@
M:_3 9('LVMF":9KEZAQ]0!Y2*95,H8RC1YYI-827,'Y(Q591GJB9IP&3L>S%
MU?XWY?ZD9_\ ?19<IPK]SA.6'.I[X$OM$'EUZ(8X#7ZF\A(%>(B(3_#C<H'.
M/IPG]*4!7_YW(+UU&UZPN#;L5X8;JP[D07T4@=T@<!W%'5=:;J%.-/K^"030
MG6:%^MMA/JS-A]9\V&/^"W!"3*5\R>!\=S3?LJ[3*FV,K0U# ;MY,)E&D^G,
MV[5#U2E&1F$M=@!Q5$,<.2':",2"[Y@T-#&LQIHED&6O<1G62:C4%E;^[3R!
MTIMRNU$+9HA]OQODN 8Y=H*\%44!_ .5&3\/T8;*,ICH# HA$7E.I4(;)DM4
MYP"O+TE*B.5F40NB?^GCHW"_(73@1U3[$3G]6#*>"0GE3KD"E-5TR>*MA*A:
M C!K* '?(.7'CA2<U%M.?D6&3VOS4Z='AKDNM &>P$9=P9Z>I&WHF]]1N-\4
M.X"'_89K?3= 8)\K"PXEF8K%EG>BK*RTT_8BPL%Q#7:*A4%/#>+6C8#?A7+%
MI,F$5<8ICX$T.J'B4PRC(#K.WTZQT93T0"4-5/(3.*TR,CI@JRB<'A][I]QX
M&O5%M"%V'+Q!&9;&LJ><H2]",U-O[7=5[95+Q,?C(5J451<XR@(WS(_#7U%W
MN.%M[";NMRL/GU(QF9P47J<4&?7$OV%L[*;L]];=^#1+PVA\C+%#:H0G/1@;
M-L9N.OY?51>=0FA%J<+9)13UP&P8'$]^1L5-3AB4D.D)@75)3?I8MKD%L/L:
M>$CAJDU%GIAK.(9\AW:D$Z3;# [@CO5_<WV2-L1/W,3?0-*2)B9T\$G:^3GP
MAB'B=V@>@FIXGKAYO@$%GUD*[GW34!T !)J"1R?,4T(/>@Z.-&Q.W&S^SL\_
M6O05<&7_(*&.R<-K]4H%DVO;0BID2:%LF^JW=9OZT39G7B->]KC0:JP!&,K9
M"E3]RPC"(<NVL9QHL;&=UY/0T,?980JM-I-& -97 AB_FI@-ZN9]_A]02P,$
M%     @ P("J4K@8^E2% @  908  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&ULE57+;MLP$/P50L@A =I(EBPE#6P!?J1H#@&"I&D/10^TM+*(4*1+
M4K;3K^^2DE7'D8WV8O.Q,SL[)%>CC50ON@0P9%MQH<=>:<SJQO=U5D)%]:5<
M@<"=0JJ*&IRJI:]7"FCN0!7WPR!(_(HRX:4CM_:@TI&L#6<"'A31=551]3H%
M+C=C;^#M%A[9LC1VP4]'*[J$)S#/JP>%,[]CR5D%0C,IB()B[$T&-[/$QKN
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M6K#O2"^J!BV2VAQEDZN]K+ )!ZW^<3+]DDR_ELRBGD;31HO)&+"E0B'I;FU
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MN.49@+7XS:!0C34QH<R$>#:;N[CO>$819##7AH+BWQK&D&6&"76\5*1.[=,
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M/VBR8N ]&(MT*3*6Z9S)%GSF3%(9+[;@*UNS!+R]9XKR)'^G(Y^?[L';-^_
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M"-"?SX0VA-5!\6"D?A V^A]02P,$%     @ P("J4C7.]HF! P  UPT  !D
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M(L<(!*3603#\6\,4A'!(R.-; QJT:[K [O4+^D>?/":S8 :F2OS!,YN/@T%
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MQ6.]O\SQRPNTFX#/ETK9EX$[V[??<I/O4$L#!!0    ( ," JE*,S8IW]0(
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MT#\ B!M [(W6RKRM*V;9>*C5&K2+)C8W\+GQ:'+#I:OBS&KZR@EGQY?&H#7
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M?K^82W@/TSQ^X!*YIW"4%60'D,[U#*P2S7NBF2A>F2OYEBNXX)MA#F\P(K0
M?-]Q:*SM1&_0O>J6OP!02P,$%     @ P("J4M -$!$I P  [!(   T   !X
M;"]S='EL97,N>&ULW5AM:]LP$/XK1AVCA5$G\>+&:QS8 H7!-@KMAWTK2BP[
M EGR9*5+^NNGLQSGI;JNZX<MG4-JZ1[=<X]TITID7)NU8#<+QDRP*H6L4[(P
MIOH0AO5\P4I:GZN*28OD2I?4V*XNPKK2C&8U.)4B'/1Z<5A2+LED+)?E56GJ
M8*Z6TJ1DV)D"]_J<I:0?OR>!HYNJC*7D[O3MCZ4REV\"]SYY=W+2NSN[/+2?
M-L 9";VDPV>0GO=P7HMAU/&SJ)]@QH@O]HFW1+]S''D=>[NN[73"-B63<:[D
M-C,1<0;+3DL6W%.1DBD5?*8Y>.6TY&+MS ,PS)50.C"V)&RX/ECJ!P?W70^J
MI>4IN52ZB>TBN+^S=O@!L.F!0"Y$)W! G&$RKJ@Q3,LKVVD&-\9'4-"V;]>5
M55AHNNX/AF3KT+QLD)G2&=-=F#[9F"9CP7*0HWFQ@+=150B@,:JTC8S30DG:
M:-AXM U+.V="W,!6^I[O<:_RG;SU(&NR:UI!;=/1N [P[[(Y[EW:P8MX@XK?
M*_-I::<CFSY4*+O6+.>KIK_*.P$8>Q]GIU4EUA\%+V3)W.2?'7 RIAN_8*$T
M?[#1H%3FUL T">Z9-GR^:_FI:77+5F933JL<USQXA9K_[CH73#)-Q:YH6_O'
MO,HO5AQ=_"O)S7^50\%>C>WY>.PBA\<O,DJ.7V-[NSAVD:]BWXR.4F38GM\[
MEX2]*T)G#> JEI)O<+$3VZ#!;,F%X;+M+7B6,?GHIF#I#9W9J_P>OQV?L9PN
MA;GMP)1LVU]9QI=ETHVZAH5H1VW;7V!Z_;B[!]I87&9LQ;)IV]7%K&D&MF&C
MM@\X'")7S>-',!^'^1' L#B8 LS'>6%Q_J?YC-#Y. S3-O(B(]1GA/HX+Q\R
M;3Y8'+]/8A__3),DBN(86]'IU*M@BJU;',/7SX9I P\L#D3ZL[7&LXU7R--U
M@.7TJ0K!9HI7(C93?*T!\:\;>"2)/]M8'/# LH#5#L3WQX&:\OM$$605TX;M
M8!Q)$@R!6O37:!PCJQ/#QY\?;)=$49+X$<#\"J((0V WX@BF #1@2!0UY^#!
M>11NSJEP^_O6Y!=02P,$%     @ P("J4I>*NQS     $P(   L   !?<F5L
M<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5Q
MD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC
M0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W
M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ
M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " # @*I2;!A!IL4#   -'0
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MU.T-7L)C>R-U<^M$W&R7"ZO36,XO!ZTOL>V#N;:RW7W-VWV)?/T_4$L#!!0
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MR7$'DN,>) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M
M(:M (:M (:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(:M$(:M$(6N"0M8$A:P)"EF3_R3KN]:KO_ZIT:YQK<KFZ,^Z/T?S3U!+ 0(4
M Q0    ( ," JE('04UB@0   +$    0              "  0    !D;V-0
M<F]P<R]A<' N>&UL4$L! A0#%     @ P("J4BRB2#_O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ P("J
M4IE<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " # @*I2.-*+VD<%  !U%0  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ P("J
M4D_[&&,C!P  Z!P  !@              ("!BPT  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( ," JE)ZLP56#@,  )((   8
M      " @>04  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" # @*I2<#J5OMT$  #K$   &               @($H&   >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ P("J4NFP-=\P P  K@@  !@
M             ("!.QT  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( ," JE*<G -ND (  !,&   8              " @:$@  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " # @*I2F+F-%D,&  #T
M&P  &               @(%G(P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ P("J4C2@P=T<!P  N!L  !@              ("!X"D
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ," JE*L/O-0
M. H  )07   8              " @3(Q  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " # @*I2$[G2M042  !7,@  &0
M@(&@.P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,"
MJE*E@@+@( @  %,6   9              " @=Q-  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ P("J4B[2+$O9 @  *P8  !D
M         ("!,U8  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " # @*I2&B"PI:@$  #7"@  &0              @(%#60  >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ," JE) J%!K:0(  +T%
M   9              " @2)>  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ P("J4C7_5M"3!P  VA(  !D              ("!PF
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " # @*I2QD"V
MANP(  !"&@  &0              @(&,:   >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( ," JE*<G&DN% 0  &X)   9
M  " @:]Q  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MP("J4I^99H%/$   LB\  !D              ("!^G4  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " # @*I2POC-+:D"  "#!0  &0
M            @(& A@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( ," JE*\4<9GH00  !L-   9              " @6")  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ P("J4BUQ 4N1 @
M5P4  !D              ("!.(X  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " # @*I2TP"@_]0$  "0"P  &0              @($
MD0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ," JE**
MXU==+04  #0-   9              " @0N6  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ P("J4E5[QI98!0  !P\  !D
M     ("!;YL  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ," JE*5V)R=^P4  ),B   9              "
M@>"M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ P("J
M4JXNW-W" @  R@<  !D              ("!$K0  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " # @*I2NV'G@(8"  #/!@  &0
M        @($+MP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( ," JE) 7*F)7 0  ,@/   9              " @<BY  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ P("J4K@8^E2% @  908
M !D              ("!6[X  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " # @*I2,P$1S=D#  "6$   &0              @($7P0
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ," JE+ 9-<2
M]0(  "((   9              " @2?%  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ P("J4N^P&2=S!   -Q(  !D
M ("!4\@  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #
M@*I2(E*R@R(#   ,"0  &0              @(']S   >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ," JE)Q+E[(R@,  %T,   9
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M970T,BYX;6Q02P$"% ,4    " # @*I2)P(;V,@#  #A#0  &0
M    @(&]XP  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M ," JE+0#1 1*0,  .P2   -              "  ;SG  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ P("J4I>*NQS     $P(   L              ( !
M$.L  %]R96QS+RYR96QS4$L! A0#%     @ P("J4FP80:;% P  #1T   \
M             ( !^>L  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,"
MJE+N2=W_G@$   @:   :              "  >OO  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ," JE*HRH?9JP$  $$:   3
M          "  <'Q  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     S #,
*W T  )WS      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>104</ContextCount>
  <ElementCount>305</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2121107 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128108 - Disclosure - Assets and Liabilities Measured at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - Basic and Diluted Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Inventories</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2316304 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Debt</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2322305 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DescriptionofBusiness</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/InventoriesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Debt - Summary of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails</Role>
      <ShortName>Debt - Summary of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Share-Based Compensation - RSUs and PBRSUs Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails</Role>
      <ShortName>Share-Based Compensation - RSUs and PBRSUs Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Share-Based Compensation - Expense Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails</Role>
      <ShortName>Share-Based Compensation - Expense Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="fold-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="fold-20210331.htm">fold-20210331.htm</File>
    <File>fold-03312021xex311.htm</File>
    <File>fold-03312021xex312.htm</File>
    <File>fold-03312021xex321.htm</File>
    <File>fold-20210331.xsd</File>
    <File>fold-20210331_cal.xml</File>
    <File>fold-20210331_def.xml</File>
    <File>fold-20210331_lab.xml</File>
    <File>fold-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fold-20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 19,
   "contextCount": 104,
   "dts": {
    "calculationLink": {
     "local": [
      "fold-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fold-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "fold-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fold-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fold-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "fold-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 373,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 16,
   "keyStandard": 289,
   "memberCustom": 12,
   "memberStandard": 24,
   "nsprefix": "fold",
   "nsuri": "http://www.amicustherapeutics.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.amicustherapeutics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Inventories",
     "role": "http://www.amicustherapeutics.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Debt",
     "role": "http://www.amicustherapeutics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Stockholders' Equity",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121107 - Disclosure - Share-Based Compensation",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128108 - Disclosure - Assets and Liabilities Measured at Fair Value",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue",
     "shortName": "Assets and Liabilities Measured at Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - Basic and Diluted Net Loss per Common Share",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare",
     "shortName": "Basic and Diluted Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Inventories (Tables)",
     "role": "http://www.amicustherapeutics.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316304 - Disclosure - Debt (Tables)",
     "role": "http://www.amicustherapeutics.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322305 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables",
     "shortName": "Assets and Liabilities Measured at Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables",
     "shortName": "Basic and Diluted Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business (Details)",
     "role": "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Cash, Cash Equivalents, And Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Inventories (Details)",
     "role": "http://www.amicustherapeutics.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Debt - Summary of Long Term Debt (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
     "shortName": "Debt - Summary of Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-2",
      "lang": "en-US",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromWarrantExercises",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Stockholders' Equity - Common Stock and Warrants (Details)",
     "role": "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails",
     "shortName": "Stockholders' Equity - Common Stock and Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iac3a273d2c644f5780e23dc81b7297ff_D20210201-20210228",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails",
     "shortName": "Share-Based Compensation - Weighted-average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i27a30ae4c9ce4d2e910e5d6a3b595381_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i27a30ae4c9ce4d2e910e5d6a3b595381_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Share-Based Compensation - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i1a9af0ca276943fa953a4dc683e3516e_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iafc0c4bbc6714c919e4c4906d4cbc02d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Share-Based Compensation - RSUs and PBRSUs Summary (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
     "shortName": "Share-Based Compensation - RSUs and PBRSUs Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iafc0c4bbc6714c919e4c4906d4cbc02d_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Share-Based Compensation - Expense Summary (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
     "shortName": "Share-Based Compensation - Expense Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i085324ad68f040cab6d186478f2dac9f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i925eb208debe4acf8dbeded140f69103_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i01cf5118ba1646a0a3dfd406beed48c6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Contingent Consideration Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i01cf5118ba1646a0a3dfd406beed48c6_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
     "shortName": "Basic and Diluted Net Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Comprehensive Loss (Unaudited) (Parenthetical)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Loss (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i517fd281a28749d78656d0a3c7970477_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "i517fd281a28749d78656d0a3c7970477_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.amicustherapeutics.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20210331.htm",
      "contextRef": "iaa63d0dc316c4791a471583f9d824d1e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fold_ATB200PompeProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to ATB-200 Pompe program.",
        "label": "ATB200 Pompe Program [Member]",
        "terseLabel": "ATB200 Pompe Program"
       }
      }
     },
     "localname": "ATB200PompeProgramMember",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated Depreciation And Amortization, Finance And Operating Right-Of-Use Leases",
        "label": "Accumulated Depreciation And Amortization, Finance And Operating Right-Of-Use Leases",
        "terseLabel": "Accumulated depreciation and amortization on finance and operating lease right-of-use leases"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AmortizationDeferredFinancingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Amortization Deferred Financing Costs",
        "terseLabel": "Amortization of deferred financing"
       }
      }
     },
     "localname": "AmortizationDeferredFinancingCosts",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CallidusBiopharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Callidus Biopharma, Inc.",
        "label": "Callidus Biopharma Inc [Member]",
        "terseLabel": "Callidus Biopharma Inc"
       }
      }
     },
     "localname": "CallidusBiopharmaIncMember",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities",
        "totalLabel": "Cost, Cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecurities",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "terseLabel": "Gross unrealized gain, Cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedLabel": "Gross unrealized loss, Cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 3.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure",
        "totalLabel": "Fair value, Cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to clinical and regulatory contingent consideration milestones.",
        "label": "Contingent Consideration Liability Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and regulatory milestones"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ContingentConsiderationMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Measurement Input",
        "label": "Contingent Consideration, Measurement Input",
        "terseLabel": "Contingent consideration, measurement input"
       }
      }
     },
     "localname": "ContingentConsiderationMeasurementInput",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "fold_ConvertibleSeniorNotes2016Due2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the \"Convertible Notes).",
        "label": "Convertible Senior Notes2016 Due2023 [Member]",
        "terseLabel": "Convertible Senior Notes 2016, Due 2023"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2016Due2023Member",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_DebtInstrumentsConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instruments, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentsConvertibleThresholdTradingDays",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "terseLabel": "Corporate debt securities, Gross Unrealized Gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current",
        "negatedTerseLabel": "Corporate debt securities, Gross Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_EmployeeAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee And Directors Stock Options [Member]",
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeAndDirectorsStockOptionsMember",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ForeignCurrencyRemeasurementGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "label": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "negatedLabel": "Foreign currency remeasurement loss"
       }
      }
     },
     "localname": "ForeignCurrencyRemeasurementGainLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_IncreaseDecreaseInNoncurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.",
        "label": "Increase (Decrease) In Noncurrent Operating Liabilities",
        "terseLabel": "Other non-current assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncurrentOperatingLiabilities",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_MeasurementInputProbabilityOfMilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "label": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "terseLabel": "Probability of achievement of milestones"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfMilestoneAchievementMember",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_PaymentsForRepurchaseOfRestrictedStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire restricted stock units during the period.",
        "label": "Payments For Repurchase Of Restricted Stock Units",
        "negatedTerseLabel": "Purchase of vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRestrictedStockUnits",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ProbabilityWeightedDiscountedCashFlowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to valuation technique of probability weighted discounted cash flow.",
        "label": "Probability Weighted Discounted Cash Flow [Member]",
        "terseLabel": "Probability weighted discounted cash flow"
       }
      }
     },
     "localname": "ProbabilityWeightedDiscountedCashFlowMember",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_SeniorSecuredTermLoanDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Term Loan due 2026",
        "label": "Senior Secured Term Loan due 2026 [Member]",
        "terseLabel": "Senior Secured Term Loan due 2026"
       }
      }
     },
     "localname": "SeniorSecuredTermLoanDue2026Member",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share",
        "terseLabel": "Expected annual dividend per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "fold_ShortTermCorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Short Term Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "ShortTermCorporateDebtSecuritiesMember",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockExercisesAt706Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Exercises at $7.06",
        "label": "Stock Exercises at $7.06 [Member]",
        "terseLabel": "Stock Exercises at $7.06"
       }
      }
     },
     "localname": "StockExercisesAt706Member",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockExercisesAt798Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Exercises at $7.98",
        "label": "Stock Exercises at $7.98 [Member]",
        "terseLabel": "Stock Exercises at $7.98"
       }
      }
     },
     "localname": "StockExercisesAt798Member",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants (in shares).",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the Company's Amended and Restated 2007 Equity Incentive Plan.",
        "label": "Stock Option Plan Amended Restated2007 Equity Incentive Plan [Member]",
        "terseLabel": "Stock Option Plan Amended Restated 2007 Equity Incentive Plan"
       }
      }
     },
     "localname": "StockOptionPlanAmendedRestated2007EquityIncentivePlanMember",
     "nsuri": "http://www.amicustherapeutics.com/20210331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r245",
      "r247",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r379",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r245",
      "r247",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r379",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r235",
      "r245",
      "r247",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r379",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r235",
      "r245",
      "r247",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r379",
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r232",
      "r233",
      "r415",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r232",
      "r233",
      "r415",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r18",
      "r161",
      "r162"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation of property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized loss on available-for-sale securities"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r48",
      "r51",
      "r53",
      "r54",
      "r329"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Accumulated other comprehensive income (loss):"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r280",
      "r281",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Restricted stock tax vesting"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of the convertible notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r248",
      "r250",
      "r286",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r250",
      "r272",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total equity compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r163",
      "r183",
      "r185",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r69",
      "r82",
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r82",
      "r342"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and deferred financing"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r172",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r146",
      "r149",
      "r155",
      "r176",
      "r309",
      "r315",
      "r330",
      "r387",
      "r403"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r47",
      "r95",
      "r176",
      "r309",
      "r315",
      "r330"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r170"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gain, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized loss, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r168",
      "r191"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r165",
      "r169",
      "r191",
      "r391"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair value, available-for-sale debt securities",
        "verboseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r167",
      "r191"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Corporate debt securities, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r251",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r244",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r244",
      "r246",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r81",
      "r305"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Non-cash changes in the fair value of contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r301",
      "r302",
      "r304"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r301",
      "r303"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r301",
      "r303"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures unpaid at the end of period"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r33",
      "r84"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 3.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value, Cash balances"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r9",
      "r85",
      "r91",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r78",
      "r84",
      "r90"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at the end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r78",
      "r331"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase(decrease) in cash, cash equivalents, and restricted cash at the end of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r93",
      "r95",
      "r116",
      "r117",
      "r118",
      "r120",
      "r122",
      "r129",
      "r130",
      "r131",
      "r176",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r221",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r236",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r42",
      "r208",
      "r392",
      "r409"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "netLabel": "Common Stock",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.01 par value, 500,000,000 shares authorized, 266,007,718 and 262,063,461 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income [Member]",
        "terseLabel": "Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r57",
      "r59",
      "r60",
      "r64",
      "r395",
      "r411"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r134",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Fair value of the Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of liability components of long term debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r236",
      "r243",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r66",
      "r380"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion, converted instrument, shares issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r388",
      "r389",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r14",
      "r212",
      "r389",
      "r402"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r40",
      "r97",
      "r216",
      "r217",
      "r218",
      "r219",
      "r340",
      "r341",
      "r343",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Debt Instruments"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r340",
      "r343"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less: debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r191"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Current",
        "totalLabel": "Corporate debt securities, Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r174",
      "r192",
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair value of available-for-sale debt securities in unrealized loss positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gain (loss) on debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation plan liability"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).",
        "label": "Deferred Credits and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r290",
      "r291"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r46",
      "r200"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "negatedLabel": "Less: deferred financing"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r82",
      "r144"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation costs, period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r105",
      "r113",
      "r115",
      "r128",
      "r180",
      "r215",
      "r220",
      "r280",
      "r281",
      "r282",
      "r295",
      "r296",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial assets and liabilities subject to fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of assets and liabilities subject to fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r321",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r236",
      "r237",
      "r242",
      "r243",
      "r321",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r321",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Changes in fair value of contingent consideration payable",
        "negatedTerseLabel": "Changes in fair value during the period, included in the Consolidated Statements of Operations"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of the period",
        "periodStartLabel": "Balance, beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r346",
      "r348"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r193",
      "r194",
      "r195",
      "r196",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r201",
      "r202",
      "r386"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r65",
      "r95",
      "r146",
      "r148",
      "r151",
      "r154",
      "r156",
      "r176",
      "r330"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r62",
      "r146",
      "r148",
      "r151",
      "r154",
      "r156",
      "r384",
      "r393",
      "r397",
      "r412"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r114",
      "r115",
      "r145",
      "r292",
      "r297",
      "r298",
      "r413"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r203",
      "r204"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "In-process research\u00a0&amp; development"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r61",
      "r143",
      "r339",
      "r342",
      "r396"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Components of total interest expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r76",
      "r79",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCostsForContractsOrProgramsPolicy": {
     "auth_ref": [
      "r28",
      "r30",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for costs relating to long-term contracts or programs. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average). Elements of costs in inventory may include retained costs representing the excess of manufacturing or production costs over the amounts charged to cost of sales or delivered or in-process units, initial tooling or other deferred startup costs.",
        "label": "Inventory Costs for Contracts or Programs, Policy [Policy Text Block]",
        "terseLabel": "Inventories and Cost of Goods Sold"
       }
      }
     },
     "localname": "InventoryCostsForContractsOrProgramsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r24",
      "r198"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r45"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r198"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r45",
      "r98",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Reserve for inventory"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r25",
      "r198"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r68",
      "r142"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r95",
      "r150",
      "r176",
      "r310",
      "r315",
      "r316",
      "r330"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r95",
      "r176",
      "r330",
      "r390",
      "r407"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r95",
      "r176",
      "r310",
      "r315",
      "r316",
      "r330"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r320"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Fair value of liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r14",
      "r213",
      "r389",
      "r404"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Net carrying value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r40",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r38"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r78",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r55",
      "r58",
      "r63",
      "r83",
      "r95",
      "r104",
      "r109",
      "r110",
      "r111",
      "r112",
      "r114",
      "r115",
      "r119",
      "r146",
      "r148",
      "r151",
      "r154",
      "r156",
      "r176",
      "r330",
      "r394",
      "r410"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to common stockholders",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r111",
      "r126",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r293",
      "r294",
      "r295",
      "r296",
      "r381",
      "r382",
      "r383",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Developments"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Ex-U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r146",
      "r148",
      "r151",
      "r154",
      "r156"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r344"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use assets, less accumulated amortization of $7,499 and $7,574 at March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r307",
      "r308",
      "r314"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized holding loss on available-for-sale securities",
        "verboseLabel": "Unrealized loss on available-for-sale securities, net of tax impact of $0 and $(56), respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r307",
      "r308",
      "r314"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment gain, net of tax impact of $132 and $1,536, respectively",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": {
     "auth_ref": [
      "r307",
      "r308",
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment, tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r49",
      "r50",
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "terseLabel": "Available-for-sale securities, tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnauditedParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r56",
      "r59",
      "r307",
      "r308",
      "r314"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Tenant improvements paid through lease incentives"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r251",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r72",
      "r73",
      "r166"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sale and redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r75",
      "r275"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r55",
      "r58",
      "r77",
      "r95",
      "r104",
      "r114",
      "r115",
      "r146",
      "r148",
      "r151",
      "r154",
      "r156",
      "r176",
      "r307",
      "r312",
      "r313",
      "r317",
      "r318",
      "r330",
      "r397"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r206",
      "r408"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, less accumulated depreciation of $15,961 and $14,487 at March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r9",
      "r84",
      "r90",
      "r385",
      "r405"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r220",
      "r283",
      "r406",
      "r423",
      "r428"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r105",
      "r113",
      "r115",
      "r180",
      "r280",
      "r281",
      "r282",
      "r295",
      "r296",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r140",
      "r141",
      "r147",
      "r152",
      "r153",
      "r157",
      "r158",
      "r160",
      "r231",
      "r232",
      "r380"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Cash, Money Market Funds, and Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of changes in contingent consideration payable"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r250",
      "r271",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Equity Compensation Expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r27",
      "r28",
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories for the period"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r9",
      "r90",
      "r385",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r251",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r253",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested RSU Activity under the Plan"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A senior loan takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors.",
        "label": "Senior Loans [Member]",
        "terseLabel": "Senior Loans"
       }
      }
     },
     "localname": "SeniorLoansMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested units (in shares)",
        "periodStartLabel": "Non-vested units (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested units (in dollars per share)",
        "periodStartLabel": "Non-vested units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Non-vested units, weighted average remaining years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r255",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding (in shares)",
        "periodStartLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding (in dollars per share)",
        "periodStartLabel": "Options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise\u00a0 Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and unvested expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options, Vested and unvested expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options, Vested and unvested expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r249",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Non-vested units, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r268",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, options vested and unvested expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r93",
      "r95",
      "r116",
      "r117",
      "r118",
      "r120",
      "r122",
      "r129",
      "r130",
      "r131",
      "r176",
      "r215",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r100",
      "r101",
      "r102",
      "r105",
      "r113",
      "r115",
      "r128",
      "r180",
      "r215",
      "r220",
      "r280",
      "r281",
      "r282",
      "r295",
      "r296",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r128",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r215",
      "r216",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Equity component of the convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Stock issued from equity financing (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r16",
      "r17",
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock tax vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r215",
      "r220",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, Exercised (in shares)",
        "terseLabel": "Stock issued from exercise of stock options, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r215",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock issued from exercise of stock options, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r21",
      "r22",
      "r95",
      "r164",
      "r176",
      "r330"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r220",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government agency bonds"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r132",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "netLabel": "Outstanding warrants, convertible to common stock",
        "terseLabel": "Outstanding warrants, convertible to common stock",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquityUnaudited",
      "http://www.amicustherapeutics.com/role/StockholdersEquityCommonStockandWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares outstanding - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r441": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r442": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r443": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r444": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r445": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0001178879-21-000006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178879-21-000006-xbrl.zip
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MT+W9B,47Y%$J_RH,"TU@6*FU&WI-E;'XG+:)L2\38D?EWA+;>:1)A*C&+/=
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M>3FYEP:H!>ZN?U_MM'S:6]W>W=C^L!]M;WS<VMZ-/NZ!T;;:WHUVMR+ 6+L
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MP=\ORJF$<XMB*C&.62K26%JB8FY@41!IHGS87%IW'76J"G>7&3GB_EOV\W_
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M:"X"2QPT9J&"V@OZHPC@\=9?(^#;^-8+91=4+;RE&.$V4#9=F(/SQ0"8H3G
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M0(*,+<W*@ +H]8<I#G6PUYRF\VSVHD[X.M1CY3!IKP(D-_+VAC&M56I,Y8$
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M[^ZN]ELCY^^:1 ?_/D*F^T]/?9:#K>-VUKK8/MK:M=W6YT_G[=WMK^W=0W8
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M=><=R(&-"I=U]: H72B V7@_7A"5C$BR!O_/^K?M%S?9[8_47M<J80HF/#4
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M;M.8:B3"OB*.I4I<C"6GQDFN68#CCV&?1UED#?O,%OM0A57"I 0=AE#,F-8
M\8!]4JV\QTYJ0?S""EI"W\>6?/=#=***Z%N@ZV)T)\.5@=[EY%35O<W_,3:L
M>*Y<'?2/\@(TLFW8[T78KW7^A2E*A#$DMBQ) >%A&<L$I;%/%'?(.$ZX_('V
MNIV9'J^X&F::9682S!KBI(J=<.'(*F]!EUD2"^P$H92$DS\75CA"BZC^_SU4
M6LUAD;HD[TRHMLVR'#2<^$*<N(>^$)*$6N$\1I2%8"_-8HVUB0VR2B26:X[8
M@]7:2S#2UJ!?]E4O6$X--[T4-Z4,24^IC+'E /%UY7%/DYA8F7IM4%@H%U9(
MDH!.2Q=3_/T.V_=Z+7B 9V!9;?COI?EO_RP4#9,B(6!3HF C8.EB+4T2.YYB
MHIQ#4LT&2&N6Q9=E) _+GZ,6@R)C-&:.V'#>3QIS(91#+J6)3H(B(^$0Y$5
M:_<':%E%VOJ\WBN=$:E^U%*%.8HH7HS"^EC=L>Z,ZVI7C'Y%BQ&T<>*@R6^N
M<W[I.ZU\?TV\X/.'Y8Q);N4G:C;Q'BJR5YMX7(<C>W$:(PL0@E%O8@W\'R=@
M$7&46)O(%(1N,1'3=,A6$^0[<_$UC=#^JM".!=FD*G5,)'$BP\XGQ2"TB=.
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M.%T_*EW@=-5P>DZL":%!*AL0]8X@3AQ%FD6&(B8L6<F,20[@%(BUN/OYB,;
M:<V\?QWEN+99WA[X,6MXUPX.JU[]>KD(8#["S!^L6B<)GBEE_<3?\@'6RG]?
M36F=T#W&EO7YU)_MG>;\17O]$;QOU&\][_?J4:MW(E]6/=OS%1#Q.I=R76U@
M,6G17.>G+^!T$CQ^TA_6YVM_&\1\2.%S_/U+%49',YR8NW$J3GQ^BW70AO'H
M^EON<62_.X[L0@JGN9^YM36F$.>E\@)KYP3'BME$L3(6:(=T 8S0C[2N;5'?
M=#28]>#$'D;D!M%^0C9!!W^SG2_V=+CQZ^*$@]EV8=QO,&3U/)^.V.:_W0">
M>44W'G2X+QF%]7!O=2L_'K8.CN+ GL0QJ.FP/4&2G9Y_=NW,;$KS%W3K7*-:
M_=2:EL2&+S2A%]>BR=7]^N5=SXY#!;WZU[6MGT+C5-<)O5]X_'[SJUYK=-0?
MPS/"L-V*7WW,:T?.]U8['4 TL[^ZL"B-AG?N9;U^G,-?O69!;SOV9!A_F_WR
M>ZB&)QU[^EO5J]M<WW1Q=8*EYESCG^&)UD\]0]/G3R\_JR]=6&DGUQ1Y1BB]
M]C)^1JZ]]KW'$OJ,&WFKQW[_&M/\YS16W_2Q5YA4,VD!RXG-^.8/O(0_W @P
ME[YZA64VF=.-\AP>#8#=[,+WCH:M%[T 6'N6FO$&N0Q^ZIC_U#(VRY#?9HLP
M^]'N4ECH1B-1AGHZU/BG:T4C-*U)>R#F1LZ4O3AJG0SZ8>QABMG.Y5.L-[27
M&^]TN]EPW-;IUER?VLWZO81/S5K) @Z>$>FY,L1R181FR01->2#QXW:]10'_
M0W?>JW@3/\?>.+X<]+NY_&!NW3_5Z.CY> @C%0=@D77&>82WAL,(_P\-.N=W
MNEM-_6W=7?Z^^X[L==]4>]O_Z<)[Z(=7>T?[VW_1O8-W7S]L_WW\_I\7\.R]
MZMS?]N[;WO'[K[NO]CH?7KT_A>_B#\>[8N];]LOMB/??7GS9_6?WR_ZV)Q?]
M;7L'T,;C%U_>T[\_05_XWO:;[NZW3VS_U?LON\>=X]V#K:_OOVWQO6]_I]UJ
MZFM[B[]\9%1)I95%*3"/.(\$&1HPLLH(+[3'6@(R2MGF^,Y)"9;5GO78FB@@
M^%1 ,(GDB?:,*::X]$Y'S9.VG)# .+:F!D$\ T%<0+#9(/CM# 03U83!=$#.
MJIR815"D@U-(D2"C\%$(RW-%\+:@ET\[KQ4(/@*ZW:0@Z9M!S//^<)1]L8?]
M?AAF48?'<H)[K7EF%LM^>I6%DC=QX^!SY>/P+8BG(.DR2'HZ1R=-+A66HD1,
M&HQ 8@QI$!Y*2L=@I,AUKP%)VX*9!IT#?>(GN=>:*!4M7I46G_,A:1UA*@@D
M.8V(DP!&(4D:&>M,2"F?Z$ZU%HLF):I[M(QG_1R,KP8Y=][)H)_N=MQ\;<Z#
MK#41JJ7UNA96P<PE,'/O^1SS"1B[$$-$.,J$N%(4.2,4(M&!%<EIBD)M; K3
MUI*MMPWY4P^D/UV-OT_25#3^UAI_SI*"U%00T'.LG$+<1HPLB0%)@&Z1F,,B
M:-!XUC9JS37^$7"H]?,:32/W>H>M^/4D]H9Q>+N*&2L,!+GG9SR":;=^U/U-
M',8ZJBE'*(;X.7;Z)[>NW]' +#-KS=1GPMGJA>UST;R8X,.+K[,](?^_XVH0
MPTX/EG@?A\/L(RGK_#+K_/P6.>;.VZ "PE0)Q(.5R#+-D4I$,VR5)\)O;$K>
M)N3.R>U*-JG&ZOG][OX6/;\G/3_G\\PS2CA7R"H>P8(G'&EI%)+:28DC=2Z9
MC4UMVF1EY\X*97]4E/UM[,"'A^W68>P!>>^T:Q)E0[?J5</1H#ZM5K9^&\"C
MIH)Z-1$3H.S6@HRF0%N@=!DHG=\&)M@PD[A'PD6">/0"&6(<LL(9*E@"TB0W
M-KELJRMR;S9M!ZGL Z\#92HJ_3-4^IP=.86%"9XCS"4'=F0BLA%;Y)5..'G.
MB%.@TKA-R9UCY,JF\&/T+#T_LKU#>%K5:R5;#5J?;6<<<UQ<Q@SH U@X^==A
M%:9'EELG]C2?32VNIY]'F:ZIQ?02!/1WEL]NM,/QH#Y/GN./W_7Z#KKU.8ME
MIW<R'@W?1&B2KSI5+;(WN1C3  ;\#SNLAK,T*:>O;-7+M9LF8<O98IVE22Z
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M!)H=(^'<$!RX!/X5/>9&.$*CX4+I&U#RLWQ<BP2\KLRU4)1KI^?[W;@U(Q#
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M-'JL/M_:<?84%J15,LY%2WJGYP>PU,3M./D7K..I7-Z<B:6L-TNM-W_-$\I
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MF]ZV,L4C>*9Y]1-_RV9+Y;^OB[2.Z(RQ93U,?&C-:=ZY!:L&WC?JMY[W>W6
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M?T5!S,3TC2"YN2_=$T2XC>WQC2O1MNEVP!='KB L)%Y)&,.OG\RLDE1:,)L
M2=2=>=V 5%59F><\9S\G&]@3[T_I$QI4/#HY5TI_]ZD6H]B_ DD&@XNS\U&R
M0@10'8(O0Y?];*\F7#T;*Z^+@;YP%TV\4GG"7;91C].C;Y(.Q6,2QO\*6;?'
MB66+%C2*/%>EPZ Z6*.X*!OI11Y6<KT-+[+_J<C;*F*V10WP"(-3&MEXIS8T
MT^K-N)RO=$%.S)*4+#,H7;1E,'LNI%[DP.B<9C"3]I+3*<='.=KG&U-VJEDY
MHYR8@B)R^48ZOZGLFSPQ2_R1GJ,[5\F1?JD'I>^O4BZ>$P)RKFN['^5CI*B4
M:Y.6D=VMESX2:I%S-VXZDF]?UHT4FU"F"40Y&H7C#3N2$OMR"GC<B<EK/P6C
ME1ZR3/)3%/^BTKJ<_'K;9-B9SPO#[Q7*]M;>QV\F&!B\#X 2Z%/[09XZ]AN@
M"+*:8V^5G@N?,>&"\2@H@07EW$@;F!26<!A/S:GPBG2!1$K;C=QYM4)1VPE<
MOOO<CJSQ)4472NF4.&5"CL5UFXGIU6#;"+4&.2AS$K_5N8I@$O>KFM T:)Q?
M1$3."6-9C= 1SU)J4Y$)';'9^]1N8W@R2-7$N6AJ1G)K&^]9Y!0E*#6^2!OS
MDY/9J9[,8'PRQ1(+VS:T?V9C)ALYU>4M6-1QRNJ>&*.5%4X2_FY^WPR_-EY9
M1BOB*53V(+[C(%I"C90N=CQ5N7J67Z%H9#*87F,RR')M=#NT$X['O_S0[4YZ
M71"E$ACH3M5R&\%]$==JQ$VZ\*/BA8D!.>5B_+.TB[\DNSBNX>]N7'HG4H9K
M),,M5]'J=BE[RVS7J8>E;<Q*X[QAV/@M7?"O47SERY11^W;J@O_&+^XTWD]6
M'06E&24;CM^YW*JIN.6D[/!_+GK#\7:F<&S.@#7]WO=4(=B/UF_<K7[^VB@O
M+_ZU.-6BMBD_H]T]OUB8.O=ZPGRW2H3="NIEGBP9+D7AHW+23Z2?>.^BZZ(N
MYSNYY&(0GS (5Z5J,LE2S%J][Z=@7$-'%O05=BI(;?RL@I(BD5P,"KIOC_WA
M^</225$Z@RJZ3O%!\E/-?'@O[K@U2%9G6,[0E[HYPW*5DB47<L&MB6(S>I1"
M'MNHX!+C#+5!2RB1A=A10IP)TCYY8EDDW738A;7TN3WX_C9:%NUA^NDUJL,'
MA]^LHH@;E;9,,4"#E\!X*H 6W@3$-89V[A@)(50X2:&PC'*L#2':>6:5ASC^
M0%^3.EPEJ"RT,T$U$D5MO)X[E4Q2)&7-"*9H)/<&13FAG=TI6^Q4/^[46!N=
MDHTVFQJS"NVH6G:!4CM=*#0JJ"WJ7?-MLDMBYGY)*!K=_3X.]Y:)4]M9UTX[
MMYWB!*FJ,7A79K?%N^;2WQ0#'@YF^]@D[;1XZL)EIB<F'1G\SX7.-;B5 N&%
M^SE? )6RU5(8XKB;]=#TYU+SS%ZTRM9F^3VXL">3<';IHDL7E<Z_49UDF?/E
MW8V%PTF=2 ^O'&RU/+AZIJ5SZJ933,&UA8?X_&KE0MEV.\C-)DU#&[_E-/<D
MPJC2T"(C!')."TR,>7EV+2J$S&EV?O6FSBI332X+'Q%)I"[?+M3]45Y8O*:=
M]=>B6V2RK+)FNBD5=/.JZ>K8&[=3UVQ+HT4G&1%MQ@E<=!6,-."[!1%,G^X$
MCR-F%1U7QC&!'/2HDE?N!U! 25F:63ARY^(+T;HXGO0&L)$QHRG<SZF\8ZL_
M>4YZEX7?.,6-)\6E(R-[N]$.C>PTSJF#"UZW;$8Z\X9)(W3C-ASY/0L?_+F^
M*N(UOE]&N",>C@+"WDVB(:,73FU^+K*?.1?N97ZZC#;_25'NEF+L.G4_*E\P
M&^IQ?<>Y98])>>B+[*4W"YSUTT&"<0!:=R?;E'?)]2[,,%QTIM*>GJ%:F]VC
M2/O-:,7QV/;*]9:5'H//X\,;%VKS5Z:8MP[>T>:;;X9S'@R#0'L9]7(O"=":
M2)!&YZB@O#06;^W"187:9T6A=IE7.__O<V:M?BXB)N\CXT55>9C6^+4]/'E;
MLD2=@M:Z?O=-6D>Q<!!P8PF@U B@)!= <JLQ11I;_IHJ=$J::7PN%-Q-SV8=
M">QN=LE6I6_%1[]QRM:+M"M8V(-MJL'BO*DU%K:CX&^RI_)I7)ZD.'9]((]I
MVE4)US1\NP@T=(LZD)%);(J"O7ZEFVC?M\_,13\9H%[WRVJSP:2Q[V];[U)=
MV4YCOVC'63>8>FR#J;ZOU/85*O8H;=*E!L)M<S'L]<NNF2<ZJH*I*&=2?I1R
M.U-*1E*R4T@II*:)NG&<!AQT,R?JB^%);M>XJ9U!#F8T^.R[&8QA):))X3")
M%E36I7,J3K2%CD<=;7HSYE*V;(J^ASENU$XV2E'TU[/VHI^CQ6G40[MHGI&<
M6<5CLK4S.:5D.%0/L6=RI"GI@OU>IY8ZCSOW0J14ZD>*P&O"OHEQ.0GE%M'X
M40;!*(([$X(;FY2V5*H'HUC?6%PE=2)9H.-<J 2"N<-HPMJI^X^H)B=UG[3[
MR3KN#Z^*"23C"IB^-SDE+[_.J'ME?-#B>TZM)?<6CN9Q4;-;21X<Y3-DTAS]
M;9R,G6/W-?4]6L1./,73ZLT"%"KS\2)B9D](<J 43M\H6LW$J:*GO+ZCB]-_
M^X/4N2]Y@I*;../0J+"ATI)OE,DQH<Z4R5=-!-5%IN@T38T$S_1K3+EAIFZ:
MW2^S::CI'4<UTT428E&D\+*9?'OM@3X^[OOC<CA6:00=I#U_S?9Q\_K[-XZL
M41)%T]@1!&@RDA6# 3 =O%8.*6KXW>UCOO):0L2Z3N\RIU$7P9'<'";SZ? 6
MDS'S3HV7C\!+-V'$(J-YW//7)@&I?[^K=LINF']8GNDH<259*"!W0SL?^-]'
M/_P1EW'>T5>_M[MYC?FBV7V+.UHF>$BUPY%*T8,T%G8R@K9,_]C)@869\;3%
M9USM2(YO_!CNH =^QA%[T)6_6BS".QR2=5KLG6^[8+CXB 2BU/&K\<T\=+BD
ML 67W#3T_"%?57-?73 ,O>"IYYD9+F_KUP8+^$XIL<TB)?9=[B0QCN3,CHE^
M[N.9GT<=\O]FYU&_S+CYN^WO;]D4ZEW$6[C!O^ZPH_>@R1*+LROA?-C(.8Z-
MT1NM%14F)?,.>W.G%WYM&P>?G$U7@O7+4?0//;I%N!!OLNQ34[?I;/G44B;"
M7<C]IDVXB=27MGFP\:+0>K==_%^S6[B\U_]C-MUXE=[['MD1UB,C$>->(DR#
M(1)YJ*&DB@:)-!$+[?Q*F@2Y5R_[7T;./XZ*.MZ4%:,'^N<X9X*LIZ/@Y/#L
M9V?_]'M<U^?3%O[<;EXW+P\//OT\^OHWVS]X UO7[SN'!]]Q\^S35;-R37S6
MQ1'^F^\?N-/6AR8Y^O#QNGG]YTEK[WWGZ. [:^Y](LVO_YSL'QQ>'>U]_)F=
M"VUX]=^#=\/F%WCY34NA6? :!*0]H#I(($.P@#*H+&<8<V^3=-B6C,PE7,QD
M52R;>]*G]^2B&@1K$'PR$/04XV"D"\I:BK242AKDK3.640.-SB (1R (:Q!<
M;1"$8Q!$V"L52#PV)T0$0>F ,HX#;!&%(D#&-=W:16);"+S>(+@!^OO#3/<7
M4]'?_01WU-)OM3OQ0L_00NFRSC K' W*:"\Q0C0$K)Q1U'IAO:($,UCKFFL$
MLU<575-H@CE7%DAM:819)8#F4 /#&8R&!=6(Z*U=RK895?>#V>?4&F?PY[5S
MJ_2!$>J1<@)2S*C4G(O@$0I>A*@KU4K16G'K1"GR07.$([=Z0J,]"*D&&G,$
M(J-RS"0T5B9NQ=OBOI9AK=[<W2A= \OQH)=F2\U%Y%_0+UD&HDFDK507U/%C
MS;JVV9>U/YLBOQZ4P53+KY647ZVW%6T30V\LM PPP1"@C!"@B&: 6*YD_+OG
M 6[M<KY-X9*-^B6PUWJX/FN<K7'VKC@;6+!(6D($$91;([VD06J*D",4:E7;
M"6N%LQ,[@7D6TI ]H+B/5GTP$AAA(LXBY!T6#&J.(\[";8;9AN/LBIH?_\XY
ME"^3W?VQ&UEQV.M?O>T-AH/WO?Z((0?[_;_*F;NOMROKJ?TFC);$0PNXA 10
M372*/0C &&$6N<")<7-=625FE& ,'221X9PFC'"*)5>*0ZM?4X?V$7V-&A6_
M+<=6?.BEMCY?*KG@FU53-_7>_91571U'T>E=IGK2U!$];D?:EV2>%]T[<Q)V
M;J2Y/56&57:P;O<'Z?VVRY]Z%\/&F1^>I,J5V6?V_8^VOTPM1:JM3U*U7E$C
M==48Q(6 L]Z/E-'?RYTT>WG&67N$"I/JK_-^[[08[%WD\R<!\2/UB-*#QJ5/
M$_XJ#7A.TF3N3COD01VC,IA)]W6;BBO+B=VYV4IEX<4]4L%@K@7,Q3W%%W-]
MS[@H,17R&%]6!%8'993E/*,2K>*)G7(<TNBUVH-J ^_1.._BLW$3T\M^>YBJ
M05TJQ2DF08Z^\S\7J>W+J&=6ZL)5ME693#^OC/)NO/MYGN<Q3BT@R8/<JBJU
MRQVWLR]6FNAB,)[I,6JF-2CH)76[S>R3F]*.2_ JO2^GV[7NC[NPO^[.J+>A
M\N[;1;M;SK7/C73*SR?'F+ZS/3/\/9WEX.+\//*:/2G*50>IK]B$.]KGYZ,O
MGL1_.GED_/A+/]J#7%:;**ZDK-P&=8XYMZN\U^]=Z4XFR'-]E3#DI<<"_C>I
M[OZ_J7=!/=#K*JK[WW@PPD6* U$E1U$3MQ0H%W]"G$JJC8"4S#5O$RP(C7F0
M1%BJ/-<F>$6PEMIR3KA_1:I$04J;J2Y4JT8GK<UR%GHY(JJ8(5KIL1QRMX*0
M"K;CBFW4%I+(.2]&]2; ^.%/TKCALBXZ7U^6YO_0_3S?-?<3VXX@=I9%95%K
M78P^&0_G/1_7^/=]UU]N%Q6X9<^QHL?%:##53(^2L?(R*/JA17'63^6LN:E"
MZJ\Q>J?AN%@\/=;G)^Z,I%9<9KGT) VK#:.S&0AZ :2&TK]M?=[_>^M?4S,R
M\MVKDS)Z"T3E;!/U7TO(NDGT#.$B.+-AZ]0E^FY=G^>ONQV49X;<&TJ2"T8Z
MBJE25%MB$'<4"6?B&L1ZP?8OZ2%RX8@'^WXTJ7NZ-C@?6-EX-[?QR&U8BDE>
M.BG3YVEP\C"UVNVGN3JCWRJ='8I6%/DY10_&405]4OC;Y42\>?Z_:4639B;C
MD5C%Q67CQ4%NTS@U K!3]&1Z.^E$HI-[-=H3G0RMQ=H*,^.'ORJ:E%9;);:G
MI[X6=DRA9N8-RI#KHM50#@0:;U"^4]D()<UL'"9+I&AJ.9D.'XV&;B\-9#(1
MM$/JSI)77@RPR+>;6>I.HW)RBV8V5NV08=$%*<)FQO(\\V-L*!9F6['-Y12+
M,+N=R?Z;;&,6(-.RXV+@BS[%$? +*RKU6^KU^T7U>7_NB=6Q$I/&30M7&O=M
M))I&NW'+>C>U\<]_IT^E*ES3KIS%CR^*W1_1U31/715#3M(TD'9IR!:<.=FX
M?T8]6.88:M&0RS$-+F#@JZDQER4IEBLMN3_^5N@PZ6\5IBZZJ_6FWC6_;IHG
MX7Z]R''GZ7L9VJ,O#Z))U$@;GZ>3)CMM/(]N"E**;9MY?-;P9K2@^39P<XIA
MT1NEU-_*3Y.'J=<%Q6_C.9^CCN+3@]Y&#5HSL YR1Y7N\7AS)D-"\^<1<N90
MS\8].>X5<ZLWDW$.IJ!KO!-S\UY+S77*B9 'F225LU-@5$5RC>]ZWKD8Y#;H
M>CR/;]P*/3O/"H=@V9=.3Z3(^4B(%5IZX[<\X3=+V[&6_J\J\I[HX;182E)2
M#^(33?)?E*-=\@U3U[N!S_W1=??^CRJE?6?BRTQSHWK]12KWC2KV6E/-8F7R
M=N6P,'S+H5>IYU8["?R"]"+9(#PWBZOOQXWX<YNKNQ@^-_1?*@YO-&.Y[%,Y
M&-N3N2?B(!IOV1C+2%>V1;Q-Q.OSJ-EEGDA-G+*#*-'.;8CRPEZM2 IE2^BX
MNK_Z4<NZ*)6+TLE5N[I:!\??'(=<X( !48X *BD"!C$&I.048\0QI_H5N:Y2
M]_ H,2>4T]CS/WRG=UY(;-#X<!&Y,G'C&Q>!M5 VIGHE;)3X?//E[_AV2($(
M72!%B/;B_IR9"!CIKT7DY_VX+7]EUZ*ZU76Z'\&KE_Y-@V'C7BWZPM_G6=?_
M;2L^:^M?C='CMD>#XP_TS_@^OQWTSB-(" K_]7OC2[8UP]7(**C<-L'>](5;
ME7=(_5SS>-ANW)[CT4E&Q;F71I,,SKU-_>BR+W_B34M/*!N7)H]??-7S3A%-
M&J]II_%QV/!IDDMWW,N_F\>]E"*X?ZPC2(\-USSZ]CIWTLQZP7"J8]<(;W//
MN^/V#]\M58K?&[^U_S59W6AQ5<LK7MOOI99U110LPOVH8YW^F1O]V[R(/^*=
MJK?*+ZJGM[&0#D5#/9^'*(P:?_9]%ER]R[@I*48RZGZ75AROC 34K0Y8_"-K
MM?&!4XMOI_\?A4W[;&(4Y'/+*YU>RI77*0<%9$HII]1DA:B<JC,_V6&G425=
MW1GTDH.BG\]YP9SJ<FIW?)UR/'%Q"'8\:6BR-C"*_(WI)X>1"I)LEX<_/LSB
MR$(_?C'27;Z!KPPW2DTR"Y? V$8NGE0>4*7EYWB69J7A;1EH31.:"VH9#/UY
MX^)\9-2DK2R%?!$K2\'8/\JC&!1SRA?/[2Y,Z^,T"7D4/ATO.BDLE2$P\2&C
M$_X1#[BKBX&%$Y)(J^CHR\'\D<\<4URGSX.5T[#*=.ZAG7+)\O&70YMFKA\-
MQBQLQNFO&Q]!-CL.LB=S EV(Y8D8<$;+*?$\:SGCLXTDDV AK2BYN;J-_^BH
MS?2O&N54C>(>^=I$*:[M\O84$T/2V-.XSC2)J1@Z_>LYB!,@K1JK_7&H>3*B
M?8V'FC^9/&[%;3^,&F@IE]=V@^X<?4HNA5'?4I?[FJ86V).-.I_2>3/WC*=P
M95Y.Z6VE-7M6I&G,DFW!C4]&MG>+V62U'!G+A650&L,H%$0'#(72PA%NG*#J
M&R5;#SKL)S_(Q70=J=4W2#E?Y1DFO,^,;W_3=5].>OWA033V/DXD]<H80U>E
M,73V#A^=?8*M4\N:N'G5//@$]_?>L:.#-U>'9X=L?^\C.CSX_/WPX#^=66/H
M\.#H[&CO$VY=?[\^O/[XL[7WB38/.IWFWG_:R;!JGOYSTOKP^:1Y]D]HQM];
ME]]4L %3"H'FR %J(0>*4 *\EX9I(^.?YR)&3@GDH16(,$AM.A7"&/3"&N7C
M@<P-77G\\/-YMIDQJN<]%[<O<B:7P1"N*2$>$4>9DBIXIZC'EA**% L+3< U
M@,_;YV+E,<HK-NTJ'7IDV%D6'K[5_9P=\$^*A:S.L*OGYMV#-^0;<LIP2SQ
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M/L+;M(X05Y(FM/;":-1KG8KPE-Y/I8-##D(N#>442H:XH1XR9[QFW-4>@Q5
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M+^2UYYQ62ET:J7AK\&P^T47K>;!/%/_K299]MSU<D;3<E;['ZPY S"7>KE7
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MG7VBAV?_?&_MN=/6Z<GWUM=WE_M[1]^;IW']!]^O#Z]=& ]Y32GS EKGD':
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MRX)".S=(^ULWX.7_;]Q1C59FRD(0V)%-?JY^^45EQ<607_V<C0TZFB\M.KL
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M.R_X5JC:;^L*RZ+3LQ\9@!H].TY\EWN<D2!(!6%N3 D@$C:/$VE"W5"'W$Q
M6M:ZI7.!=R[PS@7^)$GCC]>0O2PN*(M8EXP<6[GZ8#/4[KMIW2X7RDM%$-&
M,Z$55U3%L.4R<*F( _:<[=R[?/.G%(+M?'/F,AW*&-1NFB:$:2E ""J?<.5[
M29+&E"4IYINS\+$FJ#\>5W:>^<XS_W3FPOWPL<M6WP)X;&P$)7FJJ.0DI4J#
MC4!CPGG$B>^'2LI(:QVDV)QKU^M:R*]#K>8CM)"_CY?@+BWDGP0+[CXNL.B@
M8!4H:)K+1ZY.0 B$1/$4H" 4'A$TUL0'5 !ZT5$0 Q30IH]FUUR^TSWNV%S^
MGC;9\N;R]YE5<2O0W-!4OM9%-KW=[O?&EZ:[?,22($H!7WB: +[0-"1"44U
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M>GQR$[)J5^O!]WAY),EFMO0\-NI4/S?]P-_,]P-?85N>E(ZN^R%2\[^[IJP
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M6YPI_EW0?ZY!')5Q2%TE2(SIXBSBE"0J\HG+N?1#3A/ATT="_T?GGS5WUG=
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MO4C(6)!4)"%A2G&21#0DT@L"G].8N@KCG;O7E3H'>&>(-+-J1?(FL_$'/<Z
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M7PUS^?D'<]0<[A^X_<N_(JFT<$5(&$>W,<79O8+Y<!1I*&/@*M_U=X"H)+]
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M^&%$JW&V&5G>5N0*C1W'P90Y:ZN<HQPE,^B#M2%K;$RC^;:"C2W-UEC8$M-
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ML_:MHV,,[%\7-RR[T&(B:;.PA1V=ZY9196UB2S3R3OC_-!RT+(>SE:DY+\,
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M!,^TO;7E5L*TL>GG-1E+N#4=]VX4$&#8A(T]Y878,V_>C*H\^]FD-@SG!3/
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M2H#-(@ [N@W4]26XF<EWW46WZWR\9:.JI1J7#W8U7V&M=;ALD?SK'*^*0[X
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M88G99Z @X,(KG\$4DT_0>IJ;] NXB!Z[F4 =TF#PQ!*$YY>[>,/!PBM3HQ;
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MV^W\*G 7N0G0#C<+6Q%46B*O_TSI\-1F7UOQ78["R@T__&"$=/XO-I_"%KP
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MX_</CA*/(L) /Y07<:IO7O7B8H"A;YJD% T#U'/2L@J>"]'QS<2=:&2K*QX
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M[*C\1]>X(5+R=S^NNEJGT_FJ:PX0*XQ^1.5*?M)2 ^6BK#^%SU&,SE2SD,I
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M[$SPYQ_7GWL4%100]G=8UYH5.RQT:290'A4A*O1(>U*@"2 . :B6YT$E-.#
M#U.P+H,*Z0'A[LITG"T#C#'!E^51T3Y%TYL%&$Y9IS\7@2+D5_,.\3 WHH]:
M_E118D.A/EME7*)4N0"*P ($E?>]1>W''.^B:_ZPX.$0UN,^AA[8)1AV,L=2
M88VHL+.C=V8.NB(^[NZP9OW$#(O6QOP>=/G$O*_EMB1FW0MM#ZS[&)6&G=\)
M*I\P^^M";UJ8_9U<#AC WA0_EW_%%UD^E>:GBRY9# =EGC)E6B=:7&J7M"&0
MN4"_C,$1&BVRU= <B5D:'=#9_FZ+)[<[ D3_AA]N7TN2;>/*!C7A$2,N= -8
MO@!:43X;?%AA$S]J-A=B.L$#9I:F'1]][_YV]%'G?#:A.M9;8%#B32G=D<&(
M=[;;0]L.9T=&JSQW*7G->134:Z*@L%G3R'7<,)J<37/<XAY8H;'"V;Z^(:;*
M6?!P<JEN[#$Y]4I?3A.BH!7"@#XM?_D8JQ0@ 4QO%#L5TI_3-0#*(KE!L:*1
M9ON,.B%UB6HI+E:K=)626JTGK</H6FYD#0H3TY2-,'"OM)'XDZ[P^?H."W4A
M ^1[N^[Z[<WJN][>[!0K*F+Z1RMVG%ZYMA7U0.DJ?;]^#09W"0_%=GS0B5[A
M>^72O9$2E3L0R4X.PIZ"] Z3Q...+UBAR8H:(*CU,Q1'HJIE)!_WHVXG>AQJ
M145(.12/!0;ZT[T!][M$'H*GA2GPO=6ZXIKZ_'T1VM]<I"+M1:&?ST=;@)*3
M?IH8GV&-HGI!PO<#+B4J4Z<%7;_*;'DLUXZQG",N<XV.Z_3B_T)13VS7I^RG
MH?1AWRE5X>>>XS<-I$['&E#:CJE<2)U:Z.BED:.Z6HI"Q=^D<$;J)(O]'1WJ
MUR']O:2KL6@&YAB$ 5+);?HS/(G)&"C71T/-[WM6C\D'W!B>\62;'G1CNX^D
M!_:H %UB7*!>W+.-YNY9=#_ WNBH.Z7L&,8UO*+\]M!#+JB6B_!=AQ3R(!(:
M?<OK!R-_(ENZ\5Y$F&4$@G3B<G:T"22L ".XMFC!&LB:0/K@A>=-\4/<)_,9
M-#"0/.Y[AS?H6"@-Q(\@%SZ76>/8'V[J6,3JFP$7G:$)XL7#P,+^=%'%/5]%
M+J^2OR'1%:&8<QWXI.[K51268Y)- 1TWT2HRO)I;J?&RK(YAP6F+ 2:/,AY_
M?ZXCI7+M-U:E5TRBQ+%(M)HRBEHW&,%F4ZEE5=ZER,2C<'*GW*WW__QT3B=\
MXC:L"4NU)'ZDY3@!=1&E_A-PMKX!\)FMEDN%W^)*?[!F^![97[Q39Z!!D0(?
MUJO<4T2]2^/G%:\FKDV,6$F@P@.U.W#ZJ]>CW!U*7-ED)J2W:5OQ[&RP$=M!
MQBPU%L<LK6"TG!SM5*!3VGG9DK74N6G_T"I%[??;UL5-YZ9UT_E'6VM=G.$O
MSL.?SSK=T_/+[NUUNZNUOE[>WF@_6M>_M6^TZT[WM_WD$=R-D7I7HLE/NAW^
M'77NJ.'64%B>HJK-]*[D5IUA%*42T1,V]N1X*UT&;F!T!^F1?3!4K,DCR-%[
MF100Q7OH,[%:2I"VU%ZY'0,7SXT:?=+,0?UELX$3A/QG)Z5&NJS4_9)4<:IJ
MR:U1E08.%FKC=_>%_X"B@.M-VRU*?0D+_R::E:)_EAK^RO[,'/:BMF,@51GT
M[/Y/O!><::&9VA5UBNJS*3WWR<X3-D:04!($NLY175%L2M4R\(/>GY'#G\N]
M)K:2?8-$4MD)%0U,I?.#W&DE\@15J"$($3?2\&T*);K#/#_\5=^&M8)88LU1
M/( AA&0H@))5"%M8Z"'P*,KV'H8LH)-+<W"9ICX[=^KQ2J10Y\X3_F,F6DAH
MY;]HQ\ @I5$S!BMOXG]4#H;@Z<Z"ZI&"9DR+ !LUH7.]N.43^;J8X-&Y6K@[
M6#I<;9DA4CH!T^QE:!/6DN8VL??F8'9V\?E@9RYW+0F=QG-S /D_51O/!F2G
M4GP6N@-3L?T<J?>UA^,??$IH<SE<81YA<S=G:)<37XD..MBODT4]G@5Z4^-+
MGZ[I6  IZJ$+;[Q!T)^[@KL8PH-U!C$V5?;CR1"L&0?(G\*#4RF05:>==[Y>
M7NOJ@:%#,+1=%QC#V Y\K5ZL_84NR9!9$.PD-&+T,>P0 M$*D[O!2T4&(=B>
M"@_2@N^'M8GG-RSU,% G@ ;,$[93NY^.47*PKW3F,*<?SC#(,NUPA]ZXE)GP
MJ8_#*04V(XCI%7,-LI##0:6G*?U0[^=90;K')L,IEZO76L$$N#<*3 ZC8/-L
M$.T67UB-N?^"]",%W#:!4!ME?3B49L%,L1-^"!2G"T]9ND(/2_\Z,K@(D&O>
MN1/J;CYW4?+R44..YPW"U$+6"_C%=.;Q=LZ&(1WFFF%\,\ 3;X 8,M&4N),
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MA1-B+>&E\>GPN4[*S..@^_#.)$7H_D4U)N= R%[>L#'I-.2Z\I8%+ZE\!.5
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M.%6>G+G'&HA+$#@A;D_3T&T0,NA$^.EEQ +%-N)L!9:9K3-'GXE:QE:*1Q+
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MBMA$T=V#:4PZKAX_:CFAIN(?HH\/$ 'IBL!^A^4%HL@%BY+C("T2]I0FG D
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MN?R3)DVLUXQPM((P H2-3?+][T6UH?H_2,R_*YEN7:A1S4UU]IHNFOYUWG^
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MAAW&DDT>OW_C/C@"G$_2Y4M1!O_XV_\#4$L#!!0    ( ,& JE)Z\^DC:#L
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M--IX,1Q<YHN^+;.O)_UX1K-DHH].^N21\F2)X#*R8CV01UH\\SY$9KWSEMR
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M^EOGK-UPX!L4#\'FVZNU01+Z@NVM2V#6ZA(IM&<F*TWD$YH!),FRS=DX8ZR
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M99\@)]YDT=@G$U:4UNV+")NHN@$!WN.@/QR]&<+@*J_7J4#B),-,$ 2(>\<
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MHR_UZK";I"XNR5@2DG'(,EIXPXCCB<7:V% &&U"UV8A;ANC)>>C08@V:WMR
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MEFE?'*V\)"_8 ER6+"G8/JXDHXUE?!I6NPZK _'M$)[>*E&O.TJL)6TV(%Q
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ME^!00A1<1P9:6J;1U> J6R:\LD5#B1R:Y.K?B>H1$ZM[JS58/Z_DG$[4";-
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ML6!A21NAM89LW3J)(L=AQ24K>?=&W$1K'1OO9]+4^<55?&J"Y1*T9<(96B2
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MYWW16 KJ%#*L9:7;\K6TU0[3ZR:/W[NUUID4+1F&%LU BZ744A>@P202+Q!
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MFY'7'&?2,S$V^@!MNO%@J'0PT#J@3\'P>YWF0:/Z3= J'PRT#QKU@[72/^@
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MWF/I[*#3=UHRP>!HOR6C"\=1R_M*:)_4JZ\Z^DK<KEJSKAVU#\BA893'(4E
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MMQX$&"QUP$&Y<A%]Y'.BC8V]YYP\WS;BNQ>O;X[$CQS,G/ILHT=O13J)'9D
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M]YIN\-]$[_>)VKQ/V]1]+BW<[1NV>VO/_O=FB[GNK"M$:92%* 9$Z'3\..<
M<\E R"3A+$QHGE.[O=S._>>W(^O$LZ2 7=#2$.$$2PQRJ$]E$X(!@B(!J80H
MC'F>P) L5F+M"[!-"-?:-XD.^JG\T0%WH\];U5RMBVX[Q 8NZ&M0S:(DD7F>
M Q2R#$"(<D!03$".8@YIB(3$L57'F[$/XB3+TY3(FJU2H_'RO#!U<EU.![+O
M%G-,8Z=-8'8&F+:WRS'=#EJV'/W2V%Z%Z^WF=V-J4H8PS'+U/B>2 _5.Z][%
MB0"((7U2D&(JK!SC1T>9V\O]]O%>GWF7E:5]?QQ"L[?W:F \O\7:L-ZQM:<T
MJ\^"X[;IWK&!)FZD=T;7P^9XY[X\C@AV@P@_="&"/Y-BI0=1.TX9Q51D(,0A
M!3 3!& :8L#5UHE*$B,49C:,<'ZXN5%#+]_P%#!0:_Q>9+P=;UQ W(Q W.'H
MF4D.XIDWF/[<8-JPBSON,,/%)8E<&'%2-C'3?I]6#*\:68FU6!$E^QM!:M%U
MZR3++H^H7F FDR2,<A A'@,H,P9HP@5(PI1'.0H)E:E%CH[1H'9&VV1Y-WTJ
M7RD#V8H?++7\ENQR'F\S<KD>OHGJA'8X-8+>!!M1^[1(AV65C"!Q6K?S[(#3
MUMLTT?V@3J;11>,X95MS?4M;?8 7301.H%1X9D@Q2AQR@!F#@#.2AR0-98ZM
M3)@S8\UMM_)Z]46T/:1T&8C@?EN9?NQ6Y1S09E3B"#[/1'*TB+^',#@#-%QR
MR+GA)F40 [WW^</DDI%''^5J4Y2P-:>ZZG ;&S[)XEC", $9%SJ.-Z* )*D$
M)(2AR#*:AKF5T7-QQ+DQ2>M=^JZKV/A]5]W6]GSD(LZ&9R4NT?-];C*0=7.
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MT]':C<\DRLCU5RS57S__+%9JF.7MBM_R>S5.O=96S1?155_K^T.E4$0Q37+
M0]A4]HD Y1$%!$K"!4W#-+,*;+$:?6YK7B?\3?"Y%;^M(D-V-!A7SM%N4@Q7
M)E]0^UY3>I0[R1N0=V7OZSOZZ.DU"C:G]&TEP+3$.P:; \H<=9-Q9/>^*ID0
MO-:E+SZ2I5"C_4+6NNK6TSMY^X442\V\/Y65_N.V'M<"ATG.0BF "&.I&X+%
M@,9QJM-X8J:LAES&L0WMC91C=@2HI&M>QTIP<?_0-[.ZW]8TJS>RVQ'@V(DR
MH\()X/=,BKT&;>V>S3ST6FQ:B@UKRFT4 [*L@*ZCY(XEKT34)5^.%652YKP2
MKWT.O?9V]D&!MVKGRIO<JB7YO. 8IGF8A@ QF@$8Y1G F8 @ESFD7' IN'$*
MU,Z=Y\9X&^$"+9UYE-\N7.=9ZBH0//..H?Y687M'=;TB3F_W?I,%YAU58QB)
M=_P+(ZTV=B?XXU*\DQ?J4WS2+_XV!D/$49(C!$$B, 10)RQBJM[6G$9A&$<R
MI\C.?ALGQ]Q>ZUX-O6Y6.\?A^A/M 5P]WFL_7UEU#5!7I=JD-K]WO02;DA*/
M34SK87F<55]P9[^8CJ59.'+6#0U$_W/IVU0<3*-1=9W@MT87/]E;5^+IU(8<
M*<JTUN1U>!W8E5?>;APQ[YW:O7W45NL[V8Q;O]M6Y;NE=7.*MXC35&8\$@ C
M% $H)5%;IY0!R=2F*4MQE)',AI%M!9@;%;_<4NM?[=C1&GHS6O0)J&<^//":
MM,)K>FS%#P;RWVQ)L5?%(1F.1=$E"UK+,"G]C45HG_=&WV=\N/3KE;I54VFC
MX=*%=A&0),8ZP4,H3D,,4$@9(&%(4)HQF DC<_#,&'.CK>'6HVWFOI'7\NCK
M&*!F3'4E3!-NSMZ4J\]MH?U]K+H=F>- ZA.HN ZBWA]F\@#J$WH>"YX^]=5I
M Z?K$^%&;15AG@G*4K4WBIJF2UF> AIF&,0B$Y)G+ X3N6AC-C^N2;4V8Q,O
MLMJ\:/L2^WOG?B3J5Z8L'RH^%ZLF7**S9UL9I@E9/3_)-.0LD30#89ZIQ8(S
M!$@"0X"B#'$1A3!EK)OD5RO/L?".I[B7=X()%KKH]]RFUFS9>O;)\KSP>8PR
M=MV_UNM4S"%J^+R@WT2$L!'6KJ*!S08;78ZK2\YY,<S-^:3NUJ>,)QCQ/,H!
M33($8(A2@#*>@X@AG(10)@PEEC6YSH\X-ZMB*W"P(W&@11Z9)WX9=C/:=@JF
M9PJ^$L<QA;O,L'%<O>O"H%.7\#+#X$@=+\,+K\@X&--?NRVJ,S!6WZGM5O7I
MCJRZZ,V?F\Z+KU?OFQW8WD%,\\>79"TV7+P029+@"%,@HC@%$!,),)020!$F
M693R.&/4K@O.;'2S>?FG:;_3R.BH5<5L8+;)2IB#O#-:$QSD*G25U(;'5PT^
MR@PCJVTF0XN1]A&_[_)+#P[FFZ\$&JI@:RXXSF28T_P[SV^8A7+39SW,0NUS
MN1"S$G!L\<\O2HBR>MK6F]BX$$4<H8A+! @+"8 TEX"&* 8XS5A",IF14-H5
M^CPYUMQLDXVH.[50+KL.K3$V6^(<(>=YT1D+VH@JG!?A<%MQ\_1P$U?7O*CW
M827-RY>,8XZW8JW[#;^ORB_*C.$_/OU:Z\SIMM&P=L'J9HM-).XV'"0AC.$D
M!3R*,( A(X#*, 8Y(3 F&9)"6E7)LQ=ACCS3B!J0C:QVY#)B&LPXQR^XGJE(
M-P%L^J#WXNO-[G>_MM&,WP=;V+=:>&&J\2"Z)+ 14DS*:^-1VJ>[*^YT=?/?
M-@BE;:.Z8!*1-$\C()%45 =A#C!,B&(^0K*,P!!'EAT7CHXS-S[;;0.\V[I7
MGTVTGU@>2)S"V/0H]VKDO!_@#MOQMD)Z[<=[# =/;7EWAGJN[KS']#W3I/?H
MUT?2@R*CVQ77_]&&WQ>RU";?K2*IJGI2?-2><Y$P99AD.:"QS)2A)2&@$8D
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M2-(<KI.R[))#Z.P3FZUF8*E4 X^M;HY+R* QM%L=QAZ9D8G_62*<FR/)<F[
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M=+(=VJ0P['8L84)$D"$8\C2'"&4II"3/U-](%*(T3)/0R2OH:"_S6S^W0NI
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M^9VO ;4\YWN!81K[/+ W0GV=;L!6*S- ?;UN0*>9^IO6K;$1WUX<0_?30\^
M>SUE]"7;M*>1GA$].+7TW?[$(7;6=;5N[^Y6)O7+^W*]*M1JQ4R\]2)A2<Y%
MDL&$A%)M[ 6'-(W52I$%+(ZP%"QVVMB_F":S6TLZ,4'1R=F40;@9JX#EBWP_
MEC?S?X6O8NQ+_1<I3[G[#+? -%DY9A"SYVMP9Q&^=[4R?XU(/E]CYBVHSYM
M0SU<_VO3GC=]K71%HI(52_%!K-^7K'H0NH;&UTJ?5RG3X9O:(O)73[\I#=Z7
M'Q_-=E')Q=;%MR;I;7=Z&P8)QH%D,!)4)YA57VJ>(00I%Q@EC,0!96Z.L?Z%
MG-UZN]-14^&JTQ*48MU4$5(_U7]G^L1XH]FU4!N[3D% MAK^NZL#[@A?@.4&
M[X7'=>S-WOZ0;A4T08Z-BN 'K>2/^M?F)J!35"^D/_S6#/*/8*LNV.D[RF7
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M::(D3G@>(AAG-%+&2Z!SK/$<1DF,D&0BSB7RD53U>E'G1DZM1H"U*H'U3B=
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MV$X(SSZ'Z4DM.R5IO M7N_?<(00C4HUT:\@Z6E Q)@B*SB[N1)2D**MXF_Z
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M,FO:&*QEJ<EEBJ-R.7+-\QA(WG(UC0^JCL^6RU;,9;Y8/M**^2%Q1)]22-Q
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M5\3+^M+L)'/M5?(>F#61ME"4))[:[-IKQ3"8&DMMZII?DM))W'M ?WP_*7>
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M9_PMK.I]OZ^OR_W3&2?5JLW<,$B^3DE7AEP\R1.MQ2@,T\5&UR2+OR>]798
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M"CVM(FLA* PUL9Y*%I%;W20X/XYG>'M]/UL]#XO%U^GLPW^$DS.<:&Y8,-Q
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MVTEFC&8F<9[55K[=?]MTZDZ@V".=NHN&NF@G,H +' M:%C4#%-Z \JC!6</
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M4@)'NI;_5.Z@):A_JLKT\Z(+:*+ER4 LM1FQ=?:JT4T6IDX2*HR7)B=NNY'
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MRR<3==>:R6Q:RXOAV_]-Z$'S^.G;Z[K!LL<9JL'>/4ZLOJ5,#A'&9RFQB&(
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M4$L! A0#%     @ P8"J4E:V#@=4"   -RL  !<              ( !
M &9O;&0M,#,S,3(P,C%X97@S,3$N:'1M4$L! A0#%     @ P8"J4G[+3!U,
M"   @RL  !<              ( !B0@  &9O;&0M,#,S,3(P,C%X97@S,3(N
M:'1M4$L! A0#%     @ P8"J4LC*TM*;!0  *R$  !<              ( !
M"A$  &9O;&0M,#,S,3(P,C%X97@S,C$N:'1M4$L! A0#%     @ P8"J4O?[
MOYK\=@$ HJT0 !$              ( !VA8  &9O;&0M,C R,3 S,S$N:'1M
M4$L! A0#%     @ P8"J4L6 +KT[#   O7P  !$              ( !!8X!
M &9O;&0M,C R,3 S,S$N>'-D4$L! A0#%     @ P8"J4F;T@P4&'P  Z4,!
M !4              ( !;YH! &9O;&0M,C R,3 S,S%?8V%L+GAM;%!+ 0(4
M Q0    ( ,& JE)Z\^DC:#L  "*O @ 5              "  :BY 0!F;VQD
M+3(P,C$P,S,Q7V1E9BYX;6Q02P$"% ,4    " #!@*I2;<D)*-RW  #.G0<
M%0              @ %#]0$ 9F]L9"TR,#(Q,#,S,5]L86(N>&UL4$L! A0#
M%     @ P8"J4MH)8^]F9   V;\$ !4              ( !4JT" &9O;&0M
F,C R,3 S,S%?<')E+GAM;%!+!08     "0 ) %D"  #K$0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
